{ "version": "2.2", "instance": { "trib-20251231.htm": { "nsprefix": "trib", "nsuri": "http://trinitybiotech.com/20251231", "dts": { "inline": { "local": [ "trib-20251231.htm" ] }, "schema": { "local": [ "trib-20251231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions-ea/rol_ifrs_ea-dim_2025-03-27.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions/rol_full_ifrs-dim_2025-03-27.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd", "https://xbrl.sec.gov/country/2025/country-2025.xsd", "https://xbrl.sec.gov/currency/2025/currency-2025.xsd", "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd", "https://xbrl.sec.gov/dei/2025/dei-2025.xsd", "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd", "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" ] }, "calculationLink": { "local": [ "trib-20251231_cal.xml" ] }, "definitionLink": { "local": [ "trib-20251231_def.xml" ], "remote": [ "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions-ea/dim_ifrs_ea_2025-03-27_role-995000.xml", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions/dim_full_ifrs_2025-03-27_role-995000.xml" ] }, "labelLink": { "local": [ "trib-20251231_lab.xml" ] }, "presentationLink": { "local": [ "trib-20251231_pre.xml" ] } }, "keyStandard": 437, "keyCustom": 303, "axisStandard": 44, "axisCustom": 1, "memberStandard": 61, "memberCustom": 134, "hidden": { "total": 15, "http://xbrl.sec.gov/cyd/2025": 7, "http://xbrl.sec.gov/dei/2025": 5, "http://xbrl.sec.gov/ecd/2025": 1, "http://trinitybiotech.com/20251231": 2 }, "contextCount": 881, "entityCount": 1, "segmentCount": 220, "elementCount": 1445, "unitCount": 9, "baseTaxonomies": { "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full": 2428, "http://xbrl.sec.gov/dei/2025": 43, "http://xbrl.sec.gov/cyd/2025": 16, "http://xbrl.sec.gov/ecd/2025": 1 }, "report": { "R1": { "role": "http://trinitybiotech.com/role/DocumentAndEntityInformation", "longName": "0001 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "D20251231_3", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R2": { "role": "http://trinitybiotech.com/role/ConsolidatedStatementOfOperations", "longName": "0002 - Statement - CONSOLIDATED STATEMENT OF OPERATIONS", "shortName": "CONSOLIDATED STATEMENT OF OPERATIONS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:Revenue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutAmountRelatingFromRevenueExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:CostOfSales", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "td", "tr", "tbody", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R3": { "role": "http://trinitybiotech.com/role/ConsolidatedStatementOfComprehensiveIncome", "longName": "0003 - Statement - CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME", "shortName": "CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:ProfitLossAttributableToOwnersOfParent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "td", "tr", "tbody", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "td", "tr", "tbody", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R4": { "role": "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition", "longName": "0004 - Statement - CONSOLIDATED STATEMENT OF FINANCIAL POSITION", "shortName": "CONSOLIDATED STATEMENT OF FINANCIAL POSITION", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "I20251231", "name": "ifrs-full:PropertyPlantAndEquipment", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "I20251231", "name": "ifrs-full:NoncurrentFinancialAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R5": { "role": "http://trinitybiotech.com/role/ConsolidatedStatementOfChangesInEquity", "longName": "0005 - Statement - CONSOLIDATED STATEMENT OF CHANGES IN EQUITY", "shortName": "CONSOLIDATED STATEMENT OF CHANGES IN EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "I20221231", "name": "ifrs-full:Equity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "td", "tr", "tbody", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "I20221231_IssuedCapitalMember", "name": "ifrs-full:Equity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R6": { "role": "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows", "longName": "0006 - Statement - CONSOLIDATED STATEMENT OF CASH FLOWS", "shortName": "CONSOLIDATED STATEMENT OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:ProfitLossAttributableToOwnersOfParent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "td", "tr", "tbody", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:AdjustmentsForDepreciationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R7": { "role": "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPolicies", "longName": "0007 - Disclosure - BASIS OF PREPARATION AND SIGNIFICANT ACCOUNTING POLICIES", "shortName": "BASIS OF PREPARATION AND SIGNIFICANT ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "D20251231_3", "name": "trib:DisclosureOfBasisOfPreparationAndSignificantAccountingPoliciesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "trib:DisclosureOfBasisOfPreparationAndSignificantAccountingPoliciesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R8": { "role": "http://trinitybiotech.com/role/SegmentInformation", "longName": "0008 - Disclosure - SEGMENT INFORMATION", "shortName": "SEGMENT INFORMATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R9": { "role": "http://trinitybiotech.com/role/Employment", "longName": "0009 - Disclosure - EMPLOYMENT", "shortName": "EMPLOYMENT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R10": { "role": "http://trinitybiotech.com/role/OTHEROPERATINGINCOMEEXPENSE", "longName": "0010 - Disclosure - OTHER OPERATING INCOME / (EXPENSE)", "shortName": "OTHER OPERATING INCOME / (EXPENSE)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "D20251231_3", "name": "trib:DisclosureOfOtherOperatingIncomeExpenseTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "trib:DisclosureOfOtherOperatingIncomeExpenseTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R11": { "role": "http://trinitybiotech.com/role/IMPAIRMENTTRANSFORMATIONANDONCEOFFCOSTS", "longName": "0011 - Disclosure - IMPAIRMENT, TRANSFORMATION AND ONCE OFF COSTS", "shortName": "IMPAIRMENT, TRANSFORMATION AND ONCE OFF COSTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfImpairmentOfAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfImpairmentOfAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R12": { "role": "http://trinitybiotech.com/role/FinancialIncomeAndExpenses", "longName": "0012 - Disclosure - FINANCIAL INCOME AND EXPENSES", "shortName": "FINANCIAL INCOME AND EXPENSES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfFinanceIncomeExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfFinanceIncomeExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R13": { "role": "http://trinitybiotech.com/role/IncomeTaxCredit", "longName": "0013 - Disclosure - INCOME TAX (EXPENSE)/CREDIT", "shortName": "INCOME TAX (EXPENSE)/CREDIT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R14": { "role": "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONS", "longName": "0014 - Disclosure - (LOSS)/PROFIT FOR THE YEAR ON DISCONTINUED OPERATIONS", "shortName": "(LOSS)/PROFIT FOR THE YEAR ON DISCONTINUED OPERATIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfDiscontinuedOperationsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfDiscontinuedOperationsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R15": { "role": "http://trinitybiotech.com/role/LossBeforeTax", "longName": "0015 - Disclosure - LOSS BEFORE TAX", "shortName": "LOSS BEFORE TAX", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "D20251231_3", "name": "trib:DisclosureOfLossProfitBeforeTaxExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "trib:DisclosureOfLossProfitBeforeTaxExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R16": { "role": "http://trinitybiotech.com/role/LossPerShare", "longName": "0016 - Disclosure - LOSS PER SHARE", "shortName": "LOSS PER SHARE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R17": { "role": "http://trinitybiotech.com/role/PropertyPlantAndEquipment", "longName": "0017 - Disclosure - PROPERTY, PLANT AND EQUIPMENT", "shortName": "PROPERTY, PLANT AND EQUIPMENT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R18": { "role": "http://trinitybiotech.com/role/GOODWILLANDINTANGIBLEASSETS", "longName": "0018 - Disclosure - GOODWILL AND INTANGIBLE ASSETS", "shortName": "GOODWILL AND INTANGIBLE ASSETS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R19": { "role": "http://trinitybiotech.com/role/FINANCIALASSETS", "longName": "0019 - Disclosure - FINANCIAL ASSETS", "shortName": "FINANCIAL ASSETS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfFinancialAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfFinancialAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R20": { "role": "http://trinitybiotech.com/role/DeferredTaxAssetsAndLiabilities", "longName": "0020 - Disclosure - DEFERRED TAX ASSETS AND LIABILITIES", "shortName": "DEFERRED TAX ASSETS AND LIABILITIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfDeferredTaxesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfDeferredTaxesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R21": { "role": "http://trinitybiotech.com/role/OtherNon-currentAssets", "longName": "0021 - Disclosure - OTHER NON-CURRENT ASSETS", "shortName": "OTHER NON-CURRENT ASSETS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfOtherAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfOtherAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R22": { "role": "http://trinitybiotech.com/role/Inventories", "longName": "0022 - Disclosure - INVENTORIES", "shortName": "INVENTORIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfInventoriesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfInventoriesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R23": { "role": "http://trinitybiotech.com/role/TradeAndOtherReceivables", "longName": "0023 - Disclosure - TRADE AND OTHER RECEIVABLES", "shortName": "TRADE AND OTHER RECEIVABLES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R24": { "role": "http://trinitybiotech.com/role/CashAndCashEquivalents", "longName": "0024 - Disclosure - CASH AND CASH EQUIVALENTS", "shortName": "CASH AND CASH EQUIVALENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R25": { "role": "http://trinitybiotech.com/role/CapitalAndReserves", "longName": "0025 - Disclosure - CAPITAL AND RESERVES", "shortName": "CAPITAL AND RESERVES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R26": { "role": "http://trinitybiotech.com/role/ShareOptions", "longName": "0026 - Disclosure - SHARE OPTIONS", "shortName": "SHARE OPTIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "D20251231_3", "name": "trib:DisclosureOfShareOptionsAndShareWarrantsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "trib:DisclosureOfShareOptionsAndShareWarrantsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R27": { "role": "http://trinitybiotech.com/role/TradeAndOtherPayables", "longName": "0027 - Disclosure - TRADE AND OTHER PAYABLES", "shortName": "TRADE AND OTHER PAYABLES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R28": { "role": "http://trinitybiotech.com/role/Provisions", "longName": "0028 - Disclosure - PROVISIONS", "shortName": "PROVISIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "28", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfProvisionsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfProvisionsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R29": { "role": "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGS", "longName": "0029 - Disclosure - INTEREST-BEARING LOANS AND BORROWINGS", "shortName": "INTEREST-BEARING LOANS AND BORROWINGS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "29", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfBorrowingsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfBorrowingsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R30": { "role": "http://trinitybiotech.com/role/LeaseLiabilities", "longName": "0030 - Disclosure - LEASE LIABILITIES", "shortName": "LEASE LIABILITIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "30", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfLeasesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfLeasesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R31": { "role": "http://trinitybiotech.com/role/CommitmentsAndContingencies", "longName": "0031 - Disclosure - COMMITMENTS AND CONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "31", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R32": { "role": "http://trinitybiotech.com/role/RelatedPartyTransactions", "longName": "0032 - Disclosure - RELATED PARTY TRANSACTIONS", "shortName": "RELATED PARTY TRANSACTIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "32", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R33": { "role": "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagement", "longName": "0033 - Disclosure - CAPITAL AND FINANCIAL RISK MANAGEMENT", "shortName": "CAPITAL AND FINANCIAL RISK MANAGEMENT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "33", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R34": { "role": "http://trinitybiotech.com/role/ReconciliationOfLiabilitiesArisingFromFinancingActivities", "longName": "0034 - Disclosure - RECONCILIATION OF LIABILITIES ARISING FROM FINANCING ACTIVITIES", "shortName": "RECONCILIATION OF LIABILITIES ARISING FROM FINANCING ACTIVITIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "34", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfCashFlowStatementExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfCashFlowStatementExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R35": { "role": "http://trinitybiotech.com/role/BUSINESSCOMBINATIONS", "longName": "0035 - Disclosure - BUSINESS COMBINATIONS", "shortName": "BUSINESS COMBINATIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "35", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfBusinessCombinationsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfBusinessCombinationsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R36": { "role": "http://trinitybiotech.com/role/POSTBALANCESHEETEVENTS", "longName": "0036 - Disclosure - POST BALANCE SHEET EVENTS", "shortName": "POST BALANCE SHEET EVENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "36", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R37": { "role": "http://trinitybiotech.com/role/AccountingEstimatesAndJudgements", "longName": "0037 - Disclosure - ACCOUNTING ESTIMATES AND JUDGEMENTS", "shortName": "ACCOUNTING ESTIMATES AND JUDGEMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "37", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R38": { "role": "http://trinitybiotech.com/role/GROUPUNDERTAKINGS", "longName": "0038 - Disclosure - GROUP UNDERTAKINGS", "shortName": "GROUP UNDERTAKINGS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "38", "firstAnchor": { "contextRef": "D20251231_3", "name": "trib:DisclosureOfGroupUndertakingsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "trib:DisclosureOfGroupUndertakingsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R39": { "role": "http://trinitybiotech.com/role/AuthorisationForIssue", "longName": "0039 - Disclosure - AUTHORISATION FOR ISSUE", "shortName": "AUTHORISATION FOR ISSUE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "39", "firstAnchor": { "contextRef": "D20251231_3", "name": "trib:DisclosureOfAuthorisationForIssueExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "trib:DisclosureOfAuthorisationForIssueExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R40": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc", "longName": "995447 - Disclosure - Insider Trading Policies and Procedures", "shortName": "Insider Trading Policies and Procedures", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "40", "firstAnchor": null, "uniqueAnchor": null }, "R41": { "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure", "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure", "shortName": "Cybersecurity Risk Management and Strategy Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "41", "firstAnchor": { "contextRef": "D20251231_3", "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R42": { "role": "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesPolicies", "longName": "9960701 - Disclosure - BASIS OF PREPARATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)", "shortName": "BASIS OF PREPARATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "42", "firstAnchor": { "contextRef": "D20251231_3", "name": "trib:DescriptionOfAccountingPolicyForGeneralInformationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "trib:DisclosureOfBasisOfPreparationAndSignificantAccountingPoliciesExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "trib:DescriptionOfAccountingPolicyForGeneralInformationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "trib:DisclosureOfBasisOfPreparationAndSignificantAccountingPoliciesExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R43": { "role": "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesTables", "longName": "9960702 - Disclosure - BASIS OF PREPARATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables)", "shortName": "BASIS OF PREPARATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "43", "firstAnchor": { "contextRef": "D20251231_3", "name": "trib:DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfOwnedAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "trib:DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfOwnedAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R44": { "role": "http://trinitybiotech.com/role/SegmentInformationTables", "longName": "9960703 - Disclosure - SEGMENT INFORMATION (Tables)", "shortName": "SEGMENT INFORMATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "44", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfGeographicalAreasExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfGeographicalAreasExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R45": { "role": "http://trinitybiotech.com/role/EmploymentTables", "longName": "9960704 - Disclosure - EMPLOYMENT (Tables)", "shortName": "EMPLOYMENT (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "45", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfAdditionalInformationAboutDefinedBenefitPlansExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfAdditionalInformationAboutDefinedBenefitPlansExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R46": { "role": "http://trinitybiotech.com/role/OTHEROPERATINGINCOMEEXPENSETables", "longName": "9960705 - Disclosure - OTHER OPERATING INCOME / (EXPENSE) (Tables)", "shortName": "OTHER OPERATING INCOME / (EXPENSE) (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "46", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "trib:DisclosureOfOtherOperatingIncomeExpenseTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "trib:DisclosureOfOtherOperatingIncomeExpenseTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R47": { "role": "http://trinitybiotech.com/role/IMPAIRMENTTRANSFORMATIONANDONCEOFFCOSTSTables", "longName": "9960706 - Disclosure - IMPAIRMENT, TRANSFORMATION AND ONCE OFF COSTS (Tables)", "shortName": "IMPAIRMENT, TRANSFORMATION AND ONCE OFF COSTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "47", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfImpairmentOfAssetsExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfImpairmentOfAssetsExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R48": { "role": "http://trinitybiotech.com/role/FinancialIncomeAndExpensesTables", "longName": "9960707 - Disclosure - FINANCIAL INCOME AND EXPENSES (Tables)", "shortName": "FINANCIAL INCOME AND EXPENSES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "48", "firstAnchor": { "contextRef": "D20251231_3", "name": "trib:DisclosureOfDetailedInformationAboutFinancialIncomeAndExpensesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfFinanceIncomeExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "trib:DisclosureOfDetailedInformationAboutFinancialIncomeAndExpensesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfFinanceIncomeExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R49": { "role": "http://trinitybiotech.com/role/IncomeTaxCreditTables", "longName": "9960708 - Disclosure - INCOME TAX (EXPENSE)/CREDIT (Tables)", "shortName": "INCOME TAX (EXPENSE)/CREDIT (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "49", "firstAnchor": { "contextRef": "D20251231_3", "name": "trib:DisclosureOfDetailedInformationAboutChargeForTaxExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "trib:DisclosureOfDetailedInformationAboutChargeForTaxExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R50": { "role": "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSTables", "longName": "9960709 - Disclosure - (LOSS)/PROFIT FOR THE YEAR ON DISCONTINUED OPERATIONS (Tables)", "shortName": "(LOSS)/PROFIT FOR THE YEAR ON DISCONTINUED OPERATIONS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "50", "firstAnchor": { "contextRef": "D20251231_3", "name": "trib:DisclosureOfOperatingProfitForTheDiscontinuedOperationsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfDiscontinuedOperationsExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "trib:DisclosureOfOperatingProfitForTheDiscontinuedOperationsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfDiscontinuedOperationsExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R51": { "role": "http://trinitybiotech.com/role/LossBeforeTaxTables", "longName": "9960710 - Disclosure - LOSS BEFORE TAX (Tables)", "shortName": "LOSS BEFORE TAX (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "51", "firstAnchor": { "contextRef": "D20251231_3", "name": "trib:DisclosureOfDetailedInformationAboutLossProfitBeforeTaxExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "trib:DisclosureOfLossProfitBeforeTaxExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "trib:DisclosureOfDetailedInformationAboutLossProfitBeforeTaxExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "trib:DisclosureOfLossProfitBeforeTaxExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R52": { "role": "http://trinitybiotech.com/role/LossPerShareTables", "longName": "9960711 - Disclosure - LOSS PER SHARE (Tables)", "shortName": "LOSS PER SHARE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "52", "firstAnchor": { "contextRef": "D20251231_3", "name": "trib:DisclosureOfDetailedInformationAboutBasicEarningsPerOrdinaryShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "trib:DisclosureOfDetailedInformationAboutBasicEarningsPerOrdinaryShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R53": { "role": "http://trinitybiotech.com/role/PropertyPlantAndEquipmentTables", "longName": "9960712 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables)", "shortName": "PROPERTY, PLANT AND EQUIPMENT (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "53", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R54": { "role": "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsTables", "longName": "9960713 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables)", "shortName": "GOODWILL AND INTANGIBLE ASSETS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "54", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R55": { "role": "http://trinitybiotech.com/role/FINANCIALASSETSTables", "longName": "9960714 - Disclosure - FINANCIAL ASSETS (Tables)", "shortName": "FINANCIAL ASSETS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "55", "firstAnchor": { "contextRef": "D20251231_3", "name": "trib:DisclosureOfDetailedInformationAboutFinancialAssets", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfFinancialAssetsExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "trib:DisclosureOfDetailedInformationAboutFinancialAssets", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfFinancialAssetsExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R56": { "role": "http://trinitybiotech.com/role/DeferredTaxAssetsAndLiabilitiesTables", "longName": "9960715 - Disclosure - DEFERRED TAX ASSETS AND LIABILITIES (Tables)", "shortName": "DEFERRED TAX ASSETS AND LIABILITIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "56", "firstAnchor": { "contextRef": "D20251231_3", "name": "trib:DisclosureOfDetailedInformationAboutDeferredTaxAssetsAndLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfDeferredTaxesExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "trib:DisclosureOfDetailedInformationAboutDeferredTaxAssetsAndLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfDeferredTaxesExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R57": { "role": "http://trinitybiotech.com/role/OtherNon-currentAssetsTables", "longName": "9960716 - Disclosure - OTHER NON-CURRENT ASSETS (Tables)", "shortName": "OTHER NON-CURRENT ASSETS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "57", "firstAnchor": { "contextRef": "D20251231_3", "name": "trib:DisclosureOfDetailedInformationAboutOtherAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfOtherAssetsExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "trib:DisclosureOfDetailedInformationAboutOtherAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfOtherAssetsExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R58": { "role": "http://trinitybiotech.com/role/InventoriesTables", "longName": "9960717 - Disclosure - INVENTORIES (Tables)", "shortName": "INVENTORIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "58", "firstAnchor": { "contextRef": "D20251231_3", "name": "trib:DisclosureOfDetailedInformationAboutInventoriesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfInventoriesExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "trib:DisclosureOfDetailedInformationAboutInventoriesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfInventoriesExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R59": { "role": "http://trinitybiotech.com/role/TradeAndOtherReceivablesTables", "longName": "9960718 - Disclosure - TRADE AND OTHER RECEIVABLES (Tables)", "shortName": "TRADE AND OTHER RECEIVABLES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "59", "firstAnchor": { "contextRef": "D20251231_3", "name": "trib:DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "trib:DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R60": { "role": "http://trinitybiotech.com/role/CashAndCashEquivalentsTables", "longName": "9960719 - Disclosure - CASH AND CASH EQUIVALENTS (Tables)", "shortName": "CASH AND CASH EQUIVALENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "60", "firstAnchor": { "contextRef": "D20251231_3", "name": "trib:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "trib:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R61": { "role": "http://trinitybiotech.com/role/CapitalAndReservesTables", "longName": "9960720 - Disclosure - CAPITAL AND RESERVES (Tables)", "shortName": "CAPITAL AND RESERVES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "61", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R62": { "role": "http://trinitybiotech.com/role/ShareOptionsTables", "longName": "9960721 - Disclosure - SHARE OPTIONS (Tables)", "shortName": "SHARE OPTIONS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "62", "firstAnchor": { "contextRef": "D20251231_3", "name": "trib:DisclosureOfDetailedInformationAboutShareOptionsAndWarrantsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "trib:DisclosureOfDetailedInformationAboutShareOptionsAndWarrantsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R63": { "role": "http://trinitybiotech.com/role/TradeAndOtherPayablesTables", "longName": "9960722 - Disclosure - TRADE AND OTHER PAYABLES (Tables)", "shortName": "TRADE AND OTHER PAYABLES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "63", "firstAnchor": { "contextRef": "D20251231_3", "name": "trib:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "trib:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R64": { "role": "http://trinitybiotech.com/role/ProvisionsTables", "longName": "9960723 - Disclosure - PROVISIONS (Tables)", "shortName": "PROVISIONS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "64", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfOtherProvisionsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfProvisionsExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfOtherProvisionsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfProvisionsExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R65": { "role": "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSTables", "longName": "9960724 - Disclosure - INTEREST-BEARING LOANS AND BORROWINGS (Tables)", "shortName": "INTEREST-BEARING LOANS AND BORROWINGS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "65", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfBorrowingsExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfBorrowingsExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R66": { "role": "http://trinitybiotech.com/role/LeaseLiabilitiesTables", "longName": "9960725 - Disclosure - LEASE LIABILITIES (Tables)", "shortName": "LEASE LIABILITIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "66", "firstAnchor": { "contextRef": "D20251231_3", "name": "trib:DisclosureOfDetailedInformationAboutCarryingValuesOfFinanceLeaseLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "trib:DisclosureOfDetailedInformationAboutCarryingValuesOfFinanceLeaseLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R67": { "role": "http://trinitybiotech.com/role/RelatedPartyTransactionsTables", "longName": "9960726 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)", "shortName": "RELATED PARTY TRANSACTIONS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "67", "firstAnchor": { "contextRef": "D20251231_3", "name": "trib:DisclosureOfDetailedInformationAboutCompensationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "trib:DisclosureOfDetailedInformationAboutCompensationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R68": { "role": "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementTables", "longName": "9960727 - Disclosure - CAPITAL AND FINANCIAL RISK MANAGEMENT (Tables)", "shortName": "CAPITAL AND FINANCIAL RISK MANAGEMENT (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "68", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfFairValueMeasurementOfAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfFairValueMeasurementOfAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R69": { "role": "http://trinitybiotech.com/role/ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTables", "longName": "9960728 - Disclosure - RECONCILIATION OF LIABILITIES ARISING FROM FINANCING ACTIVITIES (Tables)", "shortName": "RECONCILIATION OF LIABILITIES ARISING FROM FINANCING ACTIVITIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "69", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfCashFlowStatementExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfCashFlowStatementExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R70": { "role": "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSTables", "longName": "9960729 - Disclosure - BUSINESS COMBINATIONS (Tables)", "shortName": "BUSINESS COMBINATIONS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "70", "firstAnchor": { "contextRef": "D20251231_WaveformTechnologiesIncorporationMember", "name": "ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfBusinessCombinationsExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_WaveformTechnologiesIncorporationMember", "name": "ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfBusinessCombinationsExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R71": { "role": "http://trinitybiotech.com/role/GROUPUNDERTAKINGSTables", "longName": "9960730 - Disclosure - GROUP UNDERTAKINGS (Tables)", "shortName": "GROUP UNDERTAKINGS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "71", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "trib:DisclosureOfGroupUndertakingsExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "trib:DisclosureOfGroupUndertakingsExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R72": { "role": "http://trinitybiotech.com/role/BASISOFPREPARATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "longName": "9960731 - Disclosure - BASIS OF PREPARATION AND SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)", "shortName": "BASIS OF PREPARATION AND SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:ProfitLossAttributableToOwnersOfParent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "td", "tr", "tbody", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "I20251231", "name": "ifrs-full:CurrentAssetsLiabilities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "ifrs-full:DisclosureOfAdditionalInformationAboutUnderstandingFinancialPositionsAndLiquidityOfEntityExplanatory", "div", "trib:DisclosureOfBasisOfPreparationAndSignificantAccountingPoliciesExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R73": { "role": "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesScheduleOfOwnedAssetsDetails", "longName": "9960732 - Disclosure - BASIS OF PREPARATION AND SIGNIFICANT ACCOUNTING POLICIES (Schedule of owned assets) (Details)", "shortName": "BASIS OF PREPARATION AND SIGNIFICANT ACCOUNTING POLICIES (Schedule of owned assets) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "D20251231_LeaseholdImprovementsMember_BottomOfRangeMember", "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfOwnedAssetsExplanatory", "div", "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_LeaseholdImprovementsMember_BottomOfRangeMember", "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfOwnedAssetsExplanatory", "div", "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R74": { "role": "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesScheduleOfAmortisationDetails", "longName": "9960733 - Disclosure - BASIS OF PREPARATION AND SIGNIFICANT ACCOUNTING POLICIES (Schedule of amortisation) (Details)", "shortName": "BASIS OF PREPARATION AND SIGNIFICANT ACCOUNTING POLICIES (Schedule of amortisation) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "D20251231_CapitalisedDevelopmentExpenditureMember", "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfIntangibleAssetsExplanatory", "div", "ix:continuation", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "D20251231_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember_BottomOfRangeMember", "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfIntangibleAssetsExplanatory", "div", "ix:continuation", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R75": { "role": "http://trinitybiotech.com/role/SEGMENTINFORMATIONNarrativeDetails", "longName": "9960734 - Disclosure - SEGMENT INFORMATION (Narrative) (Details)", "shortName": "SEGMENT INFORMATION (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "D20251231_3", "name": "trib:CapitalisedDevelopmentCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "trib:CapitalisedDevelopmentCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R76": { "role": "http://trinitybiotech.com/role/SegmentInformationScheduleOfRevenueByGeographicalAreaBasedOnLocationOfAssetsDetails", "longName": "9960735 - Disclosure - SEGMENT INFORMATION (Schedule of Revenue by Geographical Area Based on Location of Assets) (Details)", "shortName": "SEGMENT INFORMATION (Schedule of Revenue by Geographical Area Based on Location of Assets) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:RevenueFromContractsWithCustomers", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "div", "ifrs-full:DisclosureOfSegmentsMajorCustomersExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:OtherRevenue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "div", "ifrs-full:DisclosureOfGeographicalAreasExplanatory", "div", "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R77": { "role": "http://trinitybiotech.com/role/SegmentInformationScheduleOfRevenueByCustomersGeographicalAreaDetails", "longName": "9960736 - Disclosure - SEGMENT INFORMATION (Schedule of Revenue by Customers Geographical Area) (Details)", "shortName": "SEGMENT INFORMATION (Schedule of Revenue by Customers Geographical Area) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:RevenueFromContractsWithCustomers", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "div", "ifrs-full:DisclosureOfSegmentsMajorCustomersExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "D20251231_AmericaMember", "name": "ifrs-full:RevenueFromContractsWithCustomers", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "div", "ifrs-full:DisclosureOfSegmentsMajorCustomersExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R78": { "role": "http://trinitybiotech.com/role/SegmentInformationScheduleOfRevenueByMajorProductGroupDetails", "longName": "9960737 - Disclosure - SEGMENT INFORMATION (Schedule of Revenue by Major Product Group) (Details)", "shortName": "SEGMENT INFORMATION (Schedule of Revenue by Major Product Group) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:Revenue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutAmountRelatingFromRevenueExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "D20251231_ClinicalLaboratoryMember", "name": "ifrs-full:Revenue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "ifrs-full:DisclosureOfProductsAndServicesExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R79": { "role": "http://trinitybiotech.com/role/SegmentInformationScheduleOfAmountRelatingFromRevenueDetails", "longName": "9960738 - Disclosure - SEGMENT INFORMATION (Schedule of Amount Relating From Revenue) (Details)", "shortName": "SEGMENT INFORMATION (Schedule of Amount Relating From Revenue) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:RevenueFromContractsWithCustomers", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "div", "ifrs-full:DisclosureOfSegmentsMajorCustomersExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": null }, "R80": { "role": "http://trinitybiotech.com/role/SegmentInformationScheduleOfRevenueDerivesFromTransferOfGoodsAndServicesDetails", "longName": "9960739 - Disclosure - SEGMENT INFORMATION (Schedule of Revenue Derives From Transfer of Goods and Services) (Details)", "shortName": "SEGMENT INFORMATION (Schedule of Revenue Derives From Transfer of Goods and Services) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "I20251231", "name": "ifrs-full:CurrentReceivablesFromContractsWithCustomers", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "div", "trib:DisclosureOfDetailedInformationAboutRevenueDerivesFromTransferOfGoodsAndServicesExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "I20251231", "name": "ifrs-full:CurrentReceivablesFromContractsWithCustomers", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "div", "trib:DisclosureOfDetailedInformationAboutRevenueDerivesFromTransferOfGoodsAndServicesExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R81": { "role": "http://trinitybiotech.com/role/SegmentInformationScheduleOfSegmentResultsByGeographicalAreaDetails", "longName": "9960740 - Disclosure - SEGMENT INFORMATION (Schedule of Segment Results by Geographical Area) (Details)", "shortName": "SEGMENT INFORMATION (Schedule of Segment Results by Geographical Area) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "D20251231_3", "name": "trib:ResultBeforeExceptionalExpenses", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "td", "tr", "tbody", "table", "div", "ifrs-full:DisclosureOfOperatingSegmentsExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "trib:ResultBeforeExceptionalExpenses", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "td", "tr", "tbody", "table", "div", "ifrs-full:DisclosureOfOperatingSegmentsExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R82": { "role": "http://trinitybiotech.com/role/SegmentInformationScheduleOfSegmentAssetsAndSegmentLiabilitiesByGeographicalAreaDetails", "longName": "9960741 - Disclosure - SEGMENT INFORMATION (Schedule of Segment Assets and Segment Liabilities by Geographical Area) (Details)", "shortName": "SEGMENT INFORMATION (Schedule of Segment Assets and Segment Liabilities by Geographical Area) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "I20251231", "name": "trib:SegmentAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "div", "trib:DisclosureOfDetailedInformationAboutSegmentAssetsAndSegmentLiabilitiesByGeographicalAreaExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "I20251231", "name": "trib:SegmentAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "div", "trib:DisclosureOfDetailedInformationAboutSegmentAssetsAndSegmentLiabilitiesByGeographicalAreaExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R83": { "role": "http://trinitybiotech.com/role/SegmentInformationScheduleOfLongLivedAssetsDetails", "longName": "9960742 - Disclosure - SEGMENT INFORMATION (Schedule of Long Lived Assets) (Details)", "shortName": "SEGMENT INFORMATION (Schedule of Long Lived Assets) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "I20251231", "name": "trib:LongLivedAsstesBySegment", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutLongLivedAssetsExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "I20251231", "name": "trib:LongLivedAsstesBySegment", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutLongLivedAssetsExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R84": { "role": "http://trinitybiotech.com/role/SegmentInformationScheduleOfDepreciationAndAmortisationByGeographicalAreaDetails", "longName": "9960743 - Disclosure - SEGMENT INFORMATION (Schedule of Depreciation and Amortisation by Geographical Area) (Details)", "shortName": "SEGMENT INFORMATION (Schedule of Depreciation and Amortisation by Geographical Area) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DepreciationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutDepreciationAndAmortisationExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DepreciationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutDepreciationAndAmortisationExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R85": { "role": "http://trinitybiotech.com/role/SegmentInformationScheduleOfShareBasedPaymentExpenseByGeographicalAreaDetails", "longName": "9960744 - Disclosure - SEGMENT INFORMATION (Schedule of Share Based Payment Expense by Geographical Area) (Details)", "shortName": "SEGMENT INFORMATION (Schedule of Share Based Payment Expense by Geographical Area) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "85", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:AdjustmentsForSharebasedPayments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "D20251231_IE", "name": "ifrs-full:AdjustmentsForSharebasedPayments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:ScheduleOfShareBasedPaymentExpenseByGeographicalArea", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R86": { "role": "http://trinitybiotech.com/role/SegmentInformationScheduleOfTaxationExpenseByGeographicalAreaDetails", "longName": "9960745 - Disclosure - SEGMENT INFORMATION (Schedule of Taxation Expense by Geographical Area) (Details)", "shortName": "SEGMENT INFORMATION (Schedule of Taxation Expense by Geographical Area) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "86", "firstAnchor": { "contextRef": "D20251231_3", "name": "trib:IncomeTaxExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutTaxationExpenseExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "trib:IncomeTaxExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutTaxationExpenseExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R87": { "role": "http://trinitybiotech.com/role/SegmentInformationScheduleOfCapitalExpenditureByGeographicalAreaDetails", "longName": "9960746 - Disclosure - SEGMENT INFORMATION (Schedule of Capital Expenditure by Geographical Area) (Details)", "shortName": "SEGMENT INFORMATION (Schedule of Capital Expenditure by Geographical Area) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "87", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:PaymentsForDevelopmentProjectExpenditure", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutCapitalExpenditureExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:PaymentsForDevelopmentProjectExpenditure", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutCapitalExpenditureExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R88": { "role": "http://trinitybiotech.com/role/EmploymentNarrativeDetails", "longName": "9960747 - Disclosure - EMPLOYMENT (Narrative) (Details)", "shortName": "EMPLOYMENT (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "88", "firstAnchor": { "contextRef": "D20251231_3", "name": "trib:AverageNumberOfEmployeesIncludingDiscontinuedOperations", "unitRef": "EMPLOYEE", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "trib:AverageNumberOfEmployeesIncludingDiscontinuedOperations", "unitRef": "EMPLOYEE", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R89": { "role": "http://trinitybiotech.com/role/EmploymentScheduleOfAverageNumberOfPersonsEmployedDetails", "longName": "9960748 - Disclosure - EMPLOYMENT (Schedule of Average Number of Persons Employed) (Details)", "shortName": "EMPLOYMENT (Schedule of Average Number of Persons Employed) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "89", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:AverageNumberOfEmployees", "unitRef": "EMPLOYEE", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "ifrs-full:DisclosureOfAdditionalInformationAboutDefinedBenefitPlansExplanatory", "div", "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:AverageNumberOfEmployees", "unitRef": "EMPLOYEE", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "ifrs-full:DisclosureOfAdditionalInformationAboutDefinedBenefitPlansExplanatory", "div", "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R90": { "role": "http://trinitybiotech.com/role/EmploymentScheduleOfEmploymentCostsDetails", "longName": "9960749 - Disclosure - EMPLOYMENT (Schedule of Employment Costs) (Details)", "shortName": "EMPLOYMENT (Schedule of Employment Costs) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "90", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:WagesAndSalaries", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory", "div", "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:WagesAndSalaries", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory", "div", "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R91": { "role": "http://trinitybiotech.com/role/OTHEROPERATINGINCOMEEXPENSENarrativeDetails", "longName": "9960750 - Disclosure - OTHER OPERATING INCOME / (EXPENSE) (Narrative) (Details)", "shortName": "OTHER OPERATING INCOME / (EXPENSE) (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "91", "firstAnchor": { "contextRef": "I20251231", "name": "ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory", "div", "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "I20251231_ContinuousGlucoseMonitoringTechnologyMember_1", "name": "ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "span", "span", "p", "trib:DisclosureOfOtherOperatingIncomeExpenseTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R92": { "role": "http://trinitybiotech.com/role/OTHEROPERATINGINCOMEEXPENSEScheduleofOtherOperatingIncomeDetails", "longName": "9960751 - Disclosure - OTHER OPERATING INCOME / (EXPENSE) (Schedule of Other Operating Income) (Details)", "shortName": "OTHER OPERATING INCOME / (EXPENSE) (Schedule of Other Operating Income) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "92", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:OtherIncome", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory", "div", "trib:DisclosureOfOtherOperatingIncomeExpenseTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:OtherIncome", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory", "div", "trib:DisclosureOfOtherOperatingIncomeExpenseTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R93": { "role": "http://trinitybiotech.com/role/IMPAIRMENTTRANSFORMATIONANDONCEOFFCOSTSNarrativeDetails", "longName": "9960752 - Disclosure - IMPAIRMENT, TRANSFORMATION AND ONCE OFF COSTS (Narrative) (Details)", "shortName": "IMPAIRMENT, TRANSFORMATION AND ONCE OFF COSTS (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "93", "firstAnchor": { "contextRef": "D20251231_3", "name": "trib:NonTradingCosts", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "trib:NonTradingCosts", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R94": { "role": "http://trinitybiotech.com/role/IMPAIRMENTTRANSFORMATIONANDONCEOFFCOSTSScheduleoftransformationcostsincurredduringtheyearDetails", "longName": "9960753 - Disclosure - IMPAIRMENT, TRANSFORMATION AND ONCE OFF COSTS (Schedule of transformation costs incurred during the year) (Details)", "shortName": "IMPAIRMENT, TRANSFORMATION AND ONCE OFF COSTS (Schedule of transformation costs incurred during the year) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "94", "firstAnchor": { "contextRef": "D20251231_3", "name": "trib:SellingGeneralAndAdministrativeExpensesTransformationCosts", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "td", "tr", "tbody", "table", "div", "ifrs-full:DisclosureOfOperatingSegmentsExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "D20251231_PersonnelRelatedCostsMember", "name": "trib:SellingGeneralAndAdministrativeExpensesTransformationCosts", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "ifrs-full:DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory", "div", "ifrs-full:DisclosureOfImpairmentOfAssetsExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R95": { "role": "http://trinitybiotech.com/role/IMPAIRMENTTRANSFORMATIONANDONCEOFFCOSTSScheduleofStatementofOperationDetails", "longName": "9960754 - Disclosure - IMPAIRMENT, TRANSFORMATION AND ONCE OFF COSTS (Schedule of Statement of Operation) (Details)", "shortName": "IMPAIRMENT, TRANSFORMATION AND ONCE OFF COSTS (Schedule of Statement of Operation) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "95", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:WritedownsReversalsOfPropertyPlantAndEquipment", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": null }, "R96": { "role": "http://trinitybiotech.com/role/FinancialIncomeAndExpensesScheduleOfFinancialIncomeExpensesNetDetails", "longName": "9960755 - Disclosure - FINANCIAL INCOME AND EXPENSES (Schedule of Financial Income (Expenses), Net) (Details)", "shortName": "FINANCIAL INCOME AND EXPENSES (Schedule of Financial Income (Expenses), Net) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "96", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:InterestIncomeOnOtherFinancialAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutFinancialIncomeAndExpensesExplanatory", "div", "ifrs-full:DisclosureOfFinanceIncomeExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:InterestIncomeOnOtherFinancialAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutFinancialIncomeAndExpensesExplanatory", "div", "ifrs-full:DisclosureOfFinanceIncomeExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R97": { "role": "http://trinitybiotech.com/role/IncomeTaxCreditNarrativeDetails", "longName": "9960756 - Disclosure - INCOME TAX (EXPENSE)/CREDIT (Narrative) (Details)", "shortName": "INCOME TAX (EXPENSE)/CREDIT (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "97", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DeferredTaxExpenseIncome", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "td", "tr", "tbody", "table", "div", "trib:DisclosureOfDetailedInformationAboutChargeForTaxExplanatory", "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "D20251231_IE", "name": "ifrs-full:DeferredTaxExpenseIncome", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "span", "link:footnote", "p", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutChargeForTaxExplanatory", "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R98": { "role": "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfChargeForTaxDetails", "longName": "9960757 - Disclosure - INCOME TAX (EXPENSE)/CREDIT (Schedule of Charge for Tax) (Details)", "shortName": "INCOME TAX (EXPENSE)/CREDIT (Schedule of Charge for Tax) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "98", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:CurrentTaxExpenseIncome", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "td", "tr", "tbody", "table", "div", "trib:DisclosureOfDetailedInformationAboutChargeForTaxExplanatory", "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:CurrentTaxExpenseIncome", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "td", "tr", "tbody", "table", "div", "trib:DisclosureOfDetailedInformationAboutChargeForTaxExplanatory", "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R99": { "role": "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfOverseasTaxJurisdictionsDetails", "longName": "9960758 - Disclosure - INCOME TAX (EXPENSE)/CREDIT (Schedule of Overseas Tax Jurisdictions) (Details)", "shortName": "INCOME TAX (EXPENSE)/CREDIT (Schedule of Overseas Tax Jurisdictions) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "99", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:ProfitLossBeforeTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutOverseasTaxJurisdictionsExplanatory", "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "trib:TaxRateEffectOfCurrentTaxOfPriorPeriods", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "span", "span", "p", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutOverseasTaxJurisdictionsExplanatory", "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R100": { "role": "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfStatutoryTaxRateDetails", "longName": "9960759 - Disclosure - INCOME TAX (EXPENSE)/CREDIT (Schedule of Statutory Tax Rate) (Details)", "shortName": "INCOME TAX (EXPENSE)/CREDIT (Schedule of Statutory Tax Rate) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "100", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:ApplicableTaxRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "span", "span", "p", "td", "tr", "tbody", "table", "div", "trib:DisclosureOfDetailedInformationAboutStatutoryTaxRateExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:ApplicableTaxRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "span", "span", "p", "td", "tr", "tbody", "table", "div", "trib:DisclosureOfDetailedInformationAboutStatutoryTaxRateExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R101": { "role": "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfLossProfitBeforeTaxesDetails", "longName": "9960760 - Disclosure - INCOME TAX (EXPENSE)/CREDIT (Schedule of Loss Profit Before Taxes) (Details)", "shortName": "INCOME TAX (EXPENSE)/CREDIT (Schedule of Loss Profit Before Taxes) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "101", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:ProfitLossBeforeTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutOverseasTaxJurisdictionsExplanatory", "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "D20251231_OtherRegionsMember", "name": "ifrs-full:ProfitLossBeforeTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "td", "tr", "tbody", "table", "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R102": { "role": "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfNetOperatingLossesDetails", "longName": "9960761 - Disclosure - INCOME TAX (EXPENSE)/CREDIT (Schedule of Net Operating Losses) (Details)", "shortName": "INCOME TAX (EXPENSE)/CREDIT (Schedule of Net Operating Losses) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "102", "firstAnchor": { "contextRef": "D20251231_3", "name": "trib:UnutilisedNetOperatingLosses", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutLossProfitBeforeTaxesExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "trib:UnutilisedNetOperatingLosses", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutLossProfitBeforeTaxesExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R103": { "role": "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfUnrecognisedDeferredTaxAssetsDetails", "longName": "9960762 - Disclosure - INCOME TAX (EXPENSE)/CREDIT (Schedule of Unrecognised Deferred Tax Assets) (Details)", "shortName": "INCOME TAX (EXPENSE)/CREDIT (Schedule of Unrecognised Deferred Tax Assets) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "103", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:IncreaseDecreaseInDeferredTaxLiabilityAsset", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutUnusedTaxLossesAndUnusedTaxCreditsExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:IncreaseDecreaseInDeferredTaxLiabilityAsset", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutUnusedTaxLossesAndUnusedTaxCreditsExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R104": { "role": "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSNarrativeDetails", "longName": "9960763 - Disclosure - (LOSS)/PROFIT FOR THE YEAR ON DISCONTINUED OPERATIONS (Narrative) (Details)", "shortName": "(LOSS)/PROFIT FOR THE YEAR ON DISCONTINUED OPERATIONS (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "104", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:ProfitLossFromDiscontinuedOperations", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "ifrs-full:DisclosureOfDiscontinuedOperationsExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "I20241231_BiosynthMember", "name": "ifrs-full:CurrentProvisions", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "span", "span", "p", "ifrs-full:DisclosureOfDiscontinuedOperationsExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R105": { "role": "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSDetails", "longName": "9960764 - Disclosure - (LOSS)/PROFIT FOR THE YEAR ON DISCONTINUED OPERATIONS (Schedule of operating profit for the discontinued operations) (Details)", "shortName": "(LOSS)/PROFIT FOR THE YEAR ON DISCONTINUED OPERATIONS (Schedule of operating profit for the discontinued operations) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "105", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:Revenue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutAmountRelatingFromRevenueExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "D20251231_FiomiDiagnosticsMember_SE", "name": "ifrs-full:Revenue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfOperatingProfitForTheDiscontinuedOperationsTableTextBlock", "div", "ifrs-full:DisclosureOfDiscontinuedOperationsExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R106": { "role": "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSDetails1", "longName": "9960765 - Disclosure - (LOSS)/PROFIT FOR THE YEAR ON DISCONTINUED OPERATIONS (Schedule of net cashflows generated from discontinued operations) (Details)", "shortName": "(LOSS)/PROFIT FOR THE YEAR ON DISCONTINUED OPERATIONS (Schedule of net cashflows generated from discontinued operations) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "106", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "D20251231_FiomiDiagnosticsMember_SE", "name": "trib:CashReceivedFromSaleOfTheDiscontinuedOperationsNetOfTransactionCosts", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfNetCashflowsGeneratedDiscontinuedOperationsExplanatory", "div", "ifrs-full:DisclosureOfDiscontinuedOperationsExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R107": { "role": "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONDetail5", "longName": "9960766 - Disclosure - (LOSS)/PROFIT FOR THE YEAR ON DISCONTINUED OPERATIONS (Schedule of assets and liabilities disposed) (Detail)", "shortName": "(LOSS)/PROFIT FOR THE YEAR ON DISCONTINUED OPERATIONS (Schedule of assets and liabilities disposed) (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "107", "firstAnchor": { "contextRef": "I20251231", "name": "ifrs-full:PropertyPlantAndEquipment", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "I20241231_DiscontinuedOperationsMember_FiomiDiagnosticsMember_SE_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember_BiosynthMember", "name": "ifrs-full:PropertyPlantAndEquipment", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfAssetsAndLiabilitiesDisposedExplanatory", "div", "ifrs-full:DisclosureOfDiscontinuedOperationsExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R108": { "role": "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSDetails2", "longName": "9960767 - Disclosure - (LOSS)/PROFIT FOR THE YEAR ON DISCONTINUED OPERATIONS (Schedule of Earnings Per ADS for Discontinued Operations) (Details)", "shortName": "(LOSS)/PROFIT FOR THE YEAR ON DISCONTINUED OPERATIONS (Schedule of Earnings Per ADS for Discontinued Operations) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "108", "firstAnchor": { "contextRef": "D20251231_ClassAOrdinarySharesMember", "name": "ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutEarningsPerAdsForDiscontinuedOperationsExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_ClassAOrdinarySharesMember", "name": "ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutEarningsPerAdsForDiscontinuedOperationsExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R109": { "role": "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSDetails3", "longName": "9960768 - Disclosure - (LOSS)/PROFIT FOR THE YEAR ON DISCONTINUED OPERATIONS (Schedule of Cash Flows Attributable to Discontinued Operations) (Details)", "shortName": "(LOSS)/PROFIT FOR THE YEAR ON DISCONTINUED OPERATIONS (Schedule of Cash Flows Attributable to Discontinued Operations) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "109", "firstAnchor": { "contextRef": "D20251231_FiomiDiagnosticsMember", "name": "ifrs-full:CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutCashFlowsAttributableToDiscontinuedOperationsExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_FiomiDiagnosticsMember", "name": "ifrs-full:CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutCashFlowsAttributableToDiscontinuedOperationsExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R110": { "role": "http://trinitybiotech.com/role/LossBeforeTaxNarrativeDetails", "longName": "9960769 - Disclosure - LOSS BEFORE TAX (Narrative) (Details)", "shortName": "LOSS BEFORE TAX (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "110", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DepreciationAndAmortisationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "span", "link:footnote", "p", "trib:DisclosureOfDetailedInformationAboutLossProfitBeforeTaxExplanatory", "div", "trib:DisclosureOfLossProfitBeforeTaxExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DepreciationAndAmortisationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "span", "link:footnote", "p", "trib:DisclosureOfDetailedInformationAboutLossProfitBeforeTaxExplanatory", "div", "trib:DisclosureOfLossProfitBeforeTaxExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R111": { "role": "http://trinitybiotech.com/role/LossBeforeTaxScheduleOfAmountChargedToStatementOfOperationDetails", "longName": "9960770 - Disclosure - LOSS BEFORE TAX (Schedule of Amount Charged to Statement of Operation) (Details)", "shortName": "LOSS BEFORE TAX (Schedule of Amount Charged to Statement of Operation) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "111", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DirectorsRemunerationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "div", "trib:DisclosureOfDetailedInformationAboutLossProfitBeforeTaxExplanatory", "div", "trib:DisclosureOfLossProfitBeforeTaxExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "trib:DirectorPensionExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "div", "trib:DisclosureOfDetailedInformationAboutLossProfitBeforeTaxExplanatory", "div", "trib:DisclosureOfLossProfitBeforeTaxExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R112": { "role": "http://trinitybiotech.com/role/LossPerShareNarrativeDetails", "longName": "9960771 - Disclosure - LOSS PER SHARE (Narrative) (Details)", "shortName": "LOSS PER SHARE (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "112", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:ProfitLossAttributableToOwnersOfParent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "td", "tr", "tbody", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "D20251231_ClassAOrdinarySharesMember", "name": "ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R113": { "role": "http://trinitybiotech.com/role/LossPerShareScheduleOfBasicEarningsPerOrdinaryShareDetails", "longName": "9960772 - Disclosure - LOSS PER SHARE (Schedule of Basic Earnings Per Ordinary Share) (Details)", "shortName": "LOSS PER SHARE (Schedule of Basic Earnings Per Ordinary Share) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "113", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:WeightedAverageShares", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "div", "trib:DisclosureOfDetailedInformationAboutBasicEarningsPerOrdinaryShareExplanatory", "div", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "I20251231_ClassAOrdinarySharesMember", "name": "trib:NumberOfAOrdinaryWeightedAverageShares", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "div", "trib:DisclosureOfDetailedInformationAboutBasicEarningsPerOrdinaryShareExplanatory", "div", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R114": { "role": "http://trinitybiotech.com/role/LossPerShareScheduleOfDilutedEarningsPerOrdinaryShareDetails", "longName": "9960773 - Disclosure - LOSS PER SHARE (Schedule of Diluted Earnings Per Ordinary Share) (Details)", "shortName": "LOSS PER SHARE (Schedule of Diluted Earnings Per Ordinary Share) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "114", "firstAnchor": { "contextRef": "D20251231_3", "name": "trib:IssuableOnExerciseOfOptions", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutDilutedEarningsPerOrdinaryShareExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": null }, "R115": { "role": "http://trinitybiotech.com/role/LossPerShareScheduleOfEarningsPerAdsDetails", "longName": "9960774 - Disclosure - LOSS PER SHARE (Schedule of Earnings Per ADS) (Details)", "shortName": "LOSS PER SHARE (Schedule of Earnings Per ADS) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "115", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:WeightedAverageShares", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "div", "trib:DisclosureOfDetailedInformationAboutBasicEarningsPerOrdinaryShareExplanatory", "div", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "I20251231_AmericanDepositaryShareMember", "name": "trib:AmericanDepositoryShares", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "div", "trib:DisclosureOfDetailedInformationAboutBasicEarningPerAdsExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R116": { "role": "http://trinitybiotech.com/role/LossPerShareScheduleOfDilutedEarningsPerAdsShareCalculationDetails", "longName": "9960775 - Disclosure - LOSS PER SHARE (Schedule of Diluted Earnings Per ADS Share Calculation) (Details)", "shortName": "LOSS PER SHARE (Schedule of Diluted Earnings Per ADS Share Calculation) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "116", "firstAnchor": { "contextRef": "D20251231_3", "name": "trib:IssuableOnExerciseOfOptions", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutDilutedEarningsPerOrdinaryShareExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "D20251231_AmericanDepositaryShareMember", "name": "trib:IssuableOnExerciseOfOptions", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutDilutedEarningPerAdsExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R117": { "role": "http://trinitybiotech.com/role/PropertyPlantAndEquipmentNarrativeDetails", "longName": "9960776 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Narrative) (Details)", "shortName": "PROPERTY, PLANT AND EQUIPMENT (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "117", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:AdditionsToRightofuseAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "span", "link:footnote", "p", "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:AdditionsToRightofuseAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "span", "link:footnote", "p", "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R118": { "role": "http://trinitybiotech.com/role/PropertyPlantAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentRelatedToAccumulatedDepreciationDetails", "longName": "9960777 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Schedule of Composition of Property and Equipment Related to Accumulated Depreciation) (Details)", "shortName": "PROPERTY, PLANT AND EQUIPMENT (Schedule of Composition of Property and Equipment Related to Accumulated Depreciation) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "118", "firstAnchor": { "contextRef": "I20241231", "name": "ifrs-full:PropertyPlantAndEquipment", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "I20231231_GrossCarryingAmountMember", "name": "ifrs-full:PropertyPlantAndEquipment", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "div", "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R119": { "role": "http://trinitybiotech.com/role/PropertyPlantAndEquipmentScheduleOfAdditionalInformationOnRight-of-useAssetsDetails", "longName": "9960778 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Schedule of Additional Information on Right-of-use Assets) (Details)", "shortName": "PROPERTY, PLANT AND EQUIPMENT (Schedule of Additional Information on Right-of-use Assets) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "119", "firstAnchor": { "contextRef": "I20251231", "name": "trib:RightOfUseAssetsIncludingDepreciationAndImpairment", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "div", "trib:ScheduleOfAdditionalInformationOnRightOfUseAssets", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "I20251231", "name": "trib:RightOfUseAssetsIncludingDepreciationAndImpairment", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "div", "trib:ScheduleOfAdditionalInformationOnRightOfUseAssets", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R120": { "role": "http://trinitybiotech.com/role/PropertyPlantAndEquipmentScheduleOfIncomeFromSub-lettingRight-of-useBuildingsDetails", "longName": "9960779 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Schedule of Income from Sub-letting Right-of-use Buildings) (Details)", "shortName": "PROPERTY, PLANT AND EQUIPMENT (Schedule of Income from Sub-letting Right-of-use Buildings) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "120", "firstAnchor": { "contextRef": "I20251231_BuildingsMember", "name": "trib:NumberOfRightOfUseLeasedAssets", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "div", "trib:ScheduleOfIncomeFromSubLettingRightOfUseBuildings", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "I20251231_BuildingsMember", "name": "trib:NumberOfRightOfUseLeasedAssets", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "div", "trib:ScheduleOfIncomeFromSubLettingRightOfUseBuildings", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R121": { "role": "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsNarrativeDetails", "longName": "9960780 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Narrative) (Details)", "shortName": "GOODWILL AND INTANGIBLE ASSETS (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "121", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:PropertyDevelopmentAndProjectManagementExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:PropertyDevelopmentAndProjectManagementExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R122": { "role": "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfGoodwillAndIntangibleAssetsDetails", "longName": "9960781 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Schedule of Goodwill and Intangible Assets) (Details)", "shortName": "GOODWILL AND INTANGIBLE ASSETS (Schedule of Goodwill and Intangible Assets) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "122", "firstAnchor": { "contextRef": "I20241231", "name": "ifrs-full:IntangibleAssetsAndGoodwill", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "D20251231_GrossCarryingAmountMember", "name": "ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory", "div", "div", "ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R123": { "role": "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfPrincipalDevelopmentProjectsDetails", "longName": "9960782 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Schedule of Principal Development Projects) (Details)", "shortName": "GOODWILL AND INTANGIBLE ASSETS (Schedule of Principal Development Projects) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "123", "firstAnchor": { "contextRef": "D20251231_3", "name": "trib:PrincipalDevelopmentProjectsCapitalizedCosts", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "trib:PrincipalDevelopmentProjectsCapitalizedCosts", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R124": { "role": "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfImpairmentLossDetails", "longName": "9960783 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Schedule of Impairment Loss) (Details)", "shortName": "GOODWILL AND INTANGIBLE ASSETS (Schedule of Impairment Loss) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "124", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "td", "tr", "tbody", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "D20251231_ImmcoDiagnosticsIncMember_3", "name": "ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutImpairmentLossRecordedOnDiscontinuedAssetsExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R125": { "role": "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfBreakdownOfImpairmentLossDetailsUsd", "longName": "9960784 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Schedule of Breakdown of Impairment Loss) (Details) (USD $)", "shortName": "GOODWILL AND INTANGIBLE ASSETS (Schedule of Breakdown of Impairment Loss) (Details) (USD $)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "125", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutImpairmentChargesAndInventoryProvisioningExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "D20251231_IndividualAssetsOrCashgeneratingUnitsMember", "name": "ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "ifrs-full:DisclosureOfIntangibleAssetsMaterialToEntityExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R126": { "role": "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfSignificantGoodwillAndIntangibleAssetsDetails", "longName": "9960786 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Schedule of Significant Goodwill and Intangible Assets) (Details)", "shortName": "GOODWILL AND INTANGIBLE ASSETS (Schedule of Significant Goodwill and Intangible Assets) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "126", "firstAnchor": { "contextRef": "D20251231_3", "name": "trib:LongTermGrowthRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "span", "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "D20251231_WaveformTechnologiesIncMember", "name": "trib:CarryingAmountOfGoodwill", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "div", "ifrs-full:DisclosureOfGoodwillExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R127": { "role": "http://trinitybiotech.com/role/FINANCIALASSETSNarrativeDetails", "longName": "9960788 - Disclosure - FINANCIAL ASSETS (Narrative) (Details)", "shortName": "FINANCIAL ASSETS (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "127", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:AdjustmentsForImpairmentLossesReversalOfImpairmentLossesRecognisedInProfitOrLossFinancialAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "trib:RemeasurementLossRecognizedInProfitLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "div", "ifrs-full:DisclosureOfFinancialAssetsExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R128": { "role": "http://trinitybiotech.com/role/FINANCIALASSETSDetails", "longName": "9960789 - Disclosure - FINANCIAL ASSETS (Details)", "shortName": "FINANCIAL ASSETS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "128", "firstAnchor": { "contextRef": "I20241231", "name": "ifrs-full:FinancialAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutFinancialAssets", "div", "ifrs-full:DisclosureOfFinancialAssetsExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "I20231231", "name": "ifrs-full:FinancialAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutFinancialAssets", "div", "ifrs-full:DisclosureOfFinancialAssetsExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R129": { "role": "http://trinitybiotech.com/role/DeferredTaxAssetsAndLiabilitiesNarrativeDetails", "longName": "9960790 - Disclosure - DEFERRED TAX ASSETS AND LIABILITIES (Narrative) (Details)", "shortName": "DEFERRED TAX ASSETS AND LIABILITIES (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "129", "firstAnchor": { "contextRef": "D20251231_3", "name": "trib:DeferredTaxAssetIncreaseDueToIncreaseInProvision", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "ifrs-full:DisclosureOfDeferredTaxesExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "trib:DeferredTaxAssetIncreaseDueToIncreaseInProvision", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "ifrs-full:DisclosureOfDeferredTaxesExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R130": { "role": "http://trinitybiotech.com/role/DeferredTaxAssetsAndLiabilitiesScheduleOfRecognisedDeferredTaxAssetsAndLiabilitiesDetails", "longName": "9960791 - Disclosure - DEFERRED TAX ASSETS AND LIABILITIES (Schedule of Recognised Deferred Tax Assets and Liabilities) (Details)", "shortName": "DEFERRED TAX ASSETS AND LIABILITIES (Schedule of Recognised Deferred Tax Assets and Liabilities) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "130", "firstAnchor": { "contextRef": "I20251231", "name": "ifrs-full:DeferredTaxAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "I20251231_OtherPropertyPlantAndEquipmentMember", "name": "ifrs-full:DeferredTaxAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutDeferredTaxAssetsAndLiabilitiesExplanatory", "div", "ifrs-full:DisclosureOfDeferredTaxesExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R131": { "role": "http://trinitybiotech.com/role/DeferredTaxAssetsAndLiabilitiesScheduleOfUnrecognisedDeferredTaxLiabilitiesDetails", "longName": "9960792 - Disclosure - DEFERRED TAX ASSETS AND LIABILITIES (Schedule of Unrecognised Deferred Tax Liabilities) (Details)", "shortName": "DEFERRED TAX ASSETS AND LIABILITIES (Schedule of Unrecognised Deferred Tax Liabilities) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "131", "firstAnchor": { "contextRef": "I20241231", "name": "ifrs-full:DeferredTaxLiabilityAsset", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "td", "tr", "tbody", "table", "div", "trib:DisclosureOfDetailedInformationAboutUnrecognisedDeferredTaxLiabilitiesExplanatory", "div", "ifrs-full:DisclosureOfDeferredTaxesExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "div", "trib:DisclosureOfDetailedInformationAboutUnrecognisedDeferredTaxLiabilitiesExplanatory", "div", "ifrs-full:DisclosureOfDeferredTaxesExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R132": { "role": "http://trinitybiotech.com/role/DeferredTaxAssetsAndLiabilitiesScheduleOfUnrecognisedDeferredTaxAssetsDetails", "longName": "9960793 - Disclosure - DEFERRED TAX ASSETS AND LIABILITIES (Schedule of Unrecognised Deferred Tax Assets) (Details)", "shortName": "DEFERRED TAX ASSETS AND LIABILITIES (Schedule of Unrecognised Deferred Tax Assets) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "132", "firstAnchor": { "contextRef": "I20251231", "name": "trib:DeferredTaxAssetsCapitalLossCarryforward", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutUnrecognisedDeferredTaxAssetsExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "I20251231", "name": "trib:DeferredTaxAssetsCapitalLossCarryforward", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutUnrecognisedDeferredTaxAssetsExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R133": { "role": "http://trinitybiotech.com/role/OtherNon-currentAssetsDetails", "longName": "9960794 - Disclosure - OTHER NON-CURRENT ASSETS (Details)", "shortName": "OTHER NON-CURRENT ASSETS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "133", "firstAnchor": { "contextRef": "I20251231", "name": "ifrs-full:NoncurrentFinanceLeaseReceivables", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "I20251231", "name": "trib:OtherAssetNoncurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutOtherAssetsExplanatory", "div", "ifrs-full:DisclosureOfOtherAssetsExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R134": { "role": "http://trinitybiotech.com/role/InventoriesNarrativeDetails", "longName": "9960795 - Disclosure - INVENTORIES (Narrative) (Details)", "shortName": "INVENTORIES (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "134", "firstAnchor": { "contextRef": "I20251231", "name": "ifrs-full:InventoriesAtNetRealisableValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "ifrs-full:DisclosureOfInventoriesExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "ifrs-full:DisclosureOfInventoriesExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R135": { "role": "http://trinitybiotech.com/role/InventoriesScheduleOfInventoriesDetails", "longName": "9960796 - Disclosure - INVENTORIES (Schedule of inventories) (Details)", "shortName": "INVENTORIES (Schedule of inventories) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "135", "firstAnchor": { "contextRef": "I20251231", "name": "ifrs-full:CurrentRawMaterialsAndCurrentProductionSupplies", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutInventoriesExplanatory", "div", "ifrs-full:DisclosureOfInventoriesExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "I20251231", "name": "ifrs-full:CurrentRawMaterialsAndCurrentProductionSupplies", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutInventoriesExplanatory", "div", "ifrs-full:DisclosureOfInventoriesExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R136": { "role": "http://trinitybiotech.com/role/InventoriesScheduleOfMovementOnInventoryProvisionDetails", "longName": "9960797 - Disclosure - INVENTORIES (Schedule of Movement on the Inventory Provision) (Details)", "shortName": "INVENTORIES (Schedule of Movement on the Inventory Provision) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "136", "firstAnchor": { "contextRef": "I20241231", "name": "ifrs-full:OtherProvisions", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "ifrs-full:DisclosureOfOtherProvisionsExplanatory", "div", "ifrs-full:DisclosureOfProvisionsExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "I20221231_ProvisionForInventoriesMember", "name": "ifrs-full:OtherProvisions", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutMovementOnInventoryProvisionExplanatory", "div", "ifrs-full:DisclosureOfInventoriesExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R137": { "role": "http://trinitybiotech.com/role/TradeAndOtherReceivablesNarrativeDetails", "longName": "9960798 - Disclosure - TRADE AND OTHER RECEIVABLES (Narrative) (Details)", "shortName": "TRADE AND OTHER RECEIVABLES (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "137", "firstAnchor": { "contextRef": "I20251231", "name": "ifrs-full:TradeReceivables", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": null }, "R138": { "role": "http://trinitybiotech.com/role/TradeAndOtherReceivablesScheduleOfTradeAndOtherReceivablesDetails", "longName": "9960799 - Disclosure - TRADE AND OTHER RECEIVABLES (Schedule of Trade and Other Receivables) (Details)", "shortName": "TRADE AND OTHER RECEIVABLES (Schedule of Trade and Other Receivables) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "138", "firstAnchor": { "contextRef": "I20251231", "name": "ifrs-full:CurrentTradeReceivables", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatory", "div", "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "I20251231", "name": "ifrs-full:CurrentPrepayments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatory", "div", "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R139": { "role": "http://trinitybiotech.com/role/TradeAndOtherReceivablesScheduleOfFutureMinimumRentalsReceivableUnderNon-cancellableOperatingLeasesDetails", "longName": "9960801 - Disclosure - TRADE AND OTHER RECEIVABLES (Schedule of Future Minimum Rentals Receivable Under Non-Cancellable Operating Leases) (Details)", "shortName": "TRADE AND OTHER RECEIVABLES (Schedule of Future Minimum Rentals Receivable Under Non-Cancellable Operating Leases) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "139", "firstAnchor": { "contextRef": "I20251231_InstrumentsMember", "name": "ifrs-full:UndiscountedOperatingLeasePaymentsToBeReceived", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "ifrs-full:DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableExplanatory", "div", "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "I20251231_InstrumentsMember", "name": "ifrs-full:UndiscountedOperatingLeasePaymentsToBeReceived", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "ifrs-full:DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableExplanatory", "div", "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R140": { "role": "http://trinitybiotech.com/role/CashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails", "longName": "9960802 - Disclosure - CASH AND CASH EQUIVALENTS (Schedule of Cash and Cash Equivalents) (Details)", "shortName": "CASH AND CASH EQUIVALENTS (Schedule of Cash and Cash Equivalents) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "140", "firstAnchor": { "contextRef": "I20251231", "name": "ifrs-full:Cash", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory", "div", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": null }, "R141": { "role": "http://trinitybiotech.com/role/CapitalAndReservesNarrativeDetails", "longName": "9960803 - Disclosure - CAPITAL AND RESERVES (Narrative) (Details)", "shortName": "CAPITAL AND RESERVES (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "141", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "I20251231", "name": "ifrs-full:ReserveOfCashFlowHedges", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R142": { "role": "http://trinitybiotech.com/role/CapitalAndReservesScheduleOfShareCapitalDetails", "longName": "9960804 - Disclosure - CAPITAL AND RESERVES (Schedule of Share Capital) (Details)", "shortName": "CAPITAL AND RESERVES (Schedule of Share Capital) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "142", "firstAnchor": { "contextRef": "I20241231", "name": "ifrs-full:TreasuryShares", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "td", "tr", "tbody", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "D20251231_ClassAOrdinarySharesMember", "name": "trib:IssuedForNoncashConsideration", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "div", "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R143": { "role": "http://trinitybiotech.com/role/ShareOptionsNarrativeDetails", "longName": "9960805 - Disclosure - SHARE OPTIONS (Narrative) (Details)", "shortName": "SHARE OPTIONS (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "143", "firstAnchor": { "contextRef": "I20251231", "name": "ifrs-full:NumberOfOutstandingShareOptions", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "trib:DisclosureOfShareOptionsAndShareWarrantsExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "trib:ShareBasedPaymentsContinuingOperations", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R144": { "role": "http://trinitybiotech.com/role/ShareOptionsScheduleOfGrantsOfShareOptionsAndWarrantsDetails", "longName": "9960806 - Disclosure - SHARE OPTIONS (Schedule of Grants of Share Options and Warrants) (Details)", "shortName": "SHARE OPTIONS (Schedule of Grants of Share Options and Warrants) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "144", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "D20251231_ClassAOrdinarySharesMember", "name": "ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutShareOptionsAndWarrantsExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R145": { "role": "http://trinitybiotech.com/role/ShareOptionsSummaryOfRangeOfPricesOfStockOptionsDetails", "longName": "9960807 - Disclosure - SHARE OPTIONS (Summary of Range of Prices of Stock Options) (Details)", "shortName": "SHARE OPTIONS (Summary of Range of Prices of Stock Options) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "145", "firstAnchor": { "contextRef": "I20251231", "name": "ifrs-full:NumberOfOutstandingShareOptions", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "trib:DisclosureOfShareOptionsAndShareWarrantsExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "I20251231_ClassAOrdinarySharesMember", "name": "trib:NumberOfShareOptionsExercisableShareBasedPayment", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "div", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R146": { "role": "http://trinitybiotech.com/role/ShareOptionsScheduleOfAssumptionDeterminingFairValueOfShareOptionsDetails", "longName": "9960809 - Disclosure - SHARE OPTIONS (Schedule of Assumption Determining Fair Value of Share Options) (Details)", "shortName": "SHARE OPTIONS (Schedule of Assumption Determining Fair Value of Share Options) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "146", "firstAnchor": { "contextRef": "I20251231_KeyManagementPersonnelOfEntityOrParentMember", "name": "ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "I20251231_KeyManagementPersonnelOfEntityOrParentMember", "name": "ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R147": { "role": "http://trinitybiotech.com/role/TRADEANDOTHERPAYABLESNarrativesDetails", "longName": "99608091 - Disclosure - TRADE AND OTHER PAYABLES - Narratives (Details)", "shortName": "TRADE AND OTHER PAYABLES - Narratives (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "147", "firstAnchor": { "contextRef": "I20251231", "name": "trib:AccruedLiabilitiesToContractedLicencePayments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "I20251231", "name": "trib:AccruedLiabilitiesToContractedLicencePayments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R148": { "role": "http://trinitybiotech.com/role/TradeAndOtherPayablesScheduleOfTradeAndOtherPayablesDetails", "longName": "9960810 - Disclosure - TRADE AND OTHER PAYABLES (Schedule of Trade and Other Payables) (Details)", "shortName": "TRADE AND OTHER PAYABLES (Schedule of Trade and Other Payables) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "148", "firstAnchor": { "contextRef": "I20251231", "name": "ifrs-full:TradeAndOtherCurrentPayables", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory", "div", "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "I20251231", "name": "ifrs-full:CurrentValueAddedTaxPayables", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory", "div", "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R149": { "role": "http://trinitybiotech.com/role/ProvisionsNarrativeDetails", "longName": "9960811 - Disclosure - PROVISIONS (Narrative) (Details)", "shortName": "PROVISIONS (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "149", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "ifrs-full:DisclosureOfProvisionsExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "ifrs-full:DisclosureOfProvisionsExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R150": { "role": "http://trinitybiotech.com/role/ProvisionsScheduleOfProvisionsDetails", "longName": "9960812 - Disclosure - PROVISIONS (Schedule of Provisions) (Details)", "shortName": "PROVISIONS (Schedule of Provisions) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "150", "firstAnchor": { "contextRef": "I20251231", "name": "ifrs-full:WarrantyProvision", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "ifrs-full:DisclosureOfOtherProvisionsExplanatory", "div", "ifrs-full:DisclosureOfProvisionsExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "I20251231", "name": "ifrs-full:WarrantyProvision", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "ifrs-full:DisclosureOfOtherProvisionsExplanatory", "div", "ifrs-full:DisclosureOfProvisionsExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R151": { "role": "http://trinitybiotech.com/role/PROVISIONSScheduleofreconciliationofchangesinprovisionsDetails", "longName": "99608125 - Disclosure - PROVISIONS - Schedule of reconciliation of changes in provisions (Details)", "shortName": "PROVISIONS - Schedule of reconciliation of changes in provisions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "151", "firstAnchor": { "contextRef": "I20241231", "name": "ifrs-full:Provisions", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:ScheduleOfReconciliationOfChangesInProvisionsTableTextBlock", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": null }, "R152": { "role": "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails", "longName": "9960813 - Disclosure - INTEREST-BEARING LOANS AND BORROWINGS (Narrative) (Details)", "shortName": "INTEREST-BEARING LOANS AND BORROWINGS (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "152", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:ProceedsFromIssuingShares", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "I20251231", "name": "ifrs-full:DerivativeFinancialLiabilities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R153": { "role": "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails", "longName": "9960814 - Disclosure - INTEREST-BEARING LOANS AND BORROWINGS (Schedule of carrying value of interest-bearing loans, borrowings and related balances (Details)", "shortName": "INTEREST-BEARING LOANS AND BORROWINGS (Schedule of carrying value of interest-bearing loans, borrowings and related balances (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "153", "firstAnchor": { "contextRef": "I20251222_SeniorSecuredTermLoanMember", "name": "ifrs-full:Borrowings", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "I20251231_NonCurrentAssetsMember", "name": "ifrs-full:Borrowings", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "div", "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "div", "ifrs-full:DisclosureOfBorrowingsExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R154": { "role": "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails1", "longName": "9960815 - Disclosure - INTEREST-BEARING LOANS AND BORROWINGS (Schedule of movement in the Exchangeable Notes balance) (Details)", "shortName": "INTEREST-BEARING LOANS AND BORROWINGS (Schedule of movement in the Exchangeable Notes balance) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "154", "firstAnchor": { "contextRef": "D20220131_ExchangeableSeniorNotesMember", "name": "ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "ifrs-full:DisclosureOfBorrowingsExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": null }, "R155": { "role": "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSScheduleOfMovementInTermLoan", "longName": "9960816 - Disclosure - INTEREST-BEARING LOANS AND BORROWINGS (Schedule of movement in term loan) (Details)", "shortName": "INTEREST-BEARING LOANS AND BORROWINGS (Schedule of movement in term loan) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "155", "firstAnchor": { "contextRef": "D20251231_3", "name": "trib:PaymentInKindInterest", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutFinancialIncomeAndExpensesExplanatory", "div", "ifrs-full:DisclosureOfFinanceIncomeExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "D20251231_TermLoanMember_NonCurrentLiabilitiesMember", "name": "trib:LoanDrawdownUnderOldTermLoan", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "td", "tr", "tbody", "table", "trib:ScheduleOfMovementInTermLoanExplanatoryTableTextBlock", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R156": { "role": "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails4", "longName": "9960817 - Disclosure - INTEREST-BEARING LOANS AND BORROWINGS (Schedule of movement in the derivative financial asset) (Details)", "shortName": "INTEREST-BEARING LOANS AND BORROWINGS (Schedule of movement in the derivative financial asset) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "156", "firstAnchor": { "contextRef": "I20241231_NonCurrentAssetsMember_DerivativeFinancialAssetMember_1", "name": "ifrs-full:Borrowings", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutMovementInDerivativeFinancialAssetExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "I20231231_NonCurrentAssetsMember_DerivativeFinancialAssetMember", "name": "ifrs-full:Borrowings", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutMovementInDerivativeFinancialAssetExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R157": { "role": "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails3", "longName": "9960818 - Disclosure - INTEREST-BEARING LOANS AND BORROWINGS (Schedule of movement in the derivative financial liability) (Details)", "shortName": "INTEREST-BEARING LOANS AND BORROWINGS (Schedule of movement in the derivative financial liability) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "157", "firstAnchor": { "contextRef": "D20251231_3", "name": "trib:DerivativeFinancialLiabilitiesInitialRecognition", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "D20251231_NonCurrentLiabilitiesMember_DerivativeFinancialLiabilityMember", "name": "trib:DerivativeFinancialLiabilityAtDateOfIssueOfTermLoan", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutMovementInDerivativeFinancialLiabilityExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R158": { "role": "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails2", "longName": "9960819 - Disclosure - INTEREST-BEARING LOANS AND BORROWINGS (Schedule of movement in the Term Loan and the 7-year convertible notes) (Details)", "shortName": "INTEREST-BEARING LOANS AND BORROWINGS (Schedule of movement in the Term Loan and the 7-year convertible notes) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "158", "firstAnchor": { "contextRef": "I20241231_NonCurrentLiabilitiesMember", "name": "ifrs-full:Borrowings", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "div", "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "div", "ifrs-full:DisclosureOfBorrowingsExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": null }, "R159": { "role": "http://trinitybiotech.com/role/LeaseLiabilitiesScheduleOfOutstandingInterestBearingLoansAndBorrowingsDetails", "longName": "9960820 - Disclosure - LEASE LIABILITIES (Narrative) (Details)", "shortName": "LEASE LIABILITIES (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "159", "firstAnchor": { "contextRef": "D20251231_3", "name": "trib:AmountPaidInRespectOfLeaseLiabilities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "trib:AmountPaidInRespectOfLeaseLiabilities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R160": { "role": "http://trinitybiotech.com/role/LeaseLiabilitiesScheduleOfCarryingValuesOfFinanceLeaseLiabilitiesDetails", "longName": "9960821 - Disclosure - LEASE LIABILITIES (Schedule of Carrying Values of Finance Lease Liabilities) (Details)", "shortName": "LEASE LIABILITIES (Schedule of Carrying Values of Finance Lease Liabilities) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "160", "firstAnchor": { "contextRef": "I20251231", "name": "trib:LeaseLiabilitiesRelatedToRightOfUseAssetsCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutCarryingValuesOfFinanceLeaseLiabilitiesExplanatory", "div", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "I20251231", "name": "trib:LeaseLiabilitiesRelatedToRightOfUseAssetsCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutCarryingValuesOfFinanceLeaseLiabilitiesExplanatory", "div", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R161": { "role": "http://trinitybiotech.com/role/LeaseLiabilitiesScheduleOfFinanceLeaseLiabilitiesPayableDetails", "longName": "9960822 - Disclosure - LEASE LIABILITIES (Schedule of Finance Lease Liabilities Payable) (Details)", "shortName": "LEASE LIABILITIES (Schedule of Finance Lease Liabilities Payable) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "161", "firstAnchor": { "contextRef": "I20251231_LeaseLiabilitiesRelatedToRightOfUseAssetsMember", "name": "trib:MinimumFinanceLeasePaymentsPayable", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "div", "trib:DisclosureOfDetailedInformationAboutFinanceLeaseLiabilitiesPayableExplanatory", "div", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "I20251231_LeaseLiabilitiesRelatedToRightOfUseAssetsMember", "name": "trib:MinimumFinanceLeasePaymentsPayable", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "div", "trib:DisclosureOfDetailedInformationAboutFinanceLeaseLiabilitiesPayableExplanatory", "div", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R162": { "role": "http://trinitybiotech.com/role/CommitmentsAndContingenciesNarrativeDetails", "longName": "9960823 - Disclosure - COMMITMENTS AND CONTINGENCIES (Narrative) (Details)", "shortName": "COMMITMENTS AND CONTINGENCIES (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "162", "firstAnchor": { "contextRef": "I20251231", "name": "ifrs-full:CapitalCommitments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "I20251231", "name": "ifrs-full:CapitalCommitments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R163": { "role": "http://trinitybiotech.com/role/RelatedPartyTransactionsNarrativeDetails", "longName": "9960824 - Disclosure - RELATED PARTY TRANSACTIONS (Narrative) (Details)", "shortName": "RELATED PARTY TRANSACTIONS (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "163", "firstAnchor": { "contextRef": "D20220701", "name": "trib:IncreaseInAnnualRent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20220701", "name": "trib:IncreaseInAnnualRent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R164": { "role": "http://trinitybiotech.com/role/RelatedPartyTransactionsScheduleOfCompensationDetails", "longName": "9960825 - Disclosure - RELATED PARTY TRANSACTIONS (Schedule of Compensation) (Details)", "shortName": "RELATED PARTY TRANSACTIONS (Schedule of Compensation) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "164", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutCompensationExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutCompensationExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R165": { "role": "http://trinitybiotech.com/role/RelatedPartyTransactionsScheduleOfCompanysSharesAndShareOptionPlanDetails", "longName": "9960826 - Disclosure - RELATED PARTY TRANSACTIONS (Schedule of Company's Shares and Share Option Plan) (Details)", "shortName": "RELATED PARTY TRANSACTIONS (Schedule of Company's Shares and Share Option Plan) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "165", "firstAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "D20251231_DirectorsAndCompanySecretaryMember_ClassAOrdinarySharesMember", "name": "trib:SharesPurchasedDuringYear", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "div", "trib:DisclosureOfDetailedInformationAboutSharesAndShareOptionPlanExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R166": { "role": "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementNarrativeDetails", "longName": "9960827 - Disclosure - CAPITAL AND FINANCIAL RISK MANAGEMENT (Narrative) (Details)", "shortName": "CAPITAL AND FINANCIAL RISK MANAGEMENT (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "166", "firstAnchor": { "contextRef": "D20251231_3", "name": "trib:GrossIncreaseInterestIncome", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "trib:GrossIncreaseInterestIncome", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R167": { "role": "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfFairValuesOfFinancialAssetsliabilitiesDetails", "longName": "9960828 - Disclosure - CAPITAL AND FINANCIAL RISK MANAGEMENT (Schedule of Fair Values of Financial Assets/Liabilities) (Details)", "shortName": "CAPITAL AND FINANCIAL RISK MANAGEMENT (Schedule of Fair Values of Financial Assets/Liabilities) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "167", "firstAnchor": { "contextRef": "I20251231", "name": "ifrs-full:TradeReceivables", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "I20251231_Level1OfFairValueHierarchyMember", "name": "ifrs-full:TradeReceivables", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "ifrs-full:DisclosureOfFairValueMeasurementOfAssetsExplanatory", "div", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R168": { "role": "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfInterestRateRiskEffectiveAndRepricingAnalysisDetails", "longName": "9960829 - Disclosure - CAPITAL AND FINANCIAL RISK MANAGEMENT (Schedule of Interest Rate Risk Effective and Repricing Analysis) (Details)", "shortName": "CAPITAL AND FINANCIAL RISK MANAGEMENT (Schedule of Interest Rate Risk Effective and Repricing Analysis) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "168", "firstAnchor": { "contextRef": "I20251231", "name": "ifrs-full:CashAndCashEquivalents", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "ifrs-full:DisclosureOfCreditRiskExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "I20251231", "name": "trib:InterestEarningFinancialAndInterestBearingFinancialLiabilities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "td", "tr", "tbody", "table", "div", "ifrs-full:DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R169": { "role": "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfInterestRateProfileOfFinancialAssetsliabilitiesDetails", "longName": "9960830 - Disclosure - CAPITAL AND FINANCIAL RISK MANAGEMENT (Schedule of interest Rate Profile of Financial Assets/Liabilities) (Details)", "shortName": "CAPITAL AND FINANCIAL RISK MANAGEMENT (Schedule of interest Rate Profile of Financial Assets/Liabilities) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "169", "firstAnchor": { "contextRef": "I20251231", "name": "ifrs-full:Cash", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory", "div", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "I20251231", "name": "ifrs-full:SecuredBankLoansReceived", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutInterestRateProfileOfFinancialAssetsLiabilitiesExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R170": { "role": "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfLiquidityRiskEstimatedInterestPaymentsOfMaturitiesDetails", "longName": "9960831 - Disclosure - CAPITAL AND FINANCIAL RISK MANAGEMENT (Schedule of Liquidity Risk Estimated Interest Payments of Maturities) (Details)", "shortName": "CAPITAL AND FINANCIAL RISK MANAGEMENT (Schedule of Liquidity Risk Estimated Interest Payments of Maturities) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "170", "firstAnchor": { "contextRef": "I20251231", "name": "ifrs-full:NoncurrentPortionOfOtherNoncurrentBorrowings", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "I20251231_LiquidityRiskMember", "name": "ifrs-full:TradeAndOtherPayables", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "div", "trib:DisclosureOfDetailedInformationAboutLiquidityRiskEstimatedInterestPaymentsOfMaturitiesExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R171": { "role": "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfForeignCurrencyRiskShortTermFinancialAssetsAndLiabilitiesDetails", "longName": "9960832 - Disclosure - CAPITAL AND FINANCIAL RISK MANAGEMENT (Schedule of Foreign Currency Risk Short Term Financial Assets and Liabilities) (Details)", "shortName": "CAPITAL AND FINANCIAL RISK MANAGEMENT (Schedule of Foreign Currency Risk Short Term Financial Assets and Liabilities) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "171", "firstAnchor": { "contextRef": "I20251231", "name": "ifrs-full:Cash", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory", "div", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "I20251231_EUR", "name": "ifrs-full:Cash", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "div", "trib:DisclosureOfDetailedInformationAboutForeignCurrencyRiskShortTermFinancialAssetsAndLiabilitiesExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R172": { "role": "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfSensitivityAnalysisDetails", "longName": "9960833 - Disclosure - CAPITAL AND FINANCIAL RISK MANAGEMENT (Schedule of Sensitivity Analysis) (Details)", "shortName": "CAPITAL AND FINANCIAL RISK MANAGEMENT (Schedule of Sensitivity Analysis) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "172", "firstAnchor": { "contextRef": "D20251231_TenPercentStrengtheningUSDollarMember_EUR", "name": "ifrs-full:ProfitLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "div", "ifrs-full:SensitivityAnalysisForEachTypeOfMarketRisk", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_TenPercentStrengtheningUSDollarMember_EUR", "name": "ifrs-full:ProfitLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "div", "ifrs-full:SensitivityAnalysisForEachTypeOfMarketRisk", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R173": { "role": "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfMaximumCreditExposureOfFinancialAssetsDetails", "longName": "9960834 - Disclosure - CAPITAL AND FINANCIAL RISK MANAGEMENT (Schedule of Maximum Credit Exposure of Financial Assets) (Details)", "shortName": "CAPITAL AND FINANCIAL RISK MANAGEMENT (Schedule of Maximum Credit Exposure of Financial Assets) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "173", "firstAnchor": { "contextRef": "I20251231", "name": "ifrs-full:CurrentTradeReceivables", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatory", "div", "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": null }, "R174": { "role": "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfExposureOfTradeReceivablesByGeographicLocationDetails", "longName": "9960835 - Disclosure - CAPITAL AND FINANCIAL RISK MANAGEMENT (Schedule of Exposure of Trade Receivables by Geographic Location) (Details)", "shortName": "CAPITAL AND FINANCIAL RISK MANAGEMENT (Schedule of Exposure of Trade Receivables by Geographic Location) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "174", "firstAnchor": { "contextRef": "I20251231", "name": "ifrs-full:MaximumExposureToCreditRiskOfFinancialAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutExposureOfTradeReceivablesByGeographicLocationExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "I20251231_US", "name": "ifrs-full:MaximumExposureToCreditRiskOfFinancialAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutExposureOfTradeReceivablesByGeographicLocationExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R175": { "role": "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfExposureOfTradeReceivablesByCustomerDetails", "longName": "9960836 - Disclosure - CAPITAL AND FINANCIAL RISK MANAGEMENT (Schedule of Exposure of Trade Receivables by Customer) (Details)", "shortName": "CAPITAL AND FINANCIAL RISK MANAGEMENT (Schedule of Exposure of Trade Receivables by Customer) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "175", "firstAnchor": { "contextRef": "I20251231", "name": "ifrs-full:MaximumExposureToCreditRiskOfFinancialAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutExposureOfTradeReceivablesByGeographicLocationExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "I20251231_EndUserCustomersMember", "name": "ifrs-full:MaximumExposureToCreditRiskOfFinancialAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutExposureOfTradeReceivablesByCustomerExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R176": { "role": "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfAgeingOfTradeReceivablesDetails", "longName": "9960837 - Disclosure - CAPITAL AND FINANCIAL RISK MANAGEMENT (Schedule of Ageing of Trade Receivables) (Details)", "shortName": "CAPITAL AND FINANCIAL RISK MANAGEMENT (Schedule of Ageing of Trade Receivables) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "176", "firstAnchor": { "contextRef": "I20251231", "name": "ifrs-full:TradeReceivables", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "I20251231", "name": "ifrs-full:ExpectedCreditLossRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutAgeingOfTradeReceivablesExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R177": { "role": "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfMovementInAllowanceForImpairmentOfTradeReceivablesDetails", "longName": "9960838 - Disclosure - CAPITAL AND FINANCIAL RISK MANAGEMENT (Schedule of Movement in the Allowance for Impairment of Trade Receivables) (Details)", "shortName": "CAPITAL AND FINANCIAL RISK MANAGEMENT (Schedule of Movement in the Allowance for Impairment of Trade Receivables) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "177", "firstAnchor": { "contextRef": "I20241231", "name": "trib:AllowanceForImpairmentOfReceivables", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutMovementInAllowanceForImpairmentOfTradeReceivablesExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "I20231231", "name": "trib:AllowanceForImpairmentOfReceivables", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutMovementInAllowanceForImpairmentOfTradeReceivablesExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R178": { "role": "http://trinitybiotech.com/role/ReconciliationOfLiabilitiesArisingFromFinancingActivitiesScheduleOfLiabilitiesArisingFromFinancingDetails", "longName": "9960839 - Disclosure - RECONCILIATION OF LIABILITIES ARISING FROM FINANCING ACTIVITIES (Schedule of Liabilities Arising from Financing) (Details)", "shortName": "RECONCILIATION OF LIABILITIES ARISING FROM FINANCING ACTIVITIES (Schedule of Liabilities Arising from Financing) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "178", "firstAnchor": { "contextRef": "I20241231", "name": "ifrs-full:LiabilitiesArisingFromFinancingActivities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutInterestRateProfileOfFinancialAssetsLiabilitiesExplanatory", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "D20251231_LongtermBorrowingsMember", "name": "trib:PrincipalAmountLoaned", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "div", "ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory", "div", "ifrs-full:DisclosureOfCashFlowStatementExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R179": { "role": "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "longName": "9960840 - Disclosure - BUSINESS COMBINATIONS (Narrative) (Details)", "shortName": "BUSINESS COMBINATIONS (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "179", "firstAnchor": { "contextRef": "I20251231", "name": "ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory", "div", "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "D20251231_3", "name": "ifrs-full:DescriptionOfArrangementForContingentConsiderationArrangementsAndIndemnificationAssets", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "ifrs-full:DisclosureOfBusinessCombinationsExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R180": { "role": "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSDetails", "longName": "9960841 - Disclosure - BUSINESS COMBINATIONS (Schedule of acquisition of the CGM assets of Waveform Technologies, Inc) (Details)", "shortName": "BUSINESS COMBINATIONS (Schedule of acquisition of the CGM assets of Waveform Technologies, Inc) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "180", "firstAnchor": { "contextRef": "I20251231", "name": "ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "trib:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory", "div", "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "I20240130_WaveformTechnologiesIncorporationMember", "name": "ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory", "div", "ifrs-full:DisclosureOfBusinessCombinationsExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R181": { "role": "http://trinitybiotech.com/role/PostBalanceSheetEventsDetails", "longName": "9960842 - Disclosure - POST BALANCE SHEET EVENTS (Narrative) (Details)", "shortName": "POST BALANCE SHEET EVENTS (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "181", "firstAnchor": { "contextRef": "D20250807_SeniorSecuredTermLoanMember", "name": "ifrs-full:BorrowingsMaturity", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "D20260224_EventsAfterReportingPeriodMember", "name": "trib:DescriptionOfStandbyEquityPurchaseAgreement", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "unique": true } }, "R182": { "role": "http://trinitybiotech.com/role/AccountingEstimatesAndJudgementsNarrativeDetails", "longName": "9960843 - Disclosure - ACCOUNTING ESTIMATES AND JUDGEMENTS (Narrative) (Details)", "shortName": "ACCOUNTING ESTIMATES AND JUDGEMENTS (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "182", "firstAnchor": { "contextRef": "I20251231", "name": "ifrs-full:CurrentDeferredIncomeOtherThanCurrentContractLiabilities", "unitRef": "USD", "xsiNil": "true", "lang": null, "decimals": null, "ancestors": [ "span", "p", "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "I20251231", "name": "ifrs-full:CurrentDeferredIncomeOtherThanCurrentContractLiabilities", "unitRef": "USD", "xsiNil": "true", "lang": null, "decimals": null, "ancestors": [ "span", "p", "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } }, "R183": { "role": "http://trinitybiotech.com/role/GROUPUNDERTAKINGSDetails", "longName": "9960844 - Disclosure - GROUP UNDERTAKINGS (Details)", "shortName": "GROUP UNDERTAKINGS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "183", "firstAnchor": { "contextRef": "D20251231_TrinityBiotechManufacturingLimitedMember_1", "name": "ifrs-full:NameOfSubsidiary", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "div", "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory", "div", "trib:DisclosureOfGroupUndertakingsExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D20251231_TrinityBiotechManufacturingLimitedMember_1", "name": "ifrs-full:NameOfSubsidiary", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "td", "tr", "tbody", "table", "div", "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory", "div", "trib:DisclosureOfGroupUndertakingsExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "trib-20251231.htm", "first": true, "unique": true } } }, "tag": { "trib_AccountingEstimatesAndJudgementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "AccountingEstimatesAndJudgementsAbstract", "lang": { "en-us": { "role": { "label": "Accounting Estimates And Judgements [Abstract]" } } }, "auth_ref": [] }, "trib_AccretionInterestAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "AccretionInterestAccrued", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Accretion interest accrued.", "label": "Accretion Interest Accrued", "terseLabel": "Accretion interest accrued" } } }, "auth_ref": [] }, "trib_AccretionInterestAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "AccretionInterestAdjustment", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of accretion interest adjustment.", "label": "Accretion Interest Adjustment", "terseLabel": "Accretion interest adjustment" } } }, "auth_ref": [] }, "trib_AccretionInterestOnBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "AccretionInterestOnBorrowings", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails1", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails2", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSScheduleOfMovementInTermLoan" ], "lang": { "en-us": { "role": { "documentation": "The amount of accretion interest on borrowings.", "negatedTerseLabel": "Accretion interest", "label": "Accretion Interest On Borrowings", "terseLabel": "Accretion interest", "verboseLabel": "Accretion interest" } } }, "auth_ref": [] }, "trib_AccruedBonus": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "AccruedBonus", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Accrued Bonus.", "label": "Accrued Bonus" } } }, "auth_ref": [] }, "trib_AccruedLiabilitiesToContractedLicencePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "AccruedLiabilitiesToContractedLicencePayments", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/TRADEANDOTHERPAYABLESNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Accrued liabilities to contracted licence payments.", "negatedLabel": "Licence payments", "negatedTerseLabel": "Fixed rate financial liabilities (licence fees)", "label": "Accrued Liabilities To Contracted Licence Payments", "terseLabel": "Accrued liabilities to contracted licence payments" } } }, "auth_ref": [] }, "trib_AccruedLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "AccruedLiability", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/FINANCIALASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of accrued liability.", "label": "Accrued Liability" } } }, "auth_ref": [] }, "trib_AccumulatedDeficitInEquityAttributableToEquityHolders": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "AccumulatedDeficitInEquityAttributableToEquityHolders", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/BASISOFPREPARATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "accumulated deficit in equity attributable to equity holders.", "label": "Accumulated Deficit In Equity Attributable To Equity Holders", "verboseLabel": "Accumulated deficit in equity attributable to equity holders" } } }, "auth_ref": [] }, "ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AccumulatedDepreciationAmortisationAndImpairmentMember", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsNarrativeDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfGoodwillAndIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Accumulated depreciation, amortisation and impairment [member]", "terseLabel": "Accumulated amortisation and impairment losses [Member]" } } }, "auth_ref": [ "r11", "r20", "r75", "r86", "r90", "r314", "r344", "r355", "r359" ] }, "ifrs-full_AccumulatedDepreciationAndAmortisationMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AccumulatedDepreciationAndAmortisationMember", "presentation": [ "http://trinitybiotech.com/role/PropertyPlantAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentRelatedToAccumulatedDepreciationDetails" ], "lang": { "en-us": { "role": { "label": "Accumulated depreciation and impairment losses [Member]", "terseLabel": "Accumulated depreciation and impairment losses [Member]" } } }, "auth_ref": [ "r20", "r579", "r592", "r597", "r598" ] }, "ifrs-full_AccumulatedImpairmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AccumulatedImpairmentMember", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfAgeingOfTradeReceivablesDetails", "http://trinitybiotech.com/role/PropertyPlantAndEquipmentScheduleOfAdditionalInformationOnRight-of-useAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Accumulated impairment Charge [Member]", "terseLabel": "Impairment charge [Member]" } } }, "auth_ref": [ "r201", "r224", "r387", "r503", "r579", "r592", "r597", "r598" ] }, "trib_AcquisitionConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "AcquisitionConsideration", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Acquisition Consideration", "label": "Acquisition Consideration" } } }, "auth_ref": [] }, "ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AcquisitiondateFairValueOfTotalConsiderationTransferred", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSDetails", "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://trinitybiotech.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Consideration transferred, acquisition-date fair value", "terseLabel": "Consideration transferred", "totalLabel": "Total consideration" } }, "en": { "role": { "documentation": "The fair value, at acquisition date, of the consideration transferred in a business combination. [Refer: Total for all business combinations [member]]" } } }, "auth_ref": [ "r189", "r375" ] }, "ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Acquisition-related costs for transaction recognised separately from acquisition of assets and assumption of liabilities in business combination", "terseLabel": "Acquisition-related costs" } } }, "auth_ref": [ "r194" ] }, "ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsNarrativeDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfGoodwillAndIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Acquisitions through business combinations, intangible assets other than goodwill", "terseLabel": "Intangible assets acquired through business combinations", "verboseLabel": "Additions through acquisition" } }, "en": { "role": { "documentation": "The increase in intangible assets other than goodwill resulting from acquisitions through business combinations. [Refer: Total for all business combinations [member]; Intangible assets other than goodwill]" } } }, "auth_ref": [ "r76", "r345" ] }, "ifrs-full_AcquisitionsThroughBusinessCombinationsOtherProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AcquisitionsThroughBusinessCombinationsOtherProvisions", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/ProvisionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Acquisitions through business combinations, other provisions" } }, "en": { "role": { "documentation": "The increase in other provisions resulting from acquisitions through business combinations. [Refer: Total for all business combinations [member]; Other provisions]" } } }, "auth_ref": [ "r591" ] }, "ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/PropertyPlantAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentRelatedToAccumulatedDepreciationDetails" ], "lang": { "en-us": { "role": { "label": "Acquisitions through business combinations, property, plant and equipment", "verboseLabel": "Additions through acquisition" } }, "en": { "role": { "documentation": "The increase in property, plant and equipment resulting from acquisitions through business combinations. [Refer: Total for all business combinations [member]; Property, plant and equipment]" } } }, "auth_ref": [ "r13", "r316" ] }, "trib_ActuarialAssumptionOfDiscountRatePercentage": { "xbrltype": "percentItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ActuarialAssumptionOfDiscountRatePercentage", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Actuarial assumption of discount rate percentage.", "label": "Actuarial Assumption Of Discount Rate Percentage", "terseLabel": "Actuarial assumption of discount rate percentage" } } }, "auth_ref": [] }, "ifrs-full_ActuarialAssumptionOfDiscountRates": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ActuarialAssumptionOfDiscountRates", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Variation in discount rate" } }, "en": { "role": { "documentation": "The discount rate used as the significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit obligation, at present value; Actuarial assumptions [domain]]" } } }, "auth_ref": [ "r582" ] }, "trib_ActuarialAssumptionOfExpectedPensionIncreases": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ActuarialAssumptionOfExpectedPensionIncreases", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/EmploymentNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of pension accrual.", "label": "Actuarial Assumption Of Expected Pension Increases", "verboseLabel": "Pension accrual" } } }, "auth_ref": [] }, "trib_AdditionalAmountBorrowed": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "AdditionalAmountBorrowed", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/BASISOFPREPARATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails", "http://trinitybiotech.com/role/PostBalanceSheetEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of borrowings obtained additionally by the reporting entity.", "terseLabel": "Additional amount borrowed", "label": "Additional Amount Borrowed" } } }, "auth_ref": [] }, "trib_AdditionalConsiderationContingentOnAchievementOfFutureMilestone": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "AdditionalConsiderationContingentOnAchievementOfFutureMilestone", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The fair value of additional consideration contingent on the achievement of future milestone.", "label": "Additional Consideration Contingent On Achievement Of Future Milestone", "terseLabel": "Additional consideration" } } }, "auth_ref": [] }, "trib_AdditionalImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "AdditionalImpairmentLoss", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of additional impairment loss.", "label": "Additional impairment loss" } } }, "auth_ref": [] }, "trib_AdditionalImpairmentLossDueToGrowthInRevenues": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "AdditionalImpairmentLossDueToGrowthInRevenues", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Additional impairment loss due to growth in revenues.", "label": "Additional impairment loss due to growth in revenues" } } }, "auth_ref": [] }, "trib_AdditionalLiquidityRecognizedAsOfAcquisitionDate": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "AdditionalLiquidityRecognizedAsOfAcquisitionDate", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of additional liquidity recognized as of acquisition date.", "label": "Additional Liquidity Recognized As Of Acquisition Date", "terseLabel": "Additional liquidity recognized" } } }, "auth_ref": [] }, "trib_AdditionalProjectCost": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "AdditionalProjectCost", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of additional project cost.", "label": "Additional project cost" } } }, "auth_ref": [] }, "ifrs-full_AdditionalProvisionsOtherProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdditionalProvisionsOtherProvisions", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/InventoriesScheduleOfMovementOnInventoryProvisionDetails", "http://trinitybiotech.com/role/PROVISIONSScheduleofreconciliationofchangesinprovisionsDetails" ], "lang": { "en-us": { "role": { "label": "Charged during the year" } }, "en": { "role": { "documentation": "The amount of additional other provisions made. [Refer: Other provisions]" } } }, "auth_ref": [ "r71", "r340" ] }, "trib_AdditionalRestructuringCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "AdditionalRestructuringCosts", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/IMPAIRMENTTRANSFORMATIONANDONCEOFFCOSTSNarrativeDetails", "http://trinitybiotech.com/role/ProvisionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of expense relating to additional restructuring. Restructuring is a programme that is planned and controlled by management and materially changes either the scope of a business undertaken by an entity or the manner in which that business is conducted. Such programmes include: (a) the sale or termination of a line of business; (b) closure of business locations in a country or region or the relocation of activities from one country or region to another; (c) changes in management structure; and (d) fundamental reorganisations that have a material effect on the nature and focus of the entity's operations.", "label": "Additional Restructuring Costs", "terseLabel": "Additional restructuring costs" } } }, "auth_ref": [] }, "trib_AdditionalSpaceMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "AdditionalSpaceMember", "presentation": [ "http://trinitybiotech.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Additional Space [Member]", "label": "Additional Space [Member]" } } }, "auth_ref": [] }, "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfGoodwillAndIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Additions other than through business combinations, intangible assets other than goodwill", "verboseLabel": "Additions" } }, "en": { "role": { "documentation": "The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Intangible assets other than goodwill]" } } }, "auth_ref": [ "r76", "r345" ] }, "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/PropertyPlantAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentRelatedToAccumulatedDepreciationDetails" ], "lang": { "en-us": { "role": { "label": "Additions", "terseLabel": "Additions" } }, "en": { "role": { "documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Property, plant and equipment]" } } }, "auth_ref": [ "r12", "r315" ] }, "trib_AdditionsRelatedToRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "AdditionsRelatedToRightOfUseAssets", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/ReconciliationOfLiabilitiesArisingFromFinancingActivitiesScheduleOfLiabilitiesArisingFromFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of additions related to right of use assets.", "label": "Additions (related to Right of Use assets)" } } }, "auth_ref": [] }, "ifrs-full_AdditionsToRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdditionsToRightofuseAssets", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/PropertyPlantAndEquipmentNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Additions to right-of-use assets", "verboseLabel": "Additional right-of-use assets" } }, "en": { "role": { "documentation": "The amount of additions to right-of-use assets. [Refer: Right-of-use assets]" } } }, "auth_ref": [ "r152", "r268" ] }, "ifrs-full_AddressOfRegisteredOfficeOfEntity": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AddressOfRegisteredOfficeOfEntity", "presentation": [ "http://trinitybiotech.com/role/GROUPUNDERTAKINGSDetails" ], "lang": { "en-us": { "role": { "label": "Address of entity's registered office" } }, "en": { "role": { "documentation": "The address at which the entity's office is registered." } } }, "auth_ref": [ "r282", "r403", "r418" ] }, "dei_AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AddressTypeDomain", "presentation": [ "http://trinitybiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Address Type [Domain]", "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth_ref": [] }, "trib_AdjustedProfitAfterTax": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "AdjustedProfitAfterTax", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/LossPerShareNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Adjusted profit after tax.", "label": "Adjusted Profit After Tax", "terseLabel": "Adjusted profit after tax" } } }, "auth_ref": [] }, "trib_AdjustedWeightedAverageSharesDiscontinuedOperations": { "xbrltype": "sharesItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "AdjustedWeightedAverageSharesDiscontinuedOperations", "presentation": [ "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares.", "label": "Adjusted Weighted Average Shares Discontinued Operations", "verboseLabel": "Diluted earnings per share denominator" } } }, "auth_ref": [] }, "trib_AdjustmentForTransformationProvision": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "AdjustmentForTransformationProvision", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustment For Transformation Provision", "terseLabel": "Transformation provision", "documentation": "Represents the amount of provision for transformation." } } }, "auth_ref": [] }, "trib_AdjustmentOnTransitionToIfrs16PropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "AdjustmentOnTransitionToIfrs16PropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/PropertyPlantAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentRelatedToAccumulatedDepreciationDetails" ], "lang": { "en-us": { "role": { "documentation": "Adjustment on transition to IFRS 16 in property, plant and equipment.", "label": "Adjustment On Transition To Ifrs 16 Property Plant And Equipment", "terseLabel": "Additions through acquisition" } } }, "auth_ref": [] }, "trib_AdjustmentOnTransitionToIfrs16ToDepreciationAndImpairmentPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "AdjustmentOnTransitionToIfrs16ToDepreciationAndImpairmentPropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/PropertyPlantAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentRelatedToAccumulatedDepreciationDetails" ], "lang": { "en-us": { "role": { "documentation": "Adjustment on transition to IFRS 16", "negatedLabel": "Adjustment on transition to IFRS 16 to depreciation and impairment", "label": "Adjustment On Transition To Ifrs 16 To Depreciation And Impairment Property Plant And Equipment" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForAmortisationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForAmortisationExpense", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Amortisation", "verboseLabel": "Amortisation" } } }, "auth_ref": [ "r604" ] }, "ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForCurrentTaxOfPriorPeriod", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfChargeForTaxDetails" ], "lang": { "en-us": { "role": { "label": "Adjustment in respect of prior years" } } }, "auth_ref": [ "r460", "r520" ] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInInventories", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase) / decrease in inventories", "terseLabel": "Decrease/ (increase) in inventories", "verboseLabel": "(Increase) / decrease in inventories" } } }, "auth_ref": [ "r601" ] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "(Increase) / decrease in trade and other receivables", "verboseLabel": "Decrease/ (increase) in trade and other receivables" } }, "en": { "role": { "documentation": "Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]" } } }, "auth_ref": [ "r604" ] }, "ifrs-full_AdjustmentsForDepreciationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForDepreciationExpense", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Depreciation" } }, "en": { "role": { "documentation": "Adjustments for depreciation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r604" ] }, "ifrs-full_AdjustmentsForFinanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForFinanceCosts", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Financial expense" } } }, "auth_ref": [ "r603" ] }, "ifrs-full_AdjustmentsForFinanceIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForFinanceIncome", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Financial income", "label": "Adjustments for finance income" } } }, "auth_ref": [ "r604" ] }, "trib_AdjustmentsForGainLossOnSaleOfBusiness": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "AdjustmentsForGainLossOnSaleOfBusiness", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": -1.0, "order": 14.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The amount represents gain on sale of business.", "negatedLabel": "Gain on sale of business", "label": "Adjustments For Gain Loss On Sale Of Business", "terseLabel": "Gain on sale of business" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails3", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails4" ], "lang": { "en-us": { "role": { "label": "Adjustments for gains (losses) on change in fair value of derivatives", "terseLabel": "Fair value adjustments in the period (old derivative)" } }, "en": { "role": { "documentation": "Adjustments for gains (losses) on changes in the fair value of derivatives to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: At fair value [member]; Derivatives [member]; Profit (loss)]" } } }, "auth_ref": [ "r604" ] }, "ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Impairment through use or sale of the assets", "verboseLabel": "Impairment loss charge" } } }, "auth_ref": [ "r602" ] }, "ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Impairment of property, plant and equipment", "terseLabel": "Impairment of property, plant and equipment" } }, "en": { "role": { "documentation": "Adjustments for impairment loss (reversal of impairment loss) on property, plant and equipment recognised in profit or loss to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss; Property, plant and equipment]" } } }, "auth_ref": [ "r604" ] }, "ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeAndOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeAndOtherReceivables", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Impairment of prepayments" } } }, "auth_ref": [ "r604" ] }, "ifrs-full_AdjustmentsForImpairmentLossesReversalOfImpairmentLossesRecognisedInProfitOrLossFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForImpairmentLossesReversalOfImpairmentLossesRecognisedInProfitOrLossFinancialAssets", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows", "http://trinitybiotech.com/role/FINANCIALASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Adjustments for impairment losses (reversal of impairment losses) recognised in profit or loss, financial assets", "verboseLabel": "Liabilities related to financial assets (reversal)/written off", "terseLabel": "(Reversal)/Impairment of financial assets (Note 13)", "negativeLabel": "Financial assets (see Note 13)" } }, "en": { "role": { "documentation": "Adjustments for impairment losses (reversal of impairment losses) on financial assets recognised in profit or loss to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss]" } } }, "auth_ref": [ "r604" ] }, "ifrs-full_AdjustmentsForIncomeTaxExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForIncomeTaxExpense", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for income tax expense", "terseLabel": "Income tax expense/(credit)", "verboseLabel": "Tax (expense)/credit" } } }, "auth_ref": [ "r96" ] }, "trib_AdjustmentsForIncomeTaxExpenseCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "AdjustmentsForIncomeTaxExpenseCredit", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represent the adjustments for income tax expense credit.", "label": "Adjustments For Income Tax Expense Credit", "terseLabel": "Income tax credit", "verboseLabel": "Tax expense" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase / (decrease) in trade and other payables", "verboseLabel": "Increase/ (decrease) in trade and other payables" } }, "en": { "role": { "documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]" } } }, "auth_ref": [ "r604" ] }, "trib_AdjustmentsForInventoryWriteOff": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "AdjustmentsForInventoryWriteOff", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of adjustments for inventory write off.", "negatedLabel": "Inventory write off", "label": "Adjustments For Inventory Write Off" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForProvisions", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Movement in inventory provision" } } }, "auth_ref": [ "r602" ] }, "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForReconcileProfitLossAbstract", "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to cash provided by operating activities:", "verboseLabel": "Adjustments to reconcile net loss to cash provided by operating activities:" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForSharebasedPayments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForSharebasedPayments", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/EmploymentScheduleOfEmploymentCostsDetails": { "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0, "order": 1.0 }, "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows", "http://trinitybiotech.com/role/EmploymentScheduleOfEmploymentCostsDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfShareBasedPaymentExpenseByGeographicalAreaDetails" ], "lang": { "en-us": { "role": { "label": "Share-based payments (net of capitalized amounts)", "terseLabel": "Share-based payments", "totalLabel": "Total share-based payments", "verboseLabel": "Total Share-based payments" } } }, "auth_ref": [ "r602" ] }, "ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForUnrealisedForeignExchangeLossesGains", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Foreign exchange (gains)/losses on operating cash flows", "terseLabel": "Foreign exchange gains/(losses) on operating cash flows" } } }, "auth_ref": [ "r487", "r602" ] }, "trib_AdministrationAndSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "AdministrationAndSalesMember", "presentation": [ "http://trinitybiotech.com/role/EmploymentScheduleOfAverageNumberOfPersonsEmployedDetails" ], "lang": { "en-us": { "role": { "documentation": "Administration and sales [Member]", "label": "Administration and sales [Member]" } } }, "auth_ref": [] }, "ifrs-full_AdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdministrativeExpense", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Administrative expenses", "label": "Administrative expenses", "terseLabel": "Administrative expenses" } } }, "auth_ref": [ "r44", "r458", "r531" ] }, "trib_AdoptionOfIfrs16": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "AdoptionOfIfrs16", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/ReconciliationOfLiabilitiesArisingFromFinancingActivitiesScheduleOfLiabilitiesArisingFromFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of adoption of IFRS 16.", "label": "Adoption Of Ifrs 16", "terseLabel": "Adoption of IFRS 16 (Note 13)" } } }, "auth_ref": [] }, "trib_AgreementPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "AgreementPayments", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount represents agreement.", "label": "Agreement Payments" } } }, "auth_ref": [] }, "trib_AgreementTerm": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "AgreementTerm", "presentation": [ "http://trinitybiotech.com/role/FINANCIALASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Agreement Term.", "label": "Agreement Term", "terseLabel": "Agreement Term" } } }, "auth_ref": [] }, "currency_AllCurrenciesDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2025", "localname": "AllCurrenciesDomain", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfForeignCurrencyRiskShortTermFinancialAssetsAndLiabilitiesDetails", "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfSensitivityAnalysisDetails", "http://trinitybiotech.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "All Currencies [Domain]" } } }, "auth_ref": [] }, "trib_AllowanceForImpairmentOfReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "AllowanceForImpairmentOfReceivables", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfMovementInAllowanceForImpairmentOfTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Allowance for impairment of receivables.", "periodEndLabel": "Balance at December 31", "periodStartLabel": "Balance at January 1", "label": "Allowance For Impairment Of Receivables", "terseLabel": "Allowance for impairment of receivables", "verboseLabel": "Trade receivables" } } }, "auth_ref": [] }, "trib_AmendedCreditAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "AmendedCreditAgreementMember", "presentation": [ "http://trinitybiotech.com/role/BASISOFPREPARATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stand for Amended Credit Agreement.", "label": "Amended Credit Agreement [Member]" } } }, "auth_ref": [] }, "trib_AmendmentAndRestatementOfTermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "AmendmentAndRestatementOfTermLoanMember", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Amendment and restatement of Term Loan.", "label": "Amendment And Restatement Of Term Loan [Member]", "terseLabel": "Amendment and Restatement of Term Loan [Member]" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentFlag", "presentation": [ "http://trinitybiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "trib_AmericaMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "AmericaMember", "presentation": [ "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfLossProfitBeforeTaxesDetails", "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfNetOperatingLossesDetails", "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfUnrecognisedDeferredTaxAssetsDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfCapitalExpenditureByGeographicalAreaDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfDepreciationAndAmortisationByGeographicalAreaDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfLongLivedAssetsDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfRevenueByCustomersGeographicalAreaDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfRevenueDerivesFromTransferOfGoodsAndServicesDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfSegmentAssetsAndSegmentLiabilitiesByGeographicalAreaDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfSegmentResultsByGeographicalAreaDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfShareBasedPaymentExpenseByGeographicalAreaDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfTaxationExpenseByGeographicalAreaDetails" ], "lang": { "en-us": { "role": { "documentation": "Americas [Member]", "label": "America [Member]", "terseLabel": "Americas \u2013 unused tax losses [Member]", "verboseLabel": "Americas [Member]" } } }, "auth_ref": [] }, "trib_AmericanDepositaryShareMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "AmericanDepositaryShareMember", "presentation": [ "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://trinitybiotech.com/role/CapitalAndReservesScheduleOfShareCapitalDetails", "http://trinitybiotech.com/role/ConsolidatedStatementOfOperations", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails", "http://trinitybiotech.com/role/LossPerShareNarrativeDetails", "http://trinitybiotech.com/role/LossPerShareScheduleOfDilutedEarningsPerAdsShareCalculationDetails", "http://trinitybiotech.com/role/LossPerShareScheduleOfEarningsPerAdsDetails", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSDetails2", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSNarrativeDetails", "http://trinitybiotech.com/role/RelatedPartyTransactionsNarrativeDetails", "http://trinitybiotech.com/role/ShareOptionsNarrativeDetails", "http://trinitybiotech.com/role/ShareOptionsScheduleOfGrantsOfShareOptionsAndWarrantsDetails", "http://trinitybiotech.com/role/ShareOptionsSummaryOfRangeOfPricesOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "American depositary share [Member]", "label": "American depositary share [Member]" } } }, "auth_ref": [] }, "trib_AmericanDepositaryShareTreasurySharesMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "AmericanDepositaryShareTreasurySharesMember", "presentation": [ "http://trinitybiotech.com/role/CapitalAndReservesNarrativeDetails", "http://trinitybiotech.com/role/CapitalAndReservesScheduleOfShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "ADS Treasury shares [Member]", "label": "American Depositary Share Treasury Shares Member", "terseLabel": "ADS Treasury shares [Member]" } } }, "auth_ref": [] }, "trib_AmericanDepositarySharesMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "AmericanDepositarySharesMember", "presentation": [ "http://trinitybiotech.com/role/IMPAIRMENTTRANSFORMATIONANDONCEOFFCOSTSNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "American Depositary Shares [Member]" } } }, "auth_ref": [] }, "trib_AmericanDepositoryShares": { "xbrltype": "sharesItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "AmericanDepositoryShares", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementNarrativeDetails", "http://trinitybiotech.com/role/LossPerShareScheduleOfEarningsPerAdsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number Of American Depository Shares.", "terseLabel": "ADS", "periodEndLabel": "In issue at December 31", "periodStartLabel": "In issue at January 1", "label": "American Depository Shares", "totalLabel": "Total number of shares issued", "verboseLabel": "Number of American Depository Shares issued" } } }, "auth_ref": [] }, "trib_AmericanDepositorySharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "AmericanDepositorySharesIssued", "presentation": [ "http://trinitybiotech.com/role/FINANCIALASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "American depository shares issued share value.", "label": "American Depository Shares Issued", "terseLabel": "ADS issued" } } }, "auth_ref": [] }, "ifrs-full_AmortisationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AmortisationExpense", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/AccountingEstimatesAndJudgementsNarrativeDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfDepreciationAndAmortisationByGeographicalAreaDetails" ], "lang": { "en-us": { "role": { "label": "Amortisation expense", "terseLabel": "Amortisation for discontinued operations", "verboseLabel": "Amortisation" } } }, "auth_ref": [ "r612" ] }, "trib_AmortisationForDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "AmortisationForDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/LossBeforeTaxNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represent the amortizations for discontinued operations.", "label": "Amortisation For Discontinued Operations", "terseLabel": "Amortisation for discontinued operations", "verboseLabel": "Amortisation" } } }, "auth_ref": [] }, "trib_AmortisationOnIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "AmortisationOnIntangibleAssets", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/LossBeforeTaxScheduleOfAmountChargedToStatementOfOperationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amortisation on intangible assets.", "label": "Amortisation On Intangible Assets", "verboseLabel": "Amortisation" } } }, "auth_ref": [] }, "trib_AmountAvailableForDevelopmentOfTheCGM": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "AmountAvailableForDevelopmentOfTheCGM", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount available for development of the CGM.", "label": "Amount Available For Development Of The C G M", "terseLabel": "Amount available for development of the CGM" } } }, "auth_ref": [] }, "trib_AmountPaidInRespectOfLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "AmountPaidInRespectOfLeaseLiabilities", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/LeaseLiabilitiesScheduleOfOutstandingInterestBearingLoansAndBorrowingsDetails" ], "lang": { "en-us": { "role": { "documentation": "Total amount paid in respect of lease liabilities.", "label": "Amount Paid In Respect Of Lease Liabilities", "terseLabel": "Total amount paid in respect of lease liabilities" } } }, "auth_ref": [] }, "trib_AmountUsedToAcquireTheCGMAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "AmountUsedToAcquireTheCGMAssets", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount used to acquire the CGM assets.", "label": "Amount Used To Acquire The C G M Assets", "terseLabel": "Amount used to acquire the CGM assets" } } }, "auth_ref": [] }, "ifrs-full_AmountsPayableToTransfereeInRespectOfTransferredAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AmountsPayableToTransfereeInRespectOfTransferredAssets", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/TradeAndOtherPayablesScheduleOfTradeAndOtherPayablesDetails" ], "lang": { "en-us": { "role": { "label": "Other amounts payable to transferee in respect of transferred assets", "terseLabel": "Amounts payable for financial assets" } }, "en": { "role": { "documentation": "The amounts payable to the transferee in respect of transferred financial assets other than the undiscounted cash outflows that would or may be required to repurchase derecognised financial assets (for example, the strike price in an option agreement). [Refer: Financial assets]" } } }, "auth_ref": [ "r232" ] }, "trib_AnnualRentPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "AnnualRentPayable", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Annual rent payable.", "label": "Annual rent payable" } } }, "auth_ref": [] }, "trib_AnnualRentPayableForWareHouse": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "AnnualRentPayableForWareHouse", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Annual rent payable for ware house.", "label": "Annual rent payable for ware house" } } }, "auth_ref": [] }, "ifrs-full_ApplicableTaxRate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ApplicableTaxRate", "calculation": { "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfStatutoryTaxRateDetails": { "parentTag": "ifrs-full_AverageEffectiveTaxRate", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfStatutoryTaxRateDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Irish corporation tax", "label": "Corporation tax rate" } }, "en": { "role": { "documentation": "The applicable income tax rate." } } }, "auth_ref": [ "r3", "r309" ] }, "trib_AsiaOrAfricaMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "AsiaOrAfricaMember", "presentation": [ "http://trinitybiotech.com/role/SegmentInformationScheduleOfRevenueByCustomersGeographicalAreaDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfRevenueDerivesFromTransferOfGoodsAndServicesDetails" ], "lang": { "en-us": { "role": { "documentation": "Asia / Africa [Member]", "label": "Asia Or Africa Member", "terseLabel": "Asia / Africa [Member]" } } }, "auth_ref": [] }, "ifrs-full_Assets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Assets", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Assets [Default Label]", "totalLabel": "TOTAL ASSETS" } }, "en": { "role": { "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r136", "r137", "r138", "r246", "r250", "r394", "r395", "r431" ] }, "ifrs-full_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AssetsAbstract", "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Assets", "terseLabel": "ASSETS" } } }, "auth_ref": [] }, "ifrs-full_AssetsAndLiabilitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AssetsAndLiabilitiesAxis", "presentation": [ "http://trinitybiotech.com/role/LeaseLiabilitiesScheduleOfFinanceLeaseLiabilitiesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Assets and liabilities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r32", "r302", "r325", "r402", "r417" ] }, "trib_AssetsAndLiabilitiesBySegmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "AssetsAndLiabilitiesBySegmentAbstract", "presentation": [ "http://trinitybiotech.com/role/SegmentInformationScheduleOfSegmentAssetsAndSegmentLiabilitiesByGeographicalAreaDetails" ], "lang": { "en-us": { "role": { "label": "Assets And Liabilities By Segment Abstract", "terseLabel": "Assets and liabilities" } } }, "auth_ref": [] }, "ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis", "presentation": [ "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONDetail5" ], "lang": { "en-us": { "role": { "label": "Assets and liabilities classified as held for sale [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r214" ] }, "ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AssetsAndLiabilitiesClassifiedAsHeldForSaleMember", "presentation": [ "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONDetail5" ], "lang": { "en-us": { "role": { "label": "Assets and liabilities classified as held for sale [Member]" } }, "en": { "role": { "documentation": "This member stands for assets and liabilities that are classified as held for sale. [Refer: Non-current assets held for sale [member]; Liabilities included in disposal groups classified as held for sale; Disposal groups classified as held for sale [member]]" } } }, "auth_ref": [ "r214" ] }, "ifrs-full_AssetsAndLiabilitiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AssetsAndLiabilitiesDomain", "presentation": [ "http://trinitybiotech.com/role/LeaseLiabilitiesScheduleOfFinanceLeaseLiabilitiesPayableDetails" ], "lang": { "en": { "role": { "documentation": "This member stands for assets and liabilities. It also represents the standard value for the 'Assets and liabilities' axis if no other member is used. [Refer: Assets; Liabilities]" } } }, "auth_ref": [ "r32", "r302", "r325", "r402", "r417" ] }, "ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember", "presentation": [ "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONDetail5" ], "lang": { "en-us": { "role": { "label": "Assets and liabilities not classified as held for sale [Member]" } }, "en": { "role": { "documentation": "This member stands for assets and liabilities that are not classified as held for sale. It also represents the standard value for the 'Assets and liabilities classified as held for sale' axis if no other member is used. [Refer: Non-current assets held for sale [member]; Liabilities included in disposal groups classified as held for sale; Disposal groups classified as held for sale [member]]" } } }, "auth_ref": [ "r214" ] }, "trib_AssetsUnderDevelopmentCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "AssetsUnderDevelopmentCarryingValue", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Assets under development carrying value.", "label": "Assets Under Development Carrying Value", "terseLabel": "Assets under development carrying value" } } }, "auth_ref": [] }, "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AttributionOfExpensesByNatureToTheirFunctionAxis", "presentation": [ "http://trinitybiotech.com/role/IMPAIRMENTTRANSFORMATIONANDONCEOFFCOSTSNarrativeDetails", "http://trinitybiotech.com/role/IMPAIRMENTTRANSFORMATIONANDONCEOFFCOSTSScheduleoftransformationcostsincurredduringtheyearDetails", "http://trinitybiotech.com/role/ProvisionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Attribution of expenses by nature to their function [axis]" } } }, "auth_ref": [ "r609", "r612" ] }, "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AttributionOfExpensesByNatureToTheirFunctionDomain", "presentation": [ "http://trinitybiotech.com/role/IMPAIRMENTTRANSFORMATIONANDONCEOFFCOSTSNarrativeDetails", "http://trinitybiotech.com/role/IMPAIRMENTTRANSFORMATIONANDONCEOFFCOSTSScheduleoftransformationcostsincurredduringtheyearDetails", "http://trinitybiotech.com/role/ProvisionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Attribution of expenses by nature to their function [domain]" } } }, "auth_ref": [ "r609", "r612" ] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorFirmId", "presentation": [ "http://trinitybiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r543", "r544", "r557" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorLocation", "presentation": [ "http://trinitybiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r543", "r544", "r557" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorName", "presentation": [ "http://trinitybiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r543", "r544", "r557" ] }, "ifrs-full_AuditorsRemunerationAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AuditorsRemunerationAbstract", "presentation": [ "http://trinitybiotech.com/role/LossBeforeTaxScheduleOfAmountChargedToStatementOfOperationDetails" ], "lang": { "en-us": { "role": { "label": "Auditor's remuneration" } } }, "auth_ref": [] }, "ifrs-full_AuditorsRemunerationForOtherServices": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AuditorsRemunerationForOtherServices", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/LossBeforeTaxScheduleOfAmountChargedToStatementOfOperationDetails" ], "lang": { "en-us": { "role": { "label": "Other non-audit fees" } } }, "auth_ref": [ "r612" ] }, "ifrs-full_AuditorsRemunerationForTaxServices": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AuditorsRemunerationForTaxServices", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/LossBeforeTaxScheduleOfAmountChargedToStatementOfOperationDetails" ], "lang": { "en-us": { "role": { "label": "Audit fees" } } }, "auth_ref": [ "r612" ] }, "trib_AutoimmuneSmartReaderMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "AutoimmuneSmartReaderMember", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfPrincipalDevelopmentProjectsDetails" ], "lang": { "en-us": { "role": { "documentation": "Autoimmune Smart Reader [Member]", "label": "Autoimmune Smart Reader [Member]", "terseLabel": "Autoimmune smart reader [Member]" } } }, "auth_ref": [] }, "ifrs-full_AverageEffectiveTaxRate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AverageEffectiveTaxRate", "calculation": { "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfStatutoryTaxRateDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfOverseasTaxJurisdictionsDetails", "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfStatutoryTaxRateDetails" ], "lang": { "en-us": { "role": { "label": "Total (current and deferred) %", "totalLabel": "Effective tax rate" } }, "en": { "role": { "documentation": "The tax expense (income) divided by the accounting profit. [Refer: Accounting profit]" } } }, "auth_ref": [ "r3", "r309" ] }, "ifrs-full_AverageNumberOfEmployees": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AverageNumberOfEmployees", "presentation": [ "http://trinitybiotech.com/role/EmploymentScheduleOfAverageNumberOfPersonsEmployedDetails" ], "lang": { "en-us": { "role": { "label": "Average number of employees" } }, "en": { "role": { "documentation": "The average number of personnel employed by the entity during a period." } } }, "auth_ref": [ "r612" ] }, "trib_AverageNumberOfEmployeesIncludingDiscontinuedOperations": { "xbrltype": "integerItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "AverageNumberOfEmployeesIncludingDiscontinuedOperations", "presentation": [ "http://trinitybiotech.com/role/EmploymentNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represent the average number of employees, including discontinued operations.", "label": "Average Number Of Employees, Including Discontinued Operations", "terseLabel": "Average number of employees, including discontinued operations" } } }, "auth_ref": [] }, "trib_AverageRemainingLeaseTermYears": { "xbrltype": "durationItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "AverageRemainingLeaseTermYears", "presentation": [ "http://trinitybiotech.com/role/PropertyPlantAndEquipmentScheduleOfIncomeFromSub-lettingRight-of-useBuildingsDetails" ], "lang": { "en-us": { "role": { "documentation": "Average remaining lease term in years.", "label": "Average remaining lease term (years)", "terseLabel": "Average remaining lease term (years)" } } }, "auth_ref": [] }, "trib_AverageSharePriceShareOptionsExercised": { "xbrltype": "perShareItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "AverageSharePriceShareOptionsExercised", "presentation": [ "http://trinitybiotech.com/role/ShareOptionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Average share price, share options exercised.", "label": "Average Share Price Share Options Exercised", "terseLabel": "Average share price, share options exercised" } } }, "auth_ref": [] }, "currency_BRL": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2025", "localname": "BRL", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfForeignCurrencyRiskShortTermFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "BRL [Member]" } } }, "auth_ref": [] }, "ifrs-full_BasicEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BasicEarningsLossPerShare", "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfOperations" ], "lang": { "en-us": { "role": { "label": "Basic loss per ADS (US Dollars) - group", "terseLabel": "Basic loss per ADS (US Dollars) \u2013 group" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)." } } }, "auth_ref": [ "r53", "r54" ] }, "ifrs-full_BasicEarningsLossPerShareFromContinuingOperations": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BasicEarningsLossPerShareFromContinuingOperations", "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfOperations" ], "lang": { "en-us": { "role": { "label": "Basic loss per ADS (US Dollars) - continuing operations", "terseLabel": "Basic loss per ADS (US Dollars) \u2013 continuing operations" } }, "en": { "role": { "documentation": "Basic earnings (loss) per share from continuing operations. [Refer: Basic earnings (loss) per share; Continuing operations, unless line item indicates otherwise [member]]" } } }, "auth_ref": [ "r53", "r54" ] }, "ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BasicEarningsLossPerShareFromDiscontinuedOperations", "presentation": [ "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSDetails2" ], "lang": { "en-us": { "role": { "label": "Basic earnings/(loss) per ADS (US Dollars) - discontinued operations", "terseLabel": "Basic (loss)/earnings per \u2018A\u2019 share (US Dollars) \u2013 discontinued operations" } }, "en": { "role": { "documentation": "Basic earnings (loss) per share from discontinued operations. [Refer: Basic earnings (loss) per share; Discontinued operations [member]]" } } }, "auth_ref": [ "r54", "r55" ] }, "trib_BeneficialOwnershipCapPercentage": { "xbrltype": "percentItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "BeneficialOwnershipCapPercentage", "presentation": [ "http://trinitybiotech.com/role/OTHEROPERATINGINCOMEEXPENSENarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Beneficial Ownership Cap Percentage", "documentation": "Percentage of beneficial ownership cap.", "terseLabel": "Beneficial ownership cap percentage" } } }, "auth_ref": [] }, "trib_BenenTradingLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "BenenTradingLimitedMember", "presentation": [ "http://trinitybiotech.com/role/GROUPUNDERTAKINGSDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Benen Trading Limited.", "label": "Benen Trading Limited [Member]" } } }, "auth_ref": [] }, "trib_BiopoolUsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "BiopoolUsIncMember", "presentation": [ "http://trinitybiotech.com/role/GROUPUNDERTAKINGSDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfImpairmentLossDetails" ], "lang": { "en-us": { "role": { "documentation": "Biopool US Inc [Member]", "label": "Biopool US Inc [Member]" } } }, "auth_ref": [] }, "trib_BiosynthMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "BiosynthMember", "presentation": [ "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONDetail5", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Biosynth.", "label": "Biosynth [Member]", "verboseLabel": "Biosynth [Member]" } } }, "auth_ref": [] }, "ifrs-full_BorrowingCostsCapitalised": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BorrowingCostsCapitalised", "presentation": [ "http://trinitybiotech.com/role/BASISOFPREPARATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://trinitybiotech.com/role/FinancialIncomeAndExpensesScheduleOfFinancialIncomeExpensesNetDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Borrowing costs capitalised", "terseLabel": "Capitalisation of borrowing costs" } }, "en": { "role": { "documentation": "The amount of interest and other costs that an entity incurs in connection with the borrowing of funds that are directly attributable to the acquisition, construction or production of a qualifying asset and which form part of the cost of that asset." } } }, "auth_ref": [ "r34", "r327" ] }, "ifrs-full_Borrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Borrowings", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/CapitalAndReservesNarrativeDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails1", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails2", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails3", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails4", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSScheduleOfMovementInTermLoan" ], "lang": { "en-us": { "role": { "negatedPeriodEndLabel": "Balance at end of the period", "negatedPeriodStartLabel": "Balance at January 1", "netLabel": "Unsecured junior convertible note", "periodEndLabel": "Balance at end of the period", "periodStartLabel": "Balance at beginning of the period", "positiveLabel": "Outstanding amount", "positiveTerseLabel": "Convertible note", "label": "Borrowings", "terseLabel": "Remaining amount of loan", "verboseLabel": "Principal amount" } }, "en": { "role": { "documentation": "The amount of outstanding funds that the entity is obligated to repay." } } }, "auth_ref": [ "r615" ] }, "ifrs-full_BorrowingsByNameAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BorrowingsByNameAxis", "presentation": [ "http://trinitybiotech.com/role/BASISOFPREPARATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://trinitybiotech.com/role/CapitalAndReservesNarrativeDetails", "http://trinitybiotech.com/role/IMPAIRMENTTRANSFORMATIONANDONCEOFFCOSTSNarrativeDetails", "http://trinitybiotech.com/role/OTHEROPERATINGINCOMEEXPENSENarrativeDetails", "http://trinitybiotech.com/role/ProvisionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Borrowings by name [axis]", "verboseLabel": "Borrowings by name [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r607" ] }, "ifrs-full_BorrowingsByNameDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BorrowingsByNameDomain", "presentation": [ "http://trinitybiotech.com/role/BASISOFPREPARATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://trinitybiotech.com/role/CapitalAndReservesNarrativeDetails", "http://trinitybiotech.com/role/IMPAIRMENTTRANSFORMATIONANDONCEOFFCOSTSNarrativeDetails", "http://trinitybiotech.com/role/OTHEROPERATINGINCOMEEXPENSENarrativeDetails", "http://trinitybiotech.com/role/ProvisionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Borrowings by name [domain]" } }, "en": { "role": { "documentation": "This member stands for all borrowings when disaggregated by name. It also represents the standard value for the 'Borrowings by name' axis if no other member is used. [Refer: Borrowings]" } } }, "auth_ref": [ "r607" ] }, "ifrs-full_BorrowingsInterestRate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BorrowingsInterestRate", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails", "http://trinitybiotech.com/role/LeaseLiabilitiesScheduleOfOutstandingInterestBearingLoansAndBorrowingsDetails" ], "lang": { "en-us": { "role": { "positiveLabel": "Annual rate of interest", "label": "Borrowings, interest rate", "terseLabel": "Interest rate of note", "verboseLabel": "Nominal interest rate" } }, "en": { "role": { "documentation": "The interest rate on borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r607" ] }, "ifrs-full_BorrowingsInterestRateBasis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BorrowingsInterestRateBasis", "presentation": [ "http://trinitybiotech.com/role/BASISOFPREPARATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Borrowings, interest rate basis", "terseLabel": "Loan, interest rate basis" } }, "en": { "role": { "documentation": "The basis (reference rate) used for calculation of the interest rate on borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r607" ] }, "ifrs-full_BorrowingsMaturity": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BorrowingsMaturity", "presentation": [ "http://trinitybiotech.com/role/BASISOFPREPARATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://trinitybiotech.com/role/CapitalAndReservesNarrativeDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails", "http://trinitybiotech.com/role/LeaseLiabilitiesScheduleOfOutstandingInterestBearingLoansAndBorrowingsDetails", "http://trinitybiotech.com/role/PostBalanceSheetEventsDetails" ], "lang": { "en-us": { "role": { "label": "Borrowings, maturity", "terseLabel": "Maturity of unsecured junior convertible note", "verboseLabel": "Loan maturity" } }, "en": { "role": { "documentation": "The maturity of borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r607" ] }, "ifrs-full_BorrowingsOriginalCurrency": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BorrowingsOriginalCurrency", "presentation": [ "http://trinitybiotech.com/role/LeaseLiabilitiesScheduleOfOutstandingInterestBearingLoansAndBorrowingsDetails" ], "lang": { "en-us": { "role": { "label": "Currency" } }, "en": { "role": { "documentation": "The currency in which the borrowings are denominated. [Refer: Borrowings]" } } }, "auth_ref": [ "r607" ] }, "ifrs-full_BorrowingsRecognisedAsOfAcquisitionDate": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BorrowingsRecognisedAsOfAcquisitionDate", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Borrowings recognised as of acquisition date", "terseLabel": "Funding amount" } }, "en": { "role": { "documentation": "The amount recognised as of the acquisition date for borrowings assumed in a business combination. [Refer: Borrowings; Total for all business combinations [member]]" } } }, "auth_ref": [ "r606" ] }, "ifrs-full_BottomOfRangeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BottomOfRangeMember", "presentation": [ "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesScheduleOfAmortisationDetails", "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesScheduleOfOwnedAssetsDetails", "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfInterestRateRiskEffectiveAndRepricingAnalysisDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsNarrativeDetails", "http://trinitybiotech.com/role/LossPerShareNarrativeDetails", "http://trinitybiotech.com/role/PostBalanceSheetEventsDetails", "http://trinitybiotech.com/role/PropertyPlantAndEquipmentScheduleOfIncomeFromSub-lettingRight-of-useBuildingsDetails", "http://trinitybiotech.com/role/ShareOptionsNarrativeDetails", "http://trinitybiotech.com/role/ShareOptionsScheduleOfAssumptionDeterminingFairValueOfShareOptionsDetails", "http://trinitybiotech.com/role/ShareOptionsScheduleOfGrantsOfShareOptionsAndWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Bottom of range [Member]", "terseLabel": "Minimum [Member]", "verboseLabel": "Bottom of range [Member]" } }, "en": { "role": { "documentation": "This member stands for the bottom of a range." } } }, "auth_ref": [ "r101", "r140", "r164", "r181", "r296", "r490", "r491", "r607" ] }, "ifrs-full_BrandNamesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BrandNamesMember", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Primus trade name [Member]", "terseLabel": "Trade name [Member]" } }, "en": { "role": { "documentation": "This member stands for a class of intangible assets representing rights to a group of complementary assets such as a trademark (or service mark) and its related trade name, formulas, recipes and technological expertise. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r472" ] }, "ifrs-full_BuildingsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BuildingsMember", "presentation": [ "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesScheduleOfOwnedAssetsDetails", "http://trinitybiotech.com/role/PropertyPlantAndEquipmentNarrativeDetails", "http://trinitybiotech.com/role/PropertyPlantAndEquipmentScheduleOfAdditionalInformationOnRight-of-useAssetsDetails", "http://trinitybiotech.com/role/PropertyPlantAndEquipmentScheduleOfIncomeFromSub-lettingRight-of-useBuildingsDetails" ], "lang": { "en-us": { "role": { "label": "Buildings [Member]", "terseLabel": "Buildings [Member]" } }, "en": { "role": { "documentation": "This member stands for a class of plant, property and equipment representing depreciable buildings and similar structures for use in operations. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r578" ] }, "ifrs-full_BusinessCombinationsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BusinessCombinationsAxis", "presentation": [ "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSDetails", "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSTables", "http://trinitybiotech.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails", "http://trinitybiotech.com/role/OTHEROPERATINGINCOMEEXPENSENarrativeDetails", "http://trinitybiotech.com/role/RelatedPartyTransactionsNarrativeDetails", "http://trinitybiotech.com/role/TRADEANDOTHERPAYABLESNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Business combinations [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r196", "r378" ] }, "ifrs-full_BusinessCombinationsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BusinessCombinationsDomain", "presentation": [ "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSDetails", "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSTables", "http://trinitybiotech.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails", "http://trinitybiotech.com/role/OTHEROPERATINGINCOMEEXPENSENarrativeDetails", "http://trinitybiotech.com/role/RelatedPartyTransactionsNarrativeDetails", "http://trinitybiotech.com/role/TRADEANDOTHERPAYABLESNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Business combinations [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Business combinations' axis if no other member is used." } } }, "auth_ref": [ "r196", "r203", "r378" ] }, "dei_BusinessContactMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "BusinessContactMember", "presentation": [ "http://trinitybiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Business Contact [Member]", "documentation": "Business contact for the entity" } } }, "auth_ref": [ "r544", "r557" ] }, "currency_CAD": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2025", "localname": "CAD", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfForeignCurrencyRiskShortTermFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "CAD [Member]" } } }, "auth_ref": [] }, "ifrs-full_CapitalCommitments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CapitalCommitments", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Capital Commitments" } }, "en": { "role": { "documentation": "The amount of future capital expenditures that the entity is committed to make." } } }, "auth_ref": [ "r612" ] }, "ifrs-full_CapitalReserve": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CapitalReserve", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/BASISOFPREPARATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Capital reserve" } }, "en": { "role": { "documentation": "A component of equity representing the capital reserves." } } }, "auth_ref": [ "r615" ] }, "trib_CapitalisedDevelopmentCost": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "CapitalisedDevelopmentCost", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/SEGMENTINFORMATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represent the amount of capitalized development cost", "label": "Capitalised Development Cost", "terseLabel": "Capitalised development costs" } } }, "auth_ref": [] }, "ifrs-full_CapitalisedDevelopmentExpenditureMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CapitalisedDevelopmentExpenditureMember", "presentation": [ "http://trinitybiotech.com/role/AccountingEstimatesAndJudgementsNarrativeDetails", "http://trinitybiotech.com/role/BASISOFPREPARATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesScheduleOfAmortisationDetails" ], "lang": { "en-us": { "role": { "label": "Capitalised development expenditure [member]", "verboseLabel": "Capitalised development costs [Member]" } }, "en": { "role": { "documentation": "This member stands for a class of intangible assets arising from development expenditure capitalised before the start of commercial production or use. An intangible asset shall only be recognised if the entity can demonstrate all of the following: (a) the technical feasibility of completing the intangible asset so that it will be available for use or sale; (b) its intention to complete the intangible asset and use or sell it; (c) its ability to use or sell the intangible asset; (d) how the intangible asset will generate probable future economic benefits. Among other things, the entity can demonstrate the existence of a market for the output of the intangible asset or the intangible asset itself or, if it is to be used internally, the usefulness of the intangible asset; (e) the availability of adequate technical, financial and other resources to complete the development and to use or sell the intangible asset; and (f) its ability to measure reliably the expenditure attributable to the intangible asset during its development." } } }, "auth_ref": [ "r596" ] }, "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfAgeingOfTradeReceivablesDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsNarrativeDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfGoodwillAndIntangibleAssetsDetails", "http://trinitybiotech.com/role/PropertyPlantAndEquipmentScheduleOfAdditionalInformationOnRight-of-useAssetsDetails", "http://trinitybiotech.com/role/PropertyPlantAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentRelatedToAccumulatedDepreciationDetails" ], "lang": { "en-us": { "role": { "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [Axis]", "verboseLabel": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r11", "r17", "r75", "r78", "r85", "r86", "r88", "r89", "r90", "r201", "r224", "r225", "r314", "r319", "r344", "r347", "r354", "r355", "r357", "r358", "r359", "r381", "r387", "r388" ] }, "ifrs-full_CarryingAmountMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CarryingAmountMember", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfAgeingOfTradeReceivablesDetails", "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfFairValuesOfFinancialAssetsliabilitiesDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsNarrativeDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfGoodwillAndIntangibleAssetsDetails", "http://trinitybiotech.com/role/PropertyPlantAndEquipmentScheduleOfAdditionalInformationOnRight-of-useAssetsDetails", "http://trinitybiotech.com/role/PropertyPlantAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentRelatedToAccumulatedDepreciationDetails" ], "lang": { "en-us": { "role": { "label": "Carrying Amount [Member]" } } }, "auth_ref": [ "r17", "r78", "r85", "r88", "r89", "r201", "r224", "r225", "r319", "r347", "r354", "r357", "r358", "r381", "r387", "r388" ] }, "trib_CarryingAmountOfGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "CarryingAmountOfGoodwill", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsNarrativeDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfSignificantGoodwillAndIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Carrying amount of goodwill.", "label": "Carrying amount of goodwill" } } }, "auth_ref": [] }, "ifrs-full_Cash": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Cash", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONDetail5": { "parentTag": "ifrs-full_CashAndCashEquivalents", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfForeignCurrencyRiskShortTermFinancialAssetsAndLiabilitiesDetails", "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfInterestRateProfileOfFinancialAssetsliabilitiesDetails", "http://trinitybiotech.com/role/CashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Cash at bank and in hand", "label": "Cash", "terseLabel": "Cash at bank and in hand", "verboseLabel": "Cash" } }, "en": { "role": { "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]" } } }, "auth_ref": [ "r605" ] }, "trib_CashAcquiredAsOfAcquisitionDate": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "CashAcquiredAsOfAcquisitionDate", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSDetails": { "parentTag": "ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount recognised as of the acquisition date for cash and cash equivalents acquired in a business combination. [Refer: Cash and cash equivalents; Total for all business combinations [member]]", "negatedLabel": "Cash acquired", "label": "Cash Acquired As Of Acquisition Date", "terseLabel": "Cash acquired", "verboseLabel": "Less: Cash and cash equivalents" } } }, "auth_ref": [] }, "trib_CashAndCashEquivalentMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "CashAndCashEquivalentMember", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfInterestRateRiskEffectiveAndRepricingAnalysisDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Cash and cash equivalents [Member]", "label": "Cash And Cash Equivalent [Member]", "terseLabel": "Cash and cash equivalents [Member]" } } }, "auth_ref": [] }, "ifrs-full_CashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashAndCashEquivalents", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 2.0 }, "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONDetail5": { "parentTag": "ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfFairValuesOfFinancialAssetsliabilitiesDetails", "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfInterestRateRiskEffectiveAndRepricingAnalysisDetails", "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfMaximumCreditExposureOfFinancialAssetsDetails", "http://trinitybiotech.com/role/CashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails", "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONDetail5" ], "lang": { "en-us": { "role": { "positiveLabel": "Cash at bank and in hand", "positiveVerboseLabel": "Cash", "label": "Cash and cash equivalents", "terseLabel": "Cash and cash equivalents", "totalLabel": "Cash and cash equivalents", "verboseLabel": "Cash and cash equivalents and short-term investments" } }, "en": { "role": { "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]" } } }, "auth_ref": [ "r102", "r129", "r297", "r424" ] }, "ifrs-full_CashAndCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashAndCashEquivalentsAbstract", "lang": { "en-us": { "role": { "label": "Cash and cash equivalents [Abstract]", "verboseLabel": "Cash and cash equivalents [Abstract]" } } }, "auth_ref": [] }, "trib_CashAndCashEquivalentsAndShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "CashAndCashEquivalentsAndShortTermInvestments", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows", "http://trinitybiotech.com/role/SegmentInformationScheduleOfSegmentAssetsAndSegmentLiabilitiesByGeographicalAreaDetails" ], "lang": { "en-us": { "role": { "documentation": "Cash, cash equivalents, and short term investments.", "periodEndLabel": "Cash and cash equivalents and short-term investments at end of year", "periodStartLabel": "Cash and cash equivalents and short-term investments at beginning of year", "label": "Cash And Cash Equivalents And Short Term Investments", "terseLabel": "Cash and cash equivalents (Note 19)", "totalLabel": "Total cash and cash equivalents", "verboseLabel": "Cash and cash equivalents and short-term investments" } } }, "auth_ref": [] }, "ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashAndCashEquivalentsRecognisedAsOfAcquisitionDate", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSDetails": { "parentTag": "trib_NetCashOutFlowOnBusinessCombination", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: Cash and cash equivalents", "label": "Cash and cash equivalents recognised as of acquisition date", "terseLabel": "Less: Cash and cash equivalents" } }, "en": { "role": { "documentation": "The amount recognised as of the acquisition date for cash and cash equivalents acquired in a business combination. [Refer: Cash and cash equivalents; Total for all business combinations [member]]" } } }, "auth_ref": [ "r606" ] }, "ifrs-full_CashFlowsFromUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) financing activities", "totalLabel": "Net cash generated by/(used in) financing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations." } } }, "auth_ref": [ "r91", "r104" ] }, "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract", "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSDetails3" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) financing activities, discontinued operations", "verboseLabel": "Cash outflow from financing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) the entity's financing activities, related to discontinued operations. [Refer: Discontinued operations [member]; Cash flows from (used in) financing activities]" } } }, "auth_ref": [ "r212" ] }, "ifrs-full_CashFlowsFromUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) investing activities", "totalLabel": "Net cash (used in)/generated by investing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations." } } }, "auth_ref": [ "r91", "r104" ] }, "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract", "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSDetails3" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) investing activities, discontinued operations", "verboseLabel": "Cash inflow from investing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) the entity's investing activities, related to discontinued operations. [Refer: Discontinued operations [member]; Cash flows from (used in) investing activities]" } } }, "auth_ref": [ "r212" ] }, "ifrs-full_CashFlowsFromUsedInMaintainingOperatingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInMaintainingOperatingCapacity", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/BASISOFPREPARATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) maintaining operating capacity", "terseLabel": "Minimum unrestricted cash balance" } }, "en": { "role": { "documentation": "The aggregate amount of cash flows that are required to maintain the entity's current ability to execute operating activities (for example, measured by units of output per day)." } } }, "auth_ref": [ "r485" ] }, "ifrs-full_CashFlowsFromUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivities", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) operating activities", "totalLabel": "Net cash used in operating activities" } } }, "auth_ref": [ "r91", "r104" ] }, "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract", "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations", "presentation": [ "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSDetails3" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) operating activities, discontinued operations", "verboseLabel": "Cash (outflow) from operating activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) the entity's operating activities, related to discontinued operations. [Refer: Discontinued operations [member]; Cash flows from (used in) operating activities]" } } }, "auth_ref": [ "r212" ] }, "ifrs-full_CashFlowsFromUsedInOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInOperations", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) operations", "totalLabel": "Cash used in operations" } }, "en": { "role": { "documentation": "The cash from (used in) the entity's operations." } } }, "auth_ref": [ "r481", "r487" ] }, "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) operations before changes in working capital", "totalLabel": "Operating cash flows before changes in working capital" } }, "en": { "role": { "documentation": "The cash inflow (outflow) from the entity's operations before changes in working capital." } } }, "auth_ref": [ "r487", "r604" ] }, "trib_CashInterestPayableOnPppLoans": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "CashInterestPayableOnPppLoans", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/FinancialIncomeAndExpensesScheduleOfFinancialIncomeExpensesNetDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of cash interest payable on PPP loans.", "label": "Cash Interest Payable On Ppp Loans", "terseLabel": "Cash interest payable on PPP loans" } } }, "auth_ref": [] }, "trib_CashInterestPayableOnSeniorSecureTermLoan": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "CashInterestPayableOnSeniorSecureTermLoan", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/FinancialIncomeAndExpensesScheduleOfFinancialIncomeExpensesNetDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of cash interest payable on senior secure term loan.", "label": "Cash Interest Payable On Senior Secure Term Loan", "terseLabel": "Cash interest payable on senior secured term loan" } } }, "auth_ref": [] }, "trib_CashPaidToEachHolder": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "CashPaidToEachHolder", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Cash paid to each holder.", "label": "Cash Paid To Each Holder", "terseLabel": "Cash paid to each holder" } } }, "auth_ref": [] }, "trib_CashProceedsFromDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "CashProceedsFromDiscontinuedOperations", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of cash proceeds from discontinued operations.", "label": "Cash Proceeds From Discontinued Operations", "verboseLabel": "Cash proceeds from discontinued operations" } } }, "auth_ref": [] }, "trib_CashReceivedFromSaleOfTheDiscontinuedOperationsNetOfTransactionCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "CashReceivedFromSaleOfTheDiscontinuedOperationsNetOfTransactionCosts", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSDetails1": { "parentTag": "ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSDetails1" ], "lang": { "en-us": { "role": { "documentation": "Amount of Cash received from sale of the discontinued operations net of transaction costs.", "label": "Cash Received From Sale Of The Discontinued Operations Net Of Transaction Costs", "verboseLabel": "Cash received from sale of the discontinued operations net of transaction costs" } } }, "auth_ref": [] }, "trib_CashReceivedPerNominalValue": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "CashReceivedPerNominalValue", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Cash received per nominal value.", "label": "Cash Received Per Nominal Value", "terseLabel": "Cash received per nominal value" } } }, "auth_ref": [] }, "trib_CashSoldAsAPartOfDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "CashSoldAsAPartOfDiscontinuedOperations", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSDetails1": { "parentTag": "ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSDetails1" ], "lang": { "en-us": { "role": { "documentation": "Amount of cash sold as a part of discontinued operations.", "negatedLabel": "Cash sold as a part of discontinued operations", "label": "Cash Sold As A Part Of Discontinued Operations", "verboseLabel": "Cash sold as a part of discontinued operations" } } }, "auth_ref": [] }, "ifrs-full_CashTransferred": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashTransferred", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSDetails": { "parentTag": "trib_NetCashOutFlowOnBusinessCombination", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSDetails", "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Cash transferred", "terseLabel": "Cash consideration" } }, "en": { "role": { "documentation": "The fair value, at acquisition date, of cash transferred as consideration in a business combination. [Refer: Total for all business combinations [member]]" } } }, "auth_ref": [ "r187", "r373" ] }, "ifrs-full_CategoriesOfFinancialLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfFinancialLiabilitiesAbstract", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfLiquidityRiskEstimatedInterestPaymentsOfMaturitiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial liabilities" } } }, "auth_ref": [] }, "ifrs-full_CategoriesOfRelatedPartiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfRelatedPartiesAxis", "presentation": [ "http://trinitybiotech.com/role/BASISOFPREPARATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://trinitybiotech.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://trinitybiotech.com/role/RelatedPartyTransactionsNarrativeDetails", "http://trinitybiotech.com/role/RelatedPartyTransactionsScheduleOfCompanysSharesAndShareOptionPlanDetails", "http://trinitybiotech.com/role/ShareOptionsScheduleOfAssumptionDeterminingFairValueOfShareOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Categories of related parties [axis]", "verboseLabel": "Categories of related parties [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r41", "r330" ] }, "ifrs-full_CategoriesOfRelatedPartiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfRelatedPartiesDomain", "presentation": [ "http://trinitybiotech.com/role/BASISOFPREPARATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://trinitybiotech.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://trinitybiotech.com/role/RelatedPartyTransactionsNarrativeDetails", "http://trinitybiotech.com/role/RelatedPartyTransactionsScheduleOfCompanysSharesAndShareOptionPlanDetails", "http://trinitybiotech.com/role/ShareOptionsScheduleOfAssumptionDeterminingFairValueOfShareOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Categories of related parties [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used." } } }, "auth_ref": [ "r41", "r330" ] }, "trib_ChangeInAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ChangeInAllowance", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/AccountingEstimatesAndJudgementsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Change in allowance.", "label": "Change in allowance" } } }, "auth_ref": [] }, "ifrs-full_ChangesInIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ChangesInIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfGoodwillAndIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in intangible assets other than goodwill", "verboseLabel": "Charge for the year" } }, "en": { "role": { "documentation": "The increase (decrease) in intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r78", "r347" ] }, "ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract", "presentation": [ "http://trinitybiotech.com/role/ReconciliationOfLiabilitiesArisingFromFinancingActivitiesScheduleOfLiabilitiesArisingFromFinancingDetails" ], "lang": { "en-us": { "role": { "label": "Cash-flows:" } } }, "auth_ref": [] }, "trib_ChargedReversalAllowanceAccountForCreditLossesOfFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ChargedReversalAllowanceAccountForCreditLossesOfFinancialAssets", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfMovementInAllowanceForImpairmentOfTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Charged Reversal Allowance Account For Credit Losses Of Financial Assets", "terseLabel": "(Reversed)/charged to costs and expenses", "documentation": "The increase (decrease) in an allowance account for credit losses of financial assets resulting from charged (reversal) of impairment." } } }, "auth_ref": [] }, "srt_ChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "ChiefExecutiveOfficerMember", "presentation": [ "http://trinitybiotech.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]" } } }, "auth_ref": [] }, "trib_ChronomedIncMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ChronomedIncMember", "presentation": [ "http://trinitybiotech.com/role/CapitalAndReservesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Chronomed Inc [Member]", "terseLabel": "Chronomed, Inc [Member]", "documentation": "This member stands for information pertaining to \"Chronomed, Inc\"" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CityAreaCode", "presentation": [ "http://trinitybiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "trib_ClarkLaboratoriesIncMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ClarkLaboratoriesIncMember", "presentation": [ "http://trinitybiotech.com/role/GROUPUNDERTAKINGSDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfImpairmentLossDetails" ], "lang": { "en-us": { "role": { "documentation": "Clark Laboratories Inc [Member]", "label": "Clark Laboratories Inc [Member]" } } }, "auth_ref": [] }, "trib_ClassAOrdinarySharesMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ClassAOrdinarySharesMember", "presentation": [ "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://trinitybiotech.com/role/CapitalAndReservesNarrativeDetails", "http://trinitybiotech.com/role/CapitalAndReservesScheduleOfShareCapitalDetails", "http://trinitybiotech.com/role/ConsolidatedStatementOfOperations", "http://trinitybiotech.com/role/DocumentAndEntityInformation", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails", "http://trinitybiotech.com/role/LossPerShareNarrativeDetails", "http://trinitybiotech.com/role/LossPerShareScheduleOfBasicEarningsPerOrdinaryShareDetails", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSDetails2", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSNarrativeDetails", "http://trinitybiotech.com/role/RelatedPartyTransactionsScheduleOfCompanysSharesAndShareOptionPlanDetails", "http://trinitybiotech.com/role/ShareOptionsNarrativeDetails", "http://trinitybiotech.com/role/ShareOptionsScheduleOfGrantsOfShareOptionsAndWarrantsDetails", "http://trinitybiotech.com/role/ShareOptionsSummaryOfRangeOfPricesOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Class A Ordinary shares [Member]", "label": "Class A Ordinary shares [Member]" } } }, "auth_ref": [] }, "trib_ClassATreasurySharesMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ClassATreasurySharesMember", "presentation": [ "http://trinitybiotech.com/role/CapitalAndReservesScheduleOfShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Class A Treasury shares [Member]", "label": "Class A Treasury shares [Member]" } } }, "auth_ref": [] }, "ifrs-full_ClassesOfAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfAssetsAxis", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails", "http://trinitybiotech.com/role/TradeAndOtherReceivablesScheduleOfFutureMinimumRentalsReceivableUnderNon-cancellableOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Classes of assets [axis]", "verboseLabel": "Classes of assets [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r59", "r61", "r139", "r154", "r270", "r333", "r396" ] }, "ifrs-full_ClassesOfAssetsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfAssetsDomain", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails", "http://trinitybiotech.com/role/TradeAndOtherReceivablesScheduleOfFutureMinimumRentalsReceivableUnderNon-cancellableOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Classes of assets [domain]" } }, "en": { "role": { "documentation": "This member stands for a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of assets' axis if no other member is used." } } }, "auth_ref": [ "r59", "r139", "r154", "r270", "r333", "r396" ] }, "ifrs-full_ClassesOfFinancialAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialAssetsAxis", "presentation": [ "http://trinitybiotech.com/role/FINANCIALASSETSNarrativeDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails" ], "lang": { "en-us": { "role": { "label": "Classes of financial assets [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r170", "r234", "r235", "r259", "r260", "r407" ] }, "ifrs-full_ClassesOfFinancialAssetsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialAssetsDomain", "presentation": [ "http://trinitybiotech.com/role/FINANCIALASSETSNarrativeDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails" ], "lang": { "en-us": { "role": { "label": "Classes of financial assets [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated classes of financial assets. It also represents the standard value for the 'Classes of financial assets' axis if no other member is used. [Refer: Financial assets]" } } }, "auth_ref": [ "r170", "r234", "r235", "r259", "r260", "r407" ] }, "ifrs-full_ClassesOfFinancialInstrumentsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialInstrumentsAxis", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementNarrativeDetails", "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfInterestRateRiskEffectiveAndRepricingAnalysisDetails", "http://trinitybiotech.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Classes of financial instruments [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r224", "r227", "r228", "r229", "r387", "r389" ] }, "ifrs-full_ClassesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialInstrumentsDomain", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementNarrativeDetails", "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfInterestRateRiskEffectiveAndRepricingAnalysisDetails", "http://trinitybiotech.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Classes of financial instruments [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]" } } }, "auth_ref": [ "r224", "r227", "r228", "r229", "r387", "r389" ] }, "ifrs-full_ClassesOfFinancialLiabilitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialLiabilitiesAxis", "presentation": [ "http://trinitybiotech.com/role/BASISOFPREPARATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails1", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails2", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails3", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails4", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSScheduleOfMovementInTermLoan", "http://trinitybiotech.com/role/PostBalanceSheetEventsDetails" ], "lang": { "en-us": { "role": { "label": "Classes of financial liabilities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r234", "r235", "r259", "r260" ] }, "ifrs-full_ClassesOfFinancialLiabilitiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialLiabilitiesDomain", "presentation": [ "http://trinitybiotech.com/role/BASISOFPREPARATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails1", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails2", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails3", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails4", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSScheduleOfMovementInTermLoan", "http://trinitybiotech.com/role/PostBalanceSheetEventsDetails" ], "lang": { "en-us": { "role": { "label": "Classes of financial liabilities [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated classes financial liabilities. It also represents the standard value for the 'Classes of financial liabilities' axis if no other member is used. [Refer: Financial liabilities]" } } }, "auth_ref": [ "r234", "r235", "r259", "r260" ] }, "ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfIntangibleAssetsAndGoodwillAxis", "presentation": [ "http://trinitybiotech.com/role/GOODWILLANDINTANGIBLEASSETSDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsNarrativeDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfGoodwillAndIntangibleAssetsDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfIntangibleAssetsWithIndefiniteUsefulLivesDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfPrincipalDevelopmentProjectsDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfSignificantGoodwillAndIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Classes of intangible assets and goodwill [Axis]", "verboseLabel": "Classes of intangible assets and goodwill [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r595" ] }, "ifrs-full_ClassesOfIntangibleAssetsAndGoodwillDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfIntangibleAssetsAndGoodwillDomain", "presentation": [ "http://trinitybiotech.com/role/GOODWILLANDINTANGIBLEASSETSDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsNarrativeDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfGoodwillAndIntangibleAssetsDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfIntangibleAssetsWithIndefiniteUsefulLivesDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfPrincipalDevelopmentProjectsDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfSignificantGoodwillAndIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Classes of intangible assets and goodwill [domain]" } }, "en": { "role": { "documentation": "This member stands for intangible assets and goodwill. It also represents the standard value for the 'Classes of intangible assets and goodwill' axis if no other member is used. [Refer: Goodwill; Intangible assets other than goodwill]" } } }, "auth_ref": [ "r595" ] }, "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillAxis", "presentation": [ "http://trinitybiotech.com/role/AccountingEstimatesAndJudgementsNarrativeDetails", "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Classes of intangible assets other than goodwill [Axis]", "verboseLabel": "Classes of intangible assets other than goodwill [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r79", "r348" ] }, "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillDomain", "presentation": [ "http://trinitybiotech.com/role/AccountingEstimatesAndJudgementsNarrativeDetails", "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Classes of intangible assets other than goodwill [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Classes of intangible assets other than goodwill' axis if no other member is used." } } }, "auth_ref": [ "r79", "r348" ] }, "ifrs-full_ClassesOfInventoriesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfInventoriesAbstract", "lang": { "en-us": { "role": { "label": "Classes of current inventories [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_ClassesOfLiabilitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfLiabilitiesAxis", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails1", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails2", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails3", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails4", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSScheduleOfMovementInTermLoan" ], "lang": { "en-us": { "role": { "label": "Classes of liabilities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r139", "r396" ] }, "ifrs-full_ClassesOfLiabilitiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfLiabilitiesDomain", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails1", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails2", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails3", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails4", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSScheduleOfMovementInTermLoan" ], "lang": { "en-us": { "role": { "label": "Classes of liabilities [domain]" } }, "en": { "role": { "documentation": "This member stands for a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of liabilities' axis if no other member is used. [Refer: Liabilities]" } } }, "auth_ref": [ "r139", "r396" ] }, "ifrs-full_ClassesOfOtherProvisionsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfOtherProvisionsDomain", "presentation": [ "http://trinitybiotech.com/role/InventoriesScheduleOfMovementOnInventoryProvisionDetails", "http://trinitybiotech.com/role/ProvisionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Classes of other provisions [domain]" } }, "en": { "role": { "documentation": "This member stands for provisions other than provisions for employee benefits. It also represents the standard value for the 'Classes of other provisions' axis if no other member is used. [Refer: Provisions]" } } }, "auth_ref": [ "r73", "r342" ] }, "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfPropertyPlantAndEquipmentAxis", "presentation": [ "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesScheduleOfOwnedAssetsDetails", "http://trinitybiotech.com/role/PropertyPlantAndEquipmentNarrativeDetails", "http://trinitybiotech.com/role/PropertyPlantAndEquipmentScheduleOfAdditionalInformationOnRight-of-useAssetsDetails", "http://trinitybiotech.com/role/PropertyPlantAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentRelatedToAccumulatedDepreciationDetails", "http://trinitybiotech.com/role/PropertyPlantAndEquipmentScheduleOfIncomeFromSub-lettingRight-of-useBuildingsDetails" ], "lang": { "en-us": { "role": { "label": "Classes of property, plant and equipment [Axis]", "verboseLabel": "Classes of property, plant and equipment [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r18", "r320" ] }, "ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfPropertyPlantAndEquipmentDomain", "presentation": [ "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesScheduleOfOwnedAssetsDetails", "http://trinitybiotech.com/role/PropertyPlantAndEquipmentNarrativeDetails", "http://trinitybiotech.com/role/PropertyPlantAndEquipmentScheduleOfAdditionalInformationOnRight-of-useAssetsDetails", "http://trinitybiotech.com/role/PropertyPlantAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentRelatedToAccumulatedDepreciationDetails", "http://trinitybiotech.com/role/PropertyPlantAndEquipmentScheduleOfIncomeFromSub-lettingRight-of-useBuildingsDetails" ], "lang": { "en-us": { "role": { "label": "Classes of property, plant and equipment [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Classes of property, plant and equipment' axis if no other member is used." } } }, "auth_ref": [ "r18", "r320" ] }, "ifrs-full_ClassesOfProvisionsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfProvisionsAxis", "presentation": [ "http://trinitybiotech.com/role/InventoriesScheduleOfMovementOnInventoryProvisionDetails", "http://trinitybiotech.com/role/ProvisionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Classes of other provisions [axis]", "verboseLabel": "Classes of other provisions [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r73", "r342" ] }, "ifrs-full_ClassesOfShareCapitalAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfShareCapitalAxis", "presentation": [ "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://trinitybiotech.com/role/CapitalAndReservesNarrativeDetails", "http://trinitybiotech.com/role/CapitalAndReservesScheduleOfShareCapitalDetails", "http://trinitybiotech.com/role/ConsolidatedStatementOfOperations", "http://trinitybiotech.com/role/DocumentAndEntityInformation", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails", "http://trinitybiotech.com/role/LossPerShareNarrativeDetails", "http://trinitybiotech.com/role/LossPerShareScheduleOfBasicEarningsPerOrdinaryShareDetails", "http://trinitybiotech.com/role/LossPerShareScheduleOfDilutedEarningsPerAdsShareCalculationDetails", "http://trinitybiotech.com/role/LossPerShareScheduleOfEarningsPerAdsDetails", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSDetails2", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSNarrativeDetails", "http://trinitybiotech.com/role/RelatedPartyTransactionsNarrativeDetails", "http://trinitybiotech.com/role/RelatedPartyTransactionsScheduleOfCompanysSharesAndShareOptionPlanDetails", "http://trinitybiotech.com/role/ShareOptionsNarrativeDetails", "http://trinitybiotech.com/role/ShareOptionsScheduleOfGrantsOfShareOptionsAndWarrantsDetails", "http://trinitybiotech.com/role/ShareOptionsSummaryOfRangeOfPricesOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Classes of share capital [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r286", "r400", "r444" ] }, "ifrs-full_ClassesOfShareCapitalDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfShareCapitalDomain", "presentation": [ "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://trinitybiotech.com/role/CapitalAndReservesNarrativeDetails", "http://trinitybiotech.com/role/CapitalAndReservesScheduleOfShareCapitalDetails", "http://trinitybiotech.com/role/ConsolidatedStatementOfOperations", "http://trinitybiotech.com/role/DocumentAndEntityInformation", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails", "http://trinitybiotech.com/role/LossPerShareNarrativeDetails", "http://trinitybiotech.com/role/LossPerShareScheduleOfBasicEarningsPerOrdinaryShareDetails", "http://trinitybiotech.com/role/LossPerShareScheduleOfDilutedEarningsPerAdsShareCalculationDetails", "http://trinitybiotech.com/role/LossPerShareScheduleOfEarningsPerAdsDetails", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSDetails2", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSNarrativeDetails", "http://trinitybiotech.com/role/RelatedPartyTransactionsNarrativeDetails", "http://trinitybiotech.com/role/RelatedPartyTransactionsScheduleOfCompanysSharesAndShareOptionPlanDetails", "http://trinitybiotech.com/role/ShareOptionsNarrativeDetails", "http://trinitybiotech.com/role/ShareOptionsScheduleOfGrantsOfShareOptionsAndWarrantsDetails", "http://trinitybiotech.com/role/ShareOptionsSummaryOfRangeOfPricesOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Classes of share capital [domain]" } }, "en": { "role": { "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used." } } }, "auth_ref": [ "r286", "r400", "r444" ] }, "trib_ClinicalLaboratoryMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ClinicalLaboratoryMember", "presentation": [ "http://trinitybiotech.com/role/SegmentInformationScheduleOfRevenueByMajorProductGroupDetails" ], "lang": { "en-us": { "role": { "documentation": "Clinical laboratory [Member]", "label": "Clinical Laboratory Member", "terseLabel": "Clinical laboratory goods [Member]" } } }, "auth_ref": [] }, "trib_ClosingExercisePriceOfOutstandingShareOptions": { "xbrltype": "perShareItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ClosingExercisePriceOfOutstandingShareOptions", "presentation": [ "http://trinitybiotech.com/role/ShareOptionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "exercise price of outstanding share options", "label": "Closing Exercise Price Of Outstanding Share Options", "terseLabel": "Closing share price" } } }, "auth_ref": [] }, "trib_ClosureProvision": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ClosureProvision", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSDetails", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Closure provision.", "negatedLabel": "Closure provision", "label": "Closure provision", "terseLabel": "Closure costs", "verboseLabel": "Closure provision" } } }, "auth_ref": [] }, "trib_ColumnEnhancementMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ColumnEnhancementMember", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfPrincipalDevelopmentProjectsDetails" ], "lang": { "en-us": { "role": { "documentation": "Column Enhancement [Member]", "label": "Column Enhancement [Member]" } } }, "auth_ref": [] }, "ifrs-full_ComponentsOfEquityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComponentsOfEquityAxis", "presentation": [ "http://trinitybiotech.com/role/CapitalAndReservesNarrativeDetails", "http://trinitybiotech.com/role/ConsolidatedStatementOfChangesInEquity", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Components of equity [axis]", "verboseLabel": "Components of equity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r416" ] }, "ifrs-full_ComponentsOfEquityDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComponentsOfEquityDomain", "presentation": [ "http://trinitybiotech.com/role/CapitalAndReservesNarrativeDetails", "http://trinitybiotech.com/role/ConsolidatedStatementOfChangesInEquity", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Components of equity [domain]" } }, "en": { "role": { "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used." } } }, "auth_ref": [ "r416" ] }, "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossBeforeTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossBeforeTaxAbstract", "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Components of other comprehensive income that will be reclassified to profit or loss, before tax [abstract]", "terseLabel": "Items that will be reclassified subsequently to profit or loss" } } }, "auth_ref": [] }, "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComprehensiveIncomeAttributableToOwnersOfParent", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfComprehensiveIncome": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfChangesInEquity", "http://trinitybiotech.com/role/ConsolidatedStatementOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Total comprehensive loss", "terseLabel": "Total comprehensive loss", "totalLabel": "Total Comprehensive Loss (all attributable to owners of the parent)" } }, "en": { "role": { "documentation": "The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]" } } }, "auth_ref": [ "r410", "r449" ] }, "ifrs-full_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComputerEquipmentMember", "presentation": [ "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesScheduleOfOwnedAssetsDetails", "http://trinitybiotech.com/role/PropertyPlantAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentRelatedToAccumulatedDepreciationDetails" ], "lang": { "en-us": { "role": { "label": "Computer equipment [Member]", "verboseLabel": "Computer & Office Equipment [Member]", "terseLabel": "Computer & Office Equipment [Member]" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing computer equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r578" ] }, "trib_ComputerEquipmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ComputerEquipmentsMember", "presentation": [ "http://trinitybiotech.com/role/PropertyPlantAndEquipmentScheduleOfAdditionalInformationOnRight-of-useAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Computer equipment [member]", "label": "Computer Equipments [Member]", "terseLabel": "Computer and office equipment [Member]" } } }, "auth_ref": [] }, "trib_ConsiderationFromEmployeeOptionsSettledInCash": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ConsiderationFromEmployeeOptionsSettledInCash", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/CapitalAndReservesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Consideration from employee options settled in cash.", "label": "Consideration from employee options settled in cash" } } }, "auth_ref": [] }, "ifrs-full_ConsiderationPaidReceived": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ConsiderationPaidReceived", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Consideration paid (received)" } }, "en": { "role": { "documentation": "The amount of consideration paid or received in respect of both obtaining and losing control of subsidiaries or other businesses. [Refer: Total for all subsidiaries [member]]" } } }, "auth_ref": [ "r97" ] }, "trib_ConsolidatedStatementOfComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ConsolidatedStatementOfComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Consolidated Statement Of Comprehensive Income Abstract", "terseLabel": "Consolidated Statement Of Comprehensive Income" } } }, "auth_ref": [] }, "dei_ContactPersonnelFaxNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "ContactPersonnelFaxNumber", "presentation": [ "http://trinitybiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Contact Personnel Fax Number", "documentation": "Fax Number of contact personnel." } } }, "auth_ref": [ "r544" ] }, "dei_ContactPersonnelName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "ContactPersonnelName", "presentation": [ "http://trinitybiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Contact Personnel Name", "documentation": "Name of contact personnel" } } }, "auth_ref": [] }, "trib_ContingentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ContingentAssets", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of contingent assets.", "label": "Contingent Assets", "verboseLabel": "Contingent assets" } } }, "auth_ref": [] }, "trib_ContingentConsiderationClassifiedAsACurrentLiabilityRecognisedAsOfAcquisitionDate": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ContingentConsiderationClassifiedAsACurrentLiabilityRecognisedAsOfAcquisitionDate", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount, at acquisition date, of fair value of contingent consideration arrangements classified as a current liability recognised as consideration transferred in a business combination.", "label": "Contingent Consideration Classified As A Current Liability Recognised As Of Acquisition Date", "terseLabel": "Contingent consideration classified as a current liability" } } }, "auth_ref": [] }, "trib_ContingentConsiderationClassifiedAsContingentLiabilityRecognisedAsOfAcquisitionDate": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ContingentConsiderationClassifiedAsContingentLiabilityRecognisedAsOfAcquisitionDate", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount, at acquisition date, of fair value of contingent consideration arrangements classified as Contingent liability recognised as consideration transferred in a business combination.", "label": "Contingent Consideration Classified As Contingent Liability Recognised As Of Acquisition Date", "terseLabel": "Contingent consideration classified as contingent liability" } } }, "auth_ref": [] }, "trib_ContingentConsiderationNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ContingentConsiderationNonCurrent", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "documentation": "It represents the amount of contingent consideration.", "label": "Contingent Consideration Non Current", "terseLabel": "Contingent consideration" } } }, "auth_ref": [] }, "ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ContingentConsiderationRecognisedAsOfAcquisitionDate", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSDetails", "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://trinitybiotech.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://trinitybiotech.com/role/OTHEROPERATINGINCOMEEXPENSENarrativeDetails", "http://trinitybiotech.com/role/TradeAndOtherPayablesScheduleOfTradeAndOtherPayablesDetails" ], "lang": { "en-us": { "role": { "label": "Fair value of contingent consideration", "terseLabel": "Deferred contingent consideration", "verboseLabel": "Contingent consideration" } }, "en": { "role": { "documentation": "The amount, at acquisition date, of contingent consideration arrangements recognised as consideration transferred in a business combination. [Refer: Total for all business combinations [member]]" } } }, "auth_ref": [ "r190", "r376" ] }, "ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ContingentLiabilitiesRecognisedAsOfAcquisitionDate", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails", "http://trinitybiotech.com/role/TRADEANDOTHERPAYABLESNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Contingent liabilities recognised as of acquisition date", "terseLabel": "Contingent liabilities" } }, "en": { "role": { "documentation": "The amount of contingent liabilities recognised as of the acquisition date in a business combination. [Refer: Classes of contingent liabilities [domain]; Total for all business combinations [member]]" } } }, "auth_ref": [ "r497", "r499", "r523" ] }, "ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ContingentLiabilitiesRecognisedInBusinessCombination", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://trinitybiotech.com/role/OTHEROPERATINGINCOMEEXPENSENarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Contingent liabilities recognised in business combination", "terseLabel": "Liability remeasured" } }, "en": { "role": { "documentation": "The amount of contingent liabilities recognised in a business combination. [Refer: Classes of contingent liabilities [domain]; Total for all business combinations [member]]" } } }, "auth_ref": [ "r199" ] }, "trib_ContingentLiabilityMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ContingentLiabilityMember", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Contingent liability.", "label": "Contingent Liability [Member]", "verboseLabel": "Contingent liability [Member]" } } }, "auth_ref": [] }, "ifrs-full_ContinuingAndDiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ContinuingAndDiscontinuedOperationsAxis", "presentation": [ "http://trinitybiotech.com/role/EmploymentScheduleOfEmploymentCostsDetails", "http://trinitybiotech.com/role/EmploymentTables", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONDetail5" ], "lang": { "en-us": { "role": { "label": "Continuing and discontinued operations [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r215" ] }, "ifrs-full_ContinuingOperationsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ContinuingOperationsMember", "presentation": [ "http://trinitybiotech.com/role/EmploymentScheduleOfEmploymentCostsDetails", "http://trinitybiotech.com/role/EmploymentTables", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONDetail5" ], "lang": { "en-us": { "role": { "label": "Continuing operations [member]" } }, "en": { "role": { "documentation": "This member stands for components of the entity that are not discontinued operations. A component of an entity comprises operations and cash flows that can be clearly distinguished, operationally and for financial reporting purposes, from the rest of the entity. This meaning may be overridden for line items which are either intrinsically related to discontinued operations (or disposal groups held for sale), or which are typically reported for the aggregate of continuing and discontinued. This member also represents the standard value for the 'Continuing and discontinued operations' axis if no other member is used. [Refer: Discontinued operations [member]; Aggregate continuing and discontinued operations [member]]" } } }, "auth_ref": [ "r215" ] }, "trib_ContinuousGlucoseMonitoringTechnologyMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ContinuousGlucoseMonitoringTechnologyMember", "presentation": [ "http://trinitybiotech.com/role/BASISOFPREPARATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://trinitybiotech.com/role/OTHEROPERATINGINCOMEEXPENSENarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stand for continuous glucose monitoring (CGM) technology.", "label": "Continuous Glucose Monitoring Technology [Member]" } } }, "auth_ref": [] }, "trib_ContinuousGlucoseMonitoringTestingMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ContinuousGlucoseMonitoringTestingMember", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfPrincipalDevelopmentProjectsDetails" ], "lang": { "en-us": { "role": { "documentation": "Continuous glucose monitoring testing [Member]", "label": "Continuous Glucose Monitoring Testing [Member]", "verboseLabel": "Continuous glucose monitoring testing [Member]" } } }, "auth_ref": [] }, "trib_ContractualCashFlowsMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ContractualCashFlowsMember", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfLiquidityRiskEstimatedInterestPaymentsOfMaturitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Carrying amount [Member]", "label": "Contractual cash flows [Member]" } } }, "auth_ref": [] }, "trib_ContributionForTaxAuditSettlement": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ContributionForTaxAuditSettlement", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://trinitybiotech.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Contribution for tax audit settlement.", "label": "Contribution for tax audit settlement" } } }, "auth_ref": [] }, "trib_ConversionOptionWithinContingentPartnerObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ConversionOptionWithinContingentPartnerObligation", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Conversion Option Within Contingent Partner Obligation", "terseLabel": "Conversion option within contingent partner obligation", "documentation": "Amount of conversion option within contingent partner obligation." } } }, "auth_ref": [] }, "trib_ConversionOptionsOnDateOfNewLoan": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ConversionOptionsOnDateOfNewLoan", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/ReconciliationOfLiabilitiesArisingFromFinancingActivitiesScheduleOfLiabilitiesArisingFromFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of conversion options on the date of new loan.", "terseLabel": "Conversion options on the date of new loan", "label": "Conversion Options On Date Of New Loan" } } }, "auth_ref": [] }, "trib_ConvertibleNote": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ConvertibleNote", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfFairValuesOfFinancialAssetsliabilitiesDetails", "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfInterestRateProfileOfFinancialAssetsliabilitiesDetails", "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfLiquidityRiskEstimatedInterestPaymentsOfMaturitiesDetails", "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "documentation": "The amout represents convertiable note.", "negatedLabel": "Convertible note", "negatedTerseLabel": "Fixed rate financial liabilities (convertible note)", "label": "Convertible Note", "terseLabel": "Convertible note" } } }, "auth_ref": [] }, "trib_ConvertibleNoteInvestment": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ConvertibleNoteInvestment", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/FINANCIALASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of convertible note investment.", "label": "Convertible Note Investment" } } }, "auth_ref": [] }, "trib_ConvertibleNoteMaturityPeriod": { "xbrltype": "durationItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ConvertibleNoteMaturityPeriod", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementNarrativeDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Convertible Note Maturity Period", "terseLabel": "Convertible note maturity period", "documentation": "Maturity period of convertible note." } } }, "auth_ref": [] }, "trib_ConvertibleNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ConvertibleNoteMember", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementNarrativeDetails", "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfInterestRateRiskEffectiveAndRepricingAnalysisDetails", "http://trinitybiotech.com/role/CapitalAndReservesNarrativeDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Convertible Note.", "label": "Convertible Note [Member]", "verboseLabel": "Convertible note [Member]" } } }, "auth_ref": [] }, "ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember", "presentation": [ "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesScheduleOfAmortisationDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfGoodwillAndIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Patents and licences [Member]" } }, "en": { "role": { "documentation": "This member stands for a class of intangible assets representing copyrights, patents and other industrial property rights, service and operating rights. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r473" ] }, "trib_CostIncurredIssueOfShares": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "CostIncurredIssueOfShares", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/CapitalAndReservesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Cost incurred issue of shares.", "label": "Cost incurred issue of shares" } } }, "auth_ref": [] }, "ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CostOfInventoriesRecognisedAsExpenseDuringPeriod", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/InventoriesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Cost of inventories recognised as expense during period", "verboseLabel": "Cost of sales" } } }, "auth_ref": [ "r28", "r291" ] }, "ifrs-full_CostOfSales": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CostOfSales", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfOperations": { "parentTag": "ifrs-full_GrossProfit", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Cost of sales", "label": "Cost of sales [Default Label]" } } }, "auth_ref": [ "r408", "r458" ] }, "ifrs-full_CounterpartiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CounterpartiesAxis", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONDetail5" ], "lang": { "en-us": { "role": { "label": "Counterparties [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r239" ] }, "ifrs-full_CounterpartiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CounterpartiesDomain", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONDetail5" ], "lang": { "en-us": { "role": { "label": "Counterparties [domain]" } }, "en": { "role": { "documentation": "This member stands for the parties to the transaction other than the entity. It also represents the standard value for the 'Counterparties' axis if no other member is used." } } }, "auth_ref": [ "r239" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "CounterpartyNameAxis", "presentation": [ "http://trinitybiotech.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "trib_CovidTestMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "CovidTestMember", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfPrincipalDevelopmentProjectsDetails" ], "lang": { "en-us": { "role": { "documentation": "COVID test [Member]", "label": "COVID Test [Member]", "terseLabel": "COVID-19 tests [Member]" } } }, "auth_ref": [] }, "trib_CraigHallumMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "CraigHallumMember", "presentation": [ "http://trinitybiotech.com/role/CapitalAndReservesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Craig Hallum [Member]" } } }, "auth_ref": [] }, "trib_CreditAgreementAxis": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "CreditAgreementAxis", "presentation": [ "http://trinitybiotech.com/role/BASISOFPREPARATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table.", "label": "Credit Agreement [Axis]" } } }, "auth_ref": [] }, "trib_CreditAgreementDomain": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "CreditAgreementDomain", "presentation": [ "http://trinitybiotech.com/role/BASISOFPREPARATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Credit Agreement [Domain]", "label": "Credit Agreement [Domain]" } } }, "auth_ref": [] }, "srt_CurrencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "CurrencyAxis", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfForeignCurrencyRiskShortTermFinancialAssetsAndLiabilitiesDetails", "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfSensitivityAnalysisDetails", "http://trinitybiotech.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Foreign Currency Axis [Axis]", "verboseLabel": "Currency [Axis]" } } }, "auth_ref": [] }, "ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentAccruedExpensesAndOtherCurrentLiabilities", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails", "http://trinitybiotech.com/role/TradeAndOtherPayablesScheduleOfTradeAndOtherPayablesDetails" ], "lang": { "en-us": { "role": { "label": "Accruals and other liabilities" } }, "en": { "role": { "documentation": "The amount of current accrued expenses and other current liabilities. [Refer: Accruals; Other current liabilities]" } } }, "auth_ref": [ "r615" ] }, "ifrs-full_CurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentAssets", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current assets [Default Label]", "totalLabel": "Total current assets" } }, "en": { "role": { "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]" } } }, "auth_ref": [ "r122", "r435", "r489" ] }, "ifrs-full_CurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentAssetsAbstract", "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current assets" } } }, "auth_ref": [] }, "ifrs-full_CurrentAssetsLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentAssetsLiabilities", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/BASISOFPREPARATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Current assets (liabilities)", "terseLabel": "Net current assets" } }, "en": { "role": { "documentation": "The amount of current assets less the amount of current liabilities." } } }, "auth_ref": [ "r615" ] }, "ifrs-full_CurrentContractAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentContractAssets", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/TradeAndOtherReceivablesScheduleOfTradeAndOtherReceivablesDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentReceivables", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://trinitybiotech.com/role/TradeAndOtherReceivablesScheduleOfTradeAndOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Contract assets" } }, "en": { "role": { "documentation": "The amount of current contract assets. [Refer: Contract assets]" } } }, "auth_ref": [ "r141" ] }, "ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentDeferredIncomeOtherThanCurrentContractLiabilities", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/AccountingEstimatesAndJudgementsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Current deferred income other than current contract liabilities" } }, "en": { "role": { "documentation": "The amount of current deferred income other than current contract liabilities. [Refer: Deferred income other than contract liabilities]" } } }, "auth_ref": [ "r615", "r618" ] }, "trib_CurrentFinanceLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "CurrentFinanceLeaseLiabilities", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 1.0 }, "http://trinitybiotech.com/role/LeaseLiabilitiesScheduleOfCarryingValuesOfFinanceLeaseLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition", "http://trinitybiotech.com/role/LeaseLiabilitiesScheduleOfCarryingValuesOfFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Current finance lease liabilities as of balance sheet date.", "label": "Current Finance Lease Liabilities", "totalLabel": "Current liabilities", "verboseLabel": "Lease liabilities" } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://trinitybiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "ifrs-full_CurrentInvestments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentInvestments", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Current investments", "verboseLabel": "Strategic investment and partnership with MiCo" } }, "en": { "role": { "documentation": "The amount of current investments." } } }, "auth_ref": [ "r615" ] }, "trib_CurrentLeaseLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "CurrentLeaseLiabilitiesAbstract", "presentation": [ "http://trinitybiotech.com/role/LeaseLiabilitiesScheduleOfCarryingValuesOfFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Current liabilities" } } }, "auth_ref": [] }, "ifrs-full_CurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentLiabilities", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current liabilities", "totalLabel": "Total current liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period." } } }, "auth_ref": [ "r124", "r436", "r489" ] }, "ifrs-full_CurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentLiabilitiesAbstract", "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current liabilities [abstract]", "terseLabel": "Current liabilities" } } }, "auth_ref": [] }, "trib_CurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "CurrentLiabilitiesMember", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails1", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represent information about the current liabilities member.", "label": "Current Liabilities [Member]" } } }, "auth_ref": [] }, "ifrs-full_CurrentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentMember", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfAgeingOfTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Not past due [Member]" } }, "en": { "role": { "documentation": "This member stands for a current time band." } } }, "auth_ref": [ "r503", "r510" ] }, "ifrs-full_CurrentPrepayments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentPrepayments", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/TradeAndOtherReceivablesScheduleOfTradeAndOtherReceivablesDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentReceivables", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://trinitybiotech.com/role/TradeAndOtherReceivablesScheduleOfTradeAndOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Prepayments" } }, "en": { "role": { "documentation": "The amount of current prepayments. [Refer: Prepayments]" } } }, "auth_ref": [ "r527", "r535" ] }, "ifrs-full_CurrentProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentProvisions", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://trinitybiotech.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSNarrativeDetails", "http://trinitybiotech.com/role/ProvisionsScheduleOfProvisionsDetails" ], "lang": { "en-us": { "role": { "label": "Current provisions", "terseLabel": "Provisions", "verboseLabel": "Provision" } }, "en": { "role": { "documentation": "The amount of current provisions, including provisions for employee benefits. [Refer: Provisions]" } } }, "auth_ref": [ "r427" ] }, "ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentRawMaterialsAndCurrentProductionSupplies", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/InventoriesScheduleOfInventoriesDetails": { "parentTag": "ifrs-full_Inventories", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://trinitybiotech.com/role/InventoriesScheduleOfInventoriesDetails" ], "lang": { "en-us": { "role": { "label": "Raw materials and consumables" } }, "en": { "role": { "documentation": "A classification of current inventory representing the amount of current raw materials and current production supplies. [Refer: Current production supplies; Current raw materials]" } } }, "auth_ref": [ "r586" ] }, "ifrs-full_CurrentReceivablesFromContractsWithCustomers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentReceivablesFromContractsWithCustomers", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/SegmentInformationScheduleOfRevenueDerivesFromTransferOfGoodsAndServicesDetails" ], "lang": { "en-us": { "role": { "label": "At a point in time" } }, "en": { "role": { "documentation": "The amount of current receivables from contracts with customers. [Refer: Receivables from contracts with customers]" } } }, "auth_ref": [ "r141" ] }, "ifrs-full_CurrentReceivablesFromRentalOfProperties": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentReceivablesFromRentalOfProperties", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/TradeAndOtherReceivablesScheduleOfTradeAndOtherReceivablesDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentReceivables", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://trinitybiotech.com/role/TradeAndOtherReceivablesScheduleOfTradeAndOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Finance lease receivables", "terseLabel": "Finance lease receivable" } }, "en": { "role": { "documentation": "The amount of current receivables from rental of properties. [Refer: Receivables from rental of properties]" } } }, "auth_ref": [ "r616" ] }, "ifrs-full_CurrentTaxAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentTaxAssetsCurrent", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Income tax receivable" } }, "en": { "role": { "documentation": "The current amount of current tax assets. [Refer: Current tax assets]" } } }, "auth_ref": [ "r428" ] }, "ifrs-full_CurrentTaxExpenseIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentTaxExpenseIncome", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfChargeForTaxDetails" ], "lang": { "en-us": { "role": { "label": "Irish Corporation tax" } } }, "auth_ref": [ "r459", "r519" ] }, "ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfChargeForTaxDetails" ], "lang": { "en-us": { "role": { "label": "Total current tax credit", "terseLabel": "Total current tax expense/(credit)", "totalLabel": "Total current tax credit" } } }, "auth_ref": [ "r574" ] }, "ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract", "presentation": [ "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfChargeForTaxDetails" ], "lang": { "en-us": { "role": { "label": "Current tax expense/(credit)" } } }, "auth_ref": [] }, "trib_CurrentTaxForeignExpenseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "CurrentTaxForeignExpenseIncome", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfChargeForTaxDetails" ], "lang": { "en-us": { "role": { "documentation": "Current Foreign taxes.", "label": "Current Tax Foreign Expense Income", "terseLabel": "Foreign taxes" } } }, "auth_ref": [] }, "ifrs-full_CurrentTaxLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentTaxLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 2.0 }, "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONDetail5": { "parentTag": "ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONDetail5" ], "lang": { "en-us": { "role": { "negatedLabel": "Current corporation tax", "label": "Current tax liabilities, current", "terseLabel": "Income tax payable" } }, "en": { "role": { "documentation": "The current amount of current tax liabilities. [Refer: Current tax liabilities]" } } }, "auth_ref": [ "r428" ] }, "ifrs-full_CurrentTradeReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentTradeReceivables", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/TradeAndOtherReceivablesScheduleOfTradeAndOtherReceivablesDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentReceivables", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfMaximumCreditExposureOfFinancialAssetsDetails", "http://trinitybiotech.com/role/TradeAndOtherReceivablesScheduleOfTradeAndOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Trade receivables, net of impairment losses", "verboseLabel": "Third party trade receivables" } }, "en": { "role": { "documentation": "The amount of current trade receivables. [Refer: Trade receivables]" } } }, "auth_ref": [ "r527", "r533", "r535" ] }, "ifrs-full_CurrentValueAddedTaxPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentValueAddedTaxPayables", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/TradeAndOtherPayablesScheduleOfTradeAndOtherPayablesDetails" ], "lang": { "en-us": { "role": { "label": "Payroll taxes" } }, "en": { "role": { "documentation": "The amount of current value added tax payables. [Refer: Value added tax payables]" } } }, "auth_ref": [ "r618" ] }, "ifrs-full_CurrentValueAddedTaxReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentValueAddedTaxReceivables", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/TradeAndOtherReceivablesScheduleOfTradeAndOtherReceivablesDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentReceivables", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://trinitybiotech.com/role/TradeAndOtherReceivablesScheduleOfTradeAndOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Value added tax" } }, "en": { "role": { "documentation": "The amount of current value added tax receivables. [Refer: Value added tax receivables]" } } }, "auth_ref": [ "r616" ] }, "trib_CustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "CustomerMember", "presentation": [ "http://trinitybiotech.com/role/SegmentInformationScheduleOfRevenueDerivesFromTransferOfGoodsAndServicesDetails" ], "lang": { "en-us": { "role": { "documentation": "Customer [Member]", "label": "Customer [Member]" } } }, "auth_ref": [] }, "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r552", "r567" ] }, "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]" } } }, "auth_ref": [ "r552", "r567" ] }, "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]" } } }, "auth_ref": [ "r554", "r569" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]" } } }, "auth_ref": [ "r554", "r569" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]" } } }, "auth_ref": [ "r556", "r571" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]" } } }, "auth_ref": [ "r554", "r569" ] }, "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]" } } }, "auth_ref": [ "r547", "r562" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementProcessesIntegratedFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Flag]" } } }, "auth_ref": [ "r548", "r563" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Text Block]" } } }, "auth_ref": [ "r548", "r563" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract", "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]" } } }, "auth_ref": [ "r546", "r561" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]" } } }, "auth_ref": [ "r546", "r561" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]" } } }, "auth_ref": [ "r546", "r561" ] }, "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Third Party Engaged [Flag]" } } }, "auth_ref": [ "r549", "r564" ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]" } } }, "auth_ref": [ "r551", "r566" ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]" } } }, "auth_ref": [ "r551", "r566" ] }, "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r552", "r567" ] }, "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]" } } }, "auth_ref": [ "r555", "r570" ] }, "cyd_CybersecurityRiskRoleOfManagementTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskRoleOfManagementTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Role of Management [Text Block]" } } }, "auth_ref": [ "r553", "r568" ] }, "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]" } } }, "auth_ref": [ "r550", "r565" ] }, "trib_DarnickCompanyMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DarnickCompanyMember", "presentation": [ "http://trinitybiotech.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://trinitybiotech.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Darnick Company [Member]", "label": "Darnick Company [Member]" } } }, "auth_ref": [] }, "trib_DebtInstrumentConvertibleConversionPrice": { "xbrltype": "perShareItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DebtInstrumentConvertibleConversionPrice", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails", "http://trinitybiotech.com/role/PostBalanceSheetEventsDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Convertible, Conversion Price", "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "terseLabel": "Minimum conversion price" } } }, "auth_ref": [] }, "trib_DebtInstrumentConvertiblePercentageOfVolumeWeightedAveragePriceOfAmericanDepositarySharesAtTimeOfEachSuchConversionForConversionPrice": { "xbrltype": "percentItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DebtInstrumentConvertiblePercentageOfVolumeWeightedAveragePriceOfAmericanDepositarySharesAtTimeOfEachSuchConversionForConversionPrice", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails", "http://trinitybiotech.com/role/PostBalanceSheetEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of the volume\u2011weighted average price (\u201cVWAP\u201d) of the ADSs at the time of each such conversion for conversion price", "documentation": "The percentage of the volume\u2011weighted average price (\u201cVWAP\u201d) of american depositary share (\u201cADSs\u201d) price to conversion price of convertible debt instruments at the time of each such conversion.", "label": "Debt Instrument, Convertible, Percentage of volume\u2011weighted average price of American Depositary Shares at time of each such conversion for conversion price" } } }, "auth_ref": [] }, "trib_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger1": { "xbrltype": "percentItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger1", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails", "http://trinitybiotech.com/role/PostBalanceSheetEventsDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument Convertible Threshold Percentage Of Stock Price Trigger", "terseLabel": "Percentage of the 30\u2011day volume\u2011weighted average price (\u201cVWAP\u201d) of the Company\u2019s ADSs", "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion." } } }, "auth_ref": [] }, "trib_DebtInstrumentConvertibleThresholdTradingDays1": { "xbrltype": "integerItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DebtInstrumentConvertibleThresholdTradingDays1", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails", "http://trinitybiotech.com/role/PostBalanceSheetEventsDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument Convertible Threshold Trading Days", "terseLabel": "Period of volume\u2011weighted average price (\u201cVWAP\u201d) of the Company\u2019s ADSs", "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature." } } }, "auth_ref": [] }, "ifrs-full_DecreaseThroughWriteoffFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DecreaseThroughWriteoffFinancialAssets", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfMovementInAllowanceForImpairmentOfTradeReceivablesDetails", "http://trinitybiotech.com/role/FINANCIALASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Amounts written off during the year", "label": "Decrease through write-off, financial assets", "terseLabel": "Unpaid investment amount written off" } }, "en": { "role": { "documentation": "The decrease in financial assets resulting from write-off. [Refer: Financial assets]" } } }, "auth_ref": [ "r501", "r502", "r509", "r525", "r526" ] }, "trib_DeferredConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DeferredConsideration", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfFairValuesOfFinancialAssetsliabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Deferred consideration.", "label": "Deferred Consideration", "terseLabel": "Deferred Consideration (Phoenix Bio-tech)" } } }, "auth_ref": [] }, "trib_DeferredConsiderationPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DeferredConsiderationPayable", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfFairValuesOfFinancialAssetsliabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Deferred consideration payable.", "label": "Deferred Consideration Payable", "terseLabel": "Net Deferred Consideration Payable ('Fiomi')" } } }, "auth_ref": [] }, "ifrs-full_DeferredIncomeIncludingContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DeferredIncomeIncludingContractLiabilities", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/TradeAndOtherPayablesScheduleOfTradeAndOtherPayablesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Deferred tax liabilities recognised as of acquisition date", "label": "Deferred income including contract liabilities", "terseLabel": "Deferred tax liabilities", "totalLabel": "Total deferred income including contract liabilities", "verboseLabel": "Deferred income" } }, "en": { "role": { "documentation": "The amount of liabilities representing income that has been received (or the amount is due) but is not yet earned, including contract liabilities. [Refer: Contract liabilities]" } } }, "auth_ref": [ "r615", "r618" ] }, "trib_DeferredTaxAssetDecreaseDueToDecreaseInProvision": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DeferredTaxAssetDecreaseDueToDecreaseInProvision", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/DeferredTaxAssetsAndLiabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Deferred tax asset decrease due to decrease in provision.", "label": "Deferred tax asset decrease due to decrease in provision" } } }, "auth_ref": [] }, "trib_DeferredTaxAssetIncreaseDueToIncreaseInProvision": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DeferredTaxAssetIncreaseDueToIncreaseInProvision", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/DeferredTaxAssetsAndLiabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of increase in deferred tax asset due to increase in provision.", "label": "Deferred Tax Asset Increase Due To Increase In Provision", "terseLabel": "Deferred tax asset increase due to increase in provision" } } }, "auth_ref": [] }, "ifrs-full_DeferredTaxAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DeferredTaxAssets", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition", "http://trinitybiotech.com/role/DeferredTaxAssetsAndLiabilitiesScheduleOfRecognisedDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred tax assets" } }, "en": { "role": { "documentation": "The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]" } } }, "auth_ref": [ "r4", "r310", "r429", "r432" ] }, "trib_DeferredTaxAssetsAndLiabilitiesOffset": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DeferredTaxAssetsAndLiabilitiesOffset", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/DeferredTaxAssetsAndLiabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets and Liabilities Offset", "terseLabel": "Deferred tax asset liability offset", "documentation": "Amount of deferred tax asset liability offset." } } }, "auth_ref": [] }, "trib_DeferredTaxAssetsCapitalLossCarryforward": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DeferredTaxAssetsCapitalLossCarryforward", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/DeferredTaxAssetsAndLiabilitiesScheduleOfUnrecognisedDeferredTaxAssetsDetails": { "parentTag": "trib_DeferredTaxAssetsOperatingLossCarryforward", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://trinitybiotech.com/role/DeferredTaxAssetsAndLiabilitiesScheduleOfUnrecognisedDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforward.", "label": "Deferred Tax Assets Capital Loss Carryforward", "terseLabel": "Capital losses" } } }, "auth_ref": [] }, "trib_DeferredTaxAssetsOperatingLossCarryforward": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DeferredTaxAssetsOperatingLossCarryforward", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/DeferredTaxAssetsAndLiabilitiesScheduleOfUnrecognisedDeferredTaxAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://trinitybiotech.com/role/DeferredTaxAssetsAndLiabilitiesScheduleOfUnrecognisedDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforward.", "label": "Deferred Tax Assets Operating Loss Carryforward", "totalLabel": "Unrecognised deferred tax assets" } } }, "auth_ref": [] }, "trib_DeferredTaxAssetsOperatingLossCarryforwardsState": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DeferredTaxAssetsOperatingLossCarryforwardsState", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/DeferredTaxAssetsAndLiabilitiesScheduleOfUnrecognisedDeferredTaxAssetsDetails": { "parentTag": "trib_DeferredTaxAssetsOperatingLossCarryforward", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://trinitybiotech.com/role/DeferredTaxAssetsAndLiabilitiesScheduleOfUnrecognisedDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state operating loss carryforwards.", "label": "Deferred Tax Assets Operating Loss Carryforwards State", "terseLabel": "US state credit carry-forwards" } } }, "auth_ref": [] }, "trib_DeferredTaxAssetsOperatingLossDomestic": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DeferredTaxAssetsOperatingLossDomestic", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/DeferredTaxAssetsAndLiabilitiesScheduleOfUnrecognisedDeferredTaxAssetsDetails": { "parentTag": "trib_DeferredTaxAssetsOperatingLossCarryforward", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://trinitybiotech.com/role/DeferredTaxAssetsAndLiabilitiesScheduleOfUnrecognisedDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards.", "label": "Deferred Tax Assets Operating Loss Domestic", "terseLabel": "Net operating losses" } } }, "auth_ref": [] }, "trib_DeferredTaxAssetsOtherTemporaryTimingDifferences": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DeferredTaxAssetsOtherTemporaryTimingDifferences", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/DeferredTaxAssetsAndLiabilitiesScheduleOfUnrecognisedDeferredTaxAssetsDetails": { "parentTag": "trib_DeferredTaxAssetsOperatingLossCarryforward", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://trinitybiotech.com/role/DeferredTaxAssetsAndLiabilitiesScheduleOfUnrecognisedDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Other temporary timing differences.", "label": "Deferred Tax Assets Other Temporary Timing Differences", "terseLabel": "Other temporary timing differences" } } }, "auth_ref": [] }, "trib_DeferredTaxAssetsUsAlternativeMinimumTaxCredits": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DeferredTaxAssetsUsAlternativeMinimumTaxCredits", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/DeferredTaxAssetsAndLiabilitiesScheduleOfUnrecognisedDeferredTaxAssetsDetails": { "parentTag": "trib_DeferredTaxAssetsOperatingLossCarryforward", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://trinitybiotech.com/role/DeferredTaxAssetsAndLiabilitiesScheduleOfUnrecognisedDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "US alternative minimum tax credits.", "label": "Deferred Tax Assets Us Alternative Minimum Tax Credits", "terseLabel": "US alternative minimum tax credits" } } }, "auth_ref": [] }, "ifrs-full_DeferredTaxExpenseIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DeferredTaxExpenseIncome", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/IncomeTaxCreditNarrativeDetails", "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfChargeForTaxDetails" ], "lang": { "en-us": { "role": { "label": "Total deferred tax (credit)/expense", "verboseLabel": "Total deferred tax (credit)/charge" } }, "en": { "role": { "documentation": "The amount of tax expense (income) relating to changes in deferred tax liabilities and deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]" } } }, "auth_ref": [ "r5", "r311" ] }, "ifrs-full_DeferredTaxExpenseIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DeferredTaxExpenseIncomeAbstract", "presentation": [ "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfChargeForTaxDetails" ], "lang": { "en-us": { "role": { "label": "Deferred tax credit" } } }, "auth_ref": [] }, "trib_DeferredTaxExpenseIncomeRecognisedDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DeferredTaxExpenseIncomeRecognisedDiscontinuedOperations", "presentation": [ "http://trinitybiotech.com/role/DeferredTaxAssetsAndLiabilitiesScheduleOfUnrecognisedDeferredTaxLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of tax expense or income relating to changes in deferred tax liabilities and deferred tax assets, recognised in discontinued operations.", "label": "Deferred Tax Expense (Income) Recognised Discontinued Operations", "verboseLabel": "Recognised in discontinued operations" } } }, "auth_ref": [] }, "ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DeferredTaxExpenseIncomeRecognisedInProfitOrLoss", "presentation": [ "http://trinitybiotech.com/role/DeferredTaxAssetsAndLiabilitiesScheduleOfUnrecognisedDeferredTaxLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Increase in net operating losses", "verboseLabel": "Recognised in income" } } }, "auth_ref": [ "r5", "r311" ] }, "ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfChargeForTaxDetails" ], "lang": { "en-us": { "role": { "label": "Origination and reversal of temporary differences (see Note 15)", "verboseLabel": "Origination and reversal of temporary differences (see Note 14)" } } }, "auth_ref": [ "r461", "r521" ] }, "ifrs-full_DeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DeferredTaxLiabilities", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 2.0 }, "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONDetail5": { "parentTag": "ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition", "http://trinitybiotech.com/role/DeferredTaxAssetsAndLiabilitiesScheduleOfRecognisedDeferredTaxAssetsAndLiabilitiesDetails", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONDetail5" ], "lang": { "en-us": { "role": { "negatedLabel": "Deferred tax liabilities", "negatedTerseLabel": "Deferred tax liability", "label": "Deferred tax liabilities", "verboseLabel": "Deferred tax liability" } }, "en": { "role": { "documentation": "The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]" } } }, "auth_ref": [ "r4", "r310", "r429", "r432" ] }, "ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSDetails": { "parentTag": "ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSDetails", "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Deferred tax liabilities recognised as of acquisition date", "label": "Deferred tax liabilities recognised as of acquisition date", "terseLabel": "Deferred tax liabilities", "negatedTerseLabel": "Deferred tax liabilities" } }, "en": { "role": { "documentation": "The amount recognised as of the acquisition date for deferred tax liabilities assumed in a business combination. [Refer: Deferred tax liabilities; Total for all business combinations [member]]" } } }, "auth_ref": [ "r606" ] }, "ifrs-full_DeferredTaxLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DeferredTaxLiabilityAsset", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/DeferredTaxAssetsAndLiabilitiesScheduleOfRecognisedDeferredTaxAssetsAndLiabilitiesDetails", "http://trinitybiotech.com/role/DeferredTaxAssetsAndLiabilitiesScheduleOfUnrecognisedDeferredTaxLiabilitiesDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Balance at end of year", "periodStartLabel": "Balance at beginning of year", "label": "Net deferred tax assets/(liabilities)" } }, "en": { "role": { "documentation": "The amount of deferred tax liabilities or assets. [Refer: Deferred tax liabilities; Deferred tax assets]" } } }, "auth_ref": [ "r4", "r310" ] }, "trib_DeferredTaxLiabilityDecreased": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DeferredTaxLiabilityDecreased", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/DeferredTaxAssetsAndLiabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Deferred tax liability decreased.", "label": "Deferred tax liability decreased" } } }, "auth_ref": [] }, "trib_DeferredTaxLiabilityIncreased": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DeferredTaxLiabilityIncreased", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/DeferredTaxAssetsAndLiabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of increase in deferred tax liability.", "label": "Deferred Tax Liability Increased", "terseLabel": "Deferred tax liability increased" } } }, "auth_ref": [] }, "ifrs-full_DefinedBenefitPlansAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DefinedBenefitPlansAxis", "presentation": [ "http://trinitybiotech.com/role/EmploymentScheduleOfAverageNumberOfPersonsEmployedDetails" ], "lang": { "en-us": { "role": { "label": "Defined benefit plans [Axis]", "verboseLabel": "Defined benefit plans [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r23", "r322" ] }, "ifrs-full_DefinedBenefitPlansDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DefinedBenefitPlansDomain", "presentation": [ "http://trinitybiotech.com/role/EmploymentScheduleOfAverageNumberOfPersonsEmployedDetails" ], "lang": { "en": { "role": { "documentation": "This member stands for post-employment benefit plans other than defined contribution plans. Defined contribution plans are post-employment benefit plans under which an entity pays fixed contributions into a separate entity (a fund) and will have no legal or constructive obligation to pay further contributions if the fund does not hold sufficient assets to pay all employee benefits relating to employee service in the current and prior periods. It also represents the standard value for the 'Defined benefit plans' axis if no other member is used." } } }, "auth_ref": [ "r23", "r322" ] }, "trib_DeprecationForDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DeprecationForDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/LossBeforeTaxNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represent the deprecation for discontinued operations.", "label": "Deprecation For Discontinued Operations", "terseLabel": "Deprecation for discontinued operations", "verboseLabel": "Depreciation" } } }, "auth_ref": [] }, "ifrs-full_DepreciationAndAmortisationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DepreciationAndAmortisationExpense", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/LossBeforeTaxNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Depreciation on capitalised Intangible projects" } }, "en": { "role": { "documentation": "The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives." } } }, "auth_ref": [ "r130", "r244", "r252", "r409", "r458", "r530" ] }, "trib_DepreciationChargeMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DepreciationChargeMember", "presentation": [ "http://trinitybiotech.com/role/PropertyPlantAndEquipmentScheduleOfAdditionalInformationOnRight-of-useAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Depreciation charge Member.", "label": "Depreciation charge [Member]" } } }, "auth_ref": [] }, "ifrs-full_DepreciationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DepreciationExpense", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/SegmentInformationScheduleOfDepreciationAndAmortisationByGeographicalAreaDetails" ], "lang": { "en-us": { "role": { "label": "Depreciation expense", "terseLabel": "Deprecation for discontinued operations", "verboseLabel": "Depreciation" } } }, "auth_ref": [ "r612" ] }, "trib_DepreciationOnIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DepreciationOnIntangibleAssets", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/LossBeforeTaxScheduleOfAmountChargedToStatementOfOperationDetails" ], "lang": { "en-us": { "role": { "documentation": "Depreciation on intangible assets.", "label": "Depreciation On Intangible Assets", "verboseLabel": "Depreciation" } } }, "auth_ref": [] }, "ifrs-full_DepreciationRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DepreciationRightofuseAssets", "presentation": [ "http://trinitybiotech.com/role/PropertyPlantAndEquipmentNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Depreciation charged on assets under operating lease" } } }, "auth_ref": [ "r148", "r265" ] }, "trib_DerecognitionOfIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DerecognitionOfIntangibleAssetsOtherThanGoodwill", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsNarrativeDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfGoodwillAndIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Derecognition of Intangible Assets Other Than Goodwill", "negatedLabel": "Derecognition of 2024", "documentation": "Amount of derecognition of intangible assets other than goodwill.", "terseLabel": "Derecognition of 2024" } } }, "auth_ref": [] }, "trib_DerivativeFinancialAssetAtDateOfDrawdown": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DerivativeFinancialAssetAtDateOfDrawdown", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails4" ], "lang": { "en-us": { "role": { "documentation": "Derivative financial liability at date of drawdown.", "label": "Derivative Financial Asset At Date Of Drawdown", "terseLabel": "Derivative financial asset at date of drawdown" } } }, "auth_ref": [] }, "trib_DerivativeFinancialAssetAtDateOfIssue": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DerivativeFinancialAssetAtDateOfIssue", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSScheduleOfMovementInTermLoan", "http://trinitybiotech.com/role/ReconciliationOfLiabilitiesArisingFromFinancingActivitiesScheduleOfLiabilitiesArisingFromFinancingDetails" ], "lang": { "en-us": { "role": { "disclosureGuidance": "Derivative financial asset at date of drawdown", "documentation": "Derivative financial asset at date of issue.", "label": "Derivative Financial Asset At Date Of Issue", "terseLabel": "Derivative financial asset at date of issue", "verboseLabel": "Derivative financial asset at date of issue" } } }, "auth_ref": [] }, "trib_DerivativeFinancialAssetMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DerivativeFinancialAssetMember", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails4" ], "lang": { "en-us": { "role": { "documentation": "Represent information about the derivative financial asset member.", "label": "Derivative Financial Asset [Member]" } } }, "auth_ref": [] }, "ifrs-full_DerivativeFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DerivativeFinancialAssets", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Derivative financial assets" } }, "en": { "role": { "documentation": "The amount of financial assets classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]" } } }, "auth_ref": [ "r615" ] }, "trib_DerivativeFinancialAssetsInitialRecognition": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DerivativeFinancialAssetsInitialRecognition", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails4" ], "lang": { "en-us": { "role": { "label": "Derivative Financial Assets Initial Recognition", "terseLabel": "Initial recognition of new derivative asset (call option)", "documentation": "Amount of initial recognition of derivative financial assets." } } }, "auth_ref": [] }, "ifrs-full_DerivativeFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DerivativeFinancialLiabilities", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Derivative financial liabilities" } }, "en": { "role": { "documentation": "The amount of financial liabilities classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]" } } }, "auth_ref": [ "r615" ] }, "trib_DerivativeFinancialLiabilitiesInitialRecognition": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DerivativeFinancialLiabilitiesInitialRecognition", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails3", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Derivative Financial Liabilities Initial Recognition", "terseLabel": "Initial recognition of new derivative liabilities (conversion options)", "documentation": "Amount of initial recognition of derivative financial liabilities." } } }, "auth_ref": [] }, "trib_DerivativeFinancialLiabilityAtDateOfIssue": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DerivativeFinancialLiabilityAtDateOfIssue", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSScheduleOfMovementInTermLoan" ], "lang": { "en-us": { "role": { "documentation": "The amount of derivative financial liability at date of issue.", "label": "Derivative Financial Liability At Date Of Issue", "terseLabel": "Derivative financial liability at date of issue", "verboseLabel": "Derivative financial liability at date of drawdown" } } }, "auth_ref": [] }, "trib_DerivativeFinancialLiabilityAtDateOfIssueOfTermLoan": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DerivativeFinancialLiabilityAtDateOfIssueOfTermLoan", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails3" ], "lang": { "en-us": { "role": { "documentation": "The amount of derivative financial liability at date of issue of term loan.", "label": "Derivative Financial Liability At Date Of Issue Of Term Loan", "terseLabel": "Derivative financial liability at date of drawdown" } } }, "auth_ref": [] }, "trib_DerivativeFinancialLiabilityMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DerivativeFinancialLiabilityMember", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails3" ], "lang": { "en-us": { "role": { "documentation": "Represent information about the derivative financial liability member.", "label": "Derivative Financial Liability [Member]", "verboseLabel": "Derivative financial liability [Member]" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForBorrowingsExplanatory", "presentation": [ "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for borrowings [text block]", "terseLabel": "Convertible Note" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r613" ] }, "ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory", "presentation": [ "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for business combinations and goodwill [text block]", "verboseLabel": "Business combinations & goodwill" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for business combinations and goodwill. [Refer: Total for all business combinations [member]; Goodwill]" } } }, "auth_ref": [ "r613" ] }, "ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory", "presentation": [ "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basis of consolidation" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for business combinations. [Refer: Total for all business combinations [member]]" } } }, "auth_ref": [ "r613" ] }, "ifrs-full_DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsAndHedgingExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsAndHedgingExplanatory", "presentation": [ "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Exchangeable notes and derivative financial instruments" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for derivative financial instruments and hedging. [Refer: Classes of financial instruments [domain]; Derivatives [member]]" } } }, "auth_ref": [ "r613" ] }, "ifrs-full_DescriptionOfAccountingPolicyForDiscontinuedOperationsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForDiscontinuedOperationsExplanatory", "presentation": [ "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Profit or loss from discontinued operations" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for discontinued operations. [Refer: Discontinued operations [member]]" } } }, "auth_ref": [ "r613" ] }, "ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory", "presentation": [ "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Employee benefits" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment." } } }, "auth_ref": [ "r613" ] }, "trib_DescriptionOfAccountingPolicyForExpectedCreditLossesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DescriptionOfAccountingPolicyForExpectedCreditLossesExplanatory", "presentation": [ "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "The description of the entity's accounting policy for expected credit losses.", "label": "Description Of Accounting Policy For Expected Credit Losses Explanatory", "terseLabel": "Expected credit losses" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory", "presentation": [ "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Fair values" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for fair value measurement. [Refer: At fair value [member]]" } } }, "auth_ref": [ "r613" ] }, "ifrs-full_DescriptionOfAccountingPolicyForFinanceCostsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForFinanceCostsExplanatory", "presentation": [ "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cost of sales" } } }, "auth_ref": [ "r613" ] }, "ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory", "presentation": [ "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Finance income and costs" } } }, "auth_ref": [ "r613" ] }, "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory", "presentation": [ "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Foreign currency" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for foreign currency translation." } } }, "auth_ref": [ "r613" ] }, "trib_DescriptionOfAccountingPolicyForGeneralInformationExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DescriptionOfAccountingPolicyForGeneralInformationExplanatory", "presentation": [ "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "The description of the entity's accounting policy for general information.", "label": "Description Of Accounting Policy For General Information Explanatory", "terseLabel": "General information" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForGovernmentGrants", "presentation": [ "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Government grants and financial support" } }, "en": { "role": { "documentation": "The description of the entity's accounting policy for government grants, including the methods of presentation adopted in the financial statements. [Refer: Government [member]; Government grants]" } } }, "auth_ref": [ "r30", "r323" ] }, "ifrs-full_DescriptionOfAccountingPolicyForHedgingExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForHedgingExplanatory", "presentation": [ "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Hedging" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for hedging." } } }, "auth_ref": [ "r613" ] }, "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory", "presentation": [ "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Impairment" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for the impairment of assets." } } }, "auth_ref": [ "r613" ] }, "ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory", "presentation": [ "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Intangibles, including research and development (other than goodwill)" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r613" ] }, "ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForIssuedCapitalExplanatory", "presentation": [ "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "periodEndLabel": "Equity at end of period", "periodStartLabel": "Equity at beginning of period", "label": "Description of accounting policy for issued capital [text block]", "verboseLabel": "Equity" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for issued capital. [Refer: Issued capital]" } } }, "auth_ref": [ "r613" ] }, "ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForMeasuringInventories", "presentation": [ "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for measuring inventories [text block]", "verboseLabel": "Inventories" } }, "en": { "role": { "documentation": "The description of the entity's accounting policy for measuring inventories. [Refer: Inventories]" } } }, "auth_ref": [ "r26", "r289" ] }, "trib_DescriptionOfAccountingPolicyForNewStandardsAndInterpretationsNotYetAdoptedExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DescriptionOfAccountingPolicyForNewStandardsAndInterpretationsNotYetAdoptedExplanatory", "presentation": [ "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "The description of the entity's accounting policy for new standards and interpretations not yet adopted.", "label": "Description Of Accounting Policy For New Standards And Interpretations Not Yet Adopted Explanatory", "terseLabel": "New IFRS Standards", "verboseLabel": "New IFRS Standards adopted as of January 1, 2023" } } }, "auth_ref": [] }, "trib_DescriptionOfAccountingPolicyForOtherOperatingIncomeExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DescriptionOfAccountingPolicyForOtherOperatingIncomeExplanatory", "presentation": [ "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "The description of the entity's material accounting policy information for Other Operating Income.", "label": "Description Of Accounting Policy For Other Operating Income Explanatory", "terseLabel": "Other Operating Income", "verboseLabel": "Other operating income" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for property, plant and equipment [text block]", "verboseLabel": "Property, plant and equipment" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r613" ] }, "ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForProvisionsExplanatory", "presentation": [ "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for provisions [text block]", "terseLabel": "Provisions and contingent liabilities", "verboseLabel": "Provisions" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for provisions. [Refer: Provisions]" } } }, "auth_ref": [ "r613" ] }, "ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForRecognitionOfRevenue", "presentation": [ "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Revenue recognition" } } }, "auth_ref": [ "r613" ] }, "ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForSegmentReportingExplanatory", "presentation": [ "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Segment reporting" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for segment reporting." } } }, "auth_ref": [ "r613" ] }, "trib_DescriptionOfAccountingPolicyForSeniorSecuredTermLoanExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DescriptionOfAccountingPolicyForSeniorSecuredTermLoanExplanatory", "presentation": [ "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "The description of the entity's material accounting policy information for senior secured term loan.", "label": "Description Of Accounting Policy For Senior Secured Term Loan Explanatory", "terseLabel": "Senior secured term loan" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory", "presentation": [ "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Share-based payments" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Types of share-based payment arrangements [domain]]" } } }, "auth_ref": [ "r613" ] }, "trib_DescriptionOfAccountingPolicyForShortTermInvestmentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DescriptionOfAccountingPolicyForShortTermInvestmentsExplanatory", "presentation": [ "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "The description of the entity's accounting policy for short-term investments.", "label": "Description Of Accounting Policy For Short Term Investments Explanatory", "terseLabel": "Short-term investments" } } }, "auth_ref": [] }, "trib_DescriptionOfAccountingPolicyForStatementOfComplianceExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DescriptionOfAccountingPolicyForStatementOfComplianceExplanatory", "presentation": [ "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "The description of the entity's accounting policy for statements of compliance.", "label": "Description Of Accounting Policy For Statement Of Compliance Explanatory", "terseLabel": "Statement of compliance" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory", "presentation": [ "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Tax (current and deferred)" } } }, "auth_ref": [ "r613" ] }, "ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory", "presentation": [ "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for trade and other payables [text block]", "verboseLabel": "Trade and other payables" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for trade and other payables. [Refer: Trade and other payables]" } } }, "auth_ref": [ "r613" ] }, "ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory", "presentation": [ "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for trade and other receivables [text block]", "verboseLabel": "Trade and other receivables" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for trade and other receivables. [Refer: Trade and other receivables]" } } }, "auth_ref": [ "r613" ] }, "ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForTreasurySharesExplanatory", "presentation": [ "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description Of Accounting Policy For Treasury Shares Explanatory", "terseLabel": "Treasury shares" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for treasury shares. [Refer: Treasury shares]" } } }, "auth_ref": [ "r613" ] }, "trib_DescriptionOfAccountingPolicyForWarrantsAndLoanPrepaymentOptionExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DescriptionOfAccountingPolicyForWarrantsAndLoanPrepaymentOptionExplanatory", "presentation": [ "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "The description of the entity's accounting policy for warrants and loan prepayment option.", "label": "Description Of Accounting Policy For Warrants And Loan Prepayment Option Explanatory", "terseLabel": "Warrants and loan prepayment option" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents", "presentation": [ "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for determining components of cash and cash equivalents [text block]", "terseLabel": "Cash and cash equivalents" } }, "en": { "role": { "documentation": "The description of the entity's accounting policy used to determine the components of cash and cash equivalents. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r103", "r298" ] }, "trib_DescriptionOfAmericanDepositoryReceiptRatioToOrdinaryShares": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DescriptionOfAmericanDepositoryReceiptRatioToOrdinaryShares", "presentation": [ "http://trinitybiotech.com/role/ShareOptionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Description of American Depository Receipt Ratio to Ordinary Shares", "terseLabel": "ADR to ordinary shares ratio", "documentation": "Description of american depository receipt ratio to ordinary shares." } } }, "auth_ref": [] }, "trib_DescriptionOfAmericanDepositoryShareToClassAOrdinarySharesRatio": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DescriptionOfAmericanDepositoryShareToClassAOrdinarySharesRatio", "presentation": [ "http://trinitybiotech.com/role/CapitalAndReservesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Description Of American Depository Share To Class A Ordinary Shares Ratio", "terseLabel": "Description of american depository share to class A ordinary shares ratio", "documentation": "Description of american depository share to class A ordinary shares ratio." } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfArrangementForContingentConsiderationArrangementsAndIndemnificationAssets": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfArrangementForContingentConsiderationArrangementsAndIndemnificationAssets", "presentation": [ "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Description of arrangement for contingent consideration arrangements and indemnification assets", "terseLabel": "Description of arrangement for contingent consideration" } }, "en": { "role": { "documentation": "The description of the contingent consideration arrangements and the arrangements for indemnification assets." } } }, "auth_ref": [ "r191", "r377" ] }, "trib_DescriptionOfBorrowingsCovenants": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DescriptionOfBorrowingsCovenants", "presentation": [ "http://trinitybiotech.com/role/PostBalanceSheetEventsDetails" ], "lang": { "en-us": { "role": { "label": "Description Of Borrowings Covenants", "terseLabel": "Borrowings, covenants", "documentation": "Description of borrowings covenants." } } }, "auth_ref": [] }, "trib_DescriptionOfBorrowingsCovenantsUnrestrictedCash": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DescriptionOfBorrowingsCovenantsUnrestrictedCash", "presentation": [ "http://trinitybiotech.com/role/BASISOFPREPARATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Description Of Borrowings Covenants Unrestricted Cash", "terseLabel": "Borrowings, covenants unrestricted cash", "documentation": "Description of borrowings covenants unrestricted cash." } } }, "auth_ref": [] }, "trib_DescriptionOfBorrowingsInterestPayments": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DescriptionOfBorrowingsInterestPayments", "presentation": [ "http://trinitybiotech.com/role/BASISOFPREPARATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Description Of Borrowings Interest Payments", "terseLabel": "Borrowings, interest payments description", "documentation": "Description of borrowings interest payments" } } }, "auth_ref": [] }, "trib_DescriptionOfBorrowingsPaid": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DescriptionOfBorrowingsPaid", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represent information about the description of borrowings paid.", "label": "Description Of Borrowings Paid", "terseLabel": "Description of borrowings paid" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfConversionOfDebtToEquity": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfConversionOfDebtToEquity", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Description of conversion of debt to equity", "verboseLabel": "Description of conversion" } }, "en": { "role": { "documentation": "The description of the non-cash conversion of debt to equity." } } }, "auth_ref": [ "r482" ] }, "trib_DescriptionOfConversionRightsAgreement": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DescriptionOfConversionRightsAgreement", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Description of Conversion Rights Agreement", "terseLabel": "Description of conversion rights agreement", "documentation": "Description of conversion rights agreement." } } }, "auth_ref": [] }, "trib_DescriptionOfCumulativeRevenuesPayable": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DescriptionOfCumulativeRevenuesPayable", "presentation": [ "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Description of cumulative revenues payable.", "label": "Description Of Cumulative Revenues Payable", "terseLabel": "Description of cumulative revenues payable" } } }, "auth_ref": [] }, "trib_DescriptionOfDeficiencyNoticeOfListingCompliance": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DescriptionOfDeficiencyNoticeOfListingCompliance", "presentation": [ "http://trinitybiotech.com/role/PostBalanceSheetEventsDetails" ], "lang": { "en-us": { "role": { "label": "Description Of Deficiency Notice Of Listing Compliance", "terseLabel": "Description of deficiency notice of listing compliance", "documentation": "Description of deficiency notice of listing compliance." } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfDiscountRatesAppliedToCashFlowProjections", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Cash flow projections" } }, "en": { "role": { "documentation": "The discount rate applied to cash flow projections for a cash-generating unit (group of units). [Refer: Total for all cash-generating units [member]]" } } }, "auth_ref": [ "r65", "r67", "r335", "r337" ] }, "ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations", "presentation": [ "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Disclosure of expected impact of initial application of new standards or interpretations [text block]", "terseLabel": "Standards, amendments and interpretations to existing IFRS Standards that are not yet effective" } } }, "auth_ref": [ "r108", "r301" ] }, "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted", "presentation": [ "http://trinitybiotech.com/role/ShareOptionsScheduleOfAssumptionDeterminingFairValueOfShareOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average expected volatility" } }, "en": { "role": { "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time." } } }, "auth_ref": [ "r183" ] }, "ifrs-full_DescriptionOfMaximumTermOfOptionsGrantedForSharebasedPaymentArrangement": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfMaximumTermOfOptionsGrantedForSharebasedPaymentArrangement", "presentation": [ "http://trinitybiotech.com/role/ShareOptionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Description of maximum term of options granted for share-based payment arrangement", "terseLabel": "Contractual life" } }, "en": { "role": { "documentation": "The description of the maximum term of options granted for a type of share-based payment arrangement that existed at any time during the period. An entity with substantially similar types of share-based payment arrangements may aggregate this information. [Refer: Types of share-based payment arrangements [domain]]" } } }, "auth_ref": [ "r171", "r362" ] }, "ifrs-full_DescriptionOfOptionLifeShareOptionsGranted": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfOptionLifeShareOptionsGranted", "presentation": [ "http://trinitybiotech.com/role/ShareOptionsScheduleOfAssumptionDeterminingFairValueOfShareOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average expected life" } }, "en": { "role": { "documentation": "The option life of share options granted." } } }, "auth_ref": [ "r183" ] }, "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted", "presentation": [ "http://trinitybiotech.com/role/ShareOptionsScheduleOfAssumptionDeterminingFairValueOfShareOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average risk free interest rate" } }, "en": { "role": { "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]" } } }, "auth_ref": [ "r183" ] }, "trib_DescriptionOfSettlementAgreementWithUSDepartmentOfJustice": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DescriptionOfSettlementAgreementWithUSDepartmentOfJustice", "presentation": [ "http://trinitybiotech.com/role/BASISOFPREPARATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Description Of Settlement Agreement With US Department Of Justice", "terseLabel": "Settlement agreement with U.S. Department of Justice", "documentation": "Description of settlement agreement with U.S. Department of Justice." } } }, "auth_ref": [] }, "trib_DescriptionOfShareAdjustedRatio": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DescriptionOfShareAdjustedRatio", "presentation": [ "http://trinitybiotech.com/role/ShareOptionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represent the description of share-adjusted ratio.", "label": "Description Of Share Adjusted Ratio", "terseLabel": "Description of share-adjusted ratio" } } }, "auth_ref": [] }, "trib_DescriptionOfStandbyEquityPurchaseAgreement": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DescriptionOfStandbyEquityPurchaseAgreement", "presentation": [ "http://trinitybiotech.com/role/PostBalanceSheetEventsDetails" ], "lang": { "en-us": { "role": { "label": "Description Of Standby Equity Purchase Agreement", "terseLabel": "Description of standby equity purchase agreement", "documentation": "Description of standby equity purchase agreement." } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill", "presentation": [ "http://trinitybiotech.com/role/AccountingEstimatesAndJudgementsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Description of useful life, intangible assets other than goodwill" } }, "en": { "role": { "documentation": "Description of useful life used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r74", "r343" ] }, "ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfVestingRequirementsForSharebasedPaymentArrangement", "presentation": [ "http://trinitybiotech.com/role/ShareOptionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Description of vesting requirements for share-based payment arrangement", "terseLabel": "Vesting conditions" } }, "en": { "role": { "documentation": "The description of the vesting requirements for a type of share-based payment arrangement that existed at any time during the period. An entity with substantially similar types of share-based payment arrangements may aggregate this information. [Refer: Types of share-based payment arrangements [domain]]" } } }, "auth_ref": [ "r171", "r362" ] }, "ifrs-full_DescriptionOfWhetherInvestmentInAssociateIsMeasuredUsingEquityMethodOrAtFairValue": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfWhetherInvestmentInAssociateIsMeasuredUsingEquityMethodOrAtFairValue", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Description of whether investment in associate is measured using equity method or at fair value", "terseLabel": "Description of whether investment in associate is measured using equity method or at fair value" } }, "en": { "role": { "documentation": "The description of whether the investment in an associate is measured using the equity method or at fair value. [Refer: At fair value [member]; Total for all associates [member]]" } } }, "auth_ref": [ "r121", "r392" ] }, "trib_DevelopmentCostMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DevelopmentCostMember", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsNarrativeDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfGoodwillAndIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Development cost [Member]", "label": "Development cost [Member]" } } }, "auth_ref": [] }, "ifrs-full_DilutedEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DilutedEarningsLossPerShare", "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfOperations" ], "lang": { "en-us": { "role": { "label": "Diluted loss per ADS (US Dollars) - group", "terseLabel": "Diluted loss per ADS (US Dollars) \u2013 group" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } } }, "auth_ref": [ "r53", "r54" ] }, "ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DilutedEarningsLossPerShareFromContinuingOperations", "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfOperations" ], "lang": { "en-us": { "role": { "label": "Diluted loss per ADS (US Dollars) - continuing operations", "terseLabel": "Diluted loss per ADS (US Dollars) \u2013 continuing operations" } }, "en": { "role": { "documentation": "Diluted earnings (loss) per share from continuing operations. [Refer: Continuing operations, unless line item indicates otherwise [member]; Diluted earnings (loss) per share]" } } }, "auth_ref": [ "r53", "r54" ] }, "ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DilutedEarningsLossPerShareFromDiscontinuedOperations", "presentation": [ "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSDetails2" ], "lang": { "en-us": { "role": { "label": "Diluted earnings/(loss per ADS (US Dollars) - discontinued operations", "terseLabel": "Diluted earnings/(loss) per ADS (US Dollars) - discontinued operations", "verboseLabel": "Diluted (loss)/earnings per \u2018A\u2019 share (US Dollars) \u2013 discontinued operations" } }, "en": { "role": { "documentation": "Diluted earnings (loss) per share from discontinued operations. [Refer: Diluted earnings (loss) per share; Discontinued operations [member]]" } } }, "auth_ref": [ "r54", "r55" ] }, "trib_DirectorPensionExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DirectorPensionExpense", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/LossBeforeTaxScheduleOfAmountChargedToStatementOfOperationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of director pension expense.", "label": "Director Pension Expense", "terseLabel": "Pension" } } }, "auth_ref": [] }, "trib_DirectorsAndCompanySecretaryMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DirectorsAndCompanySecretaryMember", "presentation": [ "http://trinitybiotech.com/role/RelatedPartyTransactionsScheduleOfCompanysSharesAndShareOptionPlanDetails" ], "lang": { "en-us": { "role": { "documentation": "Directors' and Company Secretary's [Member]", "label": "Directors And Company Secretary [Member]", "terseLabel": "Directors and company secretary [Member]" } } }, "auth_ref": [] }, "trib_DirectorsEmolumentsIncludingNonExecutiveDirectorsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DirectorsEmolumentsIncludingNonExecutiveDirectorsAbstract", "presentation": [ "http://trinitybiotech.com/role/LossBeforeTaxScheduleOfAmountChargedToStatementOfOperationDetails" ], "lang": { "en-us": { "role": { "label": "Directors Emoluments Including Non Executive Directors Abstract", "terseLabel": "Directors' emoluments (including non- executive directors):" } } }, "auth_ref": [] }, "trib_DirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DirectorsMember", "presentation": [ "http://trinitybiotech.com/role/BASISOFPREPARATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://trinitybiotech.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Director [Member]", "label": "Directors [Member]", "terseLabel": "Director [Member]" } } }, "auth_ref": [] }, "ifrs-full_DirectorsRemunerationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DirectorsRemunerationExpense", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/LossBeforeTaxScheduleOfAmountChargedToStatementOfOperationDetails", "http://trinitybiotech.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Remuneration", "verboseLabel": "Non executive directors fees" } } }, "auth_ref": [ "r612" ] }, "trib_DisclosureOfAccountingEstimatesAndJudgementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfAccountingEstimatesAndJudgementsAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of accounting estimates and judgements [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "presentation": [ "http://trinitybiotech.com/role/AccountingEstimatesAndJudgements" ], "lang": { "en-us": { "role": { "label": "ACCOUNTING ESTIMATES AND JUDGEMENTS" } }, "en": { "role": { "documentation": "The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]" } } }, "auth_ref": [ "r608" ] }, "ifrs-full_DisclosureOfAdditionalInformationAboutDefinedBenefitPlansExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfAdditionalInformationAboutDefinedBenefitPlansExplanatory", "presentation": [ "http://trinitybiotech.com/role/EmploymentTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Persons Employed by the Group in the Financial Year" } }, "en": { "role": { "documentation": "The disclosure of additional information about defined benefit plans necessary to meet the objectives of IAS 19. [Refer: Defined benefit plans [domain]]" } } }, "auth_ref": [ "r22" ] }, "ifrs-full_DisclosureOfAdditionalInformationAboutUnderstandingFinancialPositionsAndLiquidityOfEntityExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfAdditionalInformationAboutUnderstandingFinancialPositionsAndLiquidityOfEntityExplanatory", "presentation": [ "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basis of preparation", "verboseLabel": "Basis of preparation and going concern" } }, "en": { "role": { "documentation": "The disclosure of additional information that may be relevant to users of financial statements in understanding the financial position and liquidity of an entity." } } }, "auth_ref": [ "r486" ] }, "ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [Abstract]" } } }, "auth_ref": [] }, "trib_DisclosureOfAnalysisOfDiscontinuedOperationsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfAnalysisOfDiscontinuedOperationsLineItems", "presentation": [ "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSDetails", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSDetails1", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSDetails3" ], "lang": { "en-us": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.", "label": "Disclosure Of Analysis Of Discontinued Operations [Line Items]" } } }, "auth_ref": [] }, "trib_DisclosureOfAnalysisOfDiscontinuedOperationsTable": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfAnalysisOfDiscontinuedOperationsTable", "presentation": [ "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSDetails", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSDetails1", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSDetails3" ], "lang": { "en-us": { "role": { "documentation": "Schedule disclosing information related to the analysis of discontinued operations.", "label": "Disclosure Of Analysis Of Discontinued Operations [Table]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of analysis of single amount of discontinued operations [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems", "presentation": [ "http://trinitybiotech.com/role/EmploymentScheduleOfEmploymentCostsDetails", "http://trinitybiotech.com/role/EmploymentTables", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONDetail5" ], "lang": { "en-us": { "role": { "label": "Disclosure of analysis of single amount of discontinued operations [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsTable", "presentation": [ "http://trinitybiotech.com/role/EmploymentScheduleOfEmploymentCostsDetails", "http://trinitybiotech.com/role/EmploymentTables", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONDetail5" ], "lang": { "en-us": { "role": { "label": "Disclosure of analysis of single amount of discontinued operations [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the analysis of the single amount of discontinued operations." } } }, "auth_ref": [ "r211" ] }, "trib_DisclosureOfAssetsAndLiabilitiesDisposedExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfAssetsAndLiabilitiesDisposedExplanatory", "presentation": [ "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSTables" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for assets and liabilities disposed.", "label": "Disclosure Of Assets And Liabilities Disposed Explanatory", "verboseLabel": "Schedule of Assets and Liabilities Disposed" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory", "presentation": [ "http://trinitybiotech.com/role/IMPAIRMENTTRANSFORMATIONANDONCEOFFCOSTSTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of attribution of expenses by nature to their function [text block]", "terseLabel": "Schedule of Transformation Costs" } } }, "auth_ref": [ "r609", "r612" ] }, "ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems", "presentation": [ "http://trinitybiotech.com/role/IMPAIRMENTTRANSFORMATIONANDONCEOFFCOSTSNarrativeDetails", "http://trinitybiotech.com/role/IMPAIRMENTTRANSFORMATIONANDONCEOFFCOSTSScheduleoftransformationcostsincurredduringtheyearDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of attribution of expenses by nature to their function [line items]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable", "presentation": [ "http://trinitybiotech.com/role/IMPAIRMENTTRANSFORMATIONANDONCEOFFCOSTSNarrativeDetails", "http://trinitybiotech.com/role/IMPAIRMENTTRANSFORMATIONANDONCEOFFCOSTSScheduleoftransformationcostsincurredduringtheyearDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of attribution of expenses by nature to their function [table]" } } }, "auth_ref": [ "r609", "r612" ] }, "trib_DisclosureOfAuthorisationForIssueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfAuthorisationForIssueAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of authorisation for issue [Abstract]" } } }, "auth_ref": [] }, "trib_DisclosureOfAuthorisationForIssueExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfAuthorisationForIssueExplanatory", "presentation": [ "http://trinitybiotech.com/role/AuthorisationForIssue" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for authorisation for issue.", "label": "Disclosure Of Authorisation For Issue Explanatory", "terseLabel": "AUTHORISATION FOR ISSUE" } } }, "auth_ref": [] }, "trib_DisclosureOfBasisOfPreparationAndSignificantAccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfBasisOfPreparationAndSignificantAccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of basis of preparation and significant accounting policies [Abstract]", "verboseLabel": "Basis Of Preparation And Significant Accounting Policies" } } }, "auth_ref": [] }, "trib_DisclosureOfBasisOfPreparationAndSignificantAccountingPoliciesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfBasisOfPreparationAndSignificantAccountingPoliciesExplanatory", "presentation": [ "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for basis of preparation and significant accounting policies.", "label": "Disclosure Of Basis Of Preparation And Significant Accounting Policies Explanatory", "terseLabel": "BASIS OF PREPARATION AND SIGNIFICANT ACCOUNTING POLICIES" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfBorrowingsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfBorrowingsExplanatory", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGS" ], "lang": { "en-us": { "role": { "label": "Disclosure of borrowings [text block]", "terseLabel": "INTEREST-BEARING LOANS AND BORROWINGS" } }, "en": { "role": { "documentation": "The disclosure of borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r608" ] }, "ifrs-full_DisclosureOfBusinessCombinationsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfBusinessCombinationsAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about business combination [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfBusinessCombinationsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfBusinessCombinationsExplanatory", "presentation": [ "http://trinitybiotech.com/role/BUSINESSCOMBINATIONS" ], "lang": { "en-us": { "role": { "label": "Disclosure of business combinations [text block]", "terseLabel": "BUSINESS COMBINATIONS" } }, "en": { "role": { "documentation": "The entire disclosure for business combinations." } } }, "auth_ref": [ "r204" ] }, "ifrs-full_DisclosureOfBusinessCombinationsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfBusinessCombinationsLineItems", "presentation": [ "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSDetails", "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about business combination [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfBusinessCombinationsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfBusinessCombinationsTable", "presentation": [ "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSDetails", "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about business combination [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of business combinations." } } }, "auth_ref": [ "r196", "r378" ] }, "ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfCashAndCashEquivalentsExplanatory", "presentation": [ "http://trinitybiotech.com/role/CashAndCashEquivalents" ], "lang": { "en-us": { "role": { "label": "Disclosure of cash and cash equivalents [text block]", "verboseLabel": "CASH AND CASH EQUIVALENTS" } }, "en": { "role": { "documentation": "The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r608" ] }, "ifrs-full_DisclosureOfCashFlowStatementExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfCashFlowStatementExplanatory", "presentation": [ "http://trinitybiotech.com/role/ReconciliationOfLiabilitiesArisingFromFinancingActivities" ], "lang": { "en-us": { "role": { "label": "RECONCILIATION OF LIABILITIES ARISING FROM FINANCING ACTIVITIES" } }, "en": { "role": { "documentation": "The entire disclosure for a statement of cash flows." } } }, "auth_ref": [ "r105" ] }, "ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfChangesInAccountingEstimatesLineItems", "presentation": [ "http://trinitybiotech.com/role/AccountingEstimatesAndJudgementsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of changes in accounting estimates [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfChangesInAccountingEstimatesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfChangesInAccountingEstimatesTable", "presentation": [ "http://trinitybiotech.com/role/AccountingEstimatesAndJudgementsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of changes in accounting estimates [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the changes in accounting estimates." } } }, "auth_ref": [ "r109", "r303" ] }, "ifrs-full_DisclosureOfClassesOfShareCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of classes of share capital [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalExplanatory", "presentation": [ "http://trinitybiotech.com/role/CapitalAndReservesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Share Capital" } }, "en": { "role": { "documentation": "The disclosure of classes of share capital. [Refer: Classes of share capital [domain]]" } } }, "auth_ref": [ "r286", "r400", "r444" ] }, "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalLineItems", "presentation": [ "http://trinitybiotech.com/role/CapitalAndReservesNarrativeDetails", "http://trinitybiotech.com/role/CapitalAndReservesScheduleOfShareCapitalDetails", "http://trinitybiotech.com/role/ConsolidatedStatementOfOperations", "http://trinitybiotech.com/role/LossPerShareNarrativeDetails", "http://trinitybiotech.com/role/LossPerShareScheduleOfBasicEarningsPerOrdinaryShareDetails", "http://trinitybiotech.com/role/LossPerShareScheduleOfDilutedEarningsPerAdsShareCalculationDetails", "http://trinitybiotech.com/role/LossPerShareScheduleOfEarningsPerAdsDetails", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSDetails2", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSNarrativeDetails", "http://trinitybiotech.com/role/ShareOptionsNarrativeDetails", "http://trinitybiotech.com/role/ShareOptionsScheduleOfGrantsOfShareOptionsAndWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of classes of share capital [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfClassesOfShareCapitalTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalTable", "presentation": [ "http://trinitybiotech.com/role/CapitalAndReservesNarrativeDetails", "http://trinitybiotech.com/role/CapitalAndReservesScheduleOfShareCapitalDetails", "http://trinitybiotech.com/role/ConsolidatedStatementOfOperations", "http://trinitybiotech.com/role/LossPerShareNarrativeDetails", "http://trinitybiotech.com/role/LossPerShareScheduleOfBasicEarningsPerOrdinaryShareDetails", "http://trinitybiotech.com/role/LossPerShareScheduleOfDilutedEarningsPerAdsShareCalculationDetails", "http://trinitybiotech.com/role/LossPerShareScheduleOfEarningsPerAdsDetails", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSDetails2", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSNarrativeDetails", "http://trinitybiotech.com/role/ShareOptionsNarrativeDetails", "http://trinitybiotech.com/role/ShareOptionsScheduleOfGrantsOfShareOptionsAndWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of classes of share capital [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to classes of share capital." } } }, "auth_ref": [ "r286", "r400", "r444" ] }, "ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "presentation": [ "http://trinitybiotech.com/role/CommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "COMMITMENTS AND CONTINGENCIES" } }, "en": { "role": { "documentation": "The disclosure of commitments and contingent liabilities. [Refer: Classes of contingent liabilities [domain]]" } } }, "auth_ref": [ "r608" ] }, "trib_DisclosureOfCommitmentsAndContingentLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfCommitmentsAndContingentLiabilityAbstract", "lang": { "en-us": { "role": { "label": "Disclosure Of Commitments And Contingent Liability Abstract", "terseLabel": "Disclosure of commitments and contingencies [Abstract]", "verboseLabel": "Commitments And Contingencies" } } }, "auth_ref": [] }, "trib_DisclosureOfCompositionOfGroupLineItems": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfCompositionOfGroupLineItems", "presentation": [ "http://trinitybiotech.com/role/GROUPUNDERTAKINGSDetails" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of composition of group.", "label": "Disclosure Of Composition Of Group [Line Items]" } } }, "auth_ref": [] }, "trib_DisclosureOfCompositionOfGroupTable": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfCompositionOfGroupTable", "presentation": [ "http://trinitybiotech.com/role/GROUPUNDERTAKINGSDetails" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of composition of group.", "label": "Disclosure Of Composition Of Group [Table]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfCreditRiskExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfCreditRiskExplanatory", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Maximum Credit Exposure of Financial Assets" } }, "en": { "role": { "documentation": "The disclosure of credit risk. [Refer: Credit risk [member]]" } } }, "auth_ref": [ "r240", "r608" ] }, "ifrs-full_DisclosureOfCreditRiskExposureLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfCreditRiskExposureLineItems", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfExposureOfTradeReceivablesByCustomerDetails", "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfExposureOfTradeReceivablesByGeographicLocationDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of credit risk exposure [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfCreditRiskExposureTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfCreditRiskExposureTable", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfExposureOfTradeReceivablesByCustomerDetails", "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfExposureOfTradeReceivablesByGeographicLocationDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of credit risk exposure [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the credit risk exposure." } } }, "auth_ref": [ "r228", "r389" ] }, "trib_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract", "lang": { "en-us": { "role": { "label": "Disclosure Of Deferred Tax Assets And Liabilities [Abstract]", "terseLabel": "Disclosure of deferred tax assets and liabilities [Abstract]", "verboseLabel": "Deferred Tax Assets And Liabilities" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDeferredTaxesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDeferredTaxesExplanatory", "presentation": [ "http://trinitybiotech.com/role/DeferredTaxAssetsAndLiabilities" ], "lang": { "en-us": { "role": { "label": "DEFERRED TAX ASSETS AND LIABILITIES" } }, "en": { "role": { "documentation": "The disclosure of deferred taxes. [Refer: Deferred tax liabilities; Deferred tax assets]" } } }, "auth_ref": [ "r608" ] }, "ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDefinedBenefitPlansExplanatory", "presentation": [ "http://trinitybiotech.com/role/EmploymentTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Employment Costs" } }, "en": { "role": { "documentation": "The disclosure of defined benefit plans. [Refer: Defined benefit plans [domain]]" } } }, "auth_ref": [ "r23", "r322" ] }, "ifrs-full_DisclosureOfDefinedBenefitPlansLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDefinedBenefitPlansLineItems", "presentation": [ "http://trinitybiotech.com/role/EmploymentScheduleOfAverageNumberOfPersonsEmployedDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of defined benefit plans [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDefinedBenefitPlansTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDefinedBenefitPlansTable", "presentation": [ "http://trinitybiotech.com/role/EmploymentScheduleOfAverageNumberOfPersonsEmployedDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of defined benefit plans [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to defined benefit plans." } } }, "auth_ref": [ "r23", "r322" ] }, "trib_DisclosureOfDetailedInformationAboutAgeingOfTradeReceivablesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutAgeingOfTradeReceivablesExplanatory", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about Ageing of trade receivables.", "label": "Disclosure Of Detailed Information About Ageing Of Trade Receivables Explanatory", "terseLabel": "Schedule of Ageing of Trade Receivables" } } }, "auth_ref": [] }, "trib_DisclosureOfDetailedInformationAboutAmountRelatingFromRevenueExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutAmountRelatingFromRevenueExplanatory", "presentation": [ "http://trinitybiotech.com/role/SegmentInformationTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about amount relating from revenue.", "label": "Disclosure Of Detailed Information About Amount Relating From Revenue Explanatory", "terseLabel": "Schedule of Amount Relating From Revenue" } } }, "auth_ref": [] }, "trib_DisclosureOfDetailedInformationAboutBasicEarningPerAdsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutBasicEarningPerAdsExplanatory", "presentation": [ "http://trinitybiotech.com/role/LossPerShareTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about basic earning per ADS.", "label": "Disclosure Of Detailed Information About Basic Earning Per Ads Explanatory", "terseLabel": "Schedule of Basic Earning Per ADS" } } }, "auth_ref": [] }, "trib_DisclosureOfDetailedInformationAboutBasicEarningsPerOrdinaryShareExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutBasicEarningsPerOrdinaryShareExplanatory", "presentation": [ "http://trinitybiotech.com/role/LossPerShareTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about basic earning per shares.", "label": "Disclosure Of Detailed Information About Basic Earnings Per Ordinary Share Explanatory", "terseLabel": "Schedule of Basic Earnings Per Ordinary Share" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about borrowings [text block]", "terseLabel": "Schedule of Borrowings" } }, "en": { "role": { "documentation": "The disclosure of detailed information about borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r607" ] }, "ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory", "presentation": [ "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about business combination [text block]", "terseLabel": "Schedule of Assets Acquired and Liabilities, Fair Values at Acquisition Date" } }, "en": { "role": { "documentation": "The disclosure of detailed information about business combinations. [Refer: Total for all business combinations [member]]" } } }, "auth_ref": [ "r205" ] }, "trib_DisclosureOfDetailedInformationAboutCapitalExpenditureExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutCapitalExpenditureExplanatory", "presentation": [ "http://trinitybiotech.com/role/SegmentInformationTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about capital expanditure by geographical area.", "label": "Disclosure Of Detailed Information About Capital Expenditure Explanatory", "terseLabel": "Schedule of Capital Expenditure by Geographical Area" } } }, "auth_ref": [] }, "trib_DisclosureOfDetailedInformationAboutCarryingValuesOfFinanceLeaseLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutCarryingValuesOfFinanceLeaseLiabilitiesExplanatory", "presentation": [ "http://trinitybiotech.com/role/LeaseLiabilitiesTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about carrying values of finance lease liabilities.", "label": "Disclosure Of Detailed Information About Carrying Values Of Finance Lease Liabilities Explanatory", "terseLabel": "Schedule of Carrying Values of Finance Lease Liabilities" } } }, "auth_ref": [] }, "trib_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory", "presentation": [ "http://trinitybiotech.com/role/CashAndCashEquivalentsTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about cash and cash equivalents.", "label": "Disclosure Of Detailed Information About Cash And Cash Equivalents Explanatory", "terseLabel": "Schedule of Cash and Cash Equivalents" } } }, "auth_ref": [] }, "trib_DisclosureOfDetailedInformationAboutCashFlowsAttributableToDiscontinuedOperationsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutCashFlowsAttributableToDiscontinuedOperationsExplanatory", "presentation": [ "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about cash flows attributable to discontinued operations.", "label": "Disclosure Of Detailed Information About Cash Flows Attributable To Discontinued Operations Explanatory", "terseLabel": "Schedule of Cash Flows Attributable to Discontinued Operations" } } }, "auth_ref": [] }, "trib_DisclosureOfDetailedInformationAboutChargeForTaxExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutChargeForTaxExplanatory", "presentation": [ "http://trinitybiotech.com/role/IncomeTaxCreditTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about charges for tax.", "label": "Disclosure Of Detailed Information About Charge For Tax Explanatory", "terseLabel": "Schedule of Charge for Tax" } } }, "auth_ref": [] }, "trib_DisclosureOfDetailedInformationAboutCompensationExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutCompensationExplanatory", "presentation": [ "http://trinitybiotech.com/role/RelatedPartyTransactionsTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about compensation.", "label": "Disclosure Of Detailed Information About Compensation Explanatory", "terseLabel": "Schedule of Compensation" } } }, "auth_ref": [] }, "trib_DisclosureOfDetailedInformationAboutDeferredTaxAssetsAndLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutDeferredTaxAssetsAndLiabilitiesExplanatory", "presentation": [ "http://trinitybiotech.com/role/DeferredTaxAssetsAndLiabilitiesTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about deferred tax assets and liabilities.", "label": "Disclosure Of Detailed Information About Deferred Tax Assets And Liabilities Explanatory", "terseLabel": "Schedule of Deferred Tax Assets and Liabilities" } } }, "auth_ref": [] }, "trib_DisclosureOfDetailedInformationAboutDeferredTaxAssetsNotRecognisedExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutDeferredTaxAssetsNotRecognisedExplanatory", "presentation": [ "http://trinitybiotech.com/role/DeferredTaxAssetsAndLiabilitiesTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about deferred tax assets not recognised.", "label": "Disclosure Of Detailed Information About Deferred Tax Assets Not Recognised Explanatory", "terseLabel": "Schedule of Deferred Tax Assets Not Recognised" } } }, "auth_ref": [] }, "trib_DisclosureOfDetailedInformationAboutDepreciationAndAmortisationExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutDepreciationAndAmortisationExplanatory", "presentation": [ "http://trinitybiotech.com/role/SegmentInformationTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about depreciation and amortisation by geographical area.", "label": "Disclosure Of Detailed Information About Depreciation And Amortisation Explanatory", "terseLabel": "Schedule of Depreciation and Amortisation by Geographical Area" } } }, "auth_ref": [] }, "trib_DisclosureOfDetailedInformationAboutDilutedEarningPerAdsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutDilutedEarningPerAdsExplanatory", "presentation": [ "http://trinitybiotech.com/role/LossPerShareTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about diluted earning per ADS.", "label": "Disclosure Of Detailed Information About Diluted Earning Per Ads Explanatory", "terseLabel": "Schedule of Diluted Earning Per ADS" } } }, "auth_ref": [] }, "trib_DisclosureOfDetailedInformationAboutDilutedEarningsPerOrdinaryShareExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutDilutedEarningsPerOrdinaryShareExplanatory", "presentation": [ "http://trinitybiotech.com/role/LossPerShareTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about diluted earning per shares.", "label": "Disclosure Of Detailed Information About Diluted Earnings Per Ordinary Share Explanatory", "terseLabel": "Schedule of Diluted Earnings Per Ordinary Share" } } }, "auth_ref": [] }, "trib_DisclosureOfDetailedInformationAboutEarningsPerAdsForDiscontinuedOperationsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutEarningsPerAdsForDiscontinuedOperationsExplanatory", "presentation": [ "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about earning per ADS for discontinued operations.", "label": "Disclosure Of Detailed Information About Earnings Per Ads For Discontinued Operations Explanatory", "terseLabel": "Schedule of Earnings Per ADS for Discontinued Operations" } } }, "auth_ref": [] }, "trib_DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfIntangibleAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfIntangibleAssetsExplanatory", "presentation": [ "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about estimated useful lives of intangible assets.", "label": "Disclosure Of Detailed Information About Estimated Useful Lives Of Intangible Assets Explanatory", "terseLabel": "Schedule of Estimated Useful Lives of Intangible Assets" } } }, "auth_ref": [] }, "trib_DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfOwnedAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutEstimatedUsefulLivesOfOwnedAssetsExplanatory", "presentation": [ "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about estimated useful lives of owned assets.", "label": "Disclosure Of Detailed Information About Estimated Useful Lives Of Owned Assets Explanatory", "terseLabel": "Schedule of Estimated Useful Lives of Owned Assets" } } }, "auth_ref": [] }, "trib_DisclosureOfDetailedInformationAboutExposureOfTradeReceivablesByCustomerExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutExposureOfTradeReceivablesByCustomerExplanatory", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about exposure of trade receivables by customer.", "label": "Disclosure Of Detailed Information About Exposure Of Trade Receivables By Customer Explanatory", "terseLabel": "Schedule of Exposure of Trade Receivables by Customer" } } }, "auth_ref": [] }, "trib_DisclosureOfDetailedInformationAboutExposureOfTradeReceivablesByGeographicLocationExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutExposureOfTradeReceivablesByGeographicLocationExplanatory", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about exposure of trade receivables by geographic location.", "label": "Disclosure Of Detailed Information About Exposure Of Trade Receivables By Geographic Location Explanatory", "terseLabel": "Schedule of Exposure of Trade Receivables by Geographic Location" } } }, "auth_ref": [] }, "trib_DisclosureOfDetailedInformationAboutFinanceLeaseLiabilitiesPayableExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutFinanceLeaseLiabilitiesPayableExplanatory", "presentation": [ "http://trinitybiotech.com/role/LeaseLiabilitiesTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about finance lease liabilities payable.", "label": "Disclosure Of Detailed Information About Finance Lease Liabilities Payable Explanatory", "terseLabel": "Schedule of Finance Lease Liabilities Payable" } } }, "auth_ref": [] }, "trib_DisclosureOfDetailedInformationAboutFinancialAssets": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutFinancialAssets", "presentation": [ "http://trinitybiotech.com/role/FINANCIALASSETSTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about financial assets.", "label": "Disclosure Of Detailed Information About Financial Assets", "verboseLabel": "Schedule of Financial Assets" } } }, "auth_ref": [] }, "trib_DisclosureOfDetailedInformationAboutFinancialIncomeAndExpensesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutFinancialIncomeAndExpensesExplanatory", "presentation": [ "http://trinitybiotech.com/role/FinancialIncomeAndExpensesTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about financial income and expenses.", "label": "Disclosure Of Detailed Information About Financial Income And Expenses Explanatory", "terseLabel": "Schedule of Financial Income and Expenses" } } }, "auth_ref": [] }, "trib_DisclosureOfDetailedInformationAboutForeignCurrencyRiskShortTermFinancialAssetsAndLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutForeignCurrencyRiskShortTermFinancialAssetsAndLiabilitiesExplanatory", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about foreign currency risk short term financial assets and liabilities.", "label": "Disclosure Of Detailed Information About Foreign Currency Risk Short Term Financial Assets And Liabilities Explanatory", "terseLabel": "Schedule of Foreign Currency Risk Short Term Financial Assets and Liabilities" } } }, "auth_ref": [] }, "trib_DisclosureOfDetailedInformationAboutImpairmentChargesAndInventoryProvisioningExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutImpairmentChargesAndInventoryProvisioningExplanatory", "presentation": [ "http://trinitybiotech.com/role/IMPAIRMENTTRANSFORMATIONANDONCEOFFCOSTSTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about impairment charges and inventory provisioning.", "label": "Disclosure Of Detailed Information About Impairment Charges And Inventory Provisioning Explanatory", "terseLabel": "Schedule of Impairment Charges and Inventory Provisioning" } } }, "auth_ref": [] }, "trib_DisclosureOfDetailedInformationAboutImpairmentLossRecordedOnDiscontinuedAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutImpairmentLossRecordedOnDiscontinuedAssetsExplanatory", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about impairment loss recorded on discontinued assets.", "label": "Disclosure Of Detailed Information About Impairment Loss Recorded On Discontinued Assets Explanatory", "terseLabel": "Schedule of Impairment Loss Recorded on Discontinued Assets" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Principal Development Projects" } }, "en": { "role": { "documentation": "The disclosure of detailed information about intangible assets. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r79", "r348" ] }, "trib_DisclosureOfDetailedInformationAboutInterestIncomeAndInterestExpenseExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutInterestIncomeAndInterestExpenseExplanatory", "presentation": [ "http://trinitybiotech.com/role/SegmentInformationTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about interest income and interest expense by geographical area.", "label": "Disclosure Of Detailed Information About Interest Income And Interest Expense Explanatory", "terseLabel": "Schedule of Interest Income and Interest Expense by Geographical Area" } } }, "auth_ref": [] }, "trib_DisclosureOfDetailedInformationAboutInterestRateProfileOfFinancialAssetsLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutInterestRateProfileOfFinancialAssetsLiabilitiesExplanatory", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about interest rate profile of financial assets/liabilities.", "label": "Disclosure Of Detailed Information About Interest Rate Profile Of Financial Assets Liabilities Explanatory", "verboseLabel": "Schedule of Interest Rate Profile of Financial Assets/Liabilities" } } }, "auth_ref": [] }, "trib_DisclosureOfDetailedInformationAboutInterestRatesUsedForDeterminingFairValueExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutInterestRatesUsedForDeterminingFairValueExplanatory", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about interest rates used for determining fair value.", "label": "Disclosure Of Detailed Information About Interest Rates Used For Determining Fair Value Explanatory", "terseLabel": "Schedule of Interest Rates Used for Determining Fair Value" } } }, "auth_ref": [] }, "trib_DisclosureOfDetailedInformationAboutInternalAndExternalFactorsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutInternalAndExternalFactorsExplanatory", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about internal and external fectors based on historical experience.", "label": "Disclosure Of Detailed Information About Internal And External Factors Explanatory", "terseLabel": "Schedule of Internal and External Factors Based on Historical Experience" } } }, "auth_ref": [] }, "trib_DisclosureOfDetailedInformationAboutInventoriesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutInventoriesExplanatory", "presentation": [ "http://trinitybiotech.com/role/InventoriesTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about inventory.", "label": "Disclosure Of Detailed Information About Inventories Explanatory", "terseLabel": "Schedule of Inventories" } } }, "auth_ref": [] }, "trib_DisclosureOfDetailedInformationAboutLiquidityRiskEstimatedInterestPaymentsOfMaturitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutLiquidityRiskEstimatedInterestPaymentsOfMaturitiesExplanatory", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about liquidity risk estimated interest payments of maturities.", "label": "Disclosure Of Detailed Information About Liquidity Risk Estimated Interest Payments Of Maturities Explanatory", "terseLabel": "Schedule of Liquidity Risk Estimated Interest Payments of Maturities" } } }, "auth_ref": [] }, "trib_DisclosureOfDetailedInformationAboutLongLivedAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutLongLivedAssetsExplanatory", "presentation": [ "http://trinitybiotech.com/role/SegmentInformationTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about long lived assets by geographical area.", "label": "Disclosure Of Detailed Information About Long Lived Assets Explanatory", "verboseLabel": "Schedule of Long-Lived Assets" } } }, "auth_ref": [] }, "trib_DisclosureOfDetailedInformationAboutLossProfitBeforeTaxExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutLossProfitBeforeTaxExplanatory", "presentation": [ "http://trinitybiotech.com/role/LossBeforeTaxTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about loss profit before tax.", "label": "Disclosure Of Detailed Information About Loss Profit Before Tax Explanatory", "terseLabel": "Schedule of Loss Before Tax" } } }, "auth_ref": [] }, "trib_DisclosureOfDetailedInformationAboutLossProfitBeforeTaxesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutLossProfitBeforeTaxesExplanatory", "presentation": [ "http://trinitybiotech.com/role/IncomeTaxCreditTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about loss profit before tax.", "label": "Disclosure Of Detailed Information About Loss Profit Before Taxes Explanatory", "terseLabel": "Schedule of (Loss)/Profit Before Taxes" } } }, "auth_ref": [] }, "trib_DisclosureOfDetailedInformationAboutMovementInAllowanceForImpairmentOfTradeReceivablesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutMovementInAllowanceForImpairmentOfTradeReceivablesExplanatory", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about movement in the allowance for impairment of trade receivables.", "label": "Disclosure Of Detailed Information About Movement In Allowance For Impairment Of Trade Receivables Explanatory", "terseLabel": "Schedule of Movement in Allowance for Impairment of Trade Receivables" } } }, "auth_ref": [] }, "trib_DisclosureOfDetailedInformationAboutMovementInDerivativeFinancialAssetExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutMovementInDerivativeFinancialAssetExplanatory", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about movement in derivative financial asset explanatory.", "label": "Disclosure Of Detailed Information About Movement In Derivative Financial Asset Explanatory", "terseLabel": "Schedule of Derivative Financial Asset" } } }, "auth_ref": [] }, "trib_DisclosureOfDetailedInformationAboutMovementInDerivativeFinancialLiabilityExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutMovementInDerivativeFinancialLiabilityExplanatory", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about movement in derivative financial liability explanatory.", "label": "Disclosure Of Detailed Information About Movement In Derivative Financial Liability Explanatory", "terseLabel": "Schedule of Derivative Financial Liability" } } }, "auth_ref": [] }, "trib_DisclosureOfDetailedInformationAboutMovementInExchangeableNotesBalanceExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutMovementInExchangeableNotesBalanceExplanatory", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about movement in exchangeable notes balance explanatory.", "label": "Disclosure Of Detailed Information About Movement In Exchangeable Notes Balance Explanatory", "terseLabel": "Schedule of Exchangeable Notes Balance" } } }, "auth_ref": [] }, "trib_DisclosureOfDetailedInformationAboutMovementInTermLoanAndThe7YearConvertibleNotesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutMovementInTermLoanAndThe7YearConvertibleNotesExplanatory", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about movement in term loan and the 7-year convertible notes explanatory.", "label": "Disclosure Of Detailed Information About Movement In Term Loan And The 7-Year Convertible Notes Explanatory", "terseLabel": "Schedule of Term Loan And The 7-Year Convertible Notes", "verboseLabel": "Schedule of Term Loan And The 7-Year Convertible Notes" } } }, "auth_ref": [] }, "trib_DisclosureOfDetailedInformationAboutMovementOnInventoryProvisionExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutMovementOnInventoryProvisionExplanatory", "presentation": [ "http://trinitybiotech.com/role/InventoriesTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about movement on inventory provision.", "label": "Disclosure Of Detailed Information About Movement On Inventory Provision Explanatory", "terseLabel": "Schedule of Movement on Inventory Provision" } } }, "auth_ref": [] }, "trib_DisclosureOfDetailedInformationAboutOtherAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutOtherAssetsExplanatory", "presentation": [ "http://trinitybiotech.com/role/OtherNon-currentAssetsTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about other assets.", "label": "Disclosure Of Detailed Information About Other Assets Explanatory", "terseLabel": "Schedule of Other Non-Current Assets" } } }, "auth_ref": [] }, "trib_DisclosureOfDetailedInformationAboutOutstandingInterestBearingLoansAndBorrowingsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutOutstandingInterestBearingLoansAndBorrowingsExplanatory", "presentation": [ "http://trinitybiotech.com/role/LeaseLiabilitiesTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about outstanding interest bearing loans and borrowings.", "label": "Disclosure Of Detailed Information About Outstanding Interest Bearing Loans And Borrowings Explanatory", "terseLabel": "Schedule of Outstanding Interest Bearing Loans and Borrowings" } } }, "auth_ref": [] }, "trib_DisclosureOfDetailedInformationAboutOverseasTaxJurisdictionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutOverseasTaxJurisdictionsExplanatory", "presentation": [ "http://trinitybiotech.com/role/IncomeTaxCreditTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about overseas tax jurisdictions.", "label": "Disclosure Of Detailed Information About Overseas Tax Jurisdictions Explanatory", "terseLabel": "Schedule of Overseas Tax Jurisdictions" } } }, "auth_ref": [] }, "trib_DisclosureOfDetailedInformationAboutProfitAfterTaxExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutProfitAfterTaxExplanatory", "presentation": [ "http://trinitybiotech.com/role/LossPerShareTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about profit after tax.", "label": "Disclosure Of Detailed Information About Profit After Tax Explanatory", "terseLabel": "Schedule of Profit After Tax Diluted Earnings Per Ordinary Share Calculation" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://trinitybiotech.com/role/PropertyPlantAndEquipmentTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Property, Plant and Equipment" } }, "en": { "role": { "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r18", "r320" ] }, "trib_DisclosureOfDetailedInformationAboutReconciliationOfOperatingLeaseCommitmentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutReconciliationOfOperatingLeaseCommitmentsExplanatory", "presentation": [ "http://trinitybiotech.com/role/LeaseLiabilitiesTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about reconciliation of operating lease commitments.", "label": "Disclosure Of Detailed Information About Reconciliation Of Operating Lease Commitments Explanatory", "verboseLabel": "Schedule of Reconciliation of Operating Lease Commitments" } } }, "auth_ref": [] }, "trib_DisclosureOfDetailedInformationAboutRevenueDerivesFromTransferOfGoodsAndServicesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutRevenueDerivesFromTransferOfGoodsAndServicesExplanatory", "presentation": [ "http://trinitybiotech.com/role/SegmentInformationTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about revenues derives from goods and services.", "label": "Disclosure Of Detailed Information About Revenue Derives From Transfer Of Goods And Services Explanatory", "terseLabel": "Schedule of Revenue Derives From Transfer of Goods and Services" } } }, "auth_ref": [] }, "trib_DisclosureOfDetailedInformationAboutSegmentAssetsAndSegmentLiabilitiesByGeographicalAreaExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutSegmentAssetsAndSegmentLiabilitiesByGeographicalAreaExplanatory", "presentation": [ "http://trinitybiotech.com/role/SegmentInformationTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about segment assets and segment liabilities by geographical area.", "label": "Disclosure Of Detailed Information About Segment Assets And Segment Liabilities By Geographical Area Explanatory", "terseLabel": "Schedule of Segment Assets and Segment Liabilities by Geographical Area" } } }, "auth_ref": [] }, "trib_DisclosureOfDetailedInformationAboutShareOptionsAndWarrantsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutShareOptionsAndWarrantsExplanatory", "presentation": [ "http://trinitybiotech.com/role/ShareOptionsTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about share option and warrants.", "label": "Disclosure Of Detailed Information About Share Options And Warrants Explanatory", "terseLabel": "Schedule of Grants of Share Options and Warrants" } } }, "auth_ref": [] }, "trib_DisclosureOfDetailedInformationAboutSharesAndShareOptionPlanExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutSharesAndShareOptionPlanExplanatory", "presentation": [ "http://trinitybiotech.com/role/RelatedPartyTransactionsTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about shares and share option plan.", "label": "Disclosure Of Detailed Information About Shares And Share Option Plan Explanatory", "terseLabel": "Schedule of Company's Shares and Share Option Plan" } } }, "auth_ref": [] }, "trib_DisclosureOfDetailedInformationAboutSpecificAssetImpairmentChargesExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutSpecificAssetImpairmentChargesExplanatoryTableTextBlock", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about specific asset impairment charges.", "label": "Disclosure Of Detailed Information About Specific Asset Impairment Charges Explanatory [Table Text Block]", "terseLabel": "Schedule of Specific Asset Impairment Charges" } } }, "auth_ref": [] }, "trib_DisclosureOfDetailedInformationAboutStatutoryTaxRateExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutStatutoryTaxRateExplanatory", "presentation": [ "http://trinitybiotech.com/role/IncomeTaxCreditTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about statutory tax rate.", "label": "Disclosure Of Detailed Information About Statutory Tax Rate Explanatory", "terseLabel": "Schedule of Statutory Tax Rate" } } }, "auth_ref": [] }, "trib_DisclosureOfDetailedInformationAboutTaxationExpenseExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutTaxationExpenseExplanatory", "presentation": [ "http://trinitybiotech.com/role/SegmentInformationTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about tax expense by geographical area.", "label": "Disclosure Of Detailed Information About Taxation Expense Explanatory", "terseLabel": "Schedule of Taxation Expense by Geographical Area" } } }, "auth_ref": [] }, "trib_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory", "presentation": [ "http://trinitybiotech.com/role/TradeAndOtherPayablesTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about trade and other payables.", "label": "Disclosure Of Detailed Information About Trade And Other Payables Explanatory", "terseLabel": "Schedule of Trade and Other Payables" } } }, "auth_ref": [] }, "trib_DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatory", "presentation": [ "http://trinitybiotech.com/role/TradeAndOtherReceivablesTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about trade and other receivables.", "label": "Disclosure Of Detailed Information About Trade And Other Receivables Explanatory", "terseLabel": "Schedule of Trade and Other Receivables" } } }, "auth_ref": [] }, "trib_DisclosureOfDetailedInformationAboutUnrecognisedDeferredTaxAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutUnrecognisedDeferredTaxAssetsExplanatory", "presentation": [ "http://trinitybiotech.com/role/DeferredTaxAssetsAndLiabilitiesTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about unrecognised deferred tax assets.", "label": "Disclosure Of Detailed Information About Unrecognised Deferred Tax Assets Explanatory", "verboseLabel": "Schedule of Unrecognised Deferred Tax Assets" } } }, "auth_ref": [] }, "trib_DisclosureOfDetailedInformationAboutUnrecognisedDeferredTaxLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutUnrecognisedDeferredTaxLiabilitiesExplanatory", "presentation": [ "http://trinitybiotech.com/role/DeferredTaxAssetsAndLiabilitiesTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about unrecognised tax liabilities.", "label": "Disclosure Of Detailed Information About Unrecognised Deferred Tax Liabilities Explanatory", "terseLabel": "Schedule of Unrecognised Deferred Tax Liabilities" } } }, "auth_ref": [] }, "trib_DisclosureOfDetailedInformationAboutUnusedTaxLossesAndUnusedTaxCreditsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutUnusedTaxLossesAndUnusedTaxCreditsExplanatory", "presentation": [ "http://trinitybiotech.com/role/IncomeTaxCreditTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about unused tax losses and unused tax credits.", "label": "Disclosure Of Detailed Information About Unused Tax Losses And Unused Tax Credits Explanatory", "terseLabel": "Schedule of Unused Tax Losses and Unused Tax Credits" } } }, "auth_ref": [] }, "trib_DisclosureOfDetailedInformationAboutUnutilisedNetOperatingLossesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutUnutilisedNetOperatingLossesExplanatory", "presentation": [ "http://trinitybiotech.com/role/IncomeTaxCreditTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about unutilised net operating losses.", "label": "Disclosure Of Detailed Information About Unutilised Net Operating Losses Explanatory", "terseLabel": "Schedule of Unutilised Net Operating Losses" } } }, "auth_ref": [] }, "trib_DisclosureOfDetailedInformationAboutWeightedAverageInterestRateAndWeightedAveragePeriodExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutWeightedAverageInterestRateAndWeightedAveragePeriodExplanatory", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about weighted average interest rate and weighted average period.", "label": "Disclosure Of Detailed Information About Weighted Average Interest Rate And Weighted Average Period Explanatory", "terseLabel": "Schedule of Weighted Average Interest Rate and Weighted Average Period" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems", "presentation": [ "http://trinitybiotech.com/role/IncomeTaxCreditNarrativeDetails", "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfLossProfitBeforeTaxesDetails", "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfNetOperatingLossesDetails", "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfUnrecognisedDeferredTaxAssetsDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfCapitalExpenditureByGeographicalAreaDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfDepreciationAndAmortisationByGeographicalAreaDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfLongLivedAssetsDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfRevenueByCustomersGeographicalAreaDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfRevenueByGeographicalAreaBasedOnLocationOfAssetsDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfSegmentAssetsAndSegmentLiabilitiesByGeographicalAreaDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfSegmentResultsByGeographicalAreaDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfShareBasedPaymentExpenseByGeographicalAreaDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfTaxationExpenseByGeographicalAreaDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of disaggregation of revenue from contracts with customers [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable", "presentation": [ "http://trinitybiotech.com/role/IncomeTaxCreditNarrativeDetails", "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfLossProfitBeforeTaxesDetails", "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfNetOperatingLossesDetails", "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfUnrecognisedDeferredTaxAssetsDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfCapitalExpenditureByGeographicalAreaDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfDepreciationAndAmortisationByGeographicalAreaDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfLongLivedAssetsDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfRevenueByCustomersGeographicalAreaDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfRevenueByGeographicalAreaBasedOnLocationOfAssetsDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfSegmentAssetsAndSegmentLiabilitiesByGeographicalAreaDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfSegmentResultsByGeographicalAreaDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfShareBasedPaymentExpenseByGeographicalAreaDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfTaxationExpenseByGeographicalAreaDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of disaggregation of revenue from contracts with customers [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the disaggregation of revenue from contracts with customers." } } }, "auth_ref": [ "r143", "r262" ] }, "ifrs-full_DisclosureOfDiscontinuedOperationsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDiscontinuedOperationsExplanatory", "presentation": [ "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONS" ], "lang": { "en-us": { "role": { "label": "(LOSS)/PROFIT FOR THE YEAR ON DISCONTINUED OPERATION", "terseLabel": "(LOSS)/PROFIT FOR THE YEAR ON DISCONTINUED OPERATIONS" } }, "en": { "role": { "documentation": "The disclosure of discontinued operations. [Refer: Discontinued operations [member]]" } } }, "auth_ref": [ "r608" ] }, "ifrs-full_DisclosureOfEarningsPerShareExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfEarningsPerShareExplanatory", "presentation": [ "http://trinitybiotech.com/role/LossPerShare" ], "lang": { "en-us": { "role": { "label": "LOSS PER SHARE", "terseLabel": "LOSS PER SHARE" } }, "en": { "role": { "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r58" ] }, "ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfEntitysReportableSegmentsExplanatory", "presentation": [ "http://trinitybiotech.com/role/SegmentInformation" ], "lang": { "en-us": { "role": { "label": "SEGMENT INFORMATION" } }, "en": { "role": { "documentation": "The entire disclosure for operating segments." } } }, "auth_ref": [ "r257" ] }, "ifrs-full_DisclosureOfFairValueMeasurementOfAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFairValueMeasurementOfAssetsExplanatory", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Fair Values of Financial Assets/Liabilities" } }, "en": { "role": { "documentation": "The disclosure of the fair value measurement of assets." } } }, "auth_ref": [ "r139", "r396" ] }, "ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFairValueMeasurementOfAssetsLineItems", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfFairValuesOfFinancialAssetsliabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of fair value measurement of assets [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFairValueMeasurementOfAssetsTable", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfFairValuesOfFinancialAssetsliabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of fair value measurement of assets [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the fair value measurement of assets." } } }, "auth_ref": [ "r139", "r396" ] }, "ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFairValueMeasurementOfLiabilitiesLineItems", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails1", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails2", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails3", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails4", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSScheduleOfMovementInTermLoan" ], "lang": { "en-us": { "role": { "label": "Disclosure of fair value measurement of liabilities [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFairValueMeasurementOfLiabilitiesTable", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails1", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails2", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails3", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails4", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSScheduleOfMovementInTermLoan" ], "lang": { "en-us": { "role": { "label": "Disclosure of fair value measurement of liabilities [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the fair value measurement of liabilities." } } }, "auth_ref": [ "r139", "r396" ] }, "ifrs-full_DisclosureOfFinanceIncomeExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinanceIncomeExplanatory", "presentation": [ "http://trinitybiotech.com/role/FinancialIncomeAndExpenses" ], "lang": { "en-us": { "role": { "label": "FINANCIAL INCOME AND EXPENSES" } } }, "auth_ref": [ "r608" ] }, "trib_DisclosureOfFinanceLeaseLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfFinanceLeaseLiabilitiesAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of finance lease liabilities [Abstract]", "terseLabel": "Lease Liabilities Schedule Of Carrying Values Of Finance Lease Liabilities", "verboseLabel": "Lease Liabilities" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialAssetsAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of financial assets [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialAssetsExplanatory", "presentation": [ "http://trinitybiotech.com/role/FINANCIALASSETS" ], "lang": { "en-us": { "role": { "label": "Disclosure of financial assets [text block]", "verboseLabel": "FINANCIAL ASSETS" } }, "en": { "role": { "documentation": "The disclosure of financial assets. [Refer: Financial assets]" } } }, "auth_ref": [ "r236", "r382" ] }, "ifrs-full_DisclosureOfFinancialAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialAssetsLineItems", "presentation": [ "http://trinitybiotech.com/role/FINANCIALASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of financial assets [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialAssetsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialAssetsTable", "presentation": [ "http://trinitybiotech.com/role/FINANCIALASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of financial assets [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to financial assets." } } }, "auth_ref": [ "r236", "r382" ] }, "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about financial instruments [abstract]", "terseLabel": "Disclosure of detailed information about financial instruments [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsExplanatory", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagement" ], "lang": { "en-us": { "role": { "label": "Disclosure of financial instruments [text block]", "verboseLabel": "CAPITAL AND FINANCIAL RISK MANAGEMENT" } }, "en": { "role": { "documentation": "The entire disclosure for financial instruments." } } }, "auth_ref": [ "r241" ] }, "ifrs-full_DisclosureOfFinancialInstrumentsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsLineItems", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfForeignCurrencyRiskShortTermFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about financial instruments [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialInstrumentsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsTable", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfForeignCurrencyRiskShortTermFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about financial instruments [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of financial instruments." } } }, "auth_ref": [ "r221", "r227", "r236", "r382" ] }, "ifrs-full_DisclosureOfFinancialLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialLiabilitiesLineItems", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementNarrativeDetails", "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfLiquidityRiskEstimatedInterestPaymentsOfMaturitiesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of financial liabilities [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialLiabilitiesTable", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementNarrativeDetails", "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfLiquidityRiskEstimatedInterestPaymentsOfMaturitiesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of financial liabilities [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to financial liabilities." } } }, "auth_ref": [ "r236", "r382" ] }, "trib_DisclosureOfFinancingIncomeExpensesNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfFinancingIncomeExpensesNetAbstract", "presentation": [ "http://trinitybiotech.com/role/FinancialIncomeAndExpenses" ], "lang": { "en-us": { "role": { "label": "Disclosure Of Financing Income Expenses Net [Abstract]", "terseLabel": "Financial Income And Expenses Schedule Of Financial Income Expenses Net", "verboseLabel": "Financial Income And Expenses" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfGeographicalAreasExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfGeographicalAreasExplanatory", "presentation": [ "http://trinitybiotech.com/role/SegmentInformationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Revenue by Geographical Area Based on Location of Assets" } }, "en": { "role": { "documentation": "The disclosure of geographical information." } } }, "auth_ref": [ "r255" ] }, "ifrs-full_DisclosureOfGoodwillExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfGoodwillExplanatory", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Significant Goodwill" } }, "en": { "role": { "documentation": "The disclosure of goodwill. [Refer: Goodwill]" } } }, "auth_ref": [ "r608" ] }, "trib_DisclosureOfGroupUndertakingsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfGroupUndertakingsAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of group undertakings [Abstract]" } } }, "auth_ref": [] }, "trib_DisclosureOfGroupUndertakingsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfGroupUndertakingsExplanatory", "presentation": [ "http://trinitybiotech.com/role/GROUPUNDERTAKINGS" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for group undertakings.", "label": "Disclosure Of Group Undertakings Explanatory", "verboseLabel": "GROUP UNDERTAKINGS" } } }, "auth_ref": [] }, "trib_DisclosureOfImpairmentChargesAndInventoryProvisioningAbstract": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfImpairmentChargesAndInventoryProvisioningAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of impairment charges and inventory provisioning [Abstract]", "terseLabel": "Impairment Charges Schedule Of Statement Of Operation", "verboseLabel": "Impairment Charges" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfImpairmentOfAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfImpairmentOfAssetsExplanatory", "presentation": [ "http://trinitybiotech.com/role/IMPAIRMENTTRANSFORMATIONANDONCEOFFCOSTS" ], "lang": { "en-us": { "role": { "label": "IMPAIRMENT CHARGES", "terseLabel": "IMPAIRMENT, TRANSFORMATION AND ONCE OFF COSTS" } }, "en": { "role": { "documentation": "The entire disclosure for the impairment of assets." } } }, "auth_ref": [ "r69" ] }, "trib_DisclosureOfIncomeTaxCreditAbstract": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfIncomeTaxCreditAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of income tax credit [Abstract]", "terseLabel": "Income Tax Credit Schedule Of Charge For Tax", "verboseLabel": "Income Tax Credit" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfIncomeTaxExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIncomeTaxExplanatory", "presentation": [ "http://trinitybiotech.com/role/IncomeTaxCredit" ], "lang": { "en-us": { "role": { "label": "INCOME TAX (EXPENSE)/CREDIT" } }, "en": { "role": { "documentation": "The entire disclosure for income taxes." } } }, "auth_ref": [ "r9" ] }, "ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory", "presentation": [ "http://trinitybiotech.com/role/ShareOptionsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Assumption Determining Fair Value of Share Options" } }, "en": { "role": { "documentation": "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's other equity instruments (ie other than share options)." } } }, "auth_ref": [ "r185" ] }, "ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory", "presentation": [ "http://trinitybiotech.com/role/ShareOptionsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Fair Value of the Options Vesting Period" } }, "en": { "role": { "documentation": "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options." } } }, "auth_ref": [ "r184" ] }, "ifrs-full_DisclosureOfInformationAboutAmountsThatAffectedStatementOfComprehensiveIncomeAsResultOfHedgeAccountingLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfInformationAboutAmountsThatAffectedStatementOfComprehensiveIncomeAsResultOfHedgeAccountingLineItems", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of information about amounts that affected statement of comprehensive income as result of hedge accounting [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfInformationAboutAmountsThatAffectedStatementOfComprehensiveIncomeAsResultOfHedgeAccountingTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfInformationAboutAmountsThatAffectedStatementOfComprehensiveIncomeAsResultOfHedgeAccountingTable", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of information about amounts that affected statement of comprehensive income as result of hedge accounting [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to amounts that affected the statement of comprehensive income as a result of hedge accounting." } } }, "auth_ref": [ "r219", "r385" ] }, "ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "presentation": [ "http://trinitybiotech.com/role/Employment" ], "lang": { "en-us": { "role": { "label": "EMPLOYMENT" } }, "en": { "role": { "documentation": "The disclosure of information about key management personnel. [Refer: Key management personnel of entity or parent [member]]" } } }, "auth_ref": [ "r608" ] }, "ifrs-full_DisclosureOfInformationForEachMaterialImpairmentLossRecognisedOrReversedForIndividualAssetOrCashgeneratingUnitLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfInformationForEachMaterialImpairmentLossRecognisedOrReversedForIndividualAssetOrCashgeneratingUnitLineItems", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfBreakdownOfImpairmentLossDetailsUsd", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfImpairmentLossDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of information for impairment loss recognised or reversed for individual asset or cash-generating unit [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfInformationForEachMaterialImpairmentLossRecognisedOrReversedForIndividualAssetOrCashgeneratingUnitTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfInformationForEachMaterialImpairmentLossRecognisedOrReversedForIndividualAssetOrCashgeneratingUnitTable", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfBreakdownOfImpairmentLossDetailsUsd", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfImpairmentLossDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of information for impairment loss recognised or reversed for individual asset or cash-generating unit [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to an individual asset or a cash-generating unit, for which an impairment loss has been recognised or reversed." } } }, "auth_ref": [ "r63" ] }, "ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIntangibleAssetsAndGoodwillExplanatory", "presentation": [ "http://trinitybiotech.com/role/GOODWILLANDINTANGIBLEASSETS" ], "lang": { "en-us": { "role": { "label": "Disclosure of intangible assets and goodwill [text block]", "terseLabel": "GOODWILL AND INTANGIBLE ASSETS" } }, "en": { "role": { "documentation": "The disclosure of intangible assets and goodwill. [Refer: Intangible assets and goodwill]" } } }, "auth_ref": [ "r608" ] }, "ifrs-full_DisclosureOfIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIntangibleAssetsLineItems", "presentation": [ "http://trinitybiotech.com/role/GOODWILLANDINTANGIBLEASSETSDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfGoodwillAndIntangibleAssetsDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfPrincipalDevelopmentProjectsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about intangible assets [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfIntangibleAssetsMaterialToEntityExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIntangibleAssetsMaterialToEntityExplanatory", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Impairment Loss for Each Class of Asset" } }, "en": { "role": { "documentation": "The disclosure of intangible assets that are material to the entity. [Refer: Intangible assets material to entity]" } } }, "auth_ref": [ "r81", "r350" ] }, "ifrs-full_DisclosureOfIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIntangibleAssetsTable", "presentation": [ "http://trinitybiotech.com/role/GOODWILLANDINTANGIBLEASSETSDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfGoodwillAndIntangibleAssetsDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfPrincipalDevelopmentProjectsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about intangible assets [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of intangible assets." } } }, "auth_ref": [ "r79", "r348" ] }, "ifrs-full_DisclosureOfIntangibleAssetsWithIndefiniteUsefulLifeLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIntangibleAssetsWithIndefiniteUsefulLifeLineItems", "presentation": [ "http://trinitybiotech.com/role/BASISOFPREPARATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesScheduleOfAmortisationDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of intangible assets with indefinite useful life [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfIntangibleAssetsWithIndefiniteUsefulLifeTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIntangibleAssetsWithIndefiniteUsefulLifeTable", "presentation": [ "http://trinitybiotech.com/role/BASISOFPREPARATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesScheduleOfAmortisationDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of intangible assets with indefinite useful life [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to intangible assets with an indefinite useful life." } } }, "auth_ref": [ "r80", "r349" ] }, "trib_DisclosureOfInterestbearingLoansAndBorrowingsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfInterestbearingLoansAndBorrowingsAbstract", "lang": { "en-us": { "role": { "label": "Disclosure Of Interest-bearing Loans And Borrowings [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfInventoriesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfInventoriesExplanatory", "presentation": [ "http://trinitybiotech.com/role/Inventories" ], "lang": { "en-us": { "role": { "label": "INVENTORIES" } }, "en": { "role": { "documentation": "The entire disclosure for inventories." } } }, "auth_ref": [ "r29" ] }, "trib_DisclosureOfLeasePaymentsNotRecognisedAsLiabilityExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfLeasePaymentsNotRecognisedAsLiabilityExplanatory", "presentation": [ "http://trinitybiotech.com/role/LeaseLiabilitiesTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of lease payments not recognised as liability.", "label": "Disclosure Of Lease Payments Not Recognised As Liability Explanatory", "terseLabel": "Schedule of Lease Payments Not Recognised as Liability" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfLeasesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfLeasesExplanatory", "presentation": [ "http://trinitybiotech.com/role/LeaseLiabilities" ], "lang": { "en-us": { "role": { "label": "LEASE LIABILITIES" } }, "en": { "role": { "documentation": "The entire disclosure for leases." } } }, "auth_ref": [ "r159", "r160" ] }, "trib_DisclosureOfLossOnDiscontinuedOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfLossOnDiscontinuedOperationsAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of loss on discontinued operations [Abstract]", "terseLabel": "Lossprofit For Year On Discontinued Operation Schedule Of Cash Flows Attributable", "verboseLabel": "Lossprofit For Year On Discontinued Operation" } } }, "auth_ref": [] }, "trib_DisclosureOfLossProfitBeforeTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfLossProfitBeforeTaxAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of loss profit before tax [Abstract]", "terseLabel": "Loss Before Tax Narrative", "verboseLabel": "Loss Before Tax" } } }, "auth_ref": [] }, "trib_DisclosureOfLossProfitBeforeTaxExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfLossProfitBeforeTaxExplanatory", "presentation": [ "http://trinitybiotech.com/role/LossBeforeTax" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for loss profit before tax.", "label": "Disclosure Of Loss Profit Before Tax Explanatory", "terseLabel": "LOSS BEFORE TAX" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableExplanatory", "presentation": [ "http://trinitybiotech.com/role/TradeAndOtherReceivablesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Future Minimum Rentals Receivable Under Non-Cancellable Operating Leases" } }, "en": { "role": { "documentation": "The disclosure of a maturity analysis of finance lease payments receivable. Finance lease is a lease that transfers substantially all the risks and rewards incidental to ownership of an underlying asset." } } }, "auth_ref": [ "r156", "r274" ] }, "ifrs-full_DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableLineItems", "presentation": [ "http://trinitybiotech.com/role/LeaseLiabilitiesScheduleOfOutstandingInterestBearingLoansAndBorrowingsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of maturity analysis of finance lease payments receivable [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableTable", "presentation": [ "http://trinitybiotech.com/role/LeaseLiabilitiesScheduleOfOutstandingInterestBearingLoansAndBorrowingsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of maturity analysis of finance lease payments receivable [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the maturity analysis of finance lease payments receivable." } } }, "auth_ref": [ "r156", "r274" ] }, "ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory", "presentation": [ "http://trinitybiotech.com/role/TradeAndOtherReceivablesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Future Minimum Finance Lease Receivables" } }, "en": { "role": { "documentation": "The disclosure of a maturity analysis of operating lease payments. Operating lease is a lease that does not transfer substantially all the risks and rewards incidental to ownership of an underlying asset." } } }, "auth_ref": [ "r158", "r278" ] }, "ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems", "presentation": [ "http://trinitybiotech.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://trinitybiotech.com/role/LeaseLiabilitiesScheduleOfFinanceLeaseLiabilitiesPayableDetails", "http://trinitybiotech.com/role/TradeAndOtherReceivablesNarrativeDetails", "http://trinitybiotech.com/role/TradeAndOtherReceivablesScheduleOfFutureMinimumFinanceLeaseReceivablesDetails", "http://trinitybiotech.com/role/TradeAndOtherReceivablesScheduleOfFutureMinimumRentalsReceivableUnderNon-cancellableOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of maturity analysis of operating lease payments [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable", "presentation": [ "http://trinitybiotech.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://trinitybiotech.com/role/LeaseLiabilitiesScheduleOfFinanceLeaseLiabilitiesPayableDetails", "http://trinitybiotech.com/role/TradeAndOtherReceivablesNarrativeDetails", "http://trinitybiotech.com/role/TradeAndOtherReceivablesScheduleOfFutureMinimumFinanceLeaseReceivablesDetails", "http://trinitybiotech.com/role/TradeAndOtherReceivablesScheduleOfFutureMinimumRentalsReceivableUnderNon-cancellableOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of maturity analysis of operating lease payments [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the maturity analysis of operating lease payments." } } }, "auth_ref": [ "r158", "r278" ] }, "ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Interest Rate Risk Effective and Repricing Analysis" } }, "en": { "role": { "documentation": "The disclosure of information that enables users of financial statements to evaluate the nature and extent of risks arising from financial instruments to which the entity is exposed. [Refer: Classes of financial instruments [domain]]" } } }, "auth_ref": [ "r221" ] }, "trib_DisclosureOfNetCashflowsGeneratedDiscontinuedOperationsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfNetCashflowsGeneratedDiscontinuedOperationsExplanatory", "presentation": [ "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSTables" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for net cashflows generated from discontinued operations.", "label": "Disclosure Of Net Cashflows Generated Discontinued Operations Explanatory", "verboseLabel": "Schedule of Net Cashflows Generated From Discontinued Operations" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of non-adjusting events after reporting period [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory", "presentation": [ "http://trinitybiotech.com/role/POSTBALANCESHEETEVENTS" ], "lang": { "en-us": { "role": { "label": "Disclosure of non-adjusting events after reporting period [text block]", "terseLabel": "POST BALANCE SHEET EVENTS" } }, "en": { "role": { "documentation": "The disclosure of non-adjusting events after the reporting period. [Refer: Non-adjusting events after reporting period [domain]]" } } }, "auth_ref": [ "r0", "r306" ] }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems", "presentation": [ "http://trinitybiotech.com/role/PostBalanceSheetEventsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of non-adjusting events after reporting period [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodTable", "presentation": [ "http://trinitybiotech.com/role/PostBalanceSheetEventsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of non-adjusting events after reporting period [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to non-adjusting events after the reporting period." } } }, "auth_ref": [ "r0", "r306" ] }, "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "presentation": [ "http://trinitybiotech.com/role/ShareOptionsTables" ], "lang": { "en-us": { "role": { "label": "Summary of Range of Prices of Stock Options", "terseLabel": "Schedule of Range of Prices of Stock Options" } }, "en": { "role": { "documentation": "The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r179", "r370" ] }, "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems", "presentation": [ "http://trinitybiotech.com/role/ShareOptionsSummaryOfRangeOfPricesOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable", "presentation": [ "http://trinitybiotech.com/role/ShareOptionsSummaryOfRangeOfPricesOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of number and weighted average remaining contractual life of outstanding share options [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the number and weighted average remaining contractual life of outstanding share options." } } }, "auth_ref": [ "r181" ] }, "trib_DisclosureOfOperatingProfitForTheDiscontinuedOperationsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfOperatingProfitForTheDiscontinuedOperationsTableTextBlock", "presentation": [ "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSTables" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating profit for the discontinued operations.", "label": "Disclosure Of Operating Profit For The Discontinued Operations [Table Text Block]", "verboseLabel": "Schedule of Operating Profit For The Discontinued Operations" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOperatingSegmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOperatingSegmentsAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of operating segments [abstract]", "terseLabel": "Disclosure of operating segments [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOperatingSegmentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOperatingSegmentsExplanatory", "presentation": [ "http://trinitybiotech.com/role/SegmentInformationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Segment Results by Geographical Area" } }, "en": { "role": { "documentation": "The disclosure of operating segments. [Refer: Operating segments [member]]" } } }, "auth_ref": [ "r246" ] }, "ifrs-full_DisclosureOfOperatingSegmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOperatingSegmentsLineItems", "presentation": [ "http://trinitybiotech.com/role/SegmentInformationScheduleOfRevenueDerivesFromTransferOfGoodsAndServicesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of operating segments [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOperatingSegmentsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOperatingSegmentsTable", "presentation": [ "http://trinitybiotech.com/role/SegmentInformationScheduleOfRevenueDerivesFromTransferOfGoodsAndServicesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of operating segments [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to operating segments." } } }, "auth_ref": [ "r246" ] }, "trib_DisclosureOfOtherAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfOtherAssetsAbstract", "presentation": [ "http://trinitybiotech.com/role/OtherNon-currentAssets" ], "lang": { "en-us": { "role": { "label": "Disclosure Of Other Assets Abstract", "verboseLabel": "Other Non-current Assets [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOtherAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOtherAssetsExplanatory", "presentation": [ "http://trinitybiotech.com/role/OtherNon-currentAssets" ], "lang": { "en-us": { "role": { "label": "OTHER NON-CURRENT ASSETS" } }, "en": { "role": { "documentation": "The disclosure of other assets. [Refer: Other assets]" } } }, "auth_ref": [ "r608" ] }, "trib_DisclosureOfOtherOperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfOtherOperatingIncomeExpenseAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of other operating income / (expense) [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOtherOperatingIncomeExpenseExplanatory", "presentation": [ "http://trinitybiotech.com/role/OTHEROPERATINGINCOMEEXPENSETables" ], "lang": { "en-us": { "role": { "label": "Schedule of Other Operating Income", "terseLabel": "Schedule of Other Operating Income / (Expense)" } } }, "auth_ref": [ "r608" ] }, "trib_DisclosureOfOtherOperatingIncomeExpenseTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfOtherOperatingIncomeExpenseTextBlock", "presentation": [ "http://trinitybiotech.com/role/OTHEROPERATINGINCOMEEXPENSE" ], "lang": { "en-us": { "role": { "label": "Disclosure of Other Operating Income (Expense) [Text Block]", "documentation": "The entire disclosure for other operating income/(expense).", "terseLabel": "OTHER OPERATING INCOME / (EXPENSE)" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOtherProvisionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOtherProvisionsExplanatory", "presentation": [ "http://trinitybiotech.com/role/ProvisionsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Provisions" } }, "en": { "role": { "documentation": "The disclosure of other provisions. [Refer: Other provisions]" } } }, "auth_ref": [ "r73", "r342" ] }, "ifrs-full_DisclosureOfOtherProvisionsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOtherProvisionsLineItems", "presentation": [ "http://trinitybiotech.com/role/InventoriesScheduleOfMovementOnInventoryProvisionDetails", "http://trinitybiotech.com/role/ProvisionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of other provisions [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOtherProvisionsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOtherProvisionsTable", "presentation": [ "http://trinitybiotech.com/role/InventoriesScheduleOfMovementOnInventoryProvisionDetails", "http://trinitybiotech.com/role/ProvisionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of other provisions [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to other provisions." } } }, "auth_ref": [ "r73", "r342" ] }, "ifrs-full_DisclosureOfProductsAndServicesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfProductsAndServicesExplanatory", "presentation": [ "http://trinitybiotech.com/role/SegmentInformationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Revenue by Major Product Group" } }, "en": { "role": { "documentation": "The disclosure of the entity's products and services. [Refer: Products and services [domain]]" } } }, "auth_ref": [ "r253" ] }, "ifrs-full_DisclosureOfProductsAndServicesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfProductsAndServicesLineItems", "presentation": [ "http://trinitybiotech.com/role/SegmentInformationScheduleOfRevenueByMajorProductGroupDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of products and services [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfProductsAndServicesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfProductsAndServicesTable", "presentation": [ "http://trinitybiotech.com/role/SegmentInformationScheduleOfRevenueByMajorProductGroupDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of products and services [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the entity's products and services." } } }, "auth_ref": [ "r253" ] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "PROPERTY, PLANT AND EQUIPMENT", "verboseLabel": "Disclosure of detailed information about property, plant and equipment [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://trinitybiotech.com/role/PropertyPlantAndEquipment" ], "lang": { "en-us": { "role": { "label": "Disclosure of property, plant and equipment [text block]", "terseLabel": "PROPERTY, PLANT AND EQUIPMENT" } }, "en": { "role": { "documentation": "The entire disclosure for property, plant and equipment." } } }, "auth_ref": [ "r21" ] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems", "presentation": [ "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesScheduleOfOwnedAssetsDetails", "http://trinitybiotech.com/role/PropertyPlantAndEquipmentNarrativeDetails", "http://trinitybiotech.com/role/PropertyPlantAndEquipmentScheduleOfAdditionalInformationOnRight-of-useAssetsDetails", "http://trinitybiotech.com/role/PropertyPlantAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentRelatedToAccumulatedDepreciationDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about property, plant and equipment [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentTable", "presentation": [ "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesScheduleOfOwnedAssetsDetails", "http://trinitybiotech.com/role/PropertyPlantAndEquipmentNarrativeDetails", "http://trinitybiotech.com/role/PropertyPlantAndEquipmentScheduleOfAdditionalInformationOnRight-of-useAssetsDetails", "http://trinitybiotech.com/role/PropertyPlantAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentRelatedToAccumulatedDepreciationDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about property, plant and equipment [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of property, plant and equipment." } } }, "auth_ref": [ "r18", "r320" ] }, "ifrs-full_DisclosureOfProvisionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfProvisionsExplanatory", "presentation": [ "http://trinitybiotech.com/role/Provisions" ], "lang": { "en-us": { "role": { "label": "PROVISIONS" } }, "en": { "role": { "documentation": "The disclosure of provisions. [Refer: Provisions]" } } }, "auth_ref": [ "r608" ] }, "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "presentation": [ "http://trinitybiotech.com/role/PropertyPlantAndEquipmentTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Right-of-use assets" } }, "en": { "role": { "documentation": "The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]" } } }, "auth_ref": [ "r154", "r270" ] }, "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems", "presentation": [ "http://trinitybiotech.com/role/PropertyPlantAndEquipmentScheduleOfIncomeFromSub-lettingRight-of-useBuildingsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of quantitative information about right-of-use assets [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable", "presentation": [ "http://trinitybiotech.com/role/PropertyPlantAndEquipmentScheduleOfIncomeFromSub-lettingRight-of-useBuildingsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of quantitative information about right-of-use assets [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to right-of-use assets." } } }, "auth_ref": [ "r154", "r270" ] }, "trib_DisclosureOfReconciliationFromIas17ToIfrs16Explanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfReconciliationFromIas17ToIfrs16Explanatory", "presentation": [ "http://trinitybiotech.com/role/PropertyPlantAndEquipmentTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of reconciliation from IAS 17 to IFRS 16 effect.", "label": "Disclosure Of Reconciliation From Ias 17 To Ifrs 16 Explanatory", "terseLabel": "Schedule of Reconciliation from IAS 17 to IFRS 16" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Goodwill and Intangible Assets" } }, "en": { "role": { "documentation": "The disclosure of the reconciliation of changes in intangible assets and goodwill. [Refer: Intangible assets and goodwill]" } } }, "auth_ref": [ "r595" ] }, "ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsNarrativeDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfIntangibleAssetsWithIndefiniteUsefulLivesDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfSignificantGoodwillAndIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of reconciliation of changes in intangible assets and goodwill [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsNarrativeDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfIntangibleAssetsWithIndefiniteUsefulLivesDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfSignificantGoodwillAndIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of reconciliation of changes in intangible assets and goodwill [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the reconciliation of changes in intangible assets and goodwill." } } }, "auth_ref": [ "r595" ] }, "ifrs-full_DisclosureOfReconciliationOfChangesInLossAllowanceAndExplanationOfChangesInGrossCarryingAmountForFinancialInstrumentsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfReconciliationOfChangesInLossAllowanceAndExplanationOfChangesInGrossCarryingAmountForFinancialInstrumentsLineItems", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfAgeingOfTradeReceivablesDetails", "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfInterestRateRiskEffectiveAndRepricingAnalysisDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfReconciliationOfChangesInLossAllowanceAndExplanationOfChangesInGrossCarryingAmountForFinancialInstrumentsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfReconciliationOfChangesInLossAllowanceAndExplanationOfChangesInGrossCarryingAmountForFinancialInstrumentsTable", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfAgeingOfTradeReceivablesDetails", "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfInterestRateRiskEffectiveAndRepricingAnalysisDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the reconciliation of changes in the loss allowance and explanation of changes in the gross carrying amount for financial instruments." } } }, "auth_ref": [ "r224", "r225", "r387", "r388" ] }, "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of reconciliation of liabilities arising from financing activities [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory", "presentation": [ "http://trinitybiotech.com/role/ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Liabilities Arising from Financing Activities" } }, "en": { "role": { "documentation": "The disclosure of the reconciliation of liabilities arising from financing activities. [Refer: Liabilities arising from financing activities]" } } }, "auth_ref": [ "r295", "r484" ] }, "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems", "presentation": [ "http://trinitybiotech.com/role/ReconciliationOfLiabilitiesArisingFromFinancingActivitiesScheduleOfLiabilitiesArisingFromFinancingDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of reconciliation of liabilities arising from financing activities [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable", "presentation": [ "http://trinitybiotech.com/role/ReconciliationOfLiabilitiesArisingFromFinancingActivitiesScheduleOfLiabilitiesArisingFromFinancingDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of reconciliation of liabilities arising from financing activities [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the reconciliation of liabilities arising from financing activities." } } }, "auth_ref": [ "r295", "r484" ] }, "ifrs-full_DisclosureOfRelatedPartyExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfRelatedPartyExplanatory", "presentation": [ "http://trinitybiotech.com/role/RelatedPartyTransactions" ], "lang": { "en-us": { "role": { "label": "RELATED PARTY TRANSACTIONS" } }, "en": { "role": { "documentation": "The entire disclosure for related parties." } } }, "auth_ref": [ "r42" ] }, "ifrs-full_DisclosureOfSegmentsMajorCustomersExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfSegmentsMajorCustomersExplanatory", "presentation": [ "http://trinitybiotech.com/role/SegmentInformationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Revenue by Customers' Geographical Area" } }, "en": { "role": { "documentation": "The disclosure of major customers." } } }, "auth_ref": [ "r256" ] }, "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "presentation": [ "http://trinitybiotech.com/role/CapitalAndReserves" ], "lang": { "en-us": { "role": { "label": "CAPITAL AND RESERVES" } }, "en": { "role": { "documentation": "The entire disclosure for share capital, reserves and other equity interest." } } }, "auth_ref": [ "r288", "r401", "r445" ] }, "trib_DisclosureOfShareOptionsAndShareWarrantsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfShareOptionsAndShareWarrantsAbstract", "lang": { "en-us": { "role": { "label": "Disclosure Of Share Options And Share Warrants [Abstract]", "verboseLabel": "Share Options" } } }, "auth_ref": [] }, "trib_DisclosureOfShareOptionsAndShareWarrantsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfShareOptionsAndShareWarrantsExplanatory", "presentation": [ "http://trinitybiotech.com/role/ShareOptions" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share oprtions and warrants.", "label": "Disclosure Of Share Options And Share Warrants Explanatory", "terseLabel": "SHARE OPTIONS" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory", "presentation": [ "http://trinitybiotech.com/role/GROUPUNDERTAKINGSTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of subsidiaries [text block]", "terseLabel": "Schedule of Subsidiary Undertakings" } }, "en": { "role": { "documentation": "The disclosure of subsidiaries. [Refer: Total for all subsidiaries [member]]" } } }, "auth_ref": [ "r48", "r51", "r134", "r390" ] }, "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory", "presentation": [ "http://trinitybiotech.com/role/IncomeTaxCreditTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Unrecognised Deferred Tax Assets" } }, "en": { "role": { "documentation": "The disclosure of types of temporary differences, unused tax losses and unused tax credits. [Refer: Unused tax credits [member]; Unused tax losses [member]; Temporary differences [member]]" } } }, "auth_ref": [ "r6", "r312" ] }, "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems", "presentation": [ "http://trinitybiotech.com/role/DeferredTaxAssetsAndLiabilitiesScheduleOfRecognisedDeferredTaxAssetsAndLiabilitiesDetails", "http://trinitybiotech.com/role/DeferredTaxAssetsAndLiabilitiesScheduleOfUnrecognisedDeferredTaxLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable", "presentation": [ "http://trinitybiotech.com/role/DeferredTaxAssetsAndLiabilitiesScheduleOfRecognisedDeferredTaxAssetsAndLiabilitiesDetails", "http://trinitybiotech.com/role/DeferredTaxAssetsAndLiabilitiesScheduleOfUnrecognisedDeferredTaxLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to temporary differences, unused tax losses and unused tax credits." } } }, "auth_ref": [ "r6", "r312" ] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems", "presentation": [ "http://trinitybiotech.com/role/RelatedPartyTransactionsScheduleOfCompanysSharesAndShareOptionPlanDetails", "http://trinitybiotech.com/role/ShareOptionsScheduleOfAssumptionDeterminingFairValueOfShareOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable", "presentation": [ "http://trinitybiotech.com/role/RelatedPartyTransactionsScheduleOfCompanysSharesAndShareOptionPlanDetails", "http://trinitybiotech.com/role/ShareOptionsScheduleOfAssumptionDeterminingFairValueOfShareOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of terms and conditions of share-based payment arrangement [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements." } } }, "auth_ref": [ "r182", "r371" ] }, "ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTradeAndOtherPayablesExplanatory", "presentation": [ "http://trinitybiotech.com/role/TradeAndOtherPayables" ], "lang": { "en-us": { "role": { "label": "Disclosure of trade and other payables [text block]", "verboseLabel": "TRADE AND OTHER PAYABLES" } }, "en": { "role": { "documentation": "The disclosure of trade and other payables. [Refer: Trade and other payables]" } } }, "auth_ref": [ "r608" ] }, "trib_DisclosureOfTradeAndOtherPayablesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfTradeAndOtherPayablesLineItems", "presentation": [ "http://trinitybiotech.com/role/TRADEANDOTHERPAYABLESNarrativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "TRADE AND OTHER PAYABLES", "label": "Disclosure of trade and other payables [line items]" } } }, "auth_ref": [] }, "trib_DisclosureOfTradeAndOtherPayablesTable": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisclosureOfTradeAndOtherPayablesTable", "presentation": [ "http://trinitybiotech.com/role/TRADEANDOTHERPAYABLESNarrativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of trade and other payables [table]", "documentation": "The disclosure of information about trade and other payables.", "label": "Disclosure of trade and other payables [table]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTradeAndOtherReceivablesExplanatory", "presentation": [ "http://trinitybiotech.com/role/TradeAndOtherReceivables" ], "lang": { "en-us": { "role": { "label": "Disclosure of trade and other receivables [text block]", "verboseLabel": "TRADE AND OTHER RECEIVABLES" } }, "en": { "role": { "documentation": "The disclosure of trade and other receivables. [Refer: Trade and other receivables]" } } }, "auth_ref": [ "r608" ] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of transactions between related parties [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesLineItems", "presentation": [ "http://trinitybiotech.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of transactions between related parties [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable", "presentation": [ "http://trinitybiotech.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of transactions between related parties [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to transactions between related parties." } } }, "auth_ref": [ "r41", "r330" ] }, "trib_DiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DiscontinuedOperationsAxis", "presentation": [ "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONDetail5", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSDetails", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSDetails1", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSDetails3", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Discontinued Operations [Axis]" } } }, "auth_ref": [] }, "trib_DiscontinuedOperationsDomain": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DiscontinuedOperationsDomain", "presentation": [ "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONDetail5", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSDetails", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSDetails1", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSDetails3", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "DISCONTINUED OPERATIONS", "label": "Discontinued Operations [Domain]" } } }, "auth_ref": [] }, "ifrs-full_DiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DiscontinuedOperationsMember", "presentation": [ "http://trinitybiotech.com/role/EmploymentScheduleOfEmploymentCostsDetails", "http://trinitybiotech.com/role/EmploymentTables", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONDetail5" ], "lang": { "en-us": { "role": { "label": "Discontinued operations [Member]" } }, "en": { "role": { "documentation": "This member stands for a component of an entity that either has been disposed of or is classified as held for sale, and that: (a) represents a separate major line of business or geographical area of operations; (b) is part of a single co-ordinated plan to dispose of a separate major line of business or geographical area of operations; or (c) is a subsidiary acquired exclusively with a view to resale. A component of an entity comprises operations and cash flows that can be clearly distinguished, operationally and for financial reporting purposes, from the rest of the entity. [Refer: Total for all subsidiaries [member]]" } } }, "auth_ref": [ "r215" ] }, "trib_DisposalsGoodwillAndIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisposalsGoodwillAndIntangibleAssets", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfGoodwillAndIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Disposals of goodwill and intangible assets for the period.", "negatedLabel": "Disposals or retirements", "label": "Disposals Goodwill And Intangible Assets", "verboseLabel": "Disposals or retirements" } } }, "auth_ref": [] }, "trib_DisposalsOrRetirementsPropertyAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisposalsOrRetirementsPropertyAndEquipment", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/PropertyPlantAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentRelatedToAccumulatedDepreciationDetails" ], "lang": { "en-us": { "role": { "documentation": "Disposals or retirements of property, plant and equipment during the period.", "negatedLabel": "Disposals or retirements", "label": "Disposals Or Retirements Property And Equipment" } } }, "auth_ref": [] }, "trib_DisposalsRelatedToRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DisposalsRelatedToRightOfUseAssets", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/ReconciliationOfLiabilitiesArisingFromFinancingActivitiesScheduleOfLiabilitiesArisingFromFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "Represent the amount of Disposals Related To Right Of Use Assets", "label": "Disposals Related To Right Of Use Assets", "terseLabel": "Disposals (related to Right of Use assets)" } } }, "auth_ref": [] }, "trib_DistributorsMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DistributorsMember", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfExposureOfTradeReceivablesByCustomerDetails" ], "lang": { "en-us": { "role": { "documentation": "Distributors [Member]", "label": "Distributors [Member]" } } }, "auth_ref": [] }, "ifrs-full_DividendsPaidClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DividendsPaidClassifiedAsFinancingActivities", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Payment of dividend" } }, "en": { "role": { "documentation": "The cash outflow for dividends paid by the entity, classified as financing activities." } } }, "auth_ref": [ "r95" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentAccountingStandard", "presentation": [ "http://trinitybiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r544" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentAnnualReport", "presentation": [ "http://trinitybiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r543", "r544", "r557" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://trinitybiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r543", "r544", "r557", "r559" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://trinitybiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://trinitybiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentInformationLineItems", "presentation": [ "http://trinitybiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentInformationTable", "presentation": [ "http://trinitybiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentPeriodEndDate", "presentation": [ "http://trinitybiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentRegistrationStatement", "presentation": [ "http://trinitybiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r539" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentShellCompanyReport", "presentation": [ "http://trinitybiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r544" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentTransitionReport", "presentation": [ "http://trinitybiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r558" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentType", "presentation": [ "http://trinitybiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "trib_DrJimWalshMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "DrJimWalshMember", "presentation": [ "http://trinitybiotech.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Dr. Jim Walsh [Member]" } } }, "auth_ref": [] }, "currency_EUR": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2025", "localname": "EUR", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfForeignCurrencyRiskShortTermFinancialAssetsAndLiabilitiesDetails", "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfSensitivityAnalysisDetails", "http://trinitybiotech.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Euro [Member]" } } }, "auth_ref": [] }, "trib_EarningsBeforeInterestTaxDepreciationAndAmortizationDecreaseForImpairment": { "xbrltype": "percentItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "EarningsBeforeInterestTaxDepreciationAndAmortizationDecreaseForImpairment", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfSignificantGoodwillAndIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Earnings before interest, tax, depreciation and amortization decrease for impairment loss.", "label": "Earnings Before Interest Tax Depreciation And Amortization Decrease For Impairment", "terseLabel": "EBITDA would need to decrease for an impairment to arise" } } }, "auth_ref": [] }, "ifrs-full_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Earnings per share [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Effects of exchange rate movements on cash held" } }, "en": { "role": { "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r93", "r94" ] }, "trib_EffectOfIrishIncomeTaxableAtHigherTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "EffectOfIrishIncomeTaxableAtHigherTaxRate", "calculation": { "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfStatutoryTaxRateDetails": { "parentTag": "ifrs-full_AverageEffectiveTaxRate", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfStatutoryTaxRateDetails" ], "lang": { "en-us": { "role": { "documentation": "Effect of Irish income taxable at higher tax rate.", "label": "Effect of Irish income taxable at higher tax rate" } } }, "auth_ref": [] }, "trib_EffectiveIncomeTaxRateContinuingOperationsTaxRateAbstract": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateAbstract", "presentation": [ "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfOverseasTaxJurisdictionsDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Continuing Operations Tax Rate Abstract", "terseLabel": "As a percentage of loss before\u00a0tax:", "verboseLabel": "As a percentage of loss before tax:" } } }, "auth_ref": [] }, "trib_EffectiveInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "EffectiveInterestRate", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementNarrativeDetails", "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfInterestRateRiskEffectiveAndRepricingAnalysisDetails" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate.", "label": "Effective interest rate" } } }, "auth_ref": [] }, "trib_EliminatedOnDisposalOfBusiness": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "EliminatedOnDisposalOfBusiness", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/InventoriesScheduleOfMovementOnInventoryProvisionDetails" ], "lang": { "en-us": { "role": { "documentation": "Represent the amount Eliminated on disposal of business", "negatedLabel": "Eliminated on disposal of business", "label": "Eliminated On Disposal Of Business", "verboseLabel": "Eliminated on disposal of business" } } }, "auth_ref": [] }, "trib_EliminatedOnDisposalsOfBusiness": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "EliminatedOnDisposalsOfBusiness", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfMovementInAllowanceForImpairmentOfTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of eliminated on disposal of business.", "negatedLabel": "Eliminated on disposal of business", "label": "Eliminated On Disposals Of Business" } } }, "auth_ref": [] }, "ifrs-full_EliminationOfIntersegmentAmountsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EliminationOfIntersegmentAmountsMember", "presentation": [ "http://trinitybiotech.com/role/SegmentInformationScheduleOfRevenueByGeographicalAreaBasedOnLocationOfAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Eliminations [Member]", "verboseLabel": "Eliminations [Member]" } }, "en": { "role": { "documentation": "This member stands for the elimination of intersegment amounts in the reconciliations of total segment amounts to amounts recognised in the entity's financial statements." } } }, "auth_ref": [ "r514", "r515" ] }, "ifrs-full_EmployeeBenefitsExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EmployeeBenefitsExpense", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/EmploymentScheduleOfEmploymentCostsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://trinitybiotech.com/role/EmploymentScheduleOfEmploymentCostsDetails" ], "lang": { "en-us": { "role": { "label": "Employee benefits expense", "totalLabel": "Employment Costs" } } }, "auth_ref": [ "r280", "r409", "r458", "r530" ] }, "trib_EmployeeRelatedSocialInsurance": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "EmployeeRelatedSocialInsurance", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/TradeAndOtherPayablesScheduleOfTradeAndOtherPayablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Employee related social insurance.", "label": "Employee related social insurance" } } }, "auth_ref": [] }, "trib_EndUserCustomersMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "EndUserCustomersMember", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfExposureOfTradeReceivablesByCustomerDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for End-user customers.", "label": "End User Customers [Member]" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine1", "presentation": [ "http://trinitybiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine2", "presentation": [ "http://trinitybiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCityOrTown", "presentation": [ "http://trinitybiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCountry", "presentation": [ "http://trinitybiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://trinitybiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://trinitybiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityAddressesAddressTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressesAddressTypeAxis", "presentation": [ "http://trinitybiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCentralIndexKey", "presentation": [ "http://trinitybiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r541" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://trinitybiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://trinitybiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://trinitybiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r541" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFileNumber", "presentation": [ "http://trinitybiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFilerCategory", "presentation": [ "http://trinitybiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r541" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://trinitybiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://trinitybiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r572" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityRegistrantName", "presentation": [ "http://trinitybiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r541" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityShellCompany", "presentation": [ "http://trinitybiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r541" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityVoluntaryFilers", "presentation": [ "http://trinitybiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://trinitybiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r573" ] }, "trib_EpiCaptureLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "EpiCaptureLimitedMember", "presentation": [ "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSDetails", "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSTables", "http://trinitybiotech.com/role/CapitalAndReservesNarrativeDetails", "http://trinitybiotech.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://trinitybiotech.com/role/GROUPUNDERTAKINGSDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsNarrativeDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfSignificantGoodwillAndIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Epi Capture Limited.", "label": "Epi Capture Limited [Member]", "verboseLabel": "Epi Capture Limited [Member]" } } }, "auth_ref": [] }, "ifrs-full_Equity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Equity", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://trinitybiotech.com/role/BASISOFPREPARATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://trinitybiotech.com/role/ConsolidatedStatementOfChangesInEquity", "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "periodEndLabel": "Equity at end of period", "periodStartLabel": "Equity at beginning of period", "label": "Equity", "totalLabel": "Total deficit" } }, "en": { "role": { "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities." } } }, "auth_ref": [ "r112", "r114", "r136", "r137", "r138", "r331", "r360", "r394", "r395", "r406", "r431", "r440" ] }, "ifrs-full_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityAbstract", "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Equity attributable to the equity holders of the parent" } } }, "auth_ref": [] }, "ifrs-full_EquityAndLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityAndLiabilities", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Equity and liabilities", "totalLabel": "TOTAL EQUITY AND LIABILITIES" } }, "en": { "role": { "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]" } } }, "auth_ref": [ "r431" ] }, "ifrs-full_EquityAndLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityAndLiabilitiesAbstract", "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "EQUITY AND LIABILITIES" } } }, "auth_ref": [] }, "trib_EquityComponentAtDateOfIssue": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "EquityComponentAtDateOfIssue", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails2", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of equity component at date of issue.", "label": "Equity Component At Date Of Issue", "terseLabel": "Equity component at date of issue", "verboseLabel": "Equity component at date of issue" } } }, "auth_ref": [] }, "trib_EquityComponentOfConvertibleNote": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "EquityComponentOfConvertibleNote", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount represents equity component of convertible note.", "label": "Equity Component Of Convertible Note", "terseLabel": "Equity component of convertible note", "verboseLabel": "Equity investment" } } }, "auth_ref": [] }, "trib_EquityComponentOfConvertibleNoteAtDateOfIssue": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "EquityComponentOfConvertibleNoteAtDateOfIssue", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/ReconciliationOfLiabilitiesArisingFromFinancingActivitiesScheduleOfLiabilitiesArisingFromFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "Equity component of convertible note at date of issue.", "negatedLabel": "Equity component of convertible note at date of issue", "label": "Equity Component Of Convertible Note At Date Of Issue" } } }, "auth_ref": [] }, "trib_EquityComponentOfConvertibleNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "EquityComponentOfConvertibleNoteMember", "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfChangesInEquity" ], "lang": { "en-us": { "role": { "documentation": "Equity Component of Convertible Note", "label": "Equity Component Of Convertible Note [Member]", "verboseLabel": "Equity Component of convertible Note [Member]" } } }, "auth_ref": [] }, "ifrs-full_EquityInterestsOfAcquirer": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityInterestsOfAcquirer", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSDetails", "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Equity interests of acquirer", "terseLabel": "Non-cash consideration" } }, "en": { "role": { "documentation": "The fair value, at the acquisition date, of equity interests of the acquirer transferred as consideration in a business combination. [Refer: Total for all business combinations [member]]" } } }, "auth_ref": [ "r188", "r374" ] }, "trib_EstimatedObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "EstimatedObligations", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/ProvisionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Estimated obligations.", "label": "Estimated obligations" } } }, "auth_ref": [] }, "trib_EuroZoneCountriesMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "EuroZoneCountriesMember", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfExposureOfTradeReceivablesByGeographicLocationDetails" ], "lang": { "en-us": { "role": { "documentation": "Euro-zone countries [Member]", "label": "Euro-zone countries [Member]" } } }, "auth_ref": [] }, "trib_EuropeIncludingIrelandMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "EuropeIncludingIrelandMember", "presentation": [ "http://trinitybiotech.com/role/SegmentInformationScheduleOfRevenueByCustomersGeographicalAreaDetails" ], "lang": { "en-us": { "role": { "documentation": "Europe (including Ireland) [Member]", "label": "Europe Including Ireland Member", "terseLabel": "Europe (including Ireland) [Member]" } } }, "auth_ref": [] }, "srt_EuropeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "EuropeMember", "presentation": [ "http://trinitybiotech.com/role/SegmentInformationScheduleOfRevenueDerivesFromTransferOfGoodsAndServicesDetails" ], "lang": { "en-us": { "role": { "label": "Europe [Member]" } } }, "auth_ref": [] }, "trib_EventsAfterReportingPeriodMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "EventsAfterReportingPeriodMember", "presentation": [ "http://trinitybiotech.com/role/BASISOFPREPARATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://trinitybiotech.com/role/PostBalanceSheetEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used.", "label": "Events After Reporting Period [Member]" } } }, "auth_ref": [] }, "trib_ExcessValueOfGoodwillInUseOverCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ExcessValueOfGoodwillInUseOverCarryingAmount", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfSignificantGoodwillAndIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Excess value-in-use over carrying amount.", "label": "Excess Value Of Goodwill In Use Over Carrying Amount", "terseLabel": "Excess value-in-use over carrying amount" } } }, "auth_ref": [] }, "trib_ExchangeableNoteEquityConversionOption": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ExchangeableNoteEquityConversionOption", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfFairValuesOfFinancialAssetsliabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Exchangeable note equity conversion option.", "negatedLabel": "Exchangeable note equity conversion option", "label": "Exchangeable note equity conversion option" } } }, "auth_ref": [] }, "trib_ExchangeableNoteInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ExchangeableNoteInterest", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfLiquidityRiskEstimatedInterestPaymentsOfMaturitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Exchangeable note interest.", "label": "Exchangeable note interest" } } }, "auth_ref": [] }, "trib_ExchangeableNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ExchangeableNoteMember", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfInterestRateRiskEffectiveAndRepricingAnalysisDetails" ], "lang": { "en-us": { "role": { "documentation": "Exchangeable note [Member]", "label": "Exchangeable note [Member]" } } }, "auth_ref": [] }, "trib_ExchangeableNotesAndOtherBorrowingsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ExchangeableNotesAndOtherBorrowingsCurrent", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "documentation": "Information about Exchangeable notes and other borrowings classified as current liabilities.", "positiveLabel": "Exchangeable notes", "label": "Exchangeable Notes And Other Borrowings Current", "terseLabel": "Exchangeable notes and other borrowings", "verboseLabel": "Exchangeable senior notes" } } }, "auth_ref": [] }, "trib_ExchangeableNotesDiscountRate": { "xbrltype": "pureItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ExchangeableNotesDiscountRate", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of discount rate for exchangeable notes.", "label": "Exchangeable Notes Discount Rate", "terseLabel": "Exchangeable notes discount rate" } } }, "auth_ref": [] }, "trib_ExchangeableSeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ExchangeableSeniorNotesMember", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails1", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represent information about the exchangeable senior notes member.", "label": "Exchangeable Senior Notes [Member]" } } }, "auth_ref": [] }, "trib_ExercisableAbstract": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ExercisableAbstract", "presentation": [ "http://trinitybiotech.com/role/ShareOptionsSummaryOfRangeOfPricesOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Exercisable Abstract", "terseLabel": "Exercisable" } } }, "auth_ref": [] }, "trib_ExerciseOfShareOptionsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ExerciseOfShareOptionsReceivable", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Exercise of share options receivable.", "label": "Exercise of share options receivable" } } }, "auth_ref": [] }, "trib_ExercisePriceOfWarrantsOrRights": { "xbrltype": "perShareItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ExercisePriceOfWarrantsOrRights", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Exercise Price Of Warrants Or Rights", "terseLabel": "Exercise price of warrants" } } }, "auth_ref": [] }, "ifrs-full_ExercisePriceShareOptionsGranted2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExercisePriceShareOptionsGranted2019", "presentation": [ "http://trinitybiotech.com/role/ShareOptionsScheduleOfAssumptionDeterminingFairValueOfShareOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price per 'A' share / (per ADS)" } }, "en": { "role": { "documentation": "The exercise price of share options granted." } } }, "auth_ref": [ "r183" ] }, "ifrs-full_ExpectedCreditLossRate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExpectedCreditLossRate", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfAgeingOfTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Expected credit loss rate" } }, "en": { "role": { "documentation": "The rate of expected credit losses, calculated as percentage of the gross carrying amount. Expected credit losses are the weighted average of credit losses with the respective risks of a default occurring as the weights." } } }, "auth_ref": [ "r503", "r510" ] }, "ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExpectedDividendAsPercentageShareOptionsGranted", "presentation": [ "http://trinitybiotech.com/role/ShareOptionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Expected dividend as percentage, share options granted", "terseLabel": "Expected dividend yield percentage" } }, "en": { "role": { "documentation": "The percentage of an expected dividend used to calculate the fair value of share options granted." } } }, "auth_ref": [ "r183" ] }, "ifrs-full_ExpectedReimbursementContingentLiabilitiesInBusinessCombination": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExpectedReimbursementContingentLiabilitiesInBusinessCombination", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/OTHEROPERATINGINCOMEEXPENSENarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Expected reimbursement, contingent liabilities in business combination", "terseLabel": "Unconditional right for perceptive to receive cash" } }, "en": { "role": { "documentation": "The amount expected to be reimbursed by another party on expenditures to settle contingent liabilities recognised in a business combination. [Refer: Classes of contingent liabilities [domain]; Total for all business combinations [member]]" } } }, "auth_ref": [ "r192", "r199" ] }, "trib_ExpenseOfRestructuringCost": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ExpenseOfRestructuringCost", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/EmploymentScheduleOfEmploymentCostsDetails": { "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://trinitybiotech.com/role/EmploymentScheduleOfEmploymentCostsDetails" ], "lang": { "en-us": { "role": { "label": "Expense Of Restructuring Cost", "terseLabel": "Restructuring cost", "documentation": "The amount of expense relating to restructuring. Restructuring is a programme that is planned and controlled by management and materially changes either the scope of a business undertaken by an entity or the manner in which that business is conducted. Such programmes include: (a) the sale or termination of a line of business; (b) closure of business locations in a country or region or the relocation of activities from one country or region to another; (c) changes in management structure; and (d) fundamental reorganisations that have a material effect on the nature and focus of the entity's operations.", "verboseLabel": "Transformation cost" } } }, "auth_ref": [] }, "ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/LeaseLiabilitiesScheduleOfOutstandingInterestBearingLoansAndBorrowingsDetails" ], "lang": { "en-us": { "role": { "label": "Expense relating to short-term leases for which recognition exemption has been used", "terseLabel": "Short-term lease expenses" } } }, "auth_ref": [ "r150", "r267" ] }, "ifrs-full_ExplanationOfRestrictionsOnDistributionOfRevaluationSurplusForIntangibleAssets": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExplanationOfRestrictionsOnDistributionOfRevaluationSurplusForIntangibleAssets", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Description of project completion period" } }, "en": { "role": { "documentation": "The explanation of restrictions on the distribution of the balance of the revaluation surplus for intangible assets to shareholders. [Refer: Revaluation surplus]" } } }, "auth_ref": [ "r82", "r351" ] }, "trib_ExtinguishmentOfAmountOwed": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ExtinguishmentOfAmountOwed", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://trinitybiotech.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The fair value, at acquisition date, of the consideration transferred in a business combination extinguishment of amount owed.", "label": "Extinguishment Of Amount Owed", "terseLabel": "Extinguishment of monies owed" } } }, "auth_ref": [] }, "trib_ExtinguishmentOfDebtAmounts": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ExtinguishmentOfDebtAmounts", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Gross amount of debt extinguished.", "label": "Extinguishment Of Debt, Amounts", "terseLabel": "Extinguishment of debt" } } }, "auth_ref": [] }, "trib_FairValueGainOnContingentConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "FairValueGainOnContingentConsideration", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/OTHEROPERATINGINCOMEEXPENSEScheduleofOtherOperatingIncomeDetails": { "parentTag": "ifrs-full_OtherOperatingIncomeExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://trinitybiotech.com/role/OTHEROPERATINGINCOMEEXPENSENarrativeDetails", "http://trinitybiotech.com/role/OTHEROPERATINGINCOMEEXPENSEScheduleofOtherOperatingIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Gain on Contingent Consideration", "terseLabel": "Fair value gain on contingent consideration", "documentation": "Amount of fair value gain on contingent consideration." } } }, "auth_ref": [] }, "trib_FairValueMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "FairValueMember", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfFairValuesOfFinancialAssetsliabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Fair Value [Member]", "label": "Fair Value [Member]" } } }, "auth_ref": [] }, "trib_FairValueOfContingentConsiderationRecognisedAsOfAcquisitionDate": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "FairValueOfContingentConsiderationRecognisedAsOfAcquisitionDate", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://trinitybiotech.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount, at acquisition date, of fair value of contingent consideration arrangements recognised as consideration transferred in a business combination. [Refer: Total for all business combinations [member]]", "label": "Fair Value Of Contingent Consideration Recognised As Of Acquisition Date", "terseLabel": "Fair value of contingent consideration" } } }, "auth_ref": [] }, "trib_FairValueOfDerivativeFinancialAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "FairValueOfDerivativeFinancialAsset", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Fair value of derivative financial asset.", "label": "Fair Value Of Derivative Financial Asset", "terseLabel": "Fair value of derivative financial asset" } } }, "auth_ref": [] }, "trib_FairValueOfDerivativeFinancialLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "FairValueOfDerivativeFinancialLiability", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Fair value of derivative financial liability.", "label": "Fair Value Of Derivative Financial Liability", "terseLabel": "Fair value of derivative financial liability" } } }, "auth_ref": [] }, "trib_FairValueOfFinancialAssetsLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "FairValueOfFinancialAssetsLiabilities", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfFairValuesOfFinancialAssetsliabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Total fair value of financial assets liabilities.", "negatedTotalLabel": "Total fair value of financial assets liabilities", "label": "Fair Value Of Financial Assets Liabilities", "verboseLabel": "Total fair value of financial assets liabilities" } } }, "auth_ref": [] }, "trib_FairValueOfSharesIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "FairValueOfSharesIssued", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/IMPAIRMENTTRANSFORMATIONANDONCEOFFCOSTSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents amount of fair value of shares issued.", "label": "Fair Value Of Shares Issued", "terseLabel": "Fair value of ADSs issued" } } }, "auth_ref": [] }, "trib_FairValueRemeasuredThroughProfitLossOfFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "FairValueRemeasuredThroughProfitLossOfFinancialAssets", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/FINANCIALASSETSDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of fair value remeasured through profit & loss for financial assets.", "label": "Fair Value Remeasured Through Profit & Loss Of Financial Assets", "terseLabel": "Fair value remeasured through profit & loss" } } }, "auth_ref": [] }, "trib_FairValueRemeasurementForDerivativeFinancialBalances": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "FairValueRemeasurementForDerivativeFinancialBalances", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Fair value remeasurement for derivative financial balances.", "label": "Fair Value Remeasurement For Derivative Financial Balances", "terseLabel": "Fair value remeasurement for derivative financial balances" } } }, "auth_ref": [] }, "trib_FairValueThroughProfitAndLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "FairValueThroughProfitAndLoss", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfFairValuesOfFinancialAssetsliabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Ffair value through profit and loss (FVPL).", "negatedTotalLabel": "Total fair value through profit and loss (FVPL)", "label": "Fair Value Through Profit And Loss", "terseLabel": "Total fair value through profit and loss (FVPL)" } } }, "auth_ref": [] }, "trib_FifthAmendmentToCreditAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "FifthAmendmentToCreditAgreementMember", "presentation": [ "http://trinitybiotech.com/role/BASISOFPREPARATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Fifth Amendment To Credit Agreement [Member]", "label": "Fifth Amendment To Credit Agreement [Member]" } } }, "auth_ref": [] }, "ifrs-full_FinanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinanceCosts", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfOperations": { "parentTag": "trib_NetFinancingExpenseIncome", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfOperations", "http://trinitybiotech.com/role/FinancialIncomeAndExpensesScheduleOfFinancialIncomeExpensesNetDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Financial expenses", "negatedTotalLabel": "Financial expense", "label": "Finance costs", "verboseLabel": "Financial expense" } } }, "auth_ref": [ "r451" ] }, "ifrs-full_FinanceIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinanceIncome", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfOperations": { "parentTag": "trib_NetFinancingExpenseIncome", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfOperations" ], "lang": { "en-us": { "role": { "label": "Financial income", "totalLabel": "Financial income" } } }, "auth_ref": [ "r619" ] }, "ifrs-full_FinanceIncomeCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinanceIncomeCost", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/FinancialIncomeAndExpensesScheduleOfFinancialIncomeExpensesNetDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Non-cash financial expense", "label": "Finance income (cost)", "terseLabel": "Non-cash financial expense" } } }, "auth_ref": [ "r619" ] }, "trib_FinanceIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "FinanceIncomeExpenseNet", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/FinancialIncomeAndExpensesScheduleOfFinancialIncomeExpensesNetDetails" ], "lang": { "en-us": { "role": { "documentation": "Financing expenses, net.", "label": "Finance Income Expense Net", "terseLabel": "Net financing expense" } } }, "auth_ref": [] }, "trib_FinanceLeaseLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "FinanceLeaseLiabilitiesMember", "presentation": [ "http://trinitybiotech.com/role/LeaseLiabilitiesScheduleOfOutstandingInterestBearingLoansAndBorrowingsDetails" ], "lang": { "en-us": { "role": { "documentation": "Finance lease liabilities [Member]", "label": "Finance Lease Liabilities Member", "terseLabel": "Sale and leaseback liabilities [Member]" } } }, "auth_ref": [] }, "trib_FinanceLeaseLiabilitiesTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "FinanceLeaseLiabilitiesTwoMember", "presentation": [ "http://trinitybiotech.com/role/LeaseLiabilitiesScheduleOfOutstandingInterestBearingLoansAndBorrowingsDetails" ], "lang": { "en-us": { "role": { "documentation": "Finance lease liabilities Two [Member]", "label": "Finance Lease Liabilities Two Member", "terseLabel": "Sale and leaseback liabilities Two [Member]" } } }, "auth_ref": [] }, "trib_FinanceLeaseReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "FinanceLeaseReceivableMember", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfInterestRateRiskEffectiveAndRepricingAnalysisDetails" ], "lang": { "en-us": { "role": { "documentation": "Finance lease receivable [Member]", "label": "Finance Lease Receivable Member", "terseLabel": "Lease receivable [Member]" } } }, "auth_ref": [] }, "ifrs-full_FinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialAssets", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/FINANCIALASSETSDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Cost At December 31", "periodStartLabel": "Cost At January 1", "label": "Financial assets", "verboseLabel": "Financial assets (see Note 13)" } }, "en": { "role": { "documentation": "The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose the entity\u2019s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. [Refer: Classes of financial instruments [domain]; Financial liabilities]" } } }, "auth_ref": [ "r220", "r224", "r225", "r228", "r387", "r388", "r389", "r503" ] }, "trib_FinancialAssetsAdditions": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "FinancialAssetsAdditions", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/FINANCIALASSETSDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of financial assets additions.", "label": "Financial Assets Additions", "verboseLabel": "Additions in year" } } }, "auth_ref": [] }, "ifrs-full_FinancialAssetsAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialAssetsAtFairValue", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/FINANCIALASSETSDetails", "http://trinitybiotech.com/role/FINANCIALASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Financial assets, at fair value", "verboseLabel": "Carrying amount At December 31", "terseLabel": "Financial assets, carrying amount" } }, "en": { "role": { "documentation": "The fair value of financial assets. [Refer: At fair value [member]; Financial assets]" } } }, "auth_ref": [ "r220" ] }, "trib_FinancialAssetsLeaseReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "FinancialAssetsLeaseReceivables", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfInterestRateProfileOfFinancialAssetsliabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Financial assets lease receivables.", "positiveLabel": "Finance lease receivable", "positiveTerseLabel": "Finance lease income receivable", "label": "Financial Assets Lease Receivables", "terseLabel": "Financial assets (lease receivables)", "verboseLabel": "Lease receivable" } } }, "auth_ref": [] }, "trib_FinancialAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "FinancialAssetsPolicyTextBlock", "presentation": [ "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for financial assets.", "label": "Financial Assets [Policy Text Block]", "terseLabel": "Financial Assets" } } }, "auth_ref": [] }, "ifrs-full_FinancialAssetsRecognisedAsOfAcquisitionDate": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialAssetsRecognisedAsOfAcquisitionDate", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSDetails": { "parentTag": "ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSDetails" ], "lang": { "en-us": { "role": { "label": "Financial assets recognised as of acquisition date", "terseLabel": "Financial assets", "negatedLabel": "Financial assets" } }, "en": { "role": { "documentation": "The amount recognised as of the acquisition date for financial assets acquired in a business combination. [Refer: Financial assets; Total for all business combinations [member]]" } } }, "auth_ref": [ "r497", "r499", "r523" ] }, "trib_FinancialAssetsWriteOff": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "FinancialAssetsWriteOff", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/FINANCIALASSETSDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of financial assets written off.", "label": "Financial Assets Write Off", "terseLabel": "Write off in the year" } } }, "auth_ref": [] }, "trib_FinancialAtFairValueThroughProfitOrLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "FinancialAtFairValueThroughProfitOrLossAbstract", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfFairValuesOfFinancialAssetsliabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial At Fair Value Through Profit Or Loss Abstract", "terseLabel": "Fair value through profit and loss (FVPL)" } } }, "auth_ref": [] }, "ifrs-full_FinancialEffectOfCorrectionsOfAccountingErrorsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialEffectOfCorrectionsOfAccountingErrorsMember", "presentation": [ "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSDetails", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONDetail5" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) due to corrections of prior period errors [member]", "terseLabel": "Post Disposal Adjustment [Member]", "verboseLabel": "Measurement period adjustment" } }, "en": { "role": { "documentation": "This member stands for the financial effect of corrections of prior period errors." } } }, "auth_ref": [ "r110", "r111", "r304", "r305" ] }, "trib_FinancialIncomeAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "FinancialIncomeAndExpensesAbstract", "lang": { "en-us": { "role": { "label": "Financial Income And Expenses Abstract", "verboseLabel": "Financial Income And Expenses" } } }, "auth_ref": [] }, "ifrs-full_FinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialLiabilities", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfLiquidityRiskEstimatedInterestPaymentsOfMaturitiesDetails" ], "lang": { "en-us": { "role": { "label": "Total maturities of financial liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Classes of financial instruments [domain]; Financial assets; Derivatives [member]]" } } }, "auth_ref": [ "r220" ] }, "ifrs-full_FinancialLiabilitiesAtAmortisedCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialLiabilitiesAtAmortisedCost", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfFairValuesOfFinancialAssetsliabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Total Liabilities at amortised cost", "negatedTotalLabel": "Total Liabilities at amortised cost", "label": "Financial liabilities at amortised cost", "terseLabel": "Total Liabilities at amortised cost" } }, "en": { "role": { "documentation": "The amount of financial liabilities at amortised cost. The amortised cost is the amount at which financial liabilities are measured at initial recognition minus principal repayments, plus or minus the cumulative amortisation using the effective interest method of any difference between that initial amount and the maturity amount. [Refer: Financial liabilities]" } } }, "auth_ref": [ "r237", "r383" ] }, "trib_FinancingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "FinancingExpensesAbstract", "presentation": [ "http://trinitybiotech.com/role/FinancialIncomeAndExpensesScheduleOfFinancialIncomeExpensesNetDetails" ], "lang": { "en-us": { "role": { "label": "Financing Expenses Abstract", "terseLabel": "Financial expense:" } } }, "auth_ref": [] }, "trib_FinancingIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "FinancingIncomeAbstract", "presentation": [ "http://trinitybiotech.com/role/FinancialIncomeAndExpensesScheduleOfFinancialIncomeExpensesNetDetails" ], "lang": { "en-us": { "role": { "label": "Financing Income Abstract", "terseLabel": "Financial income:" } } }, "auth_ref": [] }, "trib_FinancingIncomeBySegment": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "FinancingIncomeBySegment", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/SegmentInformationScheduleOfSegmentResultsByGeographicalAreaDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of financing income by operating segment.", "label": "Financing Income By Segment", "terseLabel": "Net financing expense (Note 6)" } } }, "auth_ref": [] }, "ifrs-full_FinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinishedGoods", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/InventoriesScheduleOfInventoriesDetails": { "parentTag": "ifrs-full_Inventories", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://trinitybiotech.com/role/InventoriesScheduleOfInventoriesDetails" ], "lang": { "en-us": { "role": { "label": "Finished goods" } }, "en": { "role": { "documentation": "A classification of current inventory representing the amount of goods that have completed the production process and are held for sale in the ordinary course of business. [Refer: Inventories]" } } }, "auth_ref": [ "r528", "r536", "r586" ] }, "trib_FiomiDiagnosticsAbMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "FiomiDiagnosticsAbMember", "presentation": [ "http://trinitybiotech.com/role/GROUPUNDERTAKINGSDetails" ], "lang": { "en-us": { "role": { "documentation": "Fiomi Diagnostics AB [Member]", "label": "Fiomi Diagnostics Ab [Member]" } } }, "auth_ref": [] }, "trib_FiomiDiagnosticsHoldingAbMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "FiomiDiagnosticsHoldingAbMember", "presentation": [ "http://trinitybiotech.com/role/GROUPUNDERTAKINGSDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Fiomi Diagnostics Holding AB.", "label": "Fiomi Diagnostics Holding Ab [Member]" } } }, "auth_ref": [] }, "trib_FiomiDiagnosticsMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "FiomiDiagnosticsMember", "presentation": [ "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONDetail5", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSDetails", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSDetails1", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSDetails3", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Fiomi Diagnostics.", "label": "Fiomi Diagnostics [Member]", "verboseLabel": "Fiomi Diagnostics (\u201cFiomi\u201d) [Member]" } } }, "auth_ref": [] }, "trib_FitzgeraldIndustriesInternationalCguRdiTradeNameMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "FitzgeraldIndustriesInternationalCguRdiTradeNameMember", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfIntangibleAssetsWithIndefiniteUsefulLivesDetails" ], "lang": { "en-us": { "role": { "documentation": "Fitzgerald Industries International CGU RDI Trade Name [Member]", "label": "Fitzgerald Industries International CGU RDI Trade Name [Member]" } } }, "auth_ref": [] }, "trib_FitzgeraldIndustriesInternationalCguTradeNameMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "FitzgeraldIndustriesInternationalCguTradeNameMember", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfIntangibleAssetsWithIndefiniteUsefulLivesDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfSignificantGoodwillAndIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Fitzgerald Industries International CGU Trade Name [Member]", "label": "Fitzgerald Industries International CGU Trade Name [Member]" } } }, "auth_ref": [] }, "trib_FitzgeraldIndustriesInternationalIncMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "FitzgeraldIndustriesInternationalIncMember", "presentation": [ "http://trinitybiotech.com/role/GROUPUNDERTAKINGSDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Fitzgerald Industries International, Inc.", "label": "Fitzgerald Industries International, Inc [Member]" } } }, "auth_ref": [] }, "trib_FixedOverheadsMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "FixedOverheadsMember", "presentation": [ "http://trinitybiotech.com/role/IMPAIRMENTTRANSFORMATIONANDONCEOFFCOSTSNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Fixed Overheads [Member]", "terseLabel": "Fixed Overheads [Member]", "documentation": "This member stands for information pertaining to \"Fixed Overheads\"" } } }, "auth_ref": [] }, "trib_FixedRateFinancialLiabilitiesBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "FixedRateFinancialLiabilitiesBorrowings", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfInterestRateProfileOfFinancialAssetsliabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Fixed rate financial liabilities of borrowings.", "negatedLabel": "Fixed rate financial liabilities (borrowings)", "label": "Fixed Rate Financial Liabilities Borrowings" } } }, "auth_ref": [] }, "trib_FixedRateInstruments": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "FixedRateInstruments", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfInterestRateProfileOfFinancialAssetsliabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of total fixed rate instruments.", "negatedLabel": "Fixed rate instruments", "negatedTotalLabel": "Fixed rate instruments", "label": "Fixed Rate Instruments" } } }, "auth_ref": [] }, "trib_FixedRateInstrumentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "FixedRateInstrumentsAbstract", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfInterestRateProfileOfFinancialAssetsliabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Fixed Rate Instruments Abstract", "terseLabel": "Fixed rate instruments" } } }, "auth_ref": [] }, "trib_ForgivenessOfBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ForgivenessOfBorrowings", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Forgiveness amount.", "label": "Forgiveness Of Borrowings", "terseLabel": "Forgiveness amount" } } }, "auth_ref": [] }, "trib_FourthAmendmentToCreditAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "FourthAmendmentToCreditAgreementMember", "presentation": [ "http://trinitybiotech.com/role/BASISOFPREPARATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Fourth Amendment To Credit Agreement [Member]", "label": "Fourth Amendment To Credit Agreement [Member]" } } }, "auth_ref": [] }, "trib_G6PDHTestMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "G6PDHTestMember", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfPrincipalDevelopmentProjectsDetails" ], "lang": { "en-us": { "role": { "documentation": "G-6-PDH test [Member]", "label": "G 6 P D H Test [Member]", "terseLabel": "G-6-PDH Test [Member]" } } }, "auth_ref": [] }, "country_GB": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2025", "localname": "GB", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfExposureOfTradeReceivablesByGeographicLocationDetails" ], "lang": { "en-us": { "role": { "label": "UNITED KINGDOM", "terseLabel": "United Kingdom [Member]" } } }, "auth_ref": [] }, "currency_GBP": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2025", "localname": "GBP", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfForeignCurrencyRiskShortTermFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "GBP [Member]" } } }, "auth_ref": [] }, "trib_GainLossOnSettlementOfLegalProceedings": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "GainLossOnSettlementOfLegalProceedings", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/IMPAIRMENTTRANSFORMATIONANDONCEOFFCOSTSNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Gain Loss On Settlement Of Legal Proceedings", "terseLabel": "Gain on settlement of legacy matter recognised in once-off items", "documentation": "Amount of gain (loss) on settlement of legal proceedings." } } }, "auth_ref": [] }, "ifrs-full_GainLossRecognisedOnMeasurementToFairValueLessCostsToSellOrOnDisposalOfAssetsOrDisposalGroupsConstitutingDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GainLossRecognisedOnMeasurementToFairValueLessCostsToSellOrOnDisposalOfAssetsOrDisposalGroupsConstitutingDiscontinuedOperation", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "(Loss)/Gain on sale of discontinued operations", "label": "Gain (loss) recognised on measurement to fair value less costs to sell or on disposal of assets or disposal groups constituting discontinued operation" } } }, "auth_ref": [ "r209" ] }, "ifrs-full_GainLossThatRelatesToIdentifiableAssetsAcquiredOrLiabilitiesAssumedInBusinessCombination": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GainLossThatRelatesToIdentifiableAssetsAcquiredOrLiabilitiesAssumedInBusinessCombination", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Gain (loss) that relates to identifiable assets acquired or liabilities assumed in business combination and is of such size, nature or incidence that disclosure is relevant to understanding combined entity's financial statements", "terseLabel": "Acquired business incurred net loss" } } }, "auth_ref": [ "r202" ] }, "ifrs-full_GeographicalAreasAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GeographicalAreasAxis", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfExposureOfTradeReceivablesByGeographicLocationDetails", "http://trinitybiotech.com/role/IncomeTaxCreditNarrativeDetails", "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfLossProfitBeforeTaxesDetails", "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfNetOperatingLossesDetails", "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfUnrecognisedDeferredTaxAssetsDetails", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONDetail5", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSDetails", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSDetails1", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSDetails3", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSNarrativeDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfCapitalExpenditureByGeographicalAreaDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfDepreciationAndAmortisationByGeographicalAreaDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfLongLivedAssetsDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfRevenueByCustomersGeographicalAreaDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfRevenueByGeographicalAreaBasedOnLocationOfAssetsDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfRevenueDerivesFromTransferOfGoodsAndServicesDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfSegmentAssetsAndSegmentLiabilitiesByGeographicalAreaDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfSegmentResultsByGeographicalAreaDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfShareBasedPaymentExpenseByGeographicalAreaDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfTaxationExpenseByGeographicalAreaDetails" ], "lang": { "en-us": { "role": { "label": "Geographical areas [Axis]", "verboseLabel": "Geographical areas [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r255", "r464", "r493", "r496", "r517" ] }, "ifrs-full_GeographicalAreasDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GeographicalAreasDomain", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfExposureOfTradeReceivablesByGeographicLocationDetails", "http://trinitybiotech.com/role/IncomeTaxCreditNarrativeDetails", "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfLossProfitBeforeTaxesDetails", "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfNetOperatingLossesDetails", "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfUnrecognisedDeferredTaxAssetsDetails", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONDetail5", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSDetails", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSDetails1", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSDetails3", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSNarrativeDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfCapitalExpenditureByGeographicalAreaDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfDepreciationAndAmortisationByGeographicalAreaDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfLongLivedAssetsDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfRevenueByCustomersGeographicalAreaDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfRevenueByGeographicalAreaBasedOnLocationOfAssetsDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfRevenueDerivesFromTransferOfGoodsAndServicesDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfSegmentAssetsAndSegmentLiabilitiesByGeographicalAreaDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfSegmentResultsByGeographicalAreaDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfShareBasedPaymentExpenseByGeographicalAreaDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfTaxationExpenseByGeographicalAreaDetails" ], "lang": { "en-us": { "role": { "label": "Geographical areas [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used." } } }, "auth_ref": [ "r255", "r464", "r493", "r496", "r517" ] }, "ifrs-full_GoodwillMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GoodwillMember", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfGoodwillAndIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Goodwill [member]" } }, "en": { "role": { "documentation": "This member stands for goodwill. [Refer: Goodwill]" } } }, "auth_ref": [ "r467", "r522" ] }, "ifrs-full_GoodwillRecognisedAsOfAcquisitionDate": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GoodwillRecognisedAsOfAcquisitionDate", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSDetails", "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Goodwill", "positiveTerseLabel": "Goodwill recognised in connection with acquisition", "label": "Goodwill recognised as of acquisition date", "terseLabel": "Goodwill and Intangible assets acquired", "verboseLabel": "Goodwill" } }, "en": { "role": { "documentation": "The amount recognised as of the business combination's acquisition date for goodwill. [Refer: Goodwill; Total for all business combinations [member]]" } } }, "auth_ref": [ "r498", "r499", "r524" ] }, "trib_GoodwillWriteOff": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "GoodwillWriteOff", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of goodwill write off.", "label": "Goodwill write off" } } }, "auth_ref": [] }, "trib_GovernmentGrantReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "GovernmentGrantReceived", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of government grant received.", "label": "Government Grant Received" } } }, "auth_ref": [] }, "trib_GovernmentSupportsCovid19": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "GovernmentSupportsCovid19", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/OTHEROPERATINGINCOMEEXPENSEScheduleofOtherOperatingIncomeDetails": { "parentTag": "ifrs-full_OtherOperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://trinitybiotech.com/role/OTHEROPERATINGINCOMEEXPENSEScheduleofOtherOperatingIncomeDetails" ], "lang": { "en-us": { "role": { "documentation": "Government supports - COVID-19.", "label": "Government supports" } } }, "auth_ref": [] }, "trib_GrantContingenciesMaximumAmountPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "GrantContingenciesMaximumAmountPayable", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Grant contingencies maximum amount payable.", "label": "Grant contingencies maximum amount payable" } } }, "auth_ref": [] }, "trib_GrantReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "GrantReceivable", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/TradeAndOtherReceivablesScheduleOfTradeAndOtherReceivablesDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentReceivables", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://trinitybiotech.com/role/TradeAndOtherReceivablesScheduleOfTradeAndOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Grant receivable.", "label": "Grant Receivable", "terseLabel": "Grant receivable" } } }, "auth_ref": [] }, "trib_GreaterThanFiveYearsMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "GreaterThanFiveYearsMember", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfInterestRateRiskEffectiveAndRepricingAnalysisDetails", "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfLiquidityRiskEstimatedInterestPaymentsOfMaturitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "5 years [Member]", "label": "Greater Than Five Years Member", "terseLabel": ">5 years [Member]" } } }, "auth_ref": [] }, "trib_GreaterThanFourMonthsMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "GreaterThanFourMonthsMember", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfAgeingOfTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Greater than 120 days [Member]", "label": "Greater Than Four Months Member", "terseLabel": "Greater than 120 days [Member]" } } }, "auth_ref": [] }, "ifrs-full_GrossCarryingAmountMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GrossCarryingAmountMember", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfAgeingOfTradeReceivablesDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfGoodwillAndIntangibleAssetsDetails", "http://trinitybiotech.com/role/PropertyPlantAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentRelatedToAccumulatedDepreciationDetails" ], "lang": { "en-us": { "role": { "label": "Cost [Member]", "terseLabel": "Cost [Member]" } } }, "auth_ref": [ "r11", "r75", "r86", "r90", "r201", "r225", "r228", "r314", "r344", "r355", "r359", "r388", "r389", "r503" ] }, "trib_GrossIncreaseInterestIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "GrossIncreaseInterestIncome", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represent the gross Increase interest income.", "label": "Gross Increase Interest Income" } } }, "auth_ref": [] }, "trib_GrossInvestmentInFinanceLease": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "GrossInvestmentInFinanceLease", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/TradeAndOtherReceivablesScheduleOfFutureMinimumFinanceLeaseReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "The aggregate of: (a) the minimum lease payments receivable by the lessor under a finance lease; and (b) any unguaranteed residual value accruing to the lessor. Minimum lease payments are payments over the lease term that the lessee is or can be required to make, excluding contingent rent, costs for services and taxes to be paid by, and reimbursed to, the lessor, together with: (a) for a lessee, any amounts guaranteed by the lessee or by a party related to the lessee; or (b) for a lessor, any residual value guaranteed to the lessor by: (i) the lessee; (ii) a party related to the lessee; or (iii) a third party unrelated to the lessor that is financially capable of discharging the obligations under the guarantee.", "label": "Gross Investment In Finance Lease", "terseLabel": "Gross investment" } } }, "auth_ref": [] }, "ifrs-full_GrossLoanCommitments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GrossLoanCommitments", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Gross loan commitments", "terseLabel": "Outstanding principal term loan" } }, "en": { "role": { "documentation": "The amount of contractual undiscounted cash flows for gross commitments to receive a loan." } } }, "auth_ref": [ "r506" ] }, "trib_GrossProceedsFromIssueOfAmericanDepositarySharesUponStandbyEquityPurchaseAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "GrossProceedsFromIssueOfAmericanDepositarySharesUponStandbyEquityPurchaseAgreement", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/PostBalanceSheetEventsDetails" ], "lang": { "en-us": { "role": { "label": "Gross proceeds from issue of American depositary shares upon standby equity purchase agreement", "documentation": "The amount of gross proceeds from issue of American depositary shares (ADSs) upon standby equity purchase agreement.", "terseLabel": "Gross proceeds from issue of American depositary shares (ADSs) upon standby equity purchase agreement" } } }, "auth_ref": [] }, "ifrs-full_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfOperations": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfOperations" ], "lang": { "en-us": { "role": { "label": "Gross profit", "totalLabel": "Gross profit" } } }, "auth_ref": [ "r531" ] }, "trib_HivOneByTwoRapidTestMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "HivOneByTwoRapidTestMember", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfPrincipalDevelopmentProjectsDetails" ], "lang": { "en-us": { "role": { "documentation": "HIV 1/2 Rapid Test [Member]", "label": "Hiv One By Two Rapid Test Member", "verboseLabel": "HIV Screening Rapid Test [Member]" } } }, "auth_ref": [] }, "country_IE": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2025", "localname": "IE", "presentation": [ "http://trinitybiotech.com/role/IncomeTaxCreditNarrativeDetails", "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfLossProfitBeforeTaxesDetails", "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfNetOperatingLossesDetails", "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfUnrecognisedDeferredTaxAssetsDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfCapitalExpenditureByGeographicalAreaDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfDepreciationAndAmortisationByGeographicalAreaDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfLongLivedAssetsDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfRevenueByGeographicalAreaBasedOnLocationOfAssetsDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfRevenueDerivesFromTransferOfGoodsAndServicesDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfSegmentAssetsAndSegmentLiabilitiesByGeographicalAreaDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfSegmentResultsByGeographicalAreaDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfShareBasedPaymentExpenseByGeographicalAreaDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfTaxationExpenseByGeographicalAreaDetails" ], "lang": { "en-us": { "role": { "label": "Ireland [Member]", "verboseLabel": "Ireland [Member]" } } }, "auth_ref": [] }, "trib_ITAndOfficeEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ITAndOfficeEquipmentMember", "presentation": [ "http://trinitybiotech.com/role/PropertyPlantAndEquipmentScheduleOfIncomeFromSub-lettingRight-of-useBuildingsDetails" ], "lang": { "en-us": { "role": { "documentation": "I.T. and office equipment [Member]", "label": "I.T. and office equipment [Member]" } } }, "auth_ref": [] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://trinitybiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r543", "r544", "r557" ] }, "ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IdentifiableAssetsAcquiredLiabilitiesAssumed", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Net assets acquired", "label": "Identifiable assets acquired (liabilities assumed)", "totalLabel": "Net assets acquired" } }, "en": { "role": { "documentation": "The amount recognised as of the acquisition date for net identifiable assets acquired or liabilities assumed in a business combination. [Refer: Total for all business combinations [member]]" } } }, "auth_ref": [ "r497", "r499", "r523" ] }, "ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSDetails": { "parentTag": "ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSDetails" ], "lang": { "en-us": { "role": { "label": "Identifiable intangible assets recognised as of acquisition date", "terseLabel": "Intangible assets - arising on acquisition", "verboseLabel": "Other intangible assets", "negatedLabel": "Intangible assets - arising on acquisition" } }, "en": { "role": { "documentation": "The amount recognised as of the acquisition date for identifiable intangible assets acquired in a business combination. [Refer: Intangible assets other than goodwill; Total for all business combinations [member]]" } } }, "auth_ref": [ "r497", "r499", "r523" ] }, "trib_ImmcoDiagnosticCGUMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ImmcoDiagnosticCGUMember", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfIntangibleAssetsWithIndefiniteUsefulLivesDetails" ], "lang": { "en-us": { "role": { "documentation": "Immco Diagnostic CGU Trade Name [Member]", "label": "Immco Diagnostic C G U Member" } } }, "auth_ref": [] }, "trib_ImmcoDiagnosticsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ImmcoDiagnosticsIncMember", "presentation": [ "http://trinitybiotech.com/role/GROUPUNDERTAKINGSDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfImpairmentLossDetails" ], "lang": { "en-us": { "role": { "documentation": "Immco Diagnostics Inc [Member]", "label": "Immco Diagnostics Inc Member", "verboseLabel": "Immco Diagnostics Inc [Member]" } } }, "auth_ref": [] }, "trib_ImpairmentChargePropertyPlantEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ImpairmentChargePropertyPlantEquipment", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/PropertyPlantAndEquipmentNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represent the amount of Impairment Charge Property, Plant & Equipment", "label": "Impairment Charge Property, Plant & Equipment" } } }, "auth_ref": [] }, "ifrs-full_ImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ImpairmentLoss", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/AccountingEstimatesAndJudgementsNarrativeDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfSegmentResultsByGeographicalAreaDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Impairment charges", "label": "Impairment loss" } }, "en": { "role": { "documentation": "The amount recognised as a reduction of the carrying amount of an asset or cash-generating unit to its recoverable amount. [Refer: Carrying amount [member]]" } } }, "auth_ref": [ "r60", "r61" ] }, "trib_ImpairmentLossForInvestment": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ImpairmentLossForInvestment", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of impairment loss for the investment.", "label": "Impairment Loss For Investment" } } }, "auth_ref": [] }, "ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ImpairmentLossRecognisedInProfitOrLossGoodwill", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Total impairment loss allocated to goodwill" } } }, "auth_ref": [ "r200", "r380" ] }, "ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill", "calculation": { "http://trinitybiotech.com/role/IMPAIRMENTTRANSFORMATIONANDONCEOFFCOSTSScheduleofStatementofOperationDetails": { "parentTag": "ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://trinitybiotech.com/role/AccountingEstimatesAndJudgementsNarrativeDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfBreakdownOfImpairmentLossDetailsUsd", "http://trinitybiotech.com/role/IMPAIRMENTTRANSFORMATIONANDONCEOFFCOSTSScheduleofStatementofOperationDetails" ], "lang": { "en-us": { "role": { "label": "Impairment of goodwill and other intangible assets (Note 12)", "terseLabel": "Impairment loss recognised in other comprehensive income", "verboseLabel": "Goodwill and other intangible assets (see Note 12)" } } }, "auth_ref": [ "r593" ] }, "ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsNarrativeDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfGoodwillAndIntangibleAssetsDetails", "http://trinitybiotech.com/role/IMPAIRMENTTRANSFORMATIONANDONCEOFFCOSTSNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Impairment of intangible assets", "terseLabel": "Impairment losses", "verboseLabel": "Impairment loss" } } }, "auth_ref": [ "r77", "r346" ] }, "ifrs-full_ImpairmentLossRecognisedInProfitOrLossInvestmentProperty": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ImpairmentLossRecognisedInProfitOrLossInvestmentProperty", "presentation": [ "http://trinitybiotech.com/role/PropertyPlantAndEquipmentNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Remaining impairment loss" } } }, "auth_ref": [ "r84", "r87", "r353", "r356" ] }, "ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment", "calculation": { "http://trinitybiotech.com/role/IMPAIRMENTTRANSFORMATIONANDONCEOFFCOSTSScheduleofStatementofOperationDetails": { "parentTag": "ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfBreakdownOfImpairmentLossDetailsUsd", "http://trinitybiotech.com/role/PropertyPlantAndEquipmentNarrativeDetails", "http://trinitybiotech.com/role/PropertyPlantAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentRelatedToAccumulatedDepreciationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Impairment loss", "positiveLabel": "Impairment of PP&E (Note 11)", "label": "Impairment of PP&E (Note 13)", "verboseLabel": "Impairment losses", "terseLabel": "Property, plant and equipment (see Note 11)" } } }, "auth_ref": [ "r15", "r317", "r455" ] }, "ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfOperations": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 5.0 }, "http://trinitybiotech.com/role/IMPAIRMENTTRANSFORMATIONANDONCEOFFCOSTSScheduleofStatementofOperationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfOperations", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfBreakdownOfImpairmentLossDetailsUsd", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfImpairmentLossDetails", "http://trinitybiotech.com/role/IMPAIRMENTTRANSFORMATIONANDONCEOFFCOSTSScheduleofStatementofOperationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Impairment charges", "label": "Impairment loss (reversal of impairment loss) recognised in profit or loss", "totalLabel": "Total impairment loss" } } }, "auth_ref": [ "r281", "r458" ] }, "trib_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossFinancialAssets", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/IMPAIRMENTTRANSFORMATIONANDONCEOFFCOSTSScheduleofStatementofOperationDetails": { "parentTag": "ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfBreakdownOfImpairmentLossDetailsUsd", "http://trinitybiotech.com/role/IMPAIRMENTTRANSFORMATIONANDONCEOFFCOSTSScheduleofStatementofOperationDetails" ], "lang": { "en-us": { "role": { "label": "Impairment loss (reversal of impairment loss) recognised in profit or loss, financial assets", "terseLabel": "(Reversal)/Impairment of financial assets (Note 13)", "documentation": "The amount of impairment loss or reversal of impairment loss recognised in profit or loss for financial assets.", "verboseLabel": "Financial assets (see Note 13)" } } }, "auth_ref": [] }, "ifrs-full_IncomeFromContinuingOperationsAttributableToOwnersOfParent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncomeFromContinuingOperationsAttributableToOwnersOfParent", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfOperations": { "parentTag": "ifrs-full_ProfitLossAttributableToOwnersOfParent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfOperations", "http://trinitybiotech.com/role/SegmentInformationScheduleOfSegmentResultsByGeographicalAreaDetails" ], "lang": { "en-us": { "role": { "label": "Income from continuing operations attributable to owners of parent", "totalLabel": "Loss for the year on continuing operations", "terseLabel": "Loss for the year on continuing operations" } }, "en": { "role": { "documentation": "The amount of income from continuing operations attributable to owners of the parent. [Refer: Continuing operations, unless line item indicates otherwise [member]]" } } }, "auth_ref": [ "r213" ] }, "ifrs-full_IncomeFromDiscontinuedOperationsAttributableToOwnersOfParent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncomeFromDiscontinuedOperationsAttributableToOwnersOfParent", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfOperations": { "parentTag": "ifrs-full_ProfitLossAttributableToOwnersOfParent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfOperations", "http://trinitybiotech.com/role/SegmentInformationScheduleOfSegmentResultsByGeographicalAreaDetails" ], "lang": { "en-us": { "role": { "label": "Income from discontinued operations attributable to owners of parent", "terseLabel": "(Loss)/profit for the year on discontinued operations", "verboseLabel": "Loss for the year on discontinued operations (Note 8)" } } }, "auth_ref": [ "r213" ] }, "trib_IncomeFromPaycheckProtectionProgramLoans": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "IncomeFromPaycheckProtectionProgramLoans", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/IncomeTaxCreditNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents amount of income from the Paycheck Protection Program loans.", "label": "Income From Paycheck Protection Program Loans", "verboseLabel": "Income from the Paycheck Protection Program loans" } } }, "auth_ref": [] }, "ifrs-full_IncomeFromSubleasingRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncomeFromSubleasingRightofuseAssets", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/PropertyPlantAndEquipmentNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Income from sub-letting right-of-use" } }, "en": { "role": { "documentation": "The amount of income from subleasing right-of-use assets. Sublease is a transaction for which an underlying asset is re-leased by a lessee (\u2018intermediate lessor\u2019) to a third party, and the lease (\u2018head lease\u2019) between the head lessor and lessee remains in effect. [Refer: Right-of-use assets]" } } }, "auth_ref": [ "r151" ] }, "ifrs-full_IncomeRelatingToVariableLeasePaymentsForOperatingLeasesThatDoNotDependOnIndexOrRate": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncomeRelatingToVariableLeasePaymentsForOperatingLeasesThatDoNotDependOnIndexOrRate", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/PropertyPlantAndEquipmentNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Net book value of assets held under operating lease" } }, "en": { "role": { "documentation": "The amount of income relating to variable lease payments for operating leases that do not depend on an index or a rate. Variable lease payments are the portion of payments made by a lessee to a lessor for the right to use an underlying asset during the lease term that varies because of changes in facts or circumstances occurring after the commencement date, other than the passage of time." } } }, "auth_ref": [ "r155", "r279" ] }, "ifrs-full_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Profit or loss [Abstract]" } } }, "auth_ref": [] }, "trib_IncomeTaxAssetsCurrentAndDeferred": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "IncomeTaxAssetsCurrentAndDeferred", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/SegmentInformationScheduleOfSegmentAssetsAndSegmentLiabilitiesByGeographicalAreaDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of income tax assets current and deferred.", "label": "Income tax assets (current and deferred)" } } }, "auth_ref": [] }, "trib_IncomeTaxExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "IncomeTaxExpense", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/SegmentInformationScheduleOfTaxationExpenseByGeographicalAreaDetails" ], "lang": { "en-us": { "role": { "documentation": "Income tax expense to reconcile profit (loss) to net cash flow from (used in) operating activities.", "label": "Income Tax Expense", "terseLabel": "Taxation expense" } } }, "auth_ref": [] }, "trib_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxAbstract", "presentation": [ "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfOverseasTaxJurisdictionsDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Expense Benefit Continuing Operations Income Tax Abstract", "terseLabel": "Effective tax rate" } } }, "auth_ref": [] }, "trib_IncomeTaxExpenseBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "IncomeTaxExpenseBenefits", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfChargeForTaxDetails" ], "lang": { "en-us": { "role": { "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax.", "label": "Income Tax Expense Benefits", "terseLabel": "Total tax charge/(credit)" } } }, "auth_ref": [] }, "ifrs-full_IncomeTaxExpenseContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncomeTaxExpenseContinuingOperations", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfOperations": { "parentTag": "ifrs-full_IncomeFromContinuingOperationsAttributableToOwnersOfParent", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfOperations", "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfChargeForTaxDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfSegmentResultsByGeographicalAreaDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Total income tax (expense)/credit", "label": "Total income tax charge/(credit) on continuing operations in statement of operations", "negatedTerseLabel": "Income tax charge (Note 7)" } } }, "auth_ref": [ "r1", "r2", "r3", "r45", "r132", "r245", "r307", "r308", "r309", "r452" ] }, "trib_IncomeTaxLiabilitiesCurrentAndDeferred": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "IncomeTaxLiabilitiesCurrentAndDeferred", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/SegmentInformationScheduleOfSegmentAssetsAndSegmentLiabilitiesByGeographicalAreaDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of income tax liabilities current and deferred.", "label": "Income tax liabilities (current and deferred)" } } }, "auth_ref": [] }, "ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncomeTaxesPaidRefundClassifiedAsOperatingActivities", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Income taxes received/(paid)", "label": "Income taxes (paid) / received" } }, "en": { "role": { "documentation": "The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]" } } }, "auth_ref": [ "r96", "r475" ] }, "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseInCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://trinitybiotech.com/role/BASISOFPREPARATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in cash and cash equivalents after effect of exchange rate changes", "terseLabel": "Cash inflows (outflows)", "totalLabel": "Decrease/(increase) in cash and cash equivalents and short-term investments" } }, "en": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]" } } }, "auth_ref": [ "r102", "r297" ] }, "ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseInContingentConsiderationAssetLiability", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Contingent liability" } }, "en": { "role": { "documentation": "The increase (decrease) in a contingent consideration asset (liability) relating to a business combination." } } }, "auth_ref": [ "r198", "r379" ] }, "ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseInDeferredTaxLiabilityAsset", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfUnrecognisedDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Unrecognised deferred tax asset" } }, "en": { "role": { "documentation": "The increase (decrease) in a deferred tax liability (asset). [Refer: Deferred tax liability (asset)]" } } }, "auth_ref": [ "r577" ] }, "ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseInNumberOfOrdinarySharesIssued", "presentation": [ "http://trinitybiotech.com/role/CapitalAndReservesNarrativeDetails", "http://trinitybiotech.com/role/CapitalAndReservesScheduleOfShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in number of ordinary shares issued", "terseLabel": "Ordinary shares issued", "verboseLabel": "Issued for a cash consideration" } }, "en": { "role": { "documentation": "The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]" } } }, "auth_ref": [ "r612" ] }, "ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseInNumberOfSharesOutstanding", "presentation": [ "http://trinitybiotech.com/role/CapitalAndReservesScheduleOfShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Purchased during the year" } }, "en": { "role": { "documentation": "The increase (decrease) in the number of shares outstanding. [Refer: Number of shares outstanding]" } } }, "auth_ref": [ "r285", "r399", "r443" ] }, "trib_IncreaseDecreaseInPercentageOfGrossInventory": { "xbrltype": "percentItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "IncreaseDecreaseInPercentageOfGrossInventory", "presentation": [ "http://trinitybiotech.com/role/AccountingEstimatesAndJudgementsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Percentage of Gross Inventory", "terseLabel": "Estimate of provision, increase or decrease in percentage of gross inventory", "documentation": "Percentage of increase decrease of gross inventory." } } }, "auth_ref": [] }, "trib_IncreaseDecreaseThroughChangesInAccretionInterestLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "IncreaseDecreaseThroughChangesInAccretionInterestLiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/ReconciliationOfLiabilitiesArisingFromFinancingActivitiesScheduleOfLiabilitiesArisingFromFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from changes in accretion interest.", "label": "Increase Decrease Through Changes In Accretion Interest Liabilities Arising From Financing Activities", "terseLabel": "Accretion interest" } } }, "auth_ref": [] }, "trib_IncreaseDecreaseThroughChangesInAdditionalFairValueLiabilitiesWarrantsArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "IncreaseDecreaseThroughChangesInAdditionalFairValueLiabilitiesWarrantsArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/ReconciliationOfLiabilitiesArisingFromFinancingActivitiesScheduleOfLiabilitiesArisingFromFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of increase decrease through changes in additional fair value liabilities warrants arising from financing activities.", "label": "Increase Decrease Through Changes In Additional Fair Value Liabilities Warrants Arising From Financing Activities", "terseLabel": "Fair value of additional derivative liability - warrants" } } }, "auth_ref": [] }, "trib_IncreaseDecreaseThroughChangesInContingentLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "IncreaseDecreaseThroughChangesInContingentLiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/ReconciliationOfLiabilitiesArisingFromFinancingActivitiesScheduleOfLiabilitiesArisingFromFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from changes in contingent liability.", "label": "Increase Decrease Through Changes In Contingent Liabilities Arising From Financing Activities", "verboseLabel": "Fair value movement on contingent liability" } } }, "auth_ref": [] }, "trib_IncreaseDecreaseThroughChangesInFairValueOfConversionWarrantsArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "IncreaseDecreaseThroughChangesInFairValueOfConversionWarrantsArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/ReconciliationOfLiabilitiesArisingFromFinancingActivitiesScheduleOfLiabilitiesArisingFromFinancingDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Fair value of conversion - warrants", "documentation": "Represents the amount of increase decrease through changes in fair value of conversion warrants arising from financing activities.", "label": "Increase Decrease Through Changes In Fair Value Of Conversion Warrants Arising From Financing Activities" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/ReconciliationOfLiabilitiesArisingFromFinancingActivitiesScheduleOfLiabilitiesArisingFromFinancingDetails" ], "lang": { "en-us": { "role": { "label": "Fair value", "terseLabel": "Fair value of derivative liability - warrants" } }, "en": { "role": { "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from changes in fair values. [Refer: Liabilities arising from financing activities]" } } }, "auth_ref": [ "r99", "r293" ] }, "trib_IncreaseDecreaseThroughChangesInInterestChargedLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "IncreaseDecreaseThroughChangesInInterestChargedLiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/ReconciliationOfLiabilitiesArisingFromFinancingActivitiesScheduleOfLiabilitiesArisingFromFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from changes in interest charged.", "label": "Increase Decrease Through Changes In Interest Charged Liabilities Arising From Financing Activities", "terseLabel": "Interest charged" } } }, "auth_ref": [] }, "trib_IncreaseDecreaseThroughChangesInPaymentInKindInterestArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "IncreaseDecreaseThroughChangesInPaymentInKindInterestArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/ReconciliationOfLiabilitiesArisingFromFinancingActivitiesScheduleOfLiabilitiesArisingFromFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from changes in payment in kind interest.", "label": "Increase Decrease Through Changes In Payment In Kind Interest Arising From Financing Activities", "verboseLabel": "Payment-in-kind (PIK) Interest" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughConversionOfConvertibleInstruments", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/CapitalAndReservesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) through conversion of convertible instruments, equity", "terseLabel": "Amount of investment from MiCo" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the conversion of convertible instruments." } } }, "auth_ref": [ "r610" ] }, "trib_IncreaseDecreaseThroughDisposalsArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "IncreaseDecreaseThroughDisposalsArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/ReconciliationOfLiabilitiesArisingFromFinancingActivitiesScheduleOfLiabilitiesArisingFromFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from disposals.", "label": "Increase Decrease Through Disposals Arising From Financing Activities", "terseLabel": "Disposals" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/ReconciliationOfLiabilitiesArisingFromFinancingActivitiesScheduleOfLiabilitiesArisingFromFinancingDetails" ], "lang": { "en-us": { "role": { "label": "Exchange adjustment" } }, "en": { "role": { "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from the effect of changes in foreign exchange rates. [Refer: Liabilities arising from financing activities]" } } }, "auth_ref": [ "r98", "r292" ] }, "ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughExerciseOfWarrantsEquity", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Options or warrants exercised" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the exercise of warrants." } } }, "auth_ref": [ "r610" ] }, "trib_IncreaseDecreaseThroughLoanForgivenLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "IncreaseDecreaseThroughLoanForgivenLiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/ReconciliationOfLiabilitiesArisingFromFinancingActivitiesScheduleOfLiabilitiesArisingFromFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from loan forgiven.", "label": "Increase Decrease Through Loan Forgiven Liabilities Arising From Financing Activities", "terseLabel": "Loan forgiven" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfGoodwillAndIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) through net exchange differences, intangible assets and goodwill", "verboseLabel": "Exchange differences" } }, "en": { "role": { "documentation": "The increase (decrease) in intangible assets and goodwill resulting from the net exchange differences arising when the financial statements are translated from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets and goodwill]" } } }, "auth_ref": [ "r594" ] }, "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/PropertyPlantAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentRelatedToAccumulatedDepreciationDetails" ], "lang": { "en-us": { "role": { "label": "Exchange adjustments" } }, "en": { "role": { "documentation": "The increase (decrease) in property, plant and equipment resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r16" ] }, "ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/ReconciliationOfLiabilitiesArisingFromFinancingActivitiesScheduleOfLiabilitiesArisingFromFinancingDetails" ], "lang": { "en-us": { "role": { "label": "Reduction in accrued interest payable" } }, "en": { "role": { "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Liabilities arising from financing activities]" } } }, "auth_ref": [ "r100", "r294" ] }, "ifrs-full_IncreaseDecreaseThroughOtherChangesPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughOtherChangesPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/PropertyPlantAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentRelatedToAccumulatedDepreciationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Charge for the year", "label": "Charge for the year" } }, "en": { "role": { "documentation": "The increase (decrease) in property, plant and equipment resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r14", "r318" ] }, "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfChangesInEquity" ], "lang": { "en-us": { "role": { "positiveLabel": "Share-based payments", "label": "Share based payment", "terseLabel": "Share based payments charge", "verboseLabel": "Total share based payments, inclusive of amounts capitalised" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]" } } }, "auth_ref": [ "r414" ] }, "trib_IncreaseDecreaseThroughSharebasedPaymentTransactionsInclusiveOfAmountsCapitalised": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactionsInclusiveOfAmountsCapitalised", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/EmploymentNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in equity resulting from share-based payment transactions inclusive of amounts capitalised.", "label": "Increase Decrease Through Sharebased Payment Transactions Inclusive Of Amounts Capitalised", "terseLabel": "Share based payments charge", "verboseLabel": "Total share based payments, inclusive of amounts capitalised" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughTransfersAndOtherChangesEquity", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/CapitalAndReservesNarrativeDetails", "http://trinitybiotech.com/role/ConsolidatedStatementOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) through other changes, equity", "terseLabel": "Reclass on reduction of nominal value of shares" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Equity]" } } }, "auth_ref": [ "r415" ] }, "ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/ProvisionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Provision for reduced warranty claims" } }, "en": { "role": { "documentation": "The increase (decrease) in other provisions resulting from transfers and changes that the entity does not separately disclose in the same statement or note. [Refer: Other provisions]" } } }, "auth_ref": [ "r591" ] }, "ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/PropertyPlantAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentRelatedToAccumulatedDepreciationDetails" ], "lang": { "en-us": { "role": { "label": "Reallocations / reclassifications" } }, "en": { "role": { "documentation": "The increase (decrease) in property, plant and equipment resulting from transfers. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r580" ] }, "trib_IncreaseInAnnualRent": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "IncreaseInAnnualRent", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount represents increase in annual rent.", "label": "Increase In Annual Rent", "terseLabel": "Increase In annual rent" } } }, "auth_ref": [] }, "trib_IncreaseInSettlementAmountDueToDepreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "IncreaseInSettlementAmountDueToDepreciation", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase in settlement amount due to depreciation.", "label": "Increase in settlement amount due to depreciation" } } }, "auth_ref": [] }, "trib_IncreasedInUnrecognisedDeferredTaxAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "IncreasedInUnrecognisedDeferredTaxAssets", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/DeferredTaxAssetsAndLiabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Increased in unrecognised deferred tax assets.", "label": "Increased in unrecognised deferred tax assets" } } }, "auth_ref": [] }, "trib_IncreasedecreasethroughequityComponentOfConvertibleNote": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "IncreasedecreasethroughequityComponentOfConvertibleNote", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfChangesInEquity" ], "lang": { "en-us": { "role": { "documentation": "The amount represents equity component of convertible note.", "label": "Increasedecreasethroughequity Component Of Convertible Note", "terseLabel": "Equity component of convertible note" } } }, "auth_ref": [] }, "ifrs-full_IndividualAssetsOrCashgeneratingUnitsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IndividualAssetsOrCashgeneratingUnitsAxis", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsNarrativeDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfBreakdownOfImpairmentLossDetailsUsd", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfImpairmentLossDetails" ], "lang": { "en-us": { "role": { "label": "Individual assets or cash-generating units [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r63" ] }, "ifrs-full_IndividualAssetsOrCashgeneratingUnitsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IndividualAssetsOrCashgeneratingUnitsDomain", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsNarrativeDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfBreakdownOfImpairmentLossDetailsUsd", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfImpairmentLossDetails" ], "lang": { "en-us": { "role": { "label": "Individual assets or cash-generating units [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Individual assets or cash-generating units' axis if no other member is used." } } }, "auth_ref": [ "r63" ] }, "ifrs-full_IndividualAssetsOrCashgeneratingUnitsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IndividualAssetsOrCashgeneratingUnitsMember", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfBreakdownOfImpairmentLossDetailsUsd", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfImpairmentLossDetails" ], "lang": { "en-us": { "role": { "label": "Total for all individual assets or cash-generating units [member]" } }, "en": { "role": { "documentation": "This member stands for individual assets or cash-generating units. [Refer: Total for all cash-generating units [member]]" } } }, "auth_ref": [ "r63" ] }, "trib_InitialExercisePriceOfWarrantsOrRights": { "xbrltype": "perShareItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "InitialExercisePriceOfWarrantsOrRights", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Initial Exercise Price Of Warrants Or Rights.", "label": "Initial Exercise Price Of Warrants Or Rights", "verboseLabel": "Initial exercise price of warrants or rights" } } }, "auth_ref": [] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r545", "r560" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r545", "r560" ] }, "trib_InstalmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "InstalmentsAxis", "presentation": [ "http://trinitybiotech.com/role/ProvisionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Instalments [Axis]" } } }, "auth_ref": [] }, "trib_InstalmentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "InstalmentsDomain", "presentation": [ "http://trinitybiotech.com/role/ProvisionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Instalments [Domain]" } } }, "auth_ref": [] }, "trib_InstrumentsMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "InstrumentsMember", "presentation": [ "http://trinitybiotech.com/role/TradeAndOtherReceivablesScheduleOfFutureMinimumRentalsReceivableUnderNon-cancellableOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Instruments.", "label": "Instruments [Member]" } } }, "auth_ref": [] }, "ifrs-full_IntangibleAssetsAndGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IntangibleAssetsAndGoodwill", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONDetail5": { "parentTag": "ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners", "weight": 1.0, "order": 0.0 }, "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://trinitybiotech.com/role/AccountingEstimatesAndJudgementsNarrativeDetails", "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsNarrativeDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfGoodwillAndIntangibleAssetsDetails", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONDetail5" ], "lang": { "en-us": { "role": { "periodEndLabel": "Balance at end of year", "periodStartLabel": "Balance at beginning year", "label": "Intangible assets and goodwill", "terseLabel": "Goodwill and intangible assets", "verboseLabel": "Carrying amounts" } }, "en": { "role": { "documentation": "The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]" } } }, "auth_ref": [ "r615" ] }, "ifrs-full_IntangibleAssetsAndGoodwillAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IntangibleAssetsAndGoodwillAbstract", "lang": { "en-us": { "role": { "label": "Intangible assets and goodwill [abstract]" } } }, "auth_ref": [] }, "ifrs-full_IntangibleAssetsUnderDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IntangibleAssetsUnderDevelopment", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/BASISOFPREPARATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://trinitybiotech.com/role/GOODWILLANDINTANGIBLEASSETSDetails" ], "lang": { "en-us": { "role": { "label": "Intangible assets under development", "terseLabel": "Internally developed intangible assets", "verboseLabel": "Development costs" } }, "en": { "role": { "documentation": "The amount of intangible assets representing such assets under development. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r474" ] }, "trib_IntangibleAssetsUnderDevelopmentImpairmentCharge": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "IntangibleAssetsUnderDevelopmentImpairmentCharge", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Intangible Assets Under Development Impairment Charge.", "label": "Intangible Assets Under Development Impairment Charge", "terseLabel": "Intangible assets under development impairment charge" } } }, "auth_ref": [] }, "trib_IntangibleAssetsUnderDevelopmentWrittenDown": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "IntangibleAssetsUnderDevelopmentWrittenDown", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Intangible assets under development written down.", "label": "Intangible Assets Under Development Written Down", "terseLabel": "Intangible assets under development written down" } } }, "auth_ref": [] }, "ifrs-full_IntangibleAssetsWithIndefiniteUsefulLife": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IntangibleAssetsWithIndefiniteUsefulLife", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsNarrativeDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfIntangibleAssetsWithIndefiniteUsefulLivesDetails" ], "lang": { "en-us": { "role": { "label": "Intangible assets with indefinite useful lives", "terseLabel": "Intangible assets with indefinite useful life" } }, "en": { "role": { "documentation": "The amount of intangible assets assessed as having an indefinite useful life. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r64", "r68", "r80", "r334", "r338", "r349" ] }, "ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IntangibleAssetsWithIndefiniteUsefulLifeAxis", "presentation": [ "http://trinitybiotech.com/role/BASISOFPREPARATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesScheduleOfAmortisationDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Intangible assets with indefinite useful life [axis]", "verboseLabel": "Intangible assets with indefinite useful life [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r80", "r349" ] }, "ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IntangibleAssetsWithIndefiniteUsefulLifeDomain", "presentation": [ "http://trinitybiotech.com/role/BASISOFPREPARATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesScheduleOfAmortisationDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Intangible assets with indefinite useful life [domain]" } }, "en": { "role": { "documentation": "This member stands for intangible assets with an indefinite useful life. It also represents the standard value for the 'Intangible assets with indefinite useful life' axis if no other member is used. [Refer: Intangible assets with indefinite useful life]" } } }, "auth_ref": [ "r80", "r349" ] }, "ifrs-full_InterestCostsCapitalised": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestCostsCapitalised", "presentation": [ "http://trinitybiotech.com/role/ReconciliationOfLiabilitiesArisingFromFinancingActivitiesScheduleOfLiabilitiesArisingFromFinancingDetails" ], "lang": { "en-us": { "role": { "label": "Interest costs capitalised", "terseLabel": "Interest capitalised on outstanding loans and balances" } }, "en": { "role": { "documentation": "The amount of interest costs that an entity incurs in connection with the borrowing of funds that are directly attributable to the acquisition, construction or production of a qualifying asset and which form part of the cost of that asset." } } }, "auth_ref": [ "r612" ] }, "trib_InterestEarningFinancialAndInterestBearingFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "InterestEarningFinancialAndInterestBearingFinancialLiabilities", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfInterestRateRiskEffectiveAndRepricingAnalysisDetails" ], "lang": { "en-us": { "role": { "documentation": "Total interest earning financial and interest bearing financial liabilities.", "negatedLabel": "Total interest earning financial and interest bearing financial liabilities", "negatedTotalLabel": "Total interest earning financial and interest bearing financial liabilities", "label": "Interest Earning Financial And Interest Bearing Financial Liabilities" } } }, "auth_ref": [] }, "ifrs-full_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestExpense", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Interest expense", "terseLabel": "Value attributable to interest", "totalLabel": "Total" } }, "en": { "role": { "documentation": "The amount of expense arising from interest." } } }, "auth_ref": [ "r131", "r243", "r252" ] }, "ifrs-full_InterestExpenseOnDebtInstrumentsIssued": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestExpenseOnDebtInstrumentsIssued", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/FinancialIncomeAndExpensesScheduleOfFinancialIncomeExpensesNetDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Cash interest on exchangeable notes", "label": "Cash interest on exchangeable notes", "verboseLabel": "Cash interest expense (Note 8)" } } }, "auth_ref": [ "r612" ] }, "ifrs-full_InterestExpenseOnLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestExpenseOnLeaseLiabilities", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/FinancialIncomeAndExpensesScheduleOfFinancialIncomeExpensesNetDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest on leases", "label": "Interest on finance leases" } } }, "auth_ref": [ "r149", "r266" ] }, "trib_InterestExpenseOnLeaseLiabilities1": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "InterestExpenseOnLeaseLiabilities1", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/LeaseLiabilitiesScheduleOfFinanceLeaseLiabilitiesPayableDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of interest expense on lease liabilities. [Refer: Lease liabilities]", "label": "Interest Expense On Lease Liabilities 1", "terseLabel": "Interest" } } }, "auth_ref": [] }, "ifrs-full_InterestExpenseOnOtherFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestExpenseOnOtherFinancialLiabilities", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/FinancialIncomeAndExpensesScheduleOfFinancialIncomeExpensesNetDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Non-cash interest on exchangeable notes", "label": "Interest Expense On Other Financial Liabilities", "terseLabel": "Accretion interest (Note 8)", "verboseLabel": "Non-cash interest on exchangeable notes (Note 8)" } } }, "auth_ref": [ "r612" ] }, "trib_InterestExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "InterestExpenses", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represent the interest expense.", "label": "Interest Expenses", "terseLabel": "Interest expense" } } }, "auth_ref": [] }, "ifrs-full_InterestIncomeOnOtherFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestIncomeOnOtherFinancialAssets", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/FinancialIncomeAndExpensesScheduleOfFinancialIncomeExpensesNetDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Non-cash financial expense/(income) (Note 8)", "label": "Non-cash financial income", "verboseLabel": "Financial income" } } }, "auth_ref": [ "r612" ] }, "ifrs-full_InterestPaidClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestPaidClassifiedAsFinancingActivities", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows", "http://trinitybiotech.com/role/ReconciliationOfLiabilitiesArisingFromFinancingActivitiesScheduleOfLiabilitiesArisingFromFinancingDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest paid on exchangeable notes", "negatedTerseLabel": "Interest paid for term loan", "label": "Interest paid, classified as financing activities" } }, "en": { "role": { "documentation": "The cash outflow for interest paid, classified as financing activities." } } }, "auth_ref": [ "r95" ] }, "trib_InterestPaidOnConvertibleNote": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "InterestPaidOnConvertibleNote", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows", "http://trinitybiotech.com/role/FinancialIncomeAndExpensesScheduleOfFinancialIncomeExpensesNetDetails", "http://trinitybiotech.com/role/ReconciliationOfLiabilitiesArisingFromFinancingActivitiesScheduleOfLiabilitiesArisingFromFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount represents interest paid on convertible note.", "negatedLabel": "Interest paid on convertible note", "negatedTerseLabel": "Cash interest payable on convertible note", "label": "Interest Paid On Convertible Note", "terseLabel": "Interest paid for convertible note" } } }, "auth_ref": [] }, "trib_InterestPaidOnSeniorSecuredTermLoan": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "InterestPaidOnSeniorSecuredTermLoan", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows", "http://trinitybiotech.com/role/ReconciliationOfLiabilitiesArisingFromFinancingActivitiesScheduleOfLiabilitiesArisingFromFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount represents interest paid on senior secured term loan.", "negatedLabel": "Interest paid on senior secured term loan", "negatedTerseLabel": "Interest paid for senior secured term loan", "label": "Interest Paid On Senior Secured Term Loan", "terseLabel": "Interest paid on senior secured term loan" } } }, "auth_ref": [] }, "ifrs-full_InterestPayable": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestPayable", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/OTHEROPERATINGINCOMEEXPENSENarrativeDetails", "http://trinitybiotech.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Interest payable", "terseLabel": "Accrued interest" } }, "en": { "role": { "documentation": "The amount of interest recognised as a liability." } } }, "auth_ref": [ "r612" ] }, "ifrs-full_InterestReceivedClassifiedAsOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestReceivedClassifiedAsOperatingActivities", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Interest received" } }, "en": { "role": { "documentation": "The cash inflow from interest received, classified as operating activities." } } }, "auth_ref": [ "r95" ] }, "ifrs-full_Inventories": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Inventories", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 0.0 }, "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONDetail5": { "parentTag": "ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners", "weight": 1.0, "order": 8.0 }, "http://trinitybiotech.com/role/InventoriesScheduleOfInventoriesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition", "http://trinitybiotech.com/role/InventoriesScheduleOfInventoriesDetails", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONDetail5" ], "lang": { "en-us": { "role": { "label": "Current inventories", "terseLabel": "Inventory", "totalLabel": "Total inventories", "verboseLabel": "Inventories" } }, "en": { "role": { "documentation": "The amount of current inventories. [Refer: Inventories]" } } }, "auth_ref": [ "r27", "r290", "r422", "r533" ] }, "ifrs-full_InventoriesAtNetRealisableValue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InventoriesAtNetRealisableValue", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/AccountingEstimatesAndJudgementsNarrativeDetails", "http://trinitybiotech.com/role/InventoriesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Inventories, at net realisable value" } }, "en": { "role": { "documentation": "The amount of inventories carried at net realisable value. [Refer: Inventories]" } } }, "auth_ref": [ "r585" ] }, "trib_InventoryMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "InventoryMember", "presentation": [ "http://trinitybiotech.com/role/DeferredTaxAssetsAndLiabilitiesScheduleOfRecognisedDeferredTaxAssetsAndLiabilitiesDetails", "http://trinitybiotech.com/role/DeferredTaxAssetsAndLiabilitiesScheduleOfUnrecognisedDeferredTaxLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Inventory [Member]", "label": "Inventory Member", "terseLabel": "Inventories [Member]" } } }, "auth_ref": [] }, "ifrs-full_InventoryRecognisedAsOfAcquisitionDate": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InventoryRecognisedAsOfAcquisitionDate", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSDetails": { "parentTag": "ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSDetails", "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Inventory", "label": "Inventory recognised as of acquisition date", "terseLabel": "Inventory" } }, "en": { "role": { "documentation": "The amount recognised as of the acquisition date for inventory acquired in a business combination. [Refer: Inventories; Total for all business combinations [member]]" } } }, "auth_ref": [ "r497", "r499", "r523" ] }, "trib_InventoryRelatedCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "InventoryRelatedCostsMember", "presentation": [ "http://trinitybiotech.com/role/IMPAIRMENTTRANSFORMATIONANDONCEOFFCOSTSScheduleoftransformationcostsincurredduringtheyearDetails" ], "lang": { "en-us": { "role": { "documentation": "Inventory Related Costs [Member]", "label": "Inventory Related Costs [Member]", "terseLabel": "Inventory related costs [Member]" } } }, "auth_ref": [] }, "ifrs-full_InvestmentAccountedForUsingEquityMethod": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InvestmentAccountedForUsingEquityMethod", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementNarrativeDetails", "http://trinitybiotech.com/role/CapitalAndReservesNarrativeDetails", "http://trinitybiotech.com/role/FINANCIALASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Investments accounted for using equity method", "verboseLabel": "Equity investment" } }, "en": { "role": { "documentation": "The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]" } } }, "auth_ref": [ "r133", "r247", "r393", "r421" ] }, "trib_InvestmentInUnsecuredJuniorConvertibleNote": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "InvestmentInUnsecuredJuniorConvertibleNote", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of investment in unsecured junior convertible notes.", "label": "Investment In Unsecured Junior Convertible Note", "verboseLabel": "Investment in unsecured junior convertible note" } } }, "auth_ref": [] }, "trib_IssuableOnConversionOfConvertibleNotes": { "xbrltype": "sharesItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "IssuableOnConversionOfConvertibleNotes", "presentation": [ "http://trinitybiotech.com/role/LossPerShareScheduleOfDilutedEarningsPerAdsShareCalculationDetails", "http://trinitybiotech.com/role/LossPerShareScheduleOfDilutedEarningsPerOrdinaryShareDetails" ], "lang": { "en-us": { "role": { "documentation": "Shares issuable on conversion of convertible notes.", "label": "Issuable On Conversion Of Convertible Notes", "terseLabel": "Issuable on conversion of Convertible notes" } } }, "auth_ref": [] }, "trib_IssuableOnExerciseOfOptions": { "xbrltype": "sharesItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "IssuableOnExerciseOfOptions", "presentation": [ "http://trinitybiotech.com/role/LossPerShareScheduleOfDilutedEarningsPerAdsShareCalculationDetails", "http://trinitybiotech.com/role/LossPerShareScheduleOfDilutedEarningsPerOrdinaryShareDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of issuable on exercise of options.", "label": "Issuable On Exercise Of Options", "terseLabel": "Issuable on exercise of options" } } }, "auth_ref": [] }, "ifrs-full_IssueOfConvertibleInstruments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssueOfConvertibleInstruments", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/FINANCIALASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Issue of convertible instruments" } }, "en": { "role": { "documentation": "The change in equity resulting from the issuing of convertible instruments." } } }, "auth_ref": [ "r610" ] }, "ifrs-full_IssueOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssueOfEquity", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Issue of equity", "terseLabel": "Shares issued in the year" } }, "en": { "role": { "documentation": "The increase in equity through the issue of equity instruments." } } }, "auth_ref": [ "r414" ] }, "ifrs-full_IssuedCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssuedCapital", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Share capital" } }, "en": { "role": { "documentation": "The nominal value of capital issued." } } }, "auth_ref": [ "r529", "r537" ] }, "ifrs-full_IssuedCapitalMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssuedCapitalMember", "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Share Capital 'A' Ordinary shares [Member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing issued capital." } } }, "auth_ref": [ "r416" ] }, "trib_IssuedForNoncashConsideration": { "xbrltype": "sharesItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "IssuedForNoncashConsideration", "presentation": [ "http://trinitybiotech.com/role/CapitalAndReservesScheduleOfShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of Issued for non-cash consideration.", "label": "Issued For Non-cash Consideration", "terseLabel": "Issued for non-cash consideration", "verboseLabel": "Shares issued as consideration for Exchangeable Notes purchase" } } }, "auth_ref": [] }, "trib_IssuenceOfExchangeableNote": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "IssuenceOfExchangeableNote", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/DeferredTaxAssetsAndLiabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Issuence of exchangeable note.", "label": "Issuence of exchangeable note" } } }, "auth_ref": [] }, "trib_JrjMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "JrjMember", "presentation": [ "http://trinitybiotech.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "JRJ [Member]", "label": "JRJ [Member]", "terseLabel": "JRJ Investments [Member]" } } }, "auth_ref": [] }, "trib_KansasRightOfUseAssetMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "KansasRightOfUseAssetMember", "presentation": [ "http://trinitybiotech.com/role/GOODWILLANDINTANGIBLEASSETSDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Kansas right-of-use asset.", "label": "Kansas Right Of Use Asset [Member]", "verboseLabel": "Kansas right-of-use asset [Member]" } } }, "auth_ref": [] }, "ifrs-full_KeyManagementPersonnelCompensation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "KeyManagementPersonnelCompensation", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/RelatedPartyTransactionsScheduleOfCompensationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://trinitybiotech.com/role/RelatedPartyTransactionsScheduleOfCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Key management personnel compensation", "totalLabel": "Total compensation" } } }, "auth_ref": [ "r39", "r328" ] }, "trib_KeyManagementPersonnelCompensationPerformanceRelatedBonus": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "KeyManagementPersonnelCompensationPerformanceRelatedBonus", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/RelatedPartyTransactionsScheduleOfCompensationDetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://trinitybiotech.com/role/RelatedPartyTransactionsScheduleOfCompensationDetails" ], "lang": { "en-us": { "role": { "documentation": "Performance related bonus.", "label": "Key Management Personnel Compensation Performance Related Bonus", "terseLabel": "Performance related bonus" } } }, "auth_ref": [] }, "ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "KeyManagementPersonnelCompensationPostemploymentBenefits", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/RelatedPartyTransactionsScheduleOfCompensationDetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://trinitybiotech.com/role/RelatedPartyTransactionsScheduleOfCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Post-employment benefits" } } }, "auth_ref": [ "r36" ] }, "trib_KeyManagementPersonnelCompensationSettlementRelatedToPayrollTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "KeyManagementPersonnelCompensationSettlementRelatedToPayrollTaxes", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/EmploymentScheduleOfEmploymentCostsDetails": { "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://trinitybiotech.com/role/EmploymentScheduleOfEmploymentCostsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of compensation to key management personnel in the form of settlement related to payroll taxes.", "label": "Key Management Personnel Compensation Settlement Related To Payroll Taxes", "terseLabel": "Tax settlement (Note 6)" } } }, "auth_ref": [] }, "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "KeyManagementPersonnelCompensationSharebasedPayment", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/RelatedPartyTransactionsScheduleOfCompensationDetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://trinitybiotech.com/role/RelatedPartyTransactionsNarrativeDetails", "http://trinitybiotech.com/role/RelatedPartyTransactionsScheduleOfCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Share-based compensation benefits", "terseLabel": "Share-based compensation benefits as calculated under IFRS 2" } } }, "auth_ref": [ "r38" ] }, "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/RelatedPartyTransactionsScheduleOfCompensationDetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://trinitybiotech.com/role/RelatedPartyTransactionsScheduleOfCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Short-term employee benefits" } } }, "auth_ref": [ "r35" ] }, "ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "KeyManagementPersonnelCompensationTerminationBenefits", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Compensation expense" } } }, "auth_ref": [ "r37" ] }, "ifrs-full_KeyManagementPersonnelOfEntityOrParentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "KeyManagementPersonnelOfEntityOrParentMember", "presentation": [ "http://trinitybiotech.com/role/ShareOptionsScheduleOfAssumptionDeterminingFairValueOfShareOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Key management personnel [Member]" } }, "en": { "role": { "documentation": "This member stands for those persons having authority and responsibility for planning, directing and controlling the activities of the entity, directly or indirectly, including any director (whether executive or otherwise) of that entity." } } }, "auth_ref": [ "r40", "r329" ] }, "trib_KonamiteLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "KonamiteLimitedMember", "presentation": [ "http://trinitybiotech.com/role/GROUPUNDERTAKINGSDetails" ], "lang": { "en-us": { "role": { "documentation": "Represent the member of Konamite Limited", "label": "Konamite Limited [Member]" } } }, "auth_ref": [] }, "trib_LaboratoryServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "LaboratoryServicesMember", "presentation": [ "http://trinitybiotech.com/role/SegmentInformationScheduleOfRevenueByMajorProductGroupDetails" ], "lang": { "en-us": { "role": { "documentation": "Laboratory services [Member]", "label": "Laboratory Services Member", "terseLabel": "Clinical laboratory services [Member]" } } }, "auth_ref": [] }, "ifrs-full_LandAndBuildingsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LandAndBuildingsMember", "presentation": [ "http://trinitybiotech.com/role/PropertyPlantAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentRelatedToAccumulatedDepreciationDetails" ], "lang": { "en-us": { "role": { "label": "Land and buildings [member]", "verboseLabel": "Land & Buildings [Member]", "terseLabel": "Land & Buildings [Member]" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing land and depreciable buildings and similar structures for use in operations. [Refer: Buildings; Land; Property, plant and equipment]" } } }, "auth_ref": [ "r462" ] }, "ifrs-full_LaterThanFiveYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LaterThanFiveYearsMember", "presentation": [ "http://trinitybiotech.com/role/LeaseLiabilitiesScheduleOfFinanceLeaseLiabilitiesPayableDetails" ], "lang": { "en-us": { "role": { "label": "More than five years [Member]", "verboseLabel": "Later than five years [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than five years." } } }, "auth_ref": [ "r156", "r158", "r169", "r273", "r277", "r505", "r507", "r511" ] }, "ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LaterThanOneMonthAndNotLaterThanTwoMonthsMember", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfAgeingOfTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Past due 0-30 days [Member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than one month and not later than two months." } } }, "auth_ref": [ "r503", "r510", "r612" ] }, "trib_LaterThanOneMonthsAndNotLaterThanFourMonthsMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "LaterThanOneMonthsAndNotLaterThanFourMonthsMember", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfAgeingOfTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Past due 31-120 days [Member]", "label": "Later Than One Months And Not Later Than Four Months Member", "terseLabel": "Past due 31-120 days [Member]" } } }, "auth_ref": [] }, "ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LaterThanOneYearAndNotLaterThanFiveYearsMember", "presentation": [ "http://trinitybiotech.com/role/TradeAndOtherReceivablesNarrativeDetails", "http://trinitybiotech.com/role/TradeAndOtherReceivablesScheduleOfFutureMinimumFinanceLeaseReceivablesDetails", "http://trinitybiotech.com/role/TradeAndOtherReceivablesScheduleOfFutureMinimumRentalsReceivableUnderNon-cancellableOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Between one and five years [Member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than one year and not later than five years." } } }, "auth_ref": [ "r272", "r276", "r504", "r511" ] }, "ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LaterThanOneYearAndNotLaterThanTwoYearsMember", "presentation": [ "http://trinitybiotech.com/role/LeaseLiabilitiesScheduleOfFinanceLeaseLiabilitiesPayableDetails" ], "lang": { "en-us": { "role": { "label": "In more than one year, but not more than two [Member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than one year and not later than two years." } } }, "auth_ref": [ "r156", "r158", "r169", "r505", "r511", "r612" ] }, "trib_LaterThanTwoYearAndNotLaterThanFiveYearsMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "LaterThanTwoYearAndNotLaterThanFiveYearsMember", "presentation": [ "http://trinitybiotech.com/role/LeaseLiabilitiesScheduleOfFinanceLeaseLiabilitiesPayableDetails" ], "lang": { "en-us": { "role": { "documentation": "In more than two years but not more than five [Member]", "label": "Later Than Two Year And Not Later Than Five Years Member", "terseLabel": "In more than two years but not more than five [Member]" } } }, "auth_ref": [] }, "ifrs-full_LeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LeaseLiabilities", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONDetail5": { "parentTag": "ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfFairValuesOfFinancialAssetsliabilitiesDetails", "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfForeignCurrencyRiskShortTermFinancialAssetsAndLiabilitiesDetails", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONDetail5" ], "lang": { "en-us": { "role": { "negatedLabel": "Lease liabilities", "positiveLabel": "Lease liabilities", "label": "Lease liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration." } } }, "auth_ref": [ "r147" ] }, "ifrs-full_LeaseLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LeaseLiabilitiesMember", "presentation": [ "http://trinitybiotech.com/role/ReconciliationOfLiabilitiesArisingFromFinancingActivitiesScheduleOfLiabilitiesArisingFromFinancingDetails" ], "lang": { "en-us": { "role": { "label": "Lease liabilities [Member]" } }, "en": { "role": { "documentation": "This member stands for lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r483", "r488" ] }, "trib_LeaseLiabilitiesRelatedToRightOfUseAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "LeaseLiabilitiesRelatedToRightOfUseAssetsCurrent", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/LeaseLiabilitiesScheduleOfCarryingValuesOfFinanceLeaseLiabilitiesDetails": { "parentTag": "trib_CurrentFinanceLeaseLiabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://trinitybiotech.com/role/LeaseLiabilitiesScheduleOfCarryingValuesOfFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Lease liabilities related to right of use assets current.", "label": "Lease Liabilities Related To Right Of Use Assets Current", "terseLabel": "Lease liabilities related to Right of Use assets" } } }, "auth_ref": [] }, "trib_LeaseLiabilitiesRelatedToRightOfUseAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "LeaseLiabilitiesRelatedToRightOfUseAssetsMember", "presentation": [ "http://trinitybiotech.com/role/LeaseLiabilitiesScheduleOfFinanceLeaseLiabilitiesPayableDetails" ], "lang": { "en-us": { "role": { "documentation": "Lease liabilities related Right of Use assets [Member]", "label": "Lease Liabilities Related To Right Of Use Assets Member", "terseLabel": "Lease liabilities related Right of Use assets [Member]" } } }, "auth_ref": [] }, "trib_LeaseLiabilitiesRelatedToRightOfUseAssetsNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "LeaseLiabilitiesRelatedToRightOfUseAssetsNonCurrent", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/LeaseLiabilitiesScheduleOfCarryingValuesOfFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Lease liabilities related to right of use assets non-current.", "label": "Lease Liabilities Related To Right Of Use Assets Non Current", "verboseLabel": "Lease liabilities related to Right of Use assets" } } }, "auth_ref": [] }, "trib_LeasePayableOnRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "LeasePayableOnRightOfUseAssets", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfInterestRateRiskEffectiveAndRepricingAnalysisDetails", "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfLiquidityRiskEstimatedInterestPaymentsOfMaturitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of lease payable on right of use assets.", "label": "Lease payable on Right of Use assets" } } }, "auth_ref": [] }, "trib_LeasePayableOnRightOfUseAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "LeasePayableOnRightOfUseAssetsMember", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfInterestRateRiskEffectiveAndRepricingAnalysisDetails" ], "lang": { "en-us": { "role": { "documentation": "Lease payable on Right of Use assets [Member]", "label": "Lease payable on Right of Use assets [Member]" } } }, "auth_ref": [] }, "trib_LeasePayableOnSaleAndLeasebackTransactions": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "LeasePayableOnSaleAndLeasebackTransactions", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfInterestRateRiskEffectiveAndRepricingAnalysisDetails", "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfLiquidityRiskEstimatedInterestPaymentsOfMaturitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of lease payable on sale and leaseback transactions.", "label": "Lease Payable On Sale And Leaseback Transactions", "terseLabel": "Lease payable on sale & leaseback transactions" } } }, "auth_ref": [] }, "trib_LeasePayableOnSaleLeasebackTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "LeasePayableOnSaleLeasebackTransactionsMember", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfInterestRateRiskEffectiveAndRepricingAnalysisDetails" ], "lang": { "en-us": { "role": { "documentation": "Lease payable on sale & leaseback transactions [Member]", "label": "Lease payable on sale & leaseback transactions [Member]" } } }, "auth_ref": [] }, "ifrs-full_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesScheduleOfOwnedAssetsDetails", "http://trinitybiotech.com/role/PropertyPlantAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentRelatedToAccumulatedDepreciationDetails" ], "lang": { "en-us": { "role": { "label": "Leasehold improvements [member]", "terseLabel": "Leasehold improvements [Member]" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing improvements to assets held under a lease agreement." } } }, "auth_ref": [ "r578" ] }, "ifrs-full_LegalProceedingsProvision": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LegalProceedingsProvision", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/ProvisionsScheduleOfProvisionsDetails": { "parentTag": "ifrs-full_Provisions", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://trinitybiotech.com/role/IMPAIRMENTTRANSFORMATIONANDONCEOFFCOSTSNarrativeDetails", "http://trinitybiotech.com/role/ProvisionsNarrativeDetails", "http://trinitybiotech.com/role/ProvisionsScheduleOfProvisionsDetails" ], "lang": { "en-us": { "role": { "label": "Legal proceedings provision", "terseLabel": "Provision", "verboseLabel": "Legal & regulatory provision" } }, "en": { "role": { "documentation": "The amount of provision for legal proceedings. [Refer: Other provisions]" } } }, "auth_ref": [ "r469", "r471" ] }, "trib_LenderMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "LenderMember", "presentation": [ "http://trinitybiotech.com/role/BASISOFPREPARATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stand for lender.", "label": "Lender [Member]" } } }, "auth_ref": [] }, "ifrs-full_Level1OfFairValueHierarchyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Level1OfFairValueHierarchyMember", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfFairValuesOfFinancialAssetsliabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Level 1 [Member]" } }, "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date." } } }, "auth_ref": [ "r24", "r62", "r66", "r137", "r336", "r395" ] }, "ifrs-full_Level2OfFairValueHierarchyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Level2OfFairValueHierarchyMember", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfFairValuesOfFinancialAssetsliabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Level 2 [Member]" } }, "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly." } } }, "auth_ref": [ "r62", "r66", "r137", "r336", "r395" ] }, "ifrs-full_Level3OfFairValueHierarchyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Level3OfFairValueHierarchyMember", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfFairValuesOfFinancialAssetsliabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Level 3 of fair value hierarchy [member]", "terseLabel": "Level 3 [Member]" } }, "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are unobservable inputs for the asset or liability. Unobservable inputs are inputs for which market data are not available and that are developed using the best information available about the assumptions that the market participants would use when pricing the asset or liability." } } }, "auth_ref": [ "r62", "r66", "r137", "r336", "r395" ] }, "ifrs-full_LevelsOfFairValueHierarchyAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LevelsOfFairValueHierarchyAxis", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfFairValuesOfFinancialAssetsliabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Levels of fair value hierarchy [Axis]", "verboseLabel": "Levels of fair value hierarchy [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r24", "r137", "r395" ] }, "ifrs-full_LevelsOfFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LevelsOfFairValueHierarchyDomain", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfFairValuesOfFinancialAssetsliabilitiesDetails" ], "lang": { "en": { "role": { "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used." } } }, "auth_ref": [ "r24", "r137", "r395" ] }, "ifrs-full_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "TOTAL LIABILITIES" } }, "en": { "role": { "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r136", "r137", "r138", "r246", "r251", "r394", "r395", "r431" ] }, "ifrs-full_LiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfInterestRateProfileOfFinancialAssetsliabilitiesDetails", "http://trinitybiotech.com/role/ReconciliationOfLiabilitiesArisingFromFinancingActivitiesScheduleOfLiabilitiesArisingFromFinancingDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Fixed rate financial liabilities (lease payables)", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "label": "Liabilities arising from financing activities", "verboseLabel": "Fair value" } }, "en": { "role": { "documentation": "The amount of liabilities for which cash flows were, or future cash flows will be, classified in the statement of cash flows as cash flows from financing activities. [Refer: Cash flows from (used in) financing activities; Liabilities]" } } }, "auth_ref": [ "r295", "r484" ] }, "ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LiabilitiesArisingFromFinancingActivitiesAxis", "presentation": [ "http://trinitybiotech.com/role/ReconciliationOfLiabilitiesArisingFromFinancingActivitiesScheduleOfLiabilitiesArisingFromFinancingDetails" ], "lang": { "en-us": { "role": { "label": "Liabilities arising from financing activities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r295", "r484" ] }, "ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LiabilitiesArisingFromFinancingActivitiesDomain", "presentation": [ "http://trinitybiotech.com/role/ReconciliationOfLiabilitiesArisingFromFinancingActivitiesScheduleOfLiabilitiesArisingFromFinancingDetails" ], "lang": { "en-us": { "role": { "label": "Liabilities arising from financing activities [domain]" } }, "en": { "role": { "documentation": "This member stands for liabilities arising from financing activities. It also represents the standard value for the 'Liabilities arising from financing activities' axis if no other member is used. [Refer: Liabilities arising from financing activities]" } } }, "auth_ref": [ "r295", "r484" ] }, "trib_LiabilitiesAtAmortisedCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "LiabilitiesAtAmortisedCostAbstract", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfFairValuesOfFinancialAssetsliabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Liabilities At Amortised Cost Abstract", "terseLabel": "Liabilities at amortised cost" } } }, "auth_ref": [] }, "trib_LicenceFee": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "LicenceFee", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfFairValuesOfFinancialAssetsliabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Licence fees.", "label": "Licence Fee", "terseLabel": "Licence fees" } } }, "auth_ref": [] }, "trib_LicenceFeePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "LicenceFeePayments", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfInterestRateRiskEffectiveAndRepricingAnalysisDetails" ], "lang": { "en-us": { "role": { "documentation": "Accrued liabilities to contracted licence payments.", "negatedLabel": "Licence payments", "negatedTerseLabel": "Fixed rate financial liabilities (licence fees)", "label": "Licence Fee Payments", "verboseLabel": "Accrued liabilities to contracted licence payments" } } }, "auth_ref": [] }, "trib_LicencePaymentsMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "LicencePaymentsMember", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfInterestRateRiskEffectiveAndRepricingAnalysisDetails" ], "lang": { "en-us": { "role": { "documentation": "Licence payments [Member]", "label": "Licence payments [Member]" } } }, "auth_ref": [] }, "ifrs-full_LiquidityRiskMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LiquidityRiskMember", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfLiquidityRiskEstimatedInterestPaymentsOfMaturitiesDetails" ], "lang": { "en-us": { "role": { "label": "Liquidity risk [Member]" } }, "en": { "role": { "documentation": "This member stands for the risk that an entity will encounter difficulty in meeting obligations associated with financial liabilities that are settled by delivering cash or another financial asset. [Refer: Financial assets; Financial liabilities]" } } }, "auth_ref": [ "r165", "r166", "r167", "r500" ] }, "trib_LoanDrawdownUnderNewTermLoan": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "LoanDrawdownUnderNewTermLoan", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSScheduleOfMovementInTermLoan", "http://trinitybiotech.com/role/ReconciliationOfLiabilitiesArisingFromFinancingActivitiesScheduleOfLiabilitiesArisingFromFinancingDetails" ], "lang": { "en-us": { "role": { "label": "Loan Drawdown under New Term Loan", "terseLabel": "Loan drawdown under new term loan", "documentation": "Amount of loan drawdown under new term loan.", "negatedLabel": "Loan drawdown under new term loan" } } }, "auth_ref": [] }, "trib_LoanDrawdownUnderOldTermLoan": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "LoanDrawdownUnderOldTermLoan", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSScheduleOfMovementInTermLoan" ], "lang": { "en-us": { "role": { "label": "Loan Drawdown Under Old Term Loan", "terseLabel": "Drawdowns under old loan (pre\u2011extinguishment)", "documentation": "Amount of loan drawdown under old term loan." } } }, "auth_ref": [] }, "trib_LoanIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "LoanIncome", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/OTHEROPERATINGINCOMEEXPENSENarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represent the amount of orginal loan income.", "label": "Loan Income" } } }, "auth_ref": [] }, "trib_LoanOriginationCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "LoanOriginationCosts", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails2", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSScheduleOfMovementInTermLoan", "http://trinitybiotech.com/role/ReconciliationOfLiabilitiesArisingFromFinancingActivitiesScheduleOfLiabilitiesArisingFromFinancingDetails" ], "lang": { "en-us": { "role": { "disclosureGuidance": "Loan drawdown costs", "documentation": "Represents the amount of loan origination costs.", "negatedLabel": "Loan origination costs", "positiveLabel": "Loan origination costs", "label": "Loan Origination Costs", "terseLabel": "Loan drawdown costs (pre\u2011extinguishment)", "verboseLabel": "Loan drawdown costs (pre\u2011extinguishment)", "negatedTerseLabel": "Loan origination costs paid" } } }, "auth_ref": [] }, "trib_LoansAndReceivablesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "LoansAndReceivablesAbstract", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfFairValuesOfFinancialAssetsliabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Loans And Receivables Abstract", "terseLabel": "Loans and receivables at amortised cost" } } }, "auth_ref": [] }, "ifrs-full_LoansPayableInDefault": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LoansPayableInDefault", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/OTHEROPERATINGINCOMEEXPENSENarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Loans payable in default" } }, "en": { "role": { "documentation": "The amount of loans payable in default." } } }, "auth_ref": [ "r216", "r384" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "LocalPhoneNumber", "presentation": [ "http://trinitybiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "trib_LongLivedAsstesBySegment": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "LongLivedAsstesBySegment", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/SegmentInformationScheduleOfLongLivedAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.", "label": "Long Lived Asstes By Segment", "terseLabel": "Long lived asstes" } } }, "auth_ref": [] }, "trib_LongTermGrowthRate": { "xbrltype": "percentItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "LongTermGrowthRate", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsNarrativeDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfSignificantGoodwillAndIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Long-term growth rate.", "label": "Long Term Growth Rate", "terseLabel": "Long term growth rate", "verboseLabel": "Long-term growth rate" } } }, "auth_ref": [] }, "ifrs-full_LongtermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LongtermBorrowings", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfFairValuesOfFinancialAssetsliabilitiesDetails", "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfInterestRateProfileOfFinancialAssetsliabilitiesDetails", "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfInterestRateRiskEffectiveAndRepricingAnalysisDetails", "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfLiquidityRiskEstimatedInterestPaymentsOfMaturitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Exchangeable note", "negatedTerseLabel": "Fixed rate financial liabilities (exchangeable note)", "periodEndLabel": "Balance at 31 December", "periodStartLabel": "Balance at 1 January", "label": "Exchangeable notes and other borrowings", "terseLabel": "Exchangeable notes", "verboseLabel": "Exchangeable senior notes" } }, "en": { "role": { "documentation": "The non-current portion of non-current borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r615" ] }, "ifrs-full_LongtermBorrowingsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LongtermBorrowingsMember", "presentation": [ "http://trinitybiotech.com/role/ReconciliationOfLiabilitiesArisingFromFinancingActivitiesScheduleOfLiabilitiesArisingFromFinancingDetails" ], "lang": { "en-us": { "role": { "label": "Borrowings & derivative financial instruments [Member]" } }, "en": { "role": { "documentation": "This member stands for long-term borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r483", "r488" ] }, "trib_LossOnDisposalOfExchangeableNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "LossOnDisposalOfExchangeableNotes", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/FinancialIncomeAndExpensesScheduleOfFinancialIncomeExpensesNetDetails", "http://trinitybiotech.com/role/ReconciliationOfLiabilitiesArisingFromFinancingActivitiesScheduleOfLiabilitiesArisingFromFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of loss on disposal of exchangeable notes.", "negatedLabel": "Loss on disposal of exchangeable notes", "label": "Loss On Disposal Of Exchangeable Notes", "terseLabel": "Loss on disposal of Exchangeable Notes" } } }, "auth_ref": [] }, "trib_LossOnDisposalOnBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "LossOnDisposalOnBorrowings", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails1", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of loss on disposal on borrowings.", "label": "Loss On Disposal On Borrowings", "terseLabel": "Loss on disposal" } } }, "auth_ref": [] }, "trib_LossOnExtinguishmentOnOldLoan": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "LossOnExtinguishmentOnOldLoan", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/FinancialIncomeAndExpensesScheduleOfFinancialIncomeExpensesNetDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Loss On Extinguishment On Old Loan", "negatedTerseLabel": "Loss on extinguishment on old loan", "documentation": "Amount of loss on extinguishment on old loan.", "terseLabel": "Loss on extinguishment on old loan" } } }, "auth_ref": [] }, "ifrs-full_LossesOnDisposalsOfPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LossesOnDisposalsOfPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/LossBeforeTaxScheduleOfAmountChargedToStatementOfOperationDetails" ], "lang": { "en-us": { "role": { "positiveLabel": "Loss on the disposal of property, plant and equipment", "label": "(Profit)/Loss on the disposal of property, plant and equipment", "terseLabel": "(Gain)/Loss on the disposal of property, plant and equipment", "verboseLabel": "(Profit)/Loss on the disposal of property, plant and equipment" } } }, "auth_ref": [ "r456" ] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "MajorCustomersAxis", "presentation": [ "http://trinitybiotech.com/role/SegmentInformationScheduleOfRevenueDerivesFromTransferOfGoodsAndServicesDetails" ], "lang": { "en-us": { "role": { "label": "Major Customers [Axis]", "verboseLabel": "Customer [Axis]" } } }, "auth_ref": [] }, "trib_ManufacturingAndQualityMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ManufacturingAndQualityMember", "presentation": [ "http://trinitybiotech.com/role/EmploymentScheduleOfAverageNumberOfPersonsEmployedDetails" ], "lang": { "en-us": { "role": { "documentation": "Manufacturing and quality [Member]", "label": "Manufacturing and quality [Member]" } } }, "auth_ref": [] }, "trib_MardxDiagnosticsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "MardxDiagnosticsIncMember", "presentation": [ "http://trinitybiotech.com/role/GROUPUNDERTAKINGSDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfImpairmentLossDetails" ], "lang": { "en-us": { "role": { "documentation": "Mardx Diagnostics Inc. [Member]", "label": "Mardx Diagnostics Inc. [Member]" } } }, "auth_ref": [] }, "ifrs-full_MaturityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MaturityAxis", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfInterestRateRiskEffectiveAndRepricingAnalysisDetails", "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfLiquidityRiskEstimatedInterestPaymentsOfMaturitiesDetails", "http://trinitybiotech.com/role/LeaseLiabilitiesScheduleOfFinanceLeaseLiabilitiesPayableDetails", "http://trinitybiotech.com/role/TradeAndOtherReceivablesNarrativeDetails", "http://trinitybiotech.com/role/TradeAndOtherReceivablesScheduleOfFutureMinimumFinanceLeaseReceivablesDetails", "http://trinitybiotech.com/role/TradeAndOtherReceivablesScheduleOfFutureMinimumRentalsReceivableUnderNon-cancellableOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Maturity [Axis]", "verboseLabel": "Maturity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r145", "r156", "r158", "r161", "r162", "r164", "r169", "r218", "r233", "r261", "r264", "r274", "r278", "r386", "r434", "r465", "r505" ] }, "trib_MaturityDateForLease": { "xbrltype": "gYearItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "MaturityDateForLease", "presentation": [ "http://trinitybiotech.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Maturity date", "label": "Maturity Date For Lease", "terseLabel": "Maturity date" } } }, "auth_ref": [] }, "trib_MaturityDateOfExchangeableSeniorNotes": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "MaturityDateOfExchangeableSeniorNotes", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Maturity date of exchangeable senior notes.", "label": "Maturity date of exchangeable senior notes" } } }, "auth_ref": [] }, "ifrs-full_MaturityDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MaturityDomain", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfInterestRateRiskEffectiveAndRepricingAnalysisDetails", "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfLiquidityRiskEstimatedInterestPaymentsOfMaturitiesDetails", "http://trinitybiotech.com/role/LeaseLiabilitiesScheduleOfFinanceLeaseLiabilitiesPayableDetails", "http://trinitybiotech.com/role/TradeAndOtherReceivablesNarrativeDetails", "http://trinitybiotech.com/role/TradeAndOtherReceivablesScheduleOfFutureMinimumFinanceLeaseReceivablesDetails", "http://trinitybiotech.com/role/TradeAndOtherReceivablesScheduleOfFutureMinimumRentalsReceivableUnderNon-cancellableOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Maturity [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used." } } }, "auth_ref": [ "r145", "r156", "r158", "r161", "r162", "r164", "r169", "r218", "r261", "r264", "r274", "r278", "r386", "r434", "r465", "r505", "r508" ] }, "ifrs-full_MaximumExposureToCreditRisk": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MaximumExposureToCreditRisk", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfFairValuesOfFinancialAssetsliabilitiesDetails", "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfMaximumCreditExposureOfFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total maximum credit exposure", "label": "Maximum exposure to credit risk", "terseLabel": "Total maximum credit exposure" } }, "en": { "role": { "documentation": "The amount that best represents the maximum exposure to credit risk without taking into account any collateral held or other credit enhancements (for example, netting agreements that do not qualify for offset in accordance with IAS 32). [Refer: Credit risk [member]]" } } }, "auth_ref": [ "r226" ] }, "ifrs-full_MaximumExposureToCreditRiskOfFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MaximumExposureToCreditRiskOfFinancialAssets", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfExposureOfTradeReceivablesByCustomerDetails", "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfExposureOfTradeReceivablesByGeographicLocationDetails" ], "lang": { "en-us": { "role": { "label": "Maximum exposure to credit risk of financial assets designated as measured at fair value through profit or loss", "terseLabel": "Maximum Exposure to credit risk for trade receivables and finance lease income receivable" } }, "en": { "role": { "documentation": "The maximum exposure to the credit risk of financial assets designated as measured at fair value through profit or loss. [Refer: Credit risk [member]; Maximum exposure to credit risk]" } } }, "auth_ref": [ "r238" ] }, "trib_MaximumWeightedAveragePriceOfAmericanDepositoryShares": { "xbrltype": "perShareItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "MaximumWeightedAveragePriceOfAmericanDepositoryShares", "presentation": [ "http://trinitybiotech.com/role/CapitalAndReservesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Maximum weighted average price of American Depository Shares.", "label": "Maximum Weighted Average Price Of American Depository Shares", "terseLabel": "Maximum weighted average price of ADS" } } }, "auth_ref": [] }, "trib_MeasurementPeriodAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "MeasurementPeriodAdjustmentMember", "presentation": [ "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Measurement Period Adjustment [Member]", "label": "Measurement Period Adjustment [Member]" } } }, "auth_ref": [] }, "ifrs-full_MeasurementPeriodAdjustmentsRecognisedForParticularAssetsLiabilitiesNoncontrollingInterestsOrItemsOfConsideration": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MeasurementPeriodAdjustmentsRecognisedForParticularAssetsLiabilitiesNoncontrollingInterestsOrItemsOfConsideration", "presentation": [ "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Measurement period adjustments recognised for particular assets, liabilities, non-controlling interests or items of consideration", "terseLabel": "Measurement period adjustments" } }, "en": { "role": { "documentation": "The amount of measurement period adjustments recognised for particular assets, liabilities, non-controlling interests or items of consideration if the initial accounting for a business combination is incomplete. The measurement period is the period after the acquisition date during which the acquirer may adjust the provisional amounts recognised for a business combination. [Refer: Non-controlling interests; Total for all business combinations [member]]" } } }, "auth_ref": [ "r197" ] }, "trib_MetabolomicDiagnosticsLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "MetabolomicDiagnosticsLimitedMember", "presentation": [ "http://trinitybiotech.com/role/CapitalAndReservesNarrativeDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "This member is stand for Metabolomic Diagnostics Limited.", "label": "Metabolomic Diagnostics Limited [Member]", "verboseLabel": "Metabolomic Diagnostics Limited [Member]" } } }, "auth_ref": [] }, "trib_MetabolomicsDiagnosticsLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "MetabolomicsDiagnosticsLimitedMember", "presentation": [ "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSDetails", "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSTables", "http://trinitybiotech.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://trinitybiotech.com/role/GROUPUNDERTAKINGSDetails", "http://trinitybiotech.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Metabolomics Diagnostics Limited [Member]", "label": "Metabolomics Diagnostics Limited [Member]", "terseLabel": "Metabolomics [Member]" } } }, "auth_ref": [] }, "trib_MetabolomicsPrePsiaMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "MetabolomicsPrePsiaMember", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfPrincipalDevelopmentProjectsDetails" ], "lang": { "en-us": { "role": { "label": "Metabolomic PrePsia [Member]", "terseLabel": "Metabolomic - PrePsia [Member]", "documentation": "This member stands for information pertaining to \"Metabolomic - PrePsia\"" } } }, "auth_ref": [] }, "ifrs-full_MethodsAndAssumptionsUsedInPreparingSensitivityAnalysis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MethodsAndAssumptionsUsedInPreparingSensitivityAnalysis", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Description of methods and assumptions used in preparing sensitivity analysis", "terseLabel": "Description of foreign currency exposure sensitivity analysis" } }, "en": { "role": { "documentation": "The description of methods and assumptions used when preparing a sensitivity analysis for types of market risk to which the entity is exposed. [Refer: Market risk [member]]" } } }, "auth_ref": [ "r231" ] }, "trib_MicoLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "MicoLtdMember", "presentation": [ "http://trinitybiotech.com/role/CapitalAndReservesNarrativeDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "MiCO LTD.", "label": "Mico Ltd [Member]", "terseLabel": "MiCo Ltd [Member]" } } }, "auth_ref": [] }, "trib_MidTierHaemoglobinsInstrumentMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "MidTierHaemoglobinsInstrumentMember", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfPrincipalDevelopmentProjectsDetails" ], "lang": { "en-us": { "role": { "documentation": "Mid-tier haemoglobins instrument [Member]", "label": "Mid-tier haemoglobins instrument [Member]" } } }, "auth_ref": [] }, "trib_MinimumFinanceLeasePaymentsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "MinimumFinanceLeasePaymentsPayable", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/LeaseLiabilitiesScheduleOfFinanceLeaseLiabilitiesPayableDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of payments over the finance lease term that the lessee is or can be required to make, excluding contingent rent, costs for services and taxes to be paid by, and reimbursed to, the lessor, together with any amounts guaranteed by the lessee or by a party related to the lessee.", "label": "Minimum Finance Lease Payments Payable", "terseLabel": "Minimum lease payments" } } }, "auth_ref": [] }, "trib_MinimumFinanceLeasePaymentsPayableAtCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "MinimumFinanceLeasePaymentsPayableAtCarryingAmount", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/LeaseLiabilitiesScheduleOfOutstandingInterestBearingLoansAndBorrowingsDetails" ], "lang": { "en-us": { "role": { "documentation": "The Carrying value of minimum finance lease payments payable.", "label": "Minimum Finance Lease Payments Payable At Carrying Amount", "terseLabel": "Carrying value" } } }, "auth_ref": [] }, "trib_MinimumFinanceLeasePaymentsPayableAtPresentValue": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "MinimumFinanceLeasePaymentsPayableAtPresentValue", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/LeaseLiabilitiesScheduleOfFinanceLeaseLiabilitiesPayableDetails", "http://trinitybiotech.com/role/LeaseLiabilitiesScheduleOfOutstandingInterestBearingLoansAndBorrowingsDetails" ], "lang": { "en-us": { "role": { "documentation": "The present value of minimum finance lease payments payable. [Refer: Minimum finance lease payments payable]", "negatedLabel": "Fixed rate financial liabilities (lease payables)", "label": "Minimum Finance Lease Payments Payable At Present Value", "terseLabel": "Principal", "verboseLabel": "Fair value" } } }, "auth_ref": [] }, "trib_MinimumFinanceLeasePaymentsReceivableAtPresentValue": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "MinimumFinanceLeasePaymentsReceivableAtPresentValue", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfFairValuesOfFinancialAssetsliabilitiesDetails", "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfInterestRateRiskEffectiveAndRepricingAnalysisDetails", "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfMaximumCreditExposureOfFinancialAssetsDetails", "http://trinitybiotech.com/role/TradeAndOtherReceivablesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Finance lease receivable.", "positiveLabel": "Finance lease receivable", "positiveTerseLabel": "Finance lease income receivable", "label": "Minimum Finance Lease Payments Receivable At Present Value", "terseLabel": "Financial assets (lease receivables)", "verboseLabel": "Lease receivable" } } }, "auth_ref": [] }, "trib_MinimumLiquidityCovenant": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "MinimumLiquidityCovenant", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/BASISOFPREPARATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represent the amount of minimum liquidity covenant", "label": "Minimum Liquidity Covenant", "verboseLabel": "Minimum Liquidity Covenant" } } }, "auth_ref": [] }, "ifrs-full_MiscellaneousNoncurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MiscellaneousNoncurrentAssetsAbstract", "lang": { "en-us": { "role": { "label": "Miscellaneous non-current assets [abstract]" } } }, "auth_ref": [] }, "ifrs-full_MiscellaneousOtherOperatingIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MiscellaneousOtherOperatingIncome", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/IMPAIRMENTTRANSFORMATIONANDONCEOFFCOSTSNarrativeDetails", "http://trinitybiotech.com/role/OTHEROPERATINGINCOMEEXPENSENarrativeDetails", "http://trinitybiotech.com/role/ProvisionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Miscellaneous other operating income", "terseLabel": "Once\u2011off costs, Credit recognised" } } }, "auth_ref": [ "r612" ] }, "trib_MoreThanOneYearMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "MoreThanOneYearMember", "presentation": [ "http://trinitybiotech.com/role/ProvisionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "More Than One Year [Member]", "label": "More Than One Year [Member]" } } }, "auth_ref": [] }, "trib_MovementInInterestAccrual": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "MovementInInterestAccrual", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/ReconciliationOfLiabilitiesArisingFromFinancingActivitiesScheduleOfLiabilitiesArisingFromFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "Movement in interest accrual.", "label": "Movement In Interest Accrual", "terseLabel": "Movement in interest accrual" } } }, "auth_ref": [] }, "trib_MrOCaoimhAndDrWalshMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "MrOCaoimhAndDrWalshMember", "presentation": [ "http://trinitybiotech.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Mr. O'Caoimh and Dr Walsh [Member]", "label": "Mr O Caoimh And Dr Walsh Member", "terseLabel": "Mr. O'Caoimh and Dr Walsh [Member]" } } }, "auth_ref": [] }, "trib_MrOCaoimhMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "MrOCaoimhMember", "presentation": [ "http://trinitybiotech.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Mr. O'Caoimh [Member]", "label": "Mr O Caoimh Member", "terseLabel": "Mr. O'Caoimh [Member]" } } }, "auth_ref": [] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://trinitybiotech.com/role/SegmentInformationScheduleOfRevenueDerivesFromTransferOfGoodsAndServicesDetails" ], "auth_ref": [] }, "ifrs-full_NameOfSubsidiary": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NameOfSubsidiary", "presentation": [ "http://trinitybiotech.com/role/GROUPUNDERTAKINGSDetails" ], "lang": { "en-us": { "role": { "label": "Name of subsidiary" } }, "en": { "role": { "documentation": "The name of a subsidiary. [Refer: Total for all subsidiaries [member]]" } } }, "auth_ref": [ "r46", "r49", "r117", "r119" ] }, "trib_NativeDesignLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "NativeDesignLimitedMember", "presentation": [ "http://trinitybiotech.com/role/CapitalAndReservesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "This member is stand for Native Design Limited.", "label": "Native Design Limited [Member]" } } }, "auth_ref": [] }, "trib_NetCarryingAmountMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "NetCarryingAmountMember", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfGoodwillAndIntangibleAssetsDetails", "http://trinitybiotech.com/role/PropertyPlantAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentRelatedToAccumulatedDepreciationDetails" ], "lang": { "en-us": { "role": { "documentation": "Carrying amounts [Member]", "label": "Net Carrying Amount Member", "terseLabel": "Carrying amounts [Member]" } } }, "auth_ref": [] }, "trib_NetCashOutFlowOnBusinessCombination": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "NetCashOutFlowOnBusinessCombination", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of cash outflow, net of cash acquired on business combination, recognised at acquisition date.", "label": "Net Cash Out Flow On Business Combination", "totalLabel": "Net cash outflow", "verboseLabel": "Net cash outflow" } } }, "auth_ref": [] }, "trib_NetCashOutflowArisingOnAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "NetCashOutflowArisingOnAcquisitionAbstract", "presentation": [ "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSDetails" ], "lang": { "en-us": { "role": { "label": "Net Cash Outflow Arising On Acquisition [Abstract]", "terseLabel": "Net cash outflow \u2013 arising on acquisition" } } }, "auth_ref": [] }, "ifrs-full_NetDeferredTaxAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NetDeferredTaxAssets", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/SegmentInformationScheduleOfSegmentAssetsAndSegmentLiabilitiesByGeographicalAreaDetails" ], "lang": { "en-us": { "role": { "label": "Net deferred tax assets", "terseLabel": "Total assets as reported in the Group balance sheet", "totalLabel": "Total assets as reported in the Group balance sheet" } }, "en": { "role": { "documentation": "The amount of deferred tax assets net of deferred tax liabilities, when the absolute amount of deferred tax assets is greater than the absolute amount of deferred tax liabilities. [Refer: Deferred tax assets; Deferred tax liabilities]" } } }, "auth_ref": [ "r576" ] }, "ifrs-full_NetDeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NetDeferredTaxLiabilities", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/SegmentInformationScheduleOfSegmentAssetsAndSegmentLiabilitiesByGeographicalAreaDetails" ], "lang": { "en-us": { "role": { "label": "Net deferred tax liabilities", "totalLabel": "Total liabilities as reported in the Group balance sheet", "verboseLabel": "Total liabilities as reported in the Group balance sheet" } }, "en": { "role": { "documentation": "The amount of deferred tax liabilities net of deferred tax assets, when the absolute amount of deferred tax liabilities is greater than the absolute amount of deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]" } } }, "auth_ref": [ "r576" ] }, "trib_NetFinancingExpenseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "NetFinancingExpenseIncome", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfOperations": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfOperations" ], "lang": { "en-us": { "role": { "documentation": "Net financing (expense)/income.", "label": "Net Financing Expense Income", "totalLabel": "Net financing expense" } } }, "auth_ref": [] }, "trib_NetForeignExchangeGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "NetForeignExchangeGainLoss", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/LossBeforeTaxScheduleOfAmountChargedToStatementOfOperationDetails" ], "lang": { "en-us": { "role": { "documentation": "Net foreign exchange gain (loss).", "label": "Net Foreign Exchange Gain Loss", "terseLabel": "Net foreign exchange differences" } } }, "auth_ref": [] }, "trib_NetInterestIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "NetInterestIncome", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represent the net interest income.", "label": "Net Interest Income", "terseLabel": "Net interest income" } } }, "auth_ref": [] }, "trib_NetOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "NetOperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/IncomeTaxCreditNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Net operating loss carryforwards.", "label": "Net operating loss carryforwards" } } }, "auth_ref": [] }, "trib_NetOperatingLossPeriod": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "NetOperatingLossPeriod", "presentation": [ "http://trinitybiotech.com/role/IncomeTaxCreditNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Description net operating loss period.", "label": "Net operating loss period" } } }, "auth_ref": [] }, "ifrs-full_NewProvisionsOtherProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NewProvisionsOtherProvisions", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/InventoriesNarrativeDetails", "http://trinitybiotech.com/role/InventoriesScheduleOfMovementOnInventoryProvisionDetails", "http://trinitybiotech.com/role/PROVISIONSScheduleofreconciliationofchangesinprovisionsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Released during the year", "label": "New provisions, other provisions", "verboseLabel": "Inventory provision released during the year", "terseLabel": "Charged during the year" } }, "en": { "role": { "documentation": "The amount recognised for new other provisions. [Refer: Other provisions]" } } }, "auth_ref": [ "r590" ] }, "trib_NominalAmountOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "NominalAmountOfDebt", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Nominal amount of debt.", "label": "Nominal Amount Of Debt", "terseLabel": "Nominal amount of debt" } } }, "auth_ref": [] }, "trib_NominalValuePerShareOfExchangeableNotes": { "xbrltype": "perShareItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "NominalValuePerShareOfExchangeableNotes", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Nominal value per share of the Exchangeable Notes.", "label": "Nominal Value Per Share Of Exchangeable Notes", "terseLabel": "Nominal value per share of the Exchangeable Notes" } } }, "auth_ref": [] }, "trib_NonCashActivityForFinancingActivityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "NonCashActivityForFinancingActivityAbstract", "presentation": [ "http://trinitybiotech.com/role/ReconciliationOfLiabilitiesArisingFromFinancingActivitiesScheduleOfLiabilitiesArisingFromFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "Non cash activity for financing activity.", "label": "Non Cash Activity For Financing Activity Abstract", "terseLabel": "Non-cash:", "verboseLabel": "Non-cash:" } } }, "auth_ref": [] }, "trib_NonCashFairValueGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "NonCashFairValueGainLoss", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of non-cash fair value gain (loss).", "label": "Non Cash Fair Value Gain Loss", "terseLabel": "Non-cash fair value gain (loss)" } } }, "auth_ref": [] }, "trib_NonCashImpairmentCharge": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "NonCashImpairmentCharge", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of non cash impairment charge.", "label": "Non-cash impairment charge" } } }, "auth_ref": [] }, "trib_NonCurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "NonCurrentAssetsMember", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails4" ], "lang": { "en-us": { "role": { "documentation": "Represent information about the non-current assets member.", "label": "Non Current Assets [Member]" } } }, "auth_ref": [] }, "trib_NonCurrentLeaseLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "NonCurrentLeaseLiabilitiesAbstract", "presentation": [ "http://trinitybiotech.com/role/LeaseLiabilitiesScheduleOfCarryingValuesOfFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Non Current Lease Liabilities Abstract", "terseLabel": "Non-Current liabilities" } } }, "auth_ref": [] }, "trib_NonCurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "NonCurrentLiabilitiesMember", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails2", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails3", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSScheduleOfMovementInTermLoan" ], "lang": { "en-us": { "role": { "documentation": "Represent information about the non-current liabilities member.", "label": "Non Current Liabilities [Member]", "terseLabel": "Non-current liability [Member]" } } }, "auth_ref": [] }, "trib_NonRadingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "NonRadingCosts", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/IMPAIRMENTTRANSFORMATIONANDONCEOFFCOSTSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of non-trading costs.", "label": "Non Rading Costs", "terseLabel": "Non-trading costs" } } }, "auth_ref": [] }, "trib_NonTradingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "NonTradingCosts", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/IMPAIRMENTTRANSFORMATIONANDONCEOFFCOSTSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents amount of non-trading costs.", "label": "Non Trading Costs", "terseLabel": "Non-trading costs" } } }, "auth_ref": [] }, "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NonadjustingEventsAfterReportingPeriodAxis", "presentation": [ "http://trinitybiotech.com/role/BASISOFPREPARATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://trinitybiotech.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails", "http://trinitybiotech.com/role/PostBalanceSheetEventsDetails" ], "lang": { "en-us": { "role": { "label": "Nonadjusting Events After Reporting Period Axis", "terseLabel": "Non-adjusting events after reporting period [axis]", "verboseLabel": "Non-adjusting events after reporting period [Axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r0", "r306" ] }, "ifrs-full_NonadjustingEventsAfterReportingPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NonadjustingEventsAfterReportingPeriodDomain", "presentation": [ "http://trinitybiotech.com/role/BASISOFPREPARATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://trinitybiotech.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails", "http://trinitybiotech.com/role/PostBalanceSheetEventsDetails" ], "lang": { "en-us": { "role": { "label": "Non-adjusting events after reporting period [domain]" } }, "en": { "role": { "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used." } } }, "auth_ref": [ "r0", "r306" ] }, "trib_NoncashInterestOnConvertibleNote": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "NoncashInterestOnConvertibleNote", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/FinancialIncomeAndExpensesScheduleOfFinancialIncomeExpensesNetDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of non-cash interest on convertible note.", "negatedLabel": "Non-cash interest on convertible note", "label": "Noncash Interest On Convertible Note" } } }, "auth_ref": [] }, "trib_NoncashInterestOnSeniorSecuredTermLoan": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "NoncashInterestOnSeniorSecuredTermLoan", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/FinancialIncomeAndExpensesScheduleOfFinancialIncomeExpensesNetDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of non-cash interest on senior secured term loan.", "negatedTerseLabel": "Non-cash interest on senior secured term loan", "label": "Noncash Interest On Senior Secured Term Loan", "terseLabel": "Non-cash interest on senior secured term loan" } } }, "auth_ref": [] }, "trib_NoncashLoanModificationGain": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "NoncashLoanModificationGain", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/FinancialIncomeAndExpensesScheduleOfFinancialIncomeExpensesNetDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSScheduleOfMovementInTermLoan", "http://trinitybiotech.com/role/ReconciliationOfLiabilitiesArisingFromFinancingActivitiesScheduleOfLiabilitiesArisingFromFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of non-cash loan modification gain.", "label": "Non-cash Loan Modification Gain", "terseLabel": "Non-cash loan modification gain" } } }, "auth_ref": [] }, "ifrs-full_NoncontrollingInterests": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncontrollingInterests", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfFairValuesOfFinancialAssetsliabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Non-controlling interests", "verboseLabel": "Equity investments in Novus" } }, "en": { "role": { "documentation": "The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Total for all subsidiaries [member]]" } } }, "auth_ref": [ "r116", "r118", "r430" ] }, "ifrs-full_NoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentAssets", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current assets [Default Label]", "totalLabel": "Total non-current assets" } }, "en": { "role": { "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]" } } }, "auth_ref": [ "r123", "r435", "r489" ] }, "ifrs-full_NoncurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentAssetsAbstract", "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current assets" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONDetail5": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONDetail5" ], "lang": { "en-us": { "role": { "label": "Non-current assets or disposal groups classified as held for sale or as held for distribution to owners", "totalLabel": "Total net assets disposed" } }, "en": { "role": { "documentation": "The amount of non-current assets or disposal groups classified as held for sale or as held for distribution to owners. [Refer: Non-current assets or disposal groups classified as held for distribution to owners; Non-current assets or disposal groups classified as held for sale]" } } }, "auth_ref": [ "r425" ] }, "ifrs-full_NoncurrentDerivativeFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentDerivativeFinancialAssets", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfFairValuesOfFinancialAssetsliabilitiesDetails", "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails" ], "lang": { "en-us": { "role": { "positiveTerseLabel": "Derivative asset \u2013 prepayment option", "label": "Non-current derivative financial assets", "terseLabel": "Derivative financial instruments", "verboseLabel": "Exchangeable note bond call option" } }, "en": { "role": { "documentation": "The amount of non-current derivative financial assets. [Refer: Derivative financial assets]" } } }, "auth_ref": [ "r615" ] }, "ifrs-full_NoncurrentDerivativeFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentDerivativeFinancialLiabilities", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfFairValuesOfFinancialAssetsliabilitiesDetails", "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Derivative liability - warrants", "label": "Non-current derivative financial liabilities", "totalLabel": "Total non-current liabilities", "verboseLabel": "Derivative financial liability" } }, "en": { "role": { "documentation": "The amount of non-current derivative financial liabilities. [Refer: Derivative financial liabilities]" } } }, "auth_ref": [ "r615" ] }, "trib_NoncurrentFinanceLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "NoncurrentFinanceLeaseLiabilities", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "documentation": "Finance lease liabilities.", "label": "Noncurrent Finance Lease Liabilities", "totalLabel": "Non-current liabilities", "verboseLabel": "Lease liabilities" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentFinanceLeaseReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentFinanceLeaseReceivables", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/OtherNon-currentAssetsDetails": { "parentTag": "ifrs-full_OtherNoncurrentAssets", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://trinitybiotech.com/role/OtherNon-currentAssetsDetails", "http://trinitybiotech.com/role/TradeAndOtherReceivablesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "non current Finance lease receivables", "terseLabel": "Finance lease receivables" } }, "en": { "role": { "documentation": "The amount of non-current finance lease receivables. [Refer: Finance lease receivables]" } } }, "auth_ref": [ "r615" ] }, "ifrs-full_NoncurrentFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentFinancialAssets", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current financial assets", "terseLabel": "Financial assets" } }, "en": { "role": { "documentation": "The amount of non-current financial assets. [Refer: Financial assets]" } } }, "auth_ref": [ "r220" ] }, "ifrs-full_NoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentLiabilities", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_Liabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current liabilities [Default Label]", "totalLabel": "Total non-current liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]" } } }, "auth_ref": [ "r125", "r436", "r489" ] }, "ifrs-full_NoncurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentLiabilitiesAbstract", "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current liabilities" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentPortionOfOtherNoncurrentBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentPortionOfOtherNoncurrentBorrowings", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfFairValuesOfFinancialAssetsliabilitiesDetails", "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfLiquidityRiskEstimatedInterestPaymentsOfMaturitiesDetails", "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "negatedLabel": "Senior secured term loan", "negatedTerseLabel": "Variable rate financial liabilities (senior secured term loan)", "label": "Non-current portion of other non-current borrowings", "terseLabel": "Senior secured term loan", "verboseLabel": "Variable rate financial liabilities (senior secured term loan)" } }, "en": { "role": { "documentation": "The non-current portion of non-current other borrowings. [Refer: Other borrowings]" } } }, "auth_ref": [ "r612" ] }, "ifrs-full_NoncurrentProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentProvisions", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition", "http://trinitybiotech.com/role/ProvisionsScheduleOfProvisionsDetails" ], "lang": { "en-us": { "role": { "label": "Non-current provisions", "terseLabel": "Provisions" } }, "en": { "role": { "documentation": "The amount of non-current provisions, including provisions for employee benefits. [Refer: Provisions]" } } }, "auth_ref": [ "r427" ] }, "ifrs-full_NoncurrentReceivablesFromContractsWithCustomers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentReceivablesFromContractsWithCustomers", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/SegmentInformationScheduleOfRevenueDerivesFromTransferOfGoodsAndServicesDetails" ], "lang": { "en-us": { "role": { "label": "Over time" } }, "en": { "role": { "documentation": "The amount of non-current receivables from contracts with customers. [Refer: Receivables from contracts with customers]" } } }, "auth_ref": [ "r141" ] }, "ifrs-full_NongovernmentCustomersMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NongovernmentCustomersMember", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfExposureOfTradeReceivablesByCustomerDetails" ], "lang": { "en-us": { "role": { "label": "Non-government customers [Member]", "terseLabel": "Non-governmental organisations [Member]" } }, "en": { "role": { "documentation": "This member stands for non-government customers. [Refer: Government [member]]" } } }, "auth_ref": [ "r494", "r518" ] }, "ifrs-full_NotLaterThanOneYearMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NotLaterThanOneYearMember", "presentation": [ "http://trinitybiotech.com/role/LeaseLiabilitiesScheduleOfFinanceLeaseLiabilitiesPayableDetails", "http://trinitybiotech.com/role/TradeAndOtherReceivablesScheduleOfFutureMinimumFinanceLeaseReceivablesDetails", "http://trinitybiotech.com/role/TradeAndOtherReceivablesScheduleOfFutureMinimumRentalsReceivableUnderNon-cancellableOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Less than one year [Member]" } }, "en": { "role": { "documentation": "This member stands for a time band of not later than one year." } } }, "auth_ref": [ "r156", "r158", "r169", "r271", "r275", "r433", "r505", "r511" ] }, "ifrs-full_NotesAndDebenturesIssued": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NotesAndDebenturesIssued", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Issuance of exchangeable senior notes" } }, "en": { "role": { "documentation": "The amount of notes and debentures issued by the entity." } } }, "auth_ref": [ "r612" ] }, "trib_NotesAndDebenturesPurchased": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "NotesAndDebenturesPurchased", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Repurchased of exchangeable senior notes.", "label": "Notes And Debentures Purchased", "terseLabel": "Repurchased of exchangeable senior notes" } } }, "auth_ref": [] }, "trib_NotesAndDebenturesRetired": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "NotesAndDebenturesRetired", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents notes and debenture retired amount.", "label": "Notes And Debentures Retired", "verboseLabel": "Notes and debenture retired" } } }, "auth_ref": [] }, "ifrs-full_NotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NotionalAmount", "presentation": [ "http://trinitybiotech.com/role/BASISOFPREPARATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails", "http://trinitybiotech.com/role/PostBalanceSheetEventsDetails" ], "lang": { "en-us": { "role": { "label": "Notional amount", "terseLabel": "Face amount of loan" } }, "en": { "role": { "documentation": "The nominal or face amount of a financial instrument, used to calculate payments made on that instrument." } } }, "auth_ref": [ "r612" ] }, "trib_NovaCenturyScientificIncMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "NovaCenturyScientificIncMember", "presentation": [ "http://trinitybiotech.com/role/GROUPUNDERTAKINGSDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Nova Century Scientific Inc.", "label": "Nova Century Scientific Inc [Member]" } } }, "auth_ref": [] }, "trib_NovusDiagnosticsLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "NovusDiagnosticsLimitedMember", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfFairValuesOfFinancialAssetsliabilitiesDetails", "http://trinitybiotech.com/role/CapitalAndReservesNarrativeDetails", "http://trinitybiotech.com/role/FINANCIALASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Novus Diagnostics Limited.", "label": "Novus Diagnostics Limited [Member]", "verboseLabel": "Novus" } } }, "auth_ref": [] }, "trib_NumberOfAOrdinaryWeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "NumberOfAOrdinaryWeightedAverageShares", "presentation": [ "http://trinitybiotech.com/role/LossPerShareScheduleOfBasicEarningsPerOrdinaryShareDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of A ordinary weighted average shares.", "periodEndLabel": "At period end", "periodStartLabel": "Number of \u2018A\u2019 ordinary shares at January 1", "positiveTerseLabel": "Number of \u2018A\u2019 ordinary shares at January 1", "label": "Number Of A Ordinary Weighted Average Shares", "terseLabel": "Number of warrant issued", "totalLabel": "Total number of shares issued" } } }, "auth_ref": [] }, "trib_NumberOfAmericanDepositorySharesWeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "NumberOfAmericanDepositorySharesWeightedAverageShares", "presentation": [ "http://trinitybiotech.com/role/LossPerShareScheduleOfEarningsPerAdsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of American Depository Shares, weighted average shares.", "periodEndLabel": "At period end", "periodStartLabel": "Number of shares at January 1", "positiveTerseLabel": "Number of ADS at January 1 (Note 18)", "label": "Number Of American Depository Shares Weighted Average Shares", "terseLabel": "Number of ADS at January 1 (Note 19)", "totalLabel": "Total number of shares issued" } } }, "auth_ref": [] }, "trib_NumberOfInternallyDevelopedIntangibleAssetsWereFullyImpaired": { "xbrltype": "integerItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "NumberOfInternallyDevelopedIntangibleAssetsWereFullyImpaired", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of internally developed intangible assets were fully impaired", "documentation": "The number of internally developed intangible assets were fully impaired during the reporting period.", "label": "Number of internally developed intangible assets were fully impaired" } } }, "auth_ref": [] }, "trib_NumberOfLeasesWithExtensionOptions": { "xbrltype": "decimalItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "NumberOfLeasesWithExtensionOptions", "presentation": [ "http://trinitybiotech.com/role/PropertyPlantAndEquipmentScheduleOfIncomeFromSub-lettingRight-of-useBuildingsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of leases with extension options.", "label": "Number Of Leases With Extension Options", "terseLabel": "No. of Leases with extension options" } } }, "auth_ref": [] }, "trib_NumberOfLeasesWithOptionsToPurchase": { "xbrltype": "decimalItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "NumberOfLeasesWithOptionsToPurchase", "presentation": [ "http://trinitybiotech.com/role/PropertyPlantAndEquipmentScheduleOfIncomeFromSub-lettingRight-of-useBuildingsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of leases with options to purchase.", "label": "Number Of Leases With Options To Purchase", "terseLabel": "No. of Leases with options to purchase" } } }, "auth_ref": [] }, "trib_NumberOfLeasesWithTerminationOptions": { "xbrltype": "decimalItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "NumberOfLeasesWithTerminationOptions", "presentation": [ "http://trinitybiotech.com/role/PropertyPlantAndEquipmentScheduleOfIncomeFromSub-lettingRight-of-useBuildingsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of leases with termination options.", "label": "Number Of Leases With Termination Options", "terseLabel": "No. of leases with termination options" } } }, "auth_ref": [] }, "trib_NumberOfLeasesWithVariablePaymentsLinkedToIndex": { "xbrltype": "decimalItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "NumberOfLeasesWithVariablePaymentsLinkedToIndex", "presentation": [ "http://trinitybiotech.com/role/PropertyPlantAndEquipmentScheduleOfIncomeFromSub-lettingRight-of-useBuildingsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of leases with variable payments linked to index.", "label": "Number Of Leases With Variable Payments Linked To Index", "terseLabel": "No. of leases with variable payments linked to index" } } }, "auth_ref": [] }, "trib_NumberOfOptionsGranted": { "xbrltype": "sharesItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "NumberOfOptionsGranted", "presentation": [ "http://trinitybiotech.com/role/LossPerShareNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of options granted.", "label": "Number Of Options Granted", "terseLabel": "Number of options granted" } } }, "auth_ref": [] }, "trib_NumberOfOptionsIssuable": { "xbrltype": "sharesItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "NumberOfOptionsIssuable", "presentation": [ "http://trinitybiotech.com/role/LossPerShareNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of options issuable.", "label": "Number Of Options Issuable", "terseLabel": "Number of options issuable" } } }, "auth_ref": [] }, "trib_NumberOfOptionsLapsedUnexercised": { "xbrltype": "sharesItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "NumberOfOptionsLapsedUnexercised", "presentation": [ "http://trinitybiotech.com/role/LossPerShareNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of options lapsed unexercised.", "label": "Number Of Options Lapsed Unexercised", "terseLabel": "Number of options lapsed unexercised" } } }, "auth_ref": [] }, "trib_NumberOfOrdinarySharesIssuableOnExerciseOfOptions": { "xbrltype": "sharesItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "NumberOfOrdinarySharesIssuableOnExerciseOfOptions", "presentation": [ "http://trinitybiotech.com/role/LossPerShareNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of ordinary shares issuable on exercise of options.", "label": "Number Of Ordinary Shares Issuable On Exercise Of Options", "terseLabel": "Number of ordinary shares issuable on exercise of options" } } }, "auth_ref": [] }, "ifrs-full_NumberOfOutstandingShareOptions": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOutstandingShareOptions", "presentation": [ "http://trinitybiotech.com/role/RelatedPartyTransactionsScheduleOfCompanysSharesAndShareOptionPlanDetails", "http://trinitybiotech.com/role/ShareOptionsNarrativeDetails", "http://trinitybiotech.com/role/ShareOptionsScheduleOfGrantsOfShareOptionsAndWarrantsDetails", "http://trinitybiotech.com/role/ShareOptionsSummaryOfRangeOfPricesOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Outstanding at end of year", "periodStartLabel": "Outstanding Beginning Balance", "label": "Number of share options outstanding in share-based payment arrangement", "verboseLabel": "Number of options" } }, "en": { "role": { "documentation": "The number of share options outstanding in a share-based payment arrangement." } } }, "auth_ref": [ "r172", "r177", "r181", "r363", "r368" ] }, "ifrs-full_NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented", "presentation": [ "http://trinitybiotech.com/role/LossPerShareScheduleOfDilutedEarningsPerAdsShareCalculationDetails", "http://trinitybiotech.com/role/LossPerShareScheduleOfDilutedEarningsPerOrdinaryShareDetails" ], "lang": { "en-us": { "role": { "label": "Number of potential ordinary shares that are antidilutive in period presented", "terseLabel": "Total number of potentially dilutive instruments excluded from the weighted average number of \u2018A\u2019 ordinary shares in calculating dilutive loss per \u2018A\u2019 ordinary share", "verboseLabel": "Total number of potentially dilutive instruments excluded from the weighted average number of ADS in calculating dilutive loss per ADS" } }, "en": { "role": { "documentation": "Number of potential ordinary shares that are antidilutive in the period presented." } } }, "auth_ref": [ "r589" ] }, "trib_NumberOfRetiredDirectorOptions": { "xbrltype": "sharesItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "NumberOfRetiredDirectorOptions", "presentation": [ "http://trinitybiotech.com/role/RelatedPartyTransactionsScheduleOfCompanysSharesAndShareOptionPlanDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of options of retired director in share-based payment arrangement.", "label": "Number Of Retired Director Options", "terseLabel": "Options of retired director" } } }, "auth_ref": [] }, "trib_NumberOfRetiredDirectorShares": { "xbrltype": "sharesItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "NumberOfRetiredDirectorShares", "presentation": [ "http://trinitybiotech.com/role/RelatedPartyTransactionsScheduleOfCompanysSharesAndShareOptionPlanDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of retired director in share-based payment arrangement.", "label": "Number Of Retired Director Shares", "terseLabel": "Shares of retired director" } } }, "auth_ref": [] }, "trib_NumberOfRightOfUseLeasedAssets": { "xbrltype": "decimalItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "NumberOfRightOfUseLeasedAssets", "presentation": [ "http://trinitybiotech.com/role/PropertyPlantAndEquipmentScheduleOfIncomeFromSub-lettingRight-of-useBuildingsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of Right-of-Use leased assets.", "label": "Number Of Right Of Use Leased Assets", "terseLabel": "No. of Right-of-Use leased assets" } } }, "auth_ref": [] }, "ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfShareOptionsExercisableInSharebasedPaymentArrangement", "presentation": [ "http://trinitybiotech.com/role/ShareOptionsScheduleOfGrantsOfShareOptionsAndWarrantsDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Exercisable at end of year", "label": "Number of share options exercisable in share-based payment arrangement", "verboseLabel": "Number of Options" } }, "en": { "role": { "documentation": "The number of share options exercisable in a share-based payment arrangement." } } }, "auth_ref": [ "r178", "r369" ] }, "trib_NumberOfShareOptionsExercisableShareBasedPayment": { "xbrltype": "sharesItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "NumberOfShareOptionsExercisableShareBasedPayment", "presentation": [ "http://trinitybiotech.com/role/ShareOptionsSummaryOfRangeOfPricesOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of share options exercisable in a share-based payment arrangement.", "label": "Number Of Share Options Exercisable Share Based Payment", "terseLabel": "Number of options" } } }, "auth_ref": [] }, "ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfShareOptionsExercisedInSharebasedPaymentArrangement", "presentation": [ "http://trinitybiotech.com/role/CapitalAndReservesNarrativeDetails", "http://trinitybiotech.com/role/ShareOptionsScheduleOfGrantsOfShareOptionsAndWarrantsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Exercised", "label": "Number of share options exercised in share-based payment arrangement", "terseLabel": "Ordinary shares issued from exercise of employee share options", "verboseLabel": "Number of share options exercised" } }, "en": { "role": { "documentation": "The number of share options exercised in a share-based payment arrangement." } } }, "auth_ref": [ "r175", "r366" ] }, "ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfShareOptionsExpiredInSharebasedPaymentArrangement", "presentation": [ "http://trinitybiotech.com/role/RelatedPartyTransactionsScheduleOfCompanysSharesAndShareOptionPlanDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Expired / forfeited", "label": "Number of share options expired in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of share options expired in a share-based payment arrangement." } } }, "auth_ref": [ "r176", "r367" ] }, "ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement", "presentation": [ "http://trinitybiotech.com/role/ShareOptionsScheduleOfGrantsOfShareOptionsAndWarrantsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Expired/ Forfeited", "label": "Number of share options forfeited in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of share options forfeited in a share-based payment arrangement." } } }, "auth_ref": [ "r174", "r365" ] }, "ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentArrangement", "presentation": [ "http://trinitybiotech.com/role/RelatedPartyTransactionsScheduleOfCompanysSharesAndShareOptionPlanDetails", "http://trinitybiotech.com/role/ShareOptionsNarrativeDetails", "http://trinitybiotech.com/role/ShareOptionsScheduleOfGrantsOfShareOptionsAndWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Granted", "terseLabel": "Share options granted", "verboseLabel": "Number of share options granted" } }, "en": { "role": { "documentation": "The number of share options granted in a share-based payment arrangement." } } }, "auth_ref": [ "r173", "r364" ] }, "ifrs-full_NumberOfSharesAuthorised": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfSharesAuthorised", "presentation": [ "http://trinitybiotech.com/role/CapitalAndReservesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Authorised share capital" } }, "en": { "role": { "documentation": "The number of shares authorised." } } }, "auth_ref": [ "r283", "r397", "r441" ] }, "trib_NumberOfSharesIssuableExerciseOfWarrantsToPerceptive": { "xbrltype": "sharesItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "NumberOfSharesIssuableExerciseOfWarrantsToPerceptive", "presentation": [ "http://trinitybiotech.com/role/LossPerShareNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issuable on exercise of warrants to perceptive.", "label": "Number Of Shares Issuable Exercise Of Warrants To Perceptive" } } }, "auth_ref": [] }, "trib_NumberOfSharesIssuableOnExerciseOfConversionOptionsToPerceptive": { "xbrltype": "sharesItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "NumberOfSharesIssuableOnExerciseOfConversionOptionsToPerceptive", "presentation": [ "http://trinitybiotech.com/role/LossPerShareScheduleOfDilutedEarningsPerAdsShareCalculationDetails", "http://trinitybiotech.com/role/LossPerShareScheduleOfDilutedEarningsPerOrdinaryShareDetails" ], "lang": { "en-us": { "role": { "label": "Number Of Shares Issuable On Exercise Of Conversion Options To Perceptive", "terseLabel": "Issuable on exercise of conversion options to Perceptive", "documentation": "Number of shares issuable on exercise of conversion options to perceptive." } } }, "auth_ref": [] }, "trib_NumberOfSharesIssuableOnExerciseOfWarrantsToPerceptive": { "xbrltype": "sharesItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "NumberOfSharesIssuableOnExerciseOfWarrantsToPerceptive", "presentation": [ "http://trinitybiotech.com/role/LossPerShareScheduleOfDilutedEarningsPerAdsShareCalculationDetails", "http://trinitybiotech.com/role/LossPerShareScheduleOfDilutedEarningsPerOrdinaryShareDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issuable on exercise of warrants to perceptive.", "label": "Number Of Shares Issuable On Exercise Of Warrants To Perceptive", "terseLabel": "Issuable on exercise of warrants to Perceptive" } } }, "auth_ref": [] }, "trib_NumberOfSharesIssuableOnExerciseOfWarrantsToPerceptiveExercisePricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "NumberOfSharesIssuableOnExerciseOfWarrantsToPerceptiveExercisePricePerShare", "presentation": [ "http://trinitybiotech.com/role/LossPerShareNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issuable on exercise of warrants to perceptive exercise price per share.", "label": "Number Of Shares Issuable On Exercise Of Warrants To Perceptive Exercise Price Per Share", "terseLabel": "Number of shares issuable on exercise of warrants to perceptive exercise price per share" } } }, "auth_ref": [] }, "ifrs-full_NumberOfSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfSharesIssued", "presentation": [ "http://trinitybiotech.com/role/CapitalAndReservesScheduleOfShareCapitalDetails", "http://trinitybiotech.com/role/IMPAIRMENTTRANSFORMATIONANDONCEOFFCOSTSNarrativeDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "At period end", "periodStartLabel": "Number of shares at January 1", "positiveTerseLabel": "Number of ADS at January 1 (Note 18)", "label": "Number of shares issued", "terseLabel": "Number of ADSs issued" } }, "en": { "role": { "documentation": "The number of shares issued by the entity." } } }, "auth_ref": [ "r610" ] }, "trib_NumberOfSharesIssuedOnExerciseOfOptions": { "xbrltype": "sharesItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "NumberOfSharesIssuedOnExerciseOfOptions", "presentation": [ "http://trinitybiotech.com/role/LossPerShareNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued on the exercise of options.", "label": "Number Of Shares Issued On Exercise Of Options", "terseLabel": "Number of shares issued on the exercise of options" } } }, "auth_ref": [] }, "ifrs-full_NumberOfSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfSharesOutstanding", "presentation": [ "http://trinitybiotech.com/role/CapitalAndReservesScheduleOfShareCapitalDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "At period end", "periodStartLabel": "Balance at January 1", "label": "Number of shares outstanding" } }, "en": { "role": { "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]" } } }, "auth_ref": [ "r285", "r399", "r443" ] }, "trib_NumberOfWarrantsRepriced": { "xbrltype": "sharesItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "NumberOfWarrantsRepriced", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of warrants repriced.", "label": "Number Of Warrants Repriced", "terseLabel": "Number of warrants repriced" } } }, "auth_ref": [] }, "ifrs-full_OfficeEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OfficeEquipmentMember", "presentation": [ "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesScheduleOfOwnedAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Office equipment and fittings [Member]" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing equipment used to support office functions, not specifically used in the production process. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r463" ] }, "trib_OnceOffExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "OnceOffExpense", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfOperations": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfOperations" ], "lang": { "en-us": { "role": { "documentation": "It represents the amount of once off items.", "negatedLabel": "Once off items", "label": "Once Off Expense" } } }, "auth_ref": [] }, "trib_OnceOffTaxCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "OnceOffTaxCredit", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/IncomeTaxCreditNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Once-off tax credit.", "label": "Once Off Tax Credit" } } }, "auth_ref": [] }, "trib_OneYearToTwoYearsMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "OneYearToTwoYearsMember", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfInterestRateRiskEffectiveAndRepricingAnalysisDetails", "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfLiquidityRiskEstimatedInterestPaymentsOfMaturitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "1-2 years [Member]", "label": "One Year To Two Years Member", "terseLabel": "1-2 years [Member]" } } }, "auth_ref": [] }, "trib_OpeningSharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "OpeningSharePrice", "presentation": [ "http://trinitybiotech.com/role/ShareOptionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represent the opening share price.", "label": "Opening Share Price", "terseLabel": "Opening share price" } } }, "auth_ref": [] }, "ifrs-full_OperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OperatingExpense", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Operating expenses", "label": "Operating expense", "verboseLabel": "Operating expenses" } } }, "auth_ref": [ "r619" ] }, "trib_OptionsAndWarrantsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "OptionsAndWarrantsAbstract", "presentation": [ "http://trinitybiotech.com/role/ShareOptionsScheduleOfGrantsOfShareOptionsAndWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Options And Warrants Abstract", "terseLabel": "Options and warrants" } } }, "auth_ref": [] }, "ifrs-full_OtherAdjustmentsForNoncashItems": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherAdjustmentsForNoncashItems", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Other non-cash items" } } }, "auth_ref": [ "r602" ] }, "ifrs-full_OtherAdjustmentsToReconcileProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherAdjustmentsToReconcileProfitLoss", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Other adjustments to reconcile profit (loss)", "terseLabel": "Once off items" } } }, "auth_ref": [ "r92" ] }, "trib_OtherAssetNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "OtherAssetNoncurrent", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/OtherNon-currentAssetsDetails": { "parentTag": "ifrs-full_OtherNoncurrentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://trinitybiotech.com/role/OtherNon-currentAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Other remaining assets non current.", "label": "Other Asset Noncurrent", "verboseLabel": "Other assets" } } }, "auth_ref": [] }, "ifrs-full_OtherBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherBorrowings", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfLiquidityRiskEstimatedInterestPaymentsOfMaturitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Other borrowings", "label": "Other borrowings" } }, "en": { "role": { "documentation": "The amount of borrowings that the entity does not separately disclose in the same statement or note. [Refer: Borrowings]" } } }, "auth_ref": [ "r612" ] }, "trib_OtherBorrowingsMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "OtherBorrowingsMember", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfInterestRateRiskEffectiveAndRepricingAnalysisDetails" ], "lang": { "en-us": { "role": { "documentation": "Other borrowings [Member]", "label": "Other borrowings [Member]" } } }, "auth_ref": [] }, "ifrs-full_OtherComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncome", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfComprehensiveIncome": { "parentTag": "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfChangesInEquity", "http://trinitybiotech.com/role/ConsolidatedStatementOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income", "totalLabel": "Other comprehensive (loss)/profit", "verboseLabel": "Other comprehensive income" } } }, "auth_ref": [ "r128", "r413", "r447", "r454" ] }, "ifrs-full_OtherComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeAbstract", "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Other comprehensive loss", "terseLabel": "Other comprehensive (loss)/profit" } } }, "auth_ref": [] }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfComprehensiveIncome": { "parentTag": "ifrs-full_OtherComprehensiveIncome", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Foreign exchange translation differences" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r437", "r454" ] }, "trib_OtherCountriesMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "OtherCountriesMember", "presentation": [ "http://trinitybiotech.com/role/IncomeTaxCreditNarrativeDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfCapitalExpenditureByGeographicalAreaDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfDepreciationAndAmortisationByGeographicalAreaDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfLongLivedAssetsDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfRevenueByGeographicalAreaBasedOnLocationOfAssetsDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfRevenueDerivesFromTransferOfGoodsAndServicesDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfSegmentAssetsAndSegmentLiabilitiesByGeographicalAreaDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfSegmentResultsByGeographicalAreaDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfShareBasedPaymentExpenseByGeographicalAreaDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfTaxationExpenseByGeographicalAreaDetails" ], "lang": { "en-us": { "role": { "documentation": "Other Countries [Member]", "label": "Other Countries [Member]", "verboseLabel": "Other [Member]" } } }, "auth_ref": [] }, "trib_OtherCurrentBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "OtherCurrentBorrowings", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfInterestRateRiskEffectiveAndRepricingAnalysisDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of current payables that the entity does not separately disclose in the same statement or note.", "negatedLabel": "Other borrowings", "label": "Other Current Borrowings", "terseLabel": "Other payables" } } }, "auth_ref": [] }, "ifrs-full_OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Other current borrowings and current portion of other non-current borrowings", "terseLabel": "Senior secured term loan" } }, "en": { "role": { "documentation": "The amount of current other borrowings and the current portion of non-current other borrowings. [Refer: Other borrowings]" } } }, "auth_ref": [ "r612" ] }, "trib_OtherEmployeesMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "OtherEmployeesMember", "presentation": [ "http://trinitybiotech.com/role/ShareOptionsScheduleOfAssumptionDeterminingFairValueOfShareOptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Other employees [Member]", "label": "Other employees [Member]" } } }, "auth_ref": [] }, "trib_OtherEuropeanCountriesMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "OtherEuropeanCountriesMember", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfExposureOfTradeReceivablesByGeographicLocationDetails" ], "lang": { "en-us": { "role": { "documentation": "Other European countries [Member]", "label": "Other European countries [Member]" } } }, "auth_ref": [] }, "ifrs-full_OtherFinanceIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherFinanceIncome", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/OTHEROPERATINGINCOMEEXPENSENarrativeDetails", "http://trinitybiotech.com/role/ProvisionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Other finance income", "terseLabel": "Other finance costs, Credit recognised" } } }, "auth_ref": [ "r612" ] }, "ifrs-full_OtherIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherIncome", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/OTHEROPERATINGINCOMEEXPENSEScheduleofOtherOperatingIncomeDetails": { "parentTag": "ifrs-full_OtherOperatingIncomeExpense", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://trinitybiotech.com/role/OTHEROPERATINGINCOMEEXPENSEScheduleofOtherOperatingIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Other income", "verboseLabel": "Government grants" } } }, "auth_ref": [ "r43", "r530", "r531" ] }, "ifrs-full_OtherIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherIntangibleAssets", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Other intangible assets" } }, "en": { "role": { "documentation": "The amount of intangible assets that the entity does not separately disclose in the same statement or note. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r596" ] }, "ifrs-full_OtherIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherIntangibleAssetsMember", "presentation": [ "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesScheduleOfAmortisationDetails", "http://trinitybiotech.com/role/DeferredTaxAssetsAndLiabilitiesScheduleOfRecognisedDeferredTaxAssetsAndLiabilitiesDetails", "http://trinitybiotech.com/role/DeferredTaxAssetsAndLiabilitiesScheduleOfUnrecognisedDeferredTaxLiabilitiesDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfGoodwillAndIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Intangible assets [Member]", "terseLabel": "Other (including acquired customer and supplier lists) [Member]", "verboseLabel": "Other [Member]" } }, "en": { "role": { "documentation": "This member stands for a class of intangible assets that the entity does not separately disclose in the same statement or note. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r596" ] }, "trib_OtherItemsMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "OtherItemsMember", "presentation": [ "http://trinitybiotech.com/role/DeferredTaxAssetsAndLiabilitiesScheduleOfRecognisedDeferredTaxAssetsAndLiabilitiesDetails", "http://trinitybiotech.com/role/DeferredTaxAssetsAndLiabilitiesScheduleOfUnrecognisedDeferredTaxLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Other item [Member]", "label": "Other items [Member]" } } }, "auth_ref": [] }, "trib_OtherNonCurrentAssets": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "OtherNonCurrentAssets", "lang": { "en-us": { "role": { "label": "Other Non Current Assets" } } }, "auth_ref": [] }, "ifrs-full_OtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherNoncurrentAssets", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/OtherNon-currentAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://trinitybiotech.com/role/OtherNon-currentAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Other non-current assets", "totalLabel": "Total other assets" } }, "en": { "role": { "documentation": "The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]" } } }, "auth_ref": [ "r615" ] }, "ifrs-full_OtherNoncurrentFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherNoncurrentFinancialAssets", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Other assets" } }, "en": { "role": { "documentation": "The amount of non-current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets]" } } }, "auth_ref": [ "r420" ] }, "ifrs-full_OtherOperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherOperatingIncomeExpense", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfOperations": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://trinitybiotech.com/role/OTHEROPERATINGINCOMEEXPENSEScheduleofOtherOperatingIncomeDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://trinitybiotech.com/role/BASISOFPREPARATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://trinitybiotech.com/role/ConsolidatedStatementOfOperations", "http://trinitybiotech.com/role/OTHEROPERATINGINCOMEEXPENSEScheduleofOtherOperatingIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Other operating income (expense)", "terseLabel": "Other operating income/(expense)", "totalLabel": "Other operating income", "verboseLabel": "Other operating income" } } }, "auth_ref": [ "r619" ] }, "trib_OtherOperatingIncomeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "OtherOperatingIncomeLineItems", "presentation": [ "http://trinitybiotech.com/role/OTHEROPERATINGINCOMEEXPENSENarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Line item for Other Operating Income.", "label": "Other Operating Income / (Expense) [Line Items]" } } }, "auth_ref": [] }, "trib_OtherOperatingIncomeTable": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "OtherOperatingIncomeTable", "presentation": [ "http://trinitybiotech.com/role/OTHEROPERATINGINCOMEEXPENSENarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Table of Other Operating Income.", "label": "Other Operating Income [Table]" } } }, "auth_ref": [] }, "trib_OtherProjectsMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "OtherProjectsMember", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfPrincipalDevelopmentProjectsDetails" ], "lang": { "en-us": { "role": { "documentation": "Other Projects with Spend less than US$100,000 in 2016 [Member]", "label": "Other Projects [Member]" } } }, "auth_ref": [] }, "ifrs-full_OtherPropertyPlantAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherPropertyPlantAndEquipmentMember", "presentation": [ "http://trinitybiotech.com/role/DeferredTaxAssetsAndLiabilitiesScheduleOfRecognisedDeferredTaxAssetsAndLiabilitiesDetails", "http://trinitybiotech.com/role/DeferredTaxAssetsAndLiabilitiesScheduleOfUnrecognisedDeferredTaxLiabilitiesDetails", "http://trinitybiotech.com/role/PropertyPlantAndEquipmentScheduleOfAdditionalInformationOnRight-of-useAssetsDetails", "http://trinitybiotech.com/role/PropertyPlantAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentRelatedToAccumulatedDepreciationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plant & Equipment, Vehicles [member]", "label": "Other property, plant and equipment [member]", "verboseLabel": "Other property, plant and equipment [member]" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing property, plant and equipment that the entity does not separately disclose in the same statement or note. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r578" ] }, "ifrs-full_OtherProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherProvisions", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/ProvisionsScheduleOfProvisionsDetails": { "parentTag": "ifrs-full_Provisions", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://trinitybiotech.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://trinitybiotech.com/role/InventoriesScheduleOfMovementOnInventoryProvisionDetails", "http://trinitybiotech.com/role/ProvisionsScheduleOfProvisionsDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Closing provision at December 31", "periodStartLabel": "Opening provision at January 1", "label": "Other provisions", "terseLabel": "Disposal-related warranty settlement provision" } }, "en": { "role": { "documentation": "The amount of provisions other than provisions for employee benefits. [Refer: Provisions]" } } }, "auth_ref": [ "r70", "r339", "r405", "r439" ] }, "ifrs-full_OtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherReceivables", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/TradeAndOtherReceivablesScheduleOfTradeAndOtherReceivablesDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentReceivables", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://trinitybiotech.com/role/TradeAndOtherReceivablesScheduleOfTradeAndOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Other receivables", "terseLabel": "Other receivables" } }, "en": { "role": { "documentation": "The amount receivable by the entity that it does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r527", "r535" ] }, "trib_OtherRegionsMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "OtherRegionsMember", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfExposureOfTradeReceivablesByGeographicLocationDetails", "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfLossProfitBeforeTaxesDetails", "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfNetOperatingLossesDetails", "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfUnrecognisedDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Other regions [Member]", "label": "Other regions [Member]", "verboseLabel": "Other regions [Member]" } } }, "auth_ref": [] }, "ifrs-full_OtherReserves": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherReserves", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Other reserves" } }, "en": { "role": { "documentation": "A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]" } } }, "auth_ref": [ "r529", "r537" ] }, "ifrs-full_OtherReservesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherReservesMember", "presentation": [ "http://trinitybiotech.com/role/CapitalAndReservesNarrativeDetails", "http://trinitybiotech.com/role/ConsolidatedStatementOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Other reserves [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]" } } }, "auth_ref": [ "r287", "r416" ] }, "ifrs-full_OtherRevenue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherRevenue", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/SegmentInformationScheduleOfRevenueByGeographicalAreaBasedOnLocationOfAssetsDetails": { "parentTag": "ifrs-full_Revenue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://trinitybiotech.com/role/SegmentInformationScheduleOfRevenueByGeographicalAreaBasedOnLocationOfAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Inter-segment revenue", "verboseLabel": "Revenue from other sources" } } }, "auth_ref": [ "r612" ] }, "ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome", "calculation": { "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfStatutoryTaxRateDetails": { "parentTag": "ifrs-full_AverageEffectiveTaxRate", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfStatutoryTaxRateDetails" ], "lang": { "en-us": { "role": { "label": "Other items" } }, "en": { "role": { "documentation": "Tax rate effects, in aggregate, on the reconciliation between the average effective tax rate and the applicable tax rate that the entity does not separately disclose in the reconciliation. [Refer: Average effective tax rate; Applicable tax rate]" } } }, "auth_ref": [ "r3", "r309" ] }, "trib_OtherTransformationCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "OtherTransformationCostsMember", "presentation": [ "http://trinitybiotech.com/role/IMPAIRMENTTRANSFORMATIONANDONCEOFFCOSTSScheduleoftransformationcostsincurredduringtheyearDetails" ], "lang": { "en-us": { "role": { "label": "Other Transformation Costs [Member]", "terseLabel": "Other transformation costs [Member]", "documentation": "This member stands for information pertaining to \"Other transformation costs\"" } } }, "auth_ref": [] }, "trib_OutsourcingCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "OutsourcingCostsMember", "presentation": [ "http://trinitybiotech.com/role/IMPAIRMENTTRANSFORMATIONANDONCEOFFCOSTSScheduleoftransformationcostsincurredduringtheyearDetails" ], "lang": { "en-us": { "role": { "documentation": "Outsourcing Costs [Member]", "label": "Outsourcing Costs [Member]", "terseLabel": "Outsourcing costs [Member]" } } }, "auth_ref": [] }, "trib_OutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "OutstandingAbstract", "presentation": [ "http://trinitybiotech.com/role/ShareOptionsSummaryOfRangeOfPricesOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Outstanding Abstract", "terseLabel": "Outstanding" } } }, "auth_ref": [] }, "trib_OverheadCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "OverheadCosts", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents amount of overhead costs.", "label": "Overhead Costs", "terseLabel": "Overhead costs" } } }, "auth_ref": [] }, "ifrs-full_ParValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ParValuePerShare", "presentation": [ "http://trinitybiotech.com/role/CapitalAndReservesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Par value of share" } }, "en": { "role": { "documentation": "The nominal value per share." } } }, "auth_ref": [ "r284", "r398", "r442" ] }, "ifrs-full_PastDueStatusAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PastDueStatusAxis", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfAgeingOfTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Past due status [Axis]", "verboseLabel": "Past due status [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r503" ] }, "ifrs-full_PastDueStatusDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PastDueStatusDomain", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfAgeingOfTradeReceivablesDetails" ], "lang": { "en": { "role": { "documentation": "This member stands for all past-due statuses. It also represents the standard value for the 'Past due status' axis if no other member is used." } } }, "auth_ref": [ "r503" ] }, "trib_PatentDividendSchemeAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "PatentDividendSchemeAmount", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Patent dividend scheme amount.", "label": "Patent dividend scheme amount" } } }, "auth_ref": [] }, "trib_PaycheckProtectionProgramLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "PaycheckProtectionProgramLoanMember", "presentation": [ "http://trinitybiotech.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://trinitybiotech.com/role/IMPAIRMENTTRANSFORMATIONANDONCEOFFCOSTSNarrativeDetails", "http://trinitybiotech.com/role/OTHEROPERATINGINCOMEEXPENSENarrativeDetails", "http://trinitybiotech.com/role/ProvisionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Paycheck Protection Program Loan [Member]", "label": "Paycheck Protection Program Loan [Member]", "terseLabel": "Paycheck Protection Program (PPP) loans" } } }, "auth_ref": [] }, "trib_PaymentInKindInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "PaymentInKindInterest", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/FinancialIncomeAndExpensesScheduleOfFinancialIncomeExpensesNetDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSScheduleOfMovementInTermLoan" ], "lang": { "en-us": { "role": { "documentation": "The amount of interest paid other than in cash for example by issuing additional debt securities.", "negatedLabel": "Payment-in-kind (PIK) Interest", "label": "Payment In Kind Interest" } } }, "auth_ref": [] }, "trib_PaymentOfPenalty": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "PaymentOfPenalty", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of payment penalty.", "label": "Payment Of Penalty", "terseLabel": "Payment of penalty" } } }, "auth_ref": [] }, "trib_PaymentsForCEOServices": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "PaymentsForCEOServices", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Payments for CEO Services.", "label": "Payments For C E O Services", "verboseLabel": "Payments for CEO Services" } } }, "auth_ref": [] }, "ifrs-full_PaymentsForDevelopmentProjectExpenditure": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PaymentsForDevelopmentProjectExpenditure", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/SegmentInformationScheduleOfCapitalExpenditureByGeographicalAreaDetails" ], "lang": { "en-us": { "role": { "label": "Capital expenditure" } }, "en": { "role": { "documentation": "The cash outflow for expenditure related to development projects." } } }, "auth_ref": [ "r599" ] }, "ifrs-full_PaymentsForShareIssueCosts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PaymentsForShareIssueCosts", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Expenses paid in connection with debt financing", "label": "Payments for share issue costs", "terseLabel": "Expenses paid in connection with debt financing" } }, "en": { "role": { "documentation": "The cash outflow for share issue costs." } } }, "auth_ref": [ "r600" ] }, "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows", "http://trinitybiotech.com/role/ReconciliationOfLiabilitiesArisingFromFinancingActivitiesScheduleOfLiabilitiesArisingFromFinancingDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Payment of lease liabilities", "negatedTerseLabel": "Repayment of leases", "label": "Payments of lease liabilities, classified as financing activities" } }, "en": { "role": { "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r480" ] }, "trib_PaymentsToAcquireFinancialAssetClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "PaymentsToAcquireFinancialAssetClassifiedAsInvestingActivities", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The amount represents payments to acquire financial asset classified as investing activities.", "negatedLabel": "Payments to acquire financial asset", "label": "Payments To Acquire Financial Asset Classified As Investing Activities" } } }, "auth_ref": [] }, "trib_PaymentsToAcquireTradesOrBusinessesClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "PaymentsToAcquireTradesOrBusinessesClassifiedAsInvestingActivities", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The amount represents payments to acquire trades or businesses classified as investing activities.", "negatedLabel": "Payments to acquire trades or businesses", "label": "Payments To Acquire Trades Or Businesses Classified As Investing Activities" } } }, "auth_ref": [] }, "trib_PenaltiesPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "PenaltiesPayments", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Penalties payments.", "label": "Penalties payments" } } }, "auth_ref": [] }, "trib_PenaltyForEarlySettlementCharged": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "PenaltyForEarlySettlementCharged", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/ReconciliationOfLiabilitiesArisingFromFinancingActivitiesScheduleOfLiabilitiesArisingFromFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "Penalty for early settlement charged.", "label": "Penalty For Early Settlement Charged", "terseLabel": "Penalty for early settlement charged" } } }, "auth_ref": [] }, "trib_PenaltyForEarlySettlementOfTermLoan": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "PenaltyForEarlySettlementOfTermLoan", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows", "http://trinitybiotech.com/role/FinancialIncomeAndExpensesScheduleOfFinancialIncomeExpensesNetDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount represents penalty for early settlement of term loan.", "label": "Penalty For Early Settlement Of Term Loan", "verboseLabel": "Penalty for early settlement of term loan" } } }, "auth_ref": [] }, "trib_PenaltyPaidForEarlySettlement": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "PenaltyPaidForEarlySettlement", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/ReconciliationOfLiabilitiesArisingFromFinancingActivitiesScheduleOfLiabilitiesArisingFromFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "Represent the Penalty Paid For Early Settlement.", "label": "Penalty Paid For Early Settlement", "terseLabel": "Penalty paid for early settlement of term loan" } } }, "auth_ref": [] }, "trib_PercentageOfGrossInventory1": { "xbrltype": "percentItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "PercentageOfGrossInventory1", "presentation": [ "http://trinitybiotech.com/role/AccountingEstimatesAndJudgementsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of gross inventory.", "label": "Percentage Of Gross Inventory 1", "terseLabel": "Percentage of gross inventory" } } }, "auth_ref": [] }, "ifrs-full_PercentageOfVotingEquityInterestsAcquired": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PercentageOfVotingEquityInterestsAcquired", "presentation": [ "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://trinitybiotech.com/role/CapitalAndReservesNarrativeDetails", "http://trinitybiotech.com/role/FINANCIALASSETSNarrativeDetails", "http://trinitybiotech.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Percentage of voting equity interests acquired", "terseLabel": "Percentage of minority shareholding", "verboseLabel": "Percentage of equity acquired" } }, "en": { "role": { "documentation": "The percentage of voting equity interests acquired in a business combination. [Refer: Total for all business combinations [member]]" } } }, "auth_ref": [ "r186", "r372" ] }, "trib_PerceptiveCreditHoldingsIiiLpMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "PerceptiveCreditHoldingsIiiLpMember", "presentation": [ "http://trinitybiotech.com/role/BASISOFPREPARATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails", "http://trinitybiotech.com/role/PostBalanceSheetEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represent information about the Perceptive Credit Holdings III, LP.", "label": "Perceptive Credit Holdings Iii, Lp [Member]" } } }, "auth_ref": [] }, "trib_PersonnelRelatedCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "PersonnelRelatedCostsMember", "presentation": [ "http://trinitybiotech.com/role/IMPAIRMENTTRANSFORMATIONANDONCEOFFCOSTSScheduleoftransformationcostsincurredduringtheyearDetails" ], "lang": { "en-us": { "role": { "label": "Personnel Related Costs [Member]", "terseLabel": "Personnel related costs [Member]" } } }, "auth_ref": [] }, "trib_PhoenixBioTechCorpMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "PhoenixBioTechCorpMember", "presentation": [ "http://trinitybiotech.com/role/GROUPUNDERTAKINGSDetails" ], "lang": { "en-us": { "role": { "documentation": "Phoenix Bio Tech Corp [Member]", "label": "Phoenix Bio Tech Corp [Member]" } } }, "auth_ref": [] }, "trib_PlantAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "PlantAndEquipmentMember", "presentation": [ "http://trinitybiotech.com/role/PropertyPlantAndEquipmentScheduleOfAdditionalInformationOnRight-of-useAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Plant and Equipment [Member]", "terseLabel": "Plant and equipment [Member]", "documentation": "This member stands for information pertaining to \"Plant and Equipment\"" } } }, "auth_ref": [] }, "trib_PointFivePercentageOfGrossInventoryMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "PointFivePercentageOfGrossInventoryMember", "presentation": [ "http://trinitybiotech.com/role/AccountingEstimatesAndJudgementsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "0.5% of gross inventory [Member]", "label": "Point Five Percentage Of Gross Inventory Member", "terseLabel": "0.5% of gross inventory [Member]" } } }, "auth_ref": [] }, "trib_PointOfCareMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "PointOfCareMember", "presentation": [ "http://trinitybiotech.com/role/SegmentInformationScheduleOfRevenueByMajorProductGroupDetails" ], "lang": { "en-us": { "role": { "documentation": "Point-of-Care [Member]", "label": "Point-of-Care [Member]" } } }, "auth_ref": [] }, "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PostemploymentBenefitExpenseDefinedBenefitPlans", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/EmploymentScheduleOfEmploymentCostsDetails": { "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://trinitybiotech.com/role/EmploymentScheduleOfEmploymentCostsDetails" ], "lang": { "en-us": { "role": { "label": "Pension costs" } } }, "auth_ref": [ "r581", "r583" ] }, "ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PostemploymentBenefitExpenseDefinedContributionPlans", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/EmploymentNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Employees contribution" } } }, "auth_ref": [ "r25", "r321" ] }, "trib_PotentiallyDilutiveInstrumentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "PotentiallyDilutiveInstrumentsAbstract", "presentation": [ "http://trinitybiotech.com/role/LossPerShareScheduleOfDilutedEarningsPerAdsShareCalculationDetails", "http://trinitybiotech.com/role/LossPerShareScheduleOfDilutedEarningsPerOrdinaryShareDetails" ], "lang": { "en-us": { "role": { "label": "Potentially Dilutive Instruments [Abstract]", "terseLabel": "Potentially Dilutive Instruments" } } }, "auth_ref": [] }, "trib_PreTaxDiscountRates": { "xbrltype": "percentItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "PreTaxDiscountRates", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of pre tax discount rates.", "label": "Pre tax discount rates" } } }, "auth_ref": [] }, "trib_PremierInstrumentMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "PremierInstrumentMember", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfPrincipalDevelopmentProjectsDetails" ], "lang": { "en-us": { "role": { "documentation": "Premier Instrument for Haemoglobin A1c Testing [Member]", "label": "Premier Instrument Member", "terseLabel": "Premier Instruments for A1c and haemoglobinopathies testing [Member]" } } }, "auth_ref": [] }, "ifrs-full_Prepayments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Prepayments", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/TradeAndOtherReceivablesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Prepayments (see Note 18)", "verboseLabel": "Prepayments of impairment" } }, "en": { "role": { "documentation": "Receivables that represent amounts paid for goods and services before they have been delivered." } } }, "auth_ref": [ "r527", "r535" ] }, "ifrs-full_PreviouslyStatedMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PreviouslyStatedMember", "presentation": [ "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSDetails", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONDetail5" ], "lang": { "en-us": { "role": { "label": "Previously stated [member]", "terseLabel": "Provisional value" } }, "en": { "role": { "documentation": "This member stands for the information previously stated in the financial statements (ie before retrospective application or retrospective restatement)." } } }, "auth_ref": [ "r106", "r107", "r110", "r299", "r300", "r304", "r411" ] }, "trib_PrimusCorpMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "PrimusCorpMember", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfImpairmentLossDetails" ], "lang": { "en-us": { "role": { "documentation": "Primus Corp [Member]", "label": "Primus Corp [Member]" } } }, "auth_ref": [] }, "trib_PrimusCorporationCguTradeNameMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "PrimusCorporationCguTradeNameMember", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfIntangibleAssetsWithIndefiniteUsefulLivesDetails" ], "lang": { "en-us": { "role": { "documentation": "Primus Corporation CGU Trade Name [Member]", "label": "Primus Corporation CGU Trade Name [Member]" } } }, "auth_ref": [] }, "trib_PrimusCorporationMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "PrimusCorporationMember", "presentation": [ "http://trinitybiotech.com/role/GROUPUNDERTAKINGSDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Primus Corporation.", "label": "Primus Corporation [Member]" } } }, "auth_ref": [] }, "trib_PrincipalActivity": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "PrincipalActivity", "presentation": [ "http://trinitybiotech.com/role/GROUPUNDERTAKINGSDetails" ], "lang": { "en-us": { "role": { "documentation": "Principal activity.", "label": "Principal Activity", "terseLabel": "Principal activity" } } }, "auth_ref": [] }, "trib_PrincipalAmountLoaned": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "PrincipalAmountLoaned", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails2", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSScheduleOfMovementInTermLoan", "http://trinitybiotech.com/role/ReconciliationOfLiabilitiesArisingFromFinancingActivitiesScheduleOfLiabilitiesArisingFromFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "Principal amount loaned.", "negatedLabel": "Principal amount loaned", "positiveLabel": "Principal amount loaned", "label": "Principal Amount Loaned", "negatedTerseLabel": "Loan drawdown under old term loan", "verboseLabel": "Principal amount loaned", "terseLabel": "Loan drawdown under old term loan" } } }, "auth_ref": [] }, "trib_PrincipalDevelopmentProjectsCapitalizedCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "PrincipalDevelopmentProjectsCapitalizedCosts", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfPrincipalDevelopmentProjectsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of principal development projects.", "label": "Principal Development Projects Capitalized Costs", "terseLabel": "Capitalised development costs" } } }, "auth_ref": [] }, "ifrs-full_PrincipalPlaceOfBusiness": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PrincipalPlaceOfBusiness", "presentation": [ "http://trinitybiotech.com/role/GROUPUNDERTAKINGSDetails" ], "lang": { "en-us": { "role": { "label": "Principal place of business", "terseLabel": "Principal Country of incorporation and operation" } }, "en": { "role": { "documentation": "The place where an entity principally conducts operations." } } }, "auth_ref": [ "r282", "r403", "r418" ] }, "ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromBorrowingsClassifiedAsFinancingActivities", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/ReconciliationOfLiabilitiesArisingFromFinancingActivitiesScheduleOfLiabilitiesArisingFromFinancingDetails" ], "lang": { "en-us": { "role": { "positiveLabel": "Proceeds from Paycheck Protection loans", "label": "Proceeds from borrowings, classified as financing activities", "terseLabel": "Proceeds from borrowings", "verboseLabel": "Loan drawdown under new term loan" } }, "en": { "role": { "documentation": "The cash inflow from borrowings obtained. [Refer: Borrowings]" } } }, "auth_ref": [ "r478" ] }, "ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 3.0 }, "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSDetails1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSDetails1" ], "lang": { "en-us": { "role": { "label": "Proceeds from disposal of non-current assets or disposal groups classified as held for sale and discontinued operations", "terseLabel": "Proceeds from sale of business", "totalLabel": "Net cash inflow on date of disposal", "verboseLabel": "Proceeds from sale of business (net of transaction costs)" } }, "en": { "role": { "documentation": "The cash inflow from the disposal of non-current assets or disposal groups classified as held for sale and discontinued operations. [Refer: Discontinued operations [member]; Disposal groups classified as held for sale [member]; Non-current assets or disposal groups classified as held for sale]" } } }, "auth_ref": [ "r599" ] }, "ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/ReconciliationOfLiabilitiesArisingFromFinancingActivitiesScheduleOfLiabilitiesArisingFromFinancingDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from government Covid-19 loan (Note 25)", "terseLabel": "Proceeds from government Covid-19 loan (Note 24)" } }, "en": { "role": { "documentation": "The cash inflow from government grants, classified as financing activities. [Refer: Government [member]; Government grants]" } } }, "auth_ref": [ "r587" ] }, "ifrs-full_ProceedsFromIssueOfOrdinaryShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromIssueOfOrdinaryShares", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/CapitalAndReservesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from issue of ordinary shares" } }, "en": { "role": { "documentation": "The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]" } } }, "auth_ref": [ "r600" ] }, "ifrs-full_ProceedsFromIssuingShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromIssuingShares", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from issuing shares", "terseLabel": "Issue of ordinary share capital including share premium (net of issuance costs)", "verboseLabel": "Shares consideration" } }, "en": { "role": { "documentation": "The cash inflow from issuing shares." } } }, "auth_ref": [ "r477" ] }, "ifrs-full_ProceedsFromNoncurrentBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromNoncurrentBorrowings", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSScheduleOfMovementInTermLoan", "http://trinitybiotech.com/role/ReconciliationOfLiabilitiesArisingFromFinancingActivitiesScheduleOfLiabilitiesArisingFromFinancingDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from non-current borrowings", "terseLabel": "Net proceeds from senior secured term loan", "verboseLabel": "Recognition of new term loan", "negatedLabel": "Initial recognition of new term loan" } }, "en": { "role": { "documentation": "The cash inflow from non-current borrowings obtained. [Refer: Borrowings]" } } }, "auth_ref": [ "r600" ] }, "trib_ProceedsFromSaleOfBusiness": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ProceedsFromSaleOfBusiness", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The cash inflow from sales of business.", "label": "Proceeds From Sale Of Business", "terseLabel": "Proceeds from sale of business", "verboseLabel": "Proceeds from sale of business (net of transaction costs)" } } }, "auth_ref": [] }, "trib_ProceedsFromSharesToBeIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ProceedsFromSharesToBeIssued", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The amount represent of proceeds from shares to be issued.", "label": "Proceeds From Shares To Be Issued", "verboseLabel": "Proceeds from shares to be issued" } } }, "auth_ref": [] }, "ifrs-full_ProductsAndServicesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProductsAndServicesAxis", "presentation": [ "http://trinitybiotech.com/role/SegmentInformationScheduleOfRevenueByMajorProductGroupDetails" ], "lang": { "en-us": { "role": { "label": "Products and services [Axis]", "verboseLabel": "Products and services [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r253", "r492", "r516" ] }, "ifrs-full_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProductsAndServicesDomain", "presentation": [ "http://trinitybiotech.com/role/SegmentInformationScheduleOfRevenueByMajorProductGroupDetails" ], "lang": { "en": { "role": { "documentation": "This member stands for the entity's products and services. It also represents the standard value for the 'Products and services' axis if no other member is used." } } }, "auth_ref": [ "r253", "r492", "r516" ] }, "ifrs-full_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLoss", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "label": "Profit or loss", "totalLabel": "Loss for the year on continuing operations" } }, "en": { "role": { "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r113", "r115", "r246", "r249", "r332", "r361", "r412", "r446", "r489", "r495" ] }, "ifrs-full_ProfitLossAttributableToOwnersOfParent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossAttributableToOwnersOfParent", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfComprehensiveIncome": { "parentTag": "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent", "weight": 1.0, "order": 0.0 }, "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 17.0 }, "http://trinitybiotech.com/role/ConsolidatedStatementOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://trinitybiotech.com/role/BASISOFPREPARATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows", "http://trinitybiotech.com/role/ConsolidatedStatementOfChangesInEquity", "http://trinitybiotech.com/role/ConsolidatedStatementOfComprehensiveIncome", "http://trinitybiotech.com/role/ConsolidatedStatementOfOperations", "http://trinitybiotech.com/role/LossPerShareNarrativeDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfSegmentResultsByGeographicalAreaDetails" ], "lang": { "en-us": { "role": { "netLabel": "Profit/(Loss) after tax for the year", "positiveLabel": "Loss for the period", "label": "Profit (loss), attributable to owners of parent", "terseLabel": "Loss for the year", "totalLabel": "Loss for the year (all attributable to owners of the parent)" } }, "en": { "role": { "documentation": "The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r448" ] }, "ifrs-full_ProfitLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossBeforeTax", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfOperations": { "parentTag": "ifrs-full_IncomeFromContinuingOperationsAttributableToOwnersOfParent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfOperations", "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfLossProfitBeforeTaxesDetails", "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfOverseasTaxJurisdictionsDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfSegmentResultsByGeographicalAreaDetails" ], "lang": { "en-us": { "role": { "positiveLabel": "Loss before taxation \u2013 continuing operations", "label": "Loss before tax", "terseLabel": "Profit/Loss before taxes", "totalLabel": "Loss before tax", "verboseLabel": "Profit/(Loss) before taxation - continuing operations" } } }, "auth_ref": [ "r207", "r512", "r513", "r530", "r531" ] }, "ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/LossPerShareNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Basic earnings per ordinary share for continuing operations" } }, "en": { "role": { "documentation": "The profit (loss) from continuing operations attributable to ordinary equity holders of the parent entity. [Refer: Continuing operations, unless line item indicates otherwise [member]; Profit (loss) from continuing operations]" } } }, "auth_ref": [ "r56" ] }, "ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/LossPerShareNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Diluted earnings per ordinary share for continuing operations" } }, "en": { "role": { "documentation": "The profit (loss) from continuing operations attributable to ordinary equity holders of the parent entity, adjusted for the effects of all dilutive potential ordinary shares. [Refer: Profit (loss) from continuing operations]" } } }, "auth_ref": [ "r56" ] }, "ifrs-full_ProfitLossFromDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossFromDiscontinuedOperations", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSDetails", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Profit (loss) from discontinued operations", "terseLabel": "(Loss)/profit for the year on discontinued operations", "totalLabel": "(Loss)/Profit for the year from discontinued operations", "verboseLabel": "Profit/loss for the year on discontinued operations (Note 8)" } } }, "auth_ref": [ "r127", "r206", "r453", "r457" ] }, "ifrs-full_ProfitLossFromDiscontinuedOperationsAttributableToOrdinaryEquityHoldersOfParentEntity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossFromDiscontinuedOperationsAttributableToOrdinaryEquityHoldersOfParentEntity", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Profit (loss) from discontinued operations attributable to ordinary equity holders of parent entity", "terseLabel": "Basic (loss)/earnings per ordinary share for discontinued operations" } } }, "auth_ref": [ "r56" ] }, "ifrs-full_ProfitLossFromDiscontinuedOperationsAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossFromDiscontinuedOperationsAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Profit (loss) from discontinued operations attributable to ordinary equity holders of parent entity including dilutive effects", "terseLabel": "Diluted (loss)/earnings per ordinary share for discontinued operations" } } }, "auth_ref": [ "r56" ] }, "ifrs-full_ProfitLossFromOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossFromOperatingActivities", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfOperations": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfOperations", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfSegmentResultsByGeographicalAreaDetails" ], "lang": { "en-us": { "role": { "positiveLabel": "Profit from operating activities", "label": "Profit (loss) from operating activities", "terseLabel": "Operating loss", "totalLabel": "Operating loss", "verboseLabel": "Profit from operating activities" } } }, "auth_ref": [ "r466", "r619" ] }, "ifrs-full_ProfitLossOfAcquiree": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossOfAcquiree", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Profit (loss) of acquiree since acquisition date", "terseLabel": "Net loss of acquiree since acquisition date" } }, "en": { "role": { "documentation": "The profit (loss) of the acquiree, since the acquisition date, included in the consolidated statement of comprehensive income. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r195" ] }, "trib_PropertyAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "PropertyAndEquipmentMember", "presentation": [ "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesScheduleOfOwnedAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Plant and equipment [Member]", "label": "Property And Equipment Member", "terseLabel": "Plant and equipment [Member]" } } }, "auth_ref": [] }, "ifrs-full_PropertyDevelopmentAndProjectManagementExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PropertyDevelopmentAndProjectManagementExpense", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Development costs not amortised" } } }, "auth_ref": [ "r619" ] }, "ifrs-full_PropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONDetail5": { "parentTag": "ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners", "weight": 1.0, "order": 1.0 }, "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONDetail5", "http://trinitybiotech.com/role/PropertyPlantAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentRelatedToAccumulatedDepreciationDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Balance at end of year", "periodStartLabel": "Balance at beginning year", "terseLabel": "Property plant & equipment", "label": "Property, plant and equipment", "verboseLabel": "Property, plant & equipment" } }, "en": { "role": { "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]" } } }, "auth_ref": [ "r17", "r319", "r419" ] }, "ifrs-full_PropertyPlantAndEquipmentByOperatingLeaseStatusAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PropertyPlantAndEquipmentByOperatingLeaseStatusAxis", "presentation": [ "http://trinitybiotech.com/role/LeaseLiabilitiesScheduleOfOutstandingInterestBearingLoansAndBorrowingsDetails" ], "lang": { "en-us": { "role": { "label": "Property, plant and equipment by operating lease status [axis]", "terseLabel": "Property, plant and equipment by operating lease status [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r157" ] }, "ifrs-full_PropertyPlantAndEquipmentByOperatingLeaseStatusDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PropertyPlantAndEquipmentByOperatingLeaseStatusDomain", "presentation": [ "http://trinitybiotech.com/role/LeaseLiabilitiesScheduleOfOutstandingInterestBearingLoansAndBorrowingsDetails" ], "lang": { "en-us": { "role": { "label": "Property Plant And Equipment By Operating Lease Status Domain" } }, "en": { "role": { "documentation": "This member stands for all property, plant and equipment when disaggregated by the operating lease status by a lessor. It also represents the standard value for the 'Property, plant and equipment by operating lease status' axis if no other member is used. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r157" ] }, "ifrs-full_PropertyPlantAndEquipmentExpendituresRecognisedForConstructions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PropertyPlantAndEquipmentExpendituresRecognisedForConstructions", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/PropertyPlantAndEquipmentNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Property, plant and equipment under construction" } }, "en": { "role": { "documentation": "The amount of expenditures recognised in the carrying amount of an item of property, plant and equipment in the course of its construction. [Refer: Carrying amount [member]; Property, plant and equipment]" } } }, "auth_ref": [ "r19" ] }, "ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSDetails": { "parentTag": "ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSDetails", "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Property, plant and equipment", "label": "Property, plant and equipment recognised as of acquisition date", "terseLabel": "Property, plant and equipment" } }, "en": { "role": { "documentation": "The amount recognised as of the acquisition date for plant, property and equipment acquired in a business combination. [Refer: Property, plant and equipment; Total for all business combinations [member]]" } } }, "auth_ref": [ "r497", "r499", "r523" ] }, "ifrs-full_ProportionOfOwnershipInterestInSubsidiary": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProportionOfOwnershipInterestInSubsidiary", "presentation": [ "http://trinitybiotech.com/role/GROUPUNDERTAKINGSDetails" ], "lang": { "en-us": { "role": { "label": "Proportion of ownership interest in subsidiary", "terseLabel": "Group % holding" } }, "en": { "role": { "documentation": "The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Total for all subsidiaries [member]]" } } }, "auth_ref": [ "r47", "r50", "r120" ] }, "trib_ProvisionForImpairment": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ProvisionForImpairment", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/FINANCIALASSETSDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of Provision for impairment.", "periodEndLabel": "Provision for impairment At December 31", "periodStartLabel": "Provision for impairment At January 1", "label": "Provision For Impairment", "terseLabel": "Provision for impairment" } } }, "auth_ref": [] }, "trib_ProvisionForInventoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ProvisionForInventoriesMember", "presentation": [ "http://trinitybiotech.com/role/InventoriesScheduleOfMovementOnInventoryProvisionDetails" ], "lang": { "en-us": { "role": { "documentation": "Provision for inventories [Member]", "label": "Provision for inventories [Member]" } } }, "auth_ref": [] }, "ifrs-full_ProvisionForTaxesOtherThanIncomeTaxMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProvisionForTaxesOtherThanIncomeTaxMember", "presentation": [ "http://trinitybiotech.com/role/DeferredTaxAssetsAndLiabilitiesScheduleOfRecognisedDeferredTaxAssetsAndLiabilitiesDetails", "http://trinitybiotech.com/role/DeferredTaxAssetsAndLiabilitiesScheduleOfUnrecognisedDeferredTaxLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Provision for taxes other than income tax [Member]" } }, "en": { "role": { "documentation": "This member stands for a provision for taxes other than income tax. Income taxes include all domestic and foreign taxes which are based on taxable profits. Income taxes also include taxes, such as withholding taxes, which are payable by a subsidiary, associate or joint arrangement on distributions to the reporting entity. [Refer: Classes of other provisions [domain]]" } } }, "auth_ref": [ "r591" ] }, "ifrs-full_ProvisionUsedOtherProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProvisionUsedOtherProvisions", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/InventoriesScheduleOfMovementOnInventoryProvisionDetails", "http://trinitybiotech.com/role/PROVISIONSScheduleofreconciliationofchangesinprovisionsDetails", "http://trinitybiotech.com/role/ProvisionsNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Utilised during the year", "label": "Provision used, other provisions", "terseLabel": "Provision utilised as part of the settlement" } }, "en": { "role": { "documentation": "The amount used (ie incurred and charged against the provision) for other provisions. [Refer: Other provisions]" } } }, "auth_ref": [ "r72", "r341" ] }, "ifrs-full_Provisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Provisions", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/ProvisionsScheduleOfProvisionsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfFairValuesOfFinancialAssetsliabilitiesDetails", "http://trinitybiotech.com/role/IMPAIRMENTTRANSFORMATIONANDONCEOFFCOSTSNarrativeDetails", "http://trinitybiotech.com/role/PROVISIONSScheduleofreconciliationofchangesinprovisionsDetails", "http://trinitybiotech.com/role/ProvisionsNarrativeDetails", "http://trinitybiotech.com/role/ProvisionsScheduleOfProvisionsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Provisions", "label": "Provisions [Default Label]", "totalLabel": "Provisions", "terseLabel": "Recognised provision", "periodStartLabel": "Opening provision at January 1", "periodEndLabel": "Closing provision at December\u00a031" } }, "en": { "role": { "documentation": "The amount of liabilities of uncertain timing or amount, including provisions for employee benefits." } } }, "auth_ref": [ "r427" ] }, "ifrs-full_ProvisionsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProvisionsAbstract", "lang": { "en-us": { "role": { "label": "Provisions [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments to acquire intangible assets", "label": "Purchase of intangible assets, classified as investing activities" } }, "en": { "role": { "documentation": "The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r476" ] }, "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Acquisition of property, plant and equipment", "label": "Purchase of property, plant and equipment, classified as investing activities" } }, "en": { "role": { "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r476" ] }, "trib_PurchaseOfTreasuryShare": { "xbrltype": "sharesItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "PurchaseOfTreasuryShare", "presentation": [ "http://trinitybiotech.com/role/CapitalAndReservesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Treasury shares purchased.", "label": "Purchase Of Treasury Share", "terseLabel": "Treasury shares purchased" } } }, "auth_ref": [] }, "ifrs-full_PurchaseOfTreasuryShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PurchaseOfTreasuryShares", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/CapitalAndReservesScheduleOfShareCapitalDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Shares purchased", "label": "Purchase of treasury shares", "verboseLabel": "Purchased during period" } }, "en": { "role": { "documentation": "The decrease in equity resulting from the purchase of treasury shares. [Refer: Treasury shares]" } } }, "auth_ref": [ "r610" ] }, "ifrs-full_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RangeAxis", "presentation": [ "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesScheduleOfAmortisationDetails", "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesScheduleOfOwnedAssetsDetails", "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfInterestRateRiskEffectiveAndRepricingAnalysisDetails", "http://trinitybiotech.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsNarrativeDetails", "http://trinitybiotech.com/role/LossPerShareNarrativeDetails", "http://trinitybiotech.com/role/PostBalanceSheetEventsDetails", "http://trinitybiotech.com/role/PropertyPlantAndEquipmentScheduleOfIncomeFromSub-lettingRight-of-useBuildingsDetails", "http://trinitybiotech.com/role/ShareOptionsNarrativeDetails", "http://trinitybiotech.com/role/ShareOptionsScheduleOfAssumptionDeterminingFairValueOfShareOptionsDetails", "http://trinitybiotech.com/role/ShareOptionsScheduleOfGrantsOfShareOptionsAndWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Range [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r101", "r140", "r164", "r181", "r296", "r490", "r491", "r607" ] }, "ifrs-full_RangeDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RangeDomain", "presentation": [ "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesScheduleOfAmortisationDetails", "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesScheduleOfOwnedAssetsDetails", "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfInterestRateRiskEffectiveAndRepricingAnalysisDetails", "http://trinitybiotech.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsNarrativeDetails", "http://trinitybiotech.com/role/LossPerShareNarrativeDetails", "http://trinitybiotech.com/role/PostBalanceSheetEventsDetails", "http://trinitybiotech.com/role/PropertyPlantAndEquipmentScheduleOfIncomeFromSub-lettingRight-of-useBuildingsDetails", "http://trinitybiotech.com/role/ShareOptionsNarrativeDetails", "http://trinitybiotech.com/role/ShareOptionsScheduleOfAssumptionDeterminingFairValueOfShareOptionsDetails", "http://trinitybiotech.com/role/ShareOptionsScheduleOfGrantsOfShareOptionsAndWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Range [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used." } } }, "auth_ref": [ "r101", "r140", "r164", "r181", "r296", "r490", "r491", "r607" ] }, "trib_RangesEightOfExercisePricesForOutstandingShareOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "RangesEightOfExercisePricesForOutstandingShareOptionsMember", "presentation": [ "http://trinitybiotech.com/role/ShareOptionsSummaryOfRangeOfPricesOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "US$12.00 -US$17.88 [Member]", "label": "Ranges Eight Of Exercise Prices For Outstanding Share Options Member", "terseLabel": "US$12.00 -US$17.45 [Member]" } } }, "auth_ref": [] }, "trib_RangesFiveOfExercisePricesForOutstandingShareOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "RangesFiveOfExercisePricesForOutstandingShareOptionsMember", "presentation": [ "http://trinitybiotech.com/role/ShareOptionsSummaryOfRangeOfPricesOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "US$2.63-US$3.96 [Member]", "label": "Ranges Five Of Exercise Prices For Outstanding Share Options Member", "terseLabel": "US$1.00-US$1.74 [Member]" } } }, "auth_ref": [] }, "trib_RangesFourOfExercisePricesForOutstandingShareOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "RangesFourOfExercisePricesForOutstandingShareOptionsMember", "presentation": [ "http://trinitybiotech.com/role/ShareOptionsSummaryOfRangeOfPricesOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "US$3.00 -US$4.47 [Member]", "label": "Ranges Four Of Exercise Prices For Outstanding Share Options Member", "terseLabel": "US$3.00 -US$4.36 [Member]", "verboseLabel": "US$20.00-US$25.80 [Member]" } } }, "auth_ref": [] }, "trib_RangesNineOfExercisePricesForOutstandingShareOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "RangesNineOfExercisePricesForOutstandingShareOptionsMember", "presentation": [ "http://trinitybiotech.com/role/ShareOptionsSummaryOfRangeOfPricesOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Ranges Nine Of Exercise Prices For Outstanding Share Options [Member]", "terseLabel": "US$1.00-US$2.05 [Member]" } } }, "auth_ref": [] }, "ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RangesOfExercisePricesForOutstandingShareOptionsAxis", "presentation": [ "http://trinitybiotech.com/role/ShareOptionsSummaryOfRangeOfPricesOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Ranges of exercise prices for outstanding share options [Axis]", "verboseLabel": "Ranges of exercise prices for outstanding share options [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r181" ] }, "ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RangesOfExercisePricesForOutstandingShareOptionsDomain", "presentation": [ "http://trinitybiotech.com/role/ShareOptionsSummaryOfRangeOfPricesOfStockOptionsDetails" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated ranges of exercise prices for outstanding share options that are meaningful for assessing the number and timing of additional shares that may be issued and the cash that may be received upon exercise of those options. It also represents the standard value for the 'Ranges of exercise prices for outstanding share options' axis if no other member is used. [Refer: Range [domain]]" } } }, "auth_ref": [ "r181" ] }, "trib_RangesOneFourOfExercisePricesForOutstandingShareOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "RangesOneFourOfExercisePricesForOutstandingShareOptionsMember", "presentation": [ "http://trinitybiotech.com/role/ShareOptionsSummaryOfRangeOfPricesOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Ranges One Four Of Exercise Prices For Outstanding Share Options [Member]", "terseLabel": "US$12.00 -US$17.45 [Member]" } } }, "auth_ref": [] }, "trib_RangesOneOfExercisePricesForOutstandingShareOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "RangesOneOfExercisePricesForOutstandingShareOptionsMember", "presentation": [ "http://trinitybiotech.com/role/ShareOptionsSummaryOfRangeOfPricesOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Ranges One Of Exercise Prices For Outstanding Share Options [Member]", "terseLabel": "US$0.12-US$0.99 [Member]", "verboseLabel": "US$0.19 - $0.99 [Member]" } } }, "auth_ref": [] }, "trib_RangesOneOfExercisePricesForOutstandingShareOptionsNineToNineteenMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "RangesOneOfExercisePricesForOutstandingShareOptionsNineToNineteenMember", "presentation": [ "http://trinitybiotech.com/role/ShareOptionsSummaryOfRangeOfPricesOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "US$0.19-US$0.99 [Member]", "label": "Ranges One Of Exercise Prices For Outstanding Share Options Nine To Nineteen Member", "terseLabel": "US$0.19-US$0.99 [Member]" } } }, "auth_ref": [] }, "trib_RangesOneOneOfExercisePricesForOutstandingShareOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "RangesOneOneOfExercisePricesForOutstandingShareOptionsMember", "presentation": [ "http://trinitybiotech.com/role/ShareOptionsSummaryOfRangeOfPricesOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Ranges One One Of Exercise Prices For Outstanding Share Options [Member]", "verboseLabel": "US$3.00 -US$4.36 [Member]" } } }, "auth_ref": [] }, "trib_RangesOneThreeOfExercisePricesForOutstandingShareOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "RangesOneThreeOfExercisePricesForOutstandingShareOptionsMember", "presentation": [ "http://trinitybiotech.com/role/ShareOptionsSummaryOfRangeOfPricesOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Ranges One Three Of Exercise Prices For Outstanding Share Options [Member]", "verboseLabel": "US$8.24- US$11.96 [Member]" } } }, "auth_ref": [] }, "trib_RangesOneTwoOfExercisePricesForOutstandingShareOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "RangesOneTwoOfExercisePricesForOutstandingShareOptionsMember", "presentation": [ "http://trinitybiotech.com/role/ShareOptionsSummaryOfRangeOfPricesOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Ranges One Two Of Exercise Prices For Outstanding Share Options [Member]", "terseLabel": "US$4.00-US$8.20 [Member]" } } }, "auth_ref": [] }, "trib_RangesOneZeroOfExercisePricesForOutstandingShareOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "RangesOneZeroOfExercisePricesForOutstandingShareOptionsMember", "presentation": [ "http://trinitybiotech.com/role/ShareOptionsSummaryOfRangeOfPricesOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Ranges One Zero Of Exercise Prices For Outstanding Share Options [Member]", "terseLabel": "US$2.06- US$2.99 [Member]" } } }, "auth_ref": [] }, "trib_RangesSevenOfExercisePricesForOutstandingShareOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "RangesSevenOfExercisePricesForOutstandingShareOptionsMember", "presentation": [ "http://trinitybiotech.com/role/ShareOptionsSummaryOfRangeOfPricesOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "US$8.24- US$11.96 [Member]", "label": "Ranges Seven Of Exercise Prices For Outstanding Share Options Member", "terseLabel": "US$35.00- US$48.60 [Member]" } } }, "auth_ref": [] }, "trib_RangesSixOfExercisePricesForOutstandingShareOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "RangesSixOfExercisePricesForOutstandingShareOptionsMember", "presentation": [ "http://trinitybiotech.com/role/ShareOptionsSummaryOfRangeOfPricesOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "US$4.00-US$8.20 [Member]", "label": "Ranges Six Of Exercise Prices For Outstanding Share Options Member", "terseLabel": "US$20.00-US$34.80 [Member]" } } }, "auth_ref": [] }, "trib_RangesThreeOfExercisePricesForOutstandingShareOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "RangesThreeOfExercisePricesForOutstandingShareOptionsMember", "presentation": [ "http://trinitybiotech.com/role/ShareOptionsSummaryOfRangeOfPricesOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "US$2.06- US$2.99 [Member]", "label": "Ranges Three Of Exercise Prices For Outstanding Share Options Member", "terseLabel": "US$1.75- US$2.43 [Member]", "verboseLabel": "US$2.40-US$19.80 [Member]" } } }, "auth_ref": [] }, "trib_RangesTwoOfExercisePricesForOutstandingShareOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "RangesTwoOfExercisePricesForOutstandingShareOptionsMember", "presentation": [ "http://trinitybiotech.com/role/ShareOptionsSummaryOfRangeOfPricesOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "US$1.00-US$2.05 [Member]", "label": "Ranges Two Of Exercise Prices For Outstanding Share Options Member", "terseLabel": "US$1.00-US$1.29 [Member]" } } }, "auth_ref": [] }, "trib_RateOfRentPerSqureFoot": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "RateOfRentPerSqureFoot", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Rate of rent per squre foot.", "label": "Rate of rent per squre foot" } } }, "auth_ref": [] }, "trib_RayvilleLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "RayvilleLimitedMember", "presentation": [ "http://trinitybiotech.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Rayville Limited [Member]", "label": "Rayville Limited [Member]" } } }, "auth_ref": [] }, "trib_ReceivablesFromConsiderationDueSaleOfBusiness": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ReceivablesFromConsiderationDueSaleOfBusiness", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/TradeAndOtherReceivablesScheduleOfTradeAndOtherReceivablesDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentReceivables", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://trinitybiotech.com/role/TradeAndOtherReceivablesScheduleOfTradeAndOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represent the amount of Consideration due from sale of business", "label": "Receivables From Consideration Due Sale Of Business", "terseLabel": "Consideration due from sale of business" } } }, "auth_ref": [] }, "ifrs-full_ReceivablesFromContractsWithCustomers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ReceivablesFromContractsWithCustomers", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/SegmentInformationScheduleOfRevenueDerivesFromTransferOfGoodsAndServicesDetails" ], "lang": { "en-us": { "role": { "label": "Total" } }, "en": { "role": { "documentation": "The amount of an entity\u2019s right to consideration in exchange for goods or services that the entity has transferred to a customer that is unconditional. A right to consideration is unconditional if only the passage of time is required before payment of that consideration is due." } } }, "auth_ref": [ "r141", "r144", "r263" ] }, "ifrs-full_ReceivablesFromContractsWithCustomersAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ReceivablesFromContractsWithCustomersAbstract", "presentation": [ "http://trinitybiotech.com/role/SegmentInformationScheduleOfRevenueDerivesFromTransferOfGoodsAndServicesDetails" ], "lang": { "en-us": { "role": { "label": "Timing of revenue recognition" } } }, "auth_ref": [] }, "trib_ReceivablesOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ReceivablesOutstanding", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The amounts represents receivables outstanding.", "label": "Receivables Outstanding", "terseLabel": "Outstanding receivables" } } }, "auth_ref": [] }, "trib_ReclassificationGoodwillAndIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ReclassificationGoodwillAndIntangibleAssets", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfGoodwillAndIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Reclassification.", "label": "Reclassification Goodwill And Intangible Assets", "terseLabel": "Reclassification" } } }, "auth_ref": [] }, "trib_ReconciliationToWeightedAverageEarningsPerShareDenominatorAbstract": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ReconciliationToWeightedAverageEarningsPerShareDenominatorAbstract", "presentation": [ "http://trinitybiotech.com/role/LossPerShareScheduleOfBasicEarningsPerOrdinaryShareDetails", "http://trinitybiotech.com/role/LossPerShareScheduleOfEarningsPerAdsDetails" ], "lang": { "en-us": { "role": { "label": "Reconciliation To Weighted Average Earnings Per Share Denominator Abstract", "terseLabel": "Reconciliation to weighted average (loss)/earnings per share denominator:", "verboseLabel": "Reconciliation to weighted average (loss)/earnings per ADS denominator:" } } }, "auth_ref": [] }, "ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019": { "xbrltype": "durationItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019", "presentation": [ "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Remaining amortisation period of intangible assets material to entity", "terseLabel": "Intangible asset amortization period" } } }, "auth_ref": [ "r81", "r350" ] }, "trib_RemainingTermInYears": { "xbrltype": "durationItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "RemainingTermInYears", "presentation": [ "http://trinitybiotech.com/role/PropertyPlantAndEquipmentScheduleOfIncomeFromSub-lettingRight-of-useBuildingsDetails" ], "lang": { "en-us": { "role": { "documentation": "Remaining term of right of use assets in years.", "label": "Remaining Term In Years", "terseLabel": "Range of remaining term in years" } } }, "auth_ref": [] }, "trib_RemeasurementLossRecognizedInProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "RemeasurementLossRecognizedInProfitLoss", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/FINANCIALASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "It represents remeasurement loss recognized in profit loss.", "label": "Remeasurement Loss Recognized In Profit Loss", "verboseLabel": "Remeasurement loss recognized in profit loss" } } }, "auth_ref": [] }, "trib_RemeasurementOfRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "RemeasurementOfRightOfUseAssets", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/ReconciliationOfLiabilitiesArisingFromFinancingActivitiesScheduleOfLiabilitiesArisingFromFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of remeasurement of ROU assets.", "label": "Remeasurement Of Right Of Use Assets", "terseLabel": "Remeasurement of ROU assets" } } }, "auth_ref": [] }, "trib_RentalIncomeFromPremises": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "RentalIncomeFromPremises", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/OTHEROPERATINGINCOMEEXPENSEScheduleofOtherOperatingIncomeDetails": { "parentTag": "ifrs-full_OtherOperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://trinitybiotech.com/role/OTHEROPERATINGINCOMEEXPENSEScheduleofOtherOperatingIncomeDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of rental income from premises.", "label": "Rental income from premises" } } }, "auth_ref": [] }, "ifrs-full_RepaymentsOfBondsNotesAndDebentures": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RepaymentsOfBondsNotesAndDebentures", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/ReconciliationOfLiabilitiesArisingFromFinancingActivitiesScheduleOfLiabilitiesArisingFromFinancingDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of exchangeable notes", "negatedTerseLabel": "Repayment of exchangeable notes", "label": "Repayments of bonds, notes and debentures", "verboseLabel": "Purchase of exchangeable notes" } }, "en": { "role": { "documentation": "The cash outflow for repayments of bonds, notes and debentures." } } }, "auth_ref": [ "r600" ] }, "ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RepaymentsOfBorrowingsClassifiedAsFinancingActivities", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails1", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSScheduleOfMovementInTermLoan", "http://trinitybiotech.com/role/ReconciliationOfLiabilitiesArisingFromFinancingActivitiesScheduleOfLiabilitiesArisingFromFinancingDetails" ], "lang": { "en-us": { "role": { "disclosureGuidance": "Debt issued/repaid", "negatedLabel": "Repayment", "negatedTerseLabel": "Repayment of term loan", "positiveLabel": "Cash repayment of principal", "positiveTerseLabel": "Debt retired / repaid", "label": "Repayments of borrowings, classified as financing activities", "terseLabel": "Repayment of term loan", "verboseLabel": "Repaid to Note holders" } }, "en": { "role": { "documentation": "The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]" } } }, "auth_ref": [ "r479" ] }, "ifrs-full_RepaymentsOfCurrentBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RepaymentsOfCurrentBorrowings", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://trinitybiotech.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Repayments of borrowings" } }, "en": { "role": { "documentation": "The cash outflow for repayments of current borrowings. [Refer: Current borrowings]" } } }, "auth_ref": [ "r600" ] }, "ifrs-full_RepaymentsOfNoncurrentBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RepaymentsOfNoncurrentBorrowings", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfCashFlows", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSScheduleOfMovementInTermLoan", "http://trinitybiotech.com/role/ReconciliationOfLiabilitiesArisingFromFinancingActivitiesScheduleOfLiabilitiesArisingFromFinancingDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Repayment of senior secured term loan", "negatedTerseLabel": "Extinguishment of old term loan", "label": "Extinguishment of old loan (IFRS 9 derecognition)", "terseLabel": "Repayment of senior secured term loan" } }, "en": { "role": { "documentation": "The cash outflow for repayments of non-current borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r600" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://trinitybiotech.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "auth_ref": [] }, "ifrs-full_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfOperations": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Research and development expenses", "label": "Research and development expense" } } }, "auth_ref": [ "r83", "r352" ] }, "trib_ResearchAndDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ResearchAndDevelopmentMember", "presentation": [ "http://trinitybiotech.com/role/EmploymentScheduleOfAverageNumberOfPersonsEmployedDetails" ], "lang": { "en-us": { "role": { "documentation": "Research and development [Member]", "label": "Research and development [Member]" } } }, "auth_ref": [] }, "ifrs-full_ReserveOfCashFlowHedges": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ReserveOfCashFlowHedges", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/CapitalAndReservesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Reserve of cash flow hedges" } }, "en": { "role": { "documentation": "A component of equity representing the accumulated portion of gain (loss) on a hedging instrument that is determined to be an effective hedge for cash flow hedges. [Refer: Cash flow hedges [member]]" } } }, "auth_ref": [ "r258", "r617" ] }, "ifrs-full_ReserveOfCashFlowHedgesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ReserveOfCashFlowHedgesMember", "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Hedging reserves [Member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing the accumulated portion of gain (loss) on a hedging instrument that is determined to be an effective hedge for cash flow hedges. [Refer: Cash flow hedges [member]]" } } }, "auth_ref": [ "r258", "r532" ] }, "ifrs-full_ReserveOfEquityComponentOfConvertibleInstruments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ReserveOfEquityComponentOfConvertibleInstruments", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/CapitalAndReservesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Reserve of equity component of convertible instruments", "terseLabel": "Equity component of the convertible note" } }, "en": { "role": { "documentation": "A component of equity representing components of convertible instruments classified as equity." } } }, "auth_ref": [ "r615" ] }, "ifrs-full_ReserveOfExchangeDifferencesOnTranslation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ReserveOfExchangeDifferencesOnTranslation", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Translation reserve" } }, "en": { "role": { "documentation": "A component of equity representing exchange differences on translation of financial statements recognised in other comprehensive income and accumulated in equity. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r31", "r324" ] }, "ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ReserveOfExchangeDifferencesOnTranslationMember", "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Translation reserve [Member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing accumulated exchange differences on the translation of financial statements recognised in other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r31", "r324", "r532" ] }, "ifrs-full_RestatedMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RestatedMember", "presentation": [ "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSDetails", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONDetail5" ], "lang": { "en-us": { "role": { "label": "Currently stated [member]" } }, "en": { "role": { "documentation": "This member stands for the information currently stated in the financial statements. It also represents the standard value for the 'Retrospective application and retrospective restatement' and 'Departure from requirement of IFRS' axes if no other member is used." } } }, "auth_ref": [ "r106", "r107", "r110", "r163", "r299", "r300", "r304", "r411", "r614" ] }, "trib_RestructuringActivitiesExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "RestructuringActivitiesExpense", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/IMPAIRMENTTRANSFORMATIONANDONCEOFFCOSTSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Restructuring Activities Expense", "negatedLabel": "Total restructuring costs", "label": "Restructuring Activities Expense", "terseLabel": "Total restructuring costs", "verboseLabel": "Restructuring cost" } } }, "auth_ref": [] }, "trib_RestructuringCost": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "RestructuringCost", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/PropertyPlantAndEquipmentNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represent the amount of restructuring costs.", "negatedLabel": "Selling, general and administrative expenses \u2013 Restructuring costs", "label": "Restructuring Cost", "terseLabel": "Restructuring Costs", "verboseLabel": "Restructuring Costs" } } }, "auth_ref": [] }, "ifrs-full_RestructuringProvisionMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RestructuringProvisionMember", "presentation": [ "http://trinitybiotech.com/role/ProvisionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring provision [member]", "verboseLabel": "Fitzgerald Industries" } }, "en": { "role": { "documentation": "This member stands for a provision for restructuring, such as the sale or termination of a line of business; closure of business locations in a country or region or relocation of activities from one country or region to another; changes in management structure; and fundamental reorganisations that have a material effect on the nature and focus of the entity's operations. [Refer: Classes of other provisions [domain]]" } } }, "auth_ref": [ "r468" ] }, "trib_ResultAfterExceptionalExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ResultAfterExceptionalExpenses", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/SegmentInformationScheduleOfSegmentResultsByGeographicalAreaDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of after exceptional expenses.", "negatedLabel": "Result after impairment", "label": "Result After Exceptional Expenses" } } }, "auth_ref": [] }, "trib_ResultBeforeExceptionalExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ResultBeforeExceptionalExpenses", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/SegmentInformationScheduleOfSegmentResultsByGeographicalAreaDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of before exceptional expenses.", "negatedLabel": "Result before impairment and unallocated expenses", "label": "Result Before Exceptional Expenses" } } }, "auth_ref": [] }, "ifrs-full_RetainedEarnings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RetainedEarnings", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "negatedLabel": "Retaining earnings", "label": "Accumulated surplus", "terseLabel": "Accumulated deficit" } }, "en": { "role": { "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit." } } }, "auth_ref": [ "r529", "r537", "r538" ] }, "ifrs-full_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RetainedEarningsMember", "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Accumulated surplus [Member]", "terseLabel": "Accumulated (deficit)/surplus [Member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit." } } }, "auth_ref": [ "r416", "r532" ] }, "ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RetrospectiveApplicationAndRetrospectiveRestatementAxis", "presentation": [ "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSDetails", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONDetail5" ], "lang": { "en-us": { "role": { "label": "Retrospective application and retrospective restatement [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r106", "r107", "r110", "r299", "r300", "r304", "r411" ] }, "ifrs-full_RevaluationIncreaseDecreasePropertyPlantAndEquipmentIncludingRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RevaluationIncreaseDecreasePropertyPlantAndEquipmentIncludingRightofuseAssets", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/PropertyPlantAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentRelatedToAccumulatedDepreciationDetails" ], "lang": { "en-us": { "role": { "label": "Revaluation increase (decrease), property, plant and equipment including right-of-use assets", "verboseLabel": "Remeasurement of ROU assets" } }, "en": { "role": { "documentation": "The increase (decrease) in property, plant and equipment including right-of-use assets resulting from revaluations to fair value. [Refer: Property, plant and equipment including right-of-use assets; Revaluation surplus]" } } }, "auth_ref": [ "r580" ] }, "ifrs-full_Revenue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Revenue", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfOperations": { "parentTag": "ifrs-full_GrossProfit", "weight": 1.0, "order": 0.0 }, "http://trinitybiotech.com/role/SegmentInformationScheduleOfRevenueByGeographicalAreaBasedOnLocationOfAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfOperations", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfAmountRelatingFromRevenueDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfRevenueByGeographicalAreaBasedOnLocationOfAssetsDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfRevenueByMajorProductGroupDetails" ], "lang": { "en-us": { "role": { "label": "Revenue", "terseLabel": "Total revenue", "totalLabel": "Total revenue", "verboseLabel": "Revenues" } } }, "auth_ref": [ "r126", "r207", "r242", "r248", "r253", "r254", "r256", "r450", "r489", "r530", "r531" ] }, "ifrs-full_RevenueFromContractsWithCustomers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RevenueFromContractsWithCustomers", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/SegmentInformationScheduleOfRevenueByGeographicalAreaBasedOnLocationOfAssetsDetails": { "parentTag": "ifrs-full_Revenue", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://trinitybiotech.com/role/SegmentInformationScheduleOfAmountRelatingFromRevenueDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfRevenueByCustomersGeographicalAreaDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfRevenueByGeographicalAreaBasedOnLocationOfAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Revenue from external customers", "verboseLabel": "Revenue from contracts with customers (a)" } } }, "auth_ref": [ "r142", "r143", "r262" ] }, "ifrs-full_RevenueFromGovernmentGrants": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RevenueFromGovernmentGrants", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/OTHEROPERATINGINCOMEEXPENSEScheduleofOtherOperatingIncomeDetails": { "parentTag": "ifrs-full_OtherOperatingIncomeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://trinitybiotech.com/role/OTHEROPERATINGINCOMEEXPENSEScheduleofOtherOperatingIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Income from government grants", "terseLabel": "Government grants" } } }, "auth_ref": [ "r588" ] }, "trib_ReversalOfImpairmentLossOnFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ReversalOfImpairmentLossOnFinancialAssets", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/FINANCIALASSETSDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of reversal of impairment loss on financial assets.", "label": "Reversal Of Impairment Loss On Financial Assets", "verboseLabel": "Reversal of impairment in the current year" } } }, "auth_ref": [] }, "trib_ReversalOfNetOperatingLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ReversalOfNetOperatingLoss", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfChargeForTaxDetails" ], "lang": { "en-us": { "role": { "documentation": "Origination and reversal of net operating losses.", "label": "Reversal Of Net Operating Loss", "terseLabel": "Origination and reversal of net operating losses (see Note 14)" } } }, "auth_ref": [] }, "trib_RevertsMinimumLiquidityCovenant": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "RevertsMinimumLiquidityCovenant", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/BASISOFPREPARATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represent the amount of reverts minimum liquidity covenant", "label": "Reverts Minimum Liquidity Covenant" } } }, "auth_ref": [] }, "trib_RightOfUseAssetsImpairmentAdjustmentOnTransition": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "RightOfUseAssetsImpairmentAdjustmentOnTransition", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/PropertyPlantAndEquipmentNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Right-of-use assets, Impairment adjustment on transition.", "negatedLabel": "Impairment adjustment on transition", "label": "Right Of Use Assets Impairment Adjustment On Transition", "terseLabel": "Right-of-use assets, Impairment adjustment on transition" } } }, "auth_ref": [] }, "trib_RightOfUseAssetsIncludingDepreciationAndImpairment": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "RightOfUseAssetsIncludingDepreciationAndImpairment", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/PropertyPlantAndEquipmentScheduleOfAdditionalInformationOnRight-of-useAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Right-of-use assets including depreciation and impairment.", "label": "Right Of Use Assets Including Depreciation And Impairment", "verboseLabel": "Right-of-use assets" } } }, "auth_ref": [] }, "ifrs-full_RightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RightofuseAssets", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/PropertyPlantAndEquipmentNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Right-of-use assets", "verboseLabel": "Right-of-use assets" } }, "en": { "role": { "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee." } } }, "auth_ref": [ "r146", "r153", "r269" ] }, "country_SE": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2025", "localname": "SE", "presentation": [ "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONDetail5", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSDetails", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSDetails1", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSDetails3", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Sweden [Member]" } } }, "auth_ref": [] }, "currency_SEK": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2025", "localname": "SEK", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfForeignCurrencyRiskShortTermFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "SEK [Member]" } } }, "auth_ref": [] }, "trib_SaleAndLeasebackLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "SaleAndLeasebackLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/LeaseLiabilitiesScheduleOfCarryingValuesOfFinanceLeaseLiabilitiesDetails": { "parentTag": "trib_CurrentFinanceLeaseLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://trinitybiotech.com/role/LeaseLiabilitiesScheduleOfCarryingValuesOfFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Sale and leaseback liabilities current.", "label": "Sale And Leaseback Liabilities Current", "terseLabel": "Sale and leaseback liabilities" } } }, "auth_ref": [] }, "trib_SaleAndLeasebackLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "SaleAndLeasebackLiabilitiesMember", "presentation": [ "http://trinitybiotech.com/role/LeaseLiabilitiesScheduleOfFinanceLeaseLiabilitiesPayableDetails" ], "lang": { "en-us": { "role": { "documentation": "Sale and leaseback liabilities [Member]", "label": "Sale And Leaseback Liabilities Member", "verboseLabel": "Sale and leaseback liabilities [Member]" } } }, "auth_ref": [] }, "trib_SaleOfFitzgeraldIndustriesMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "SaleOfFitzgeraldIndustriesMember", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Sale Of Fitzgerald Industries [Member]", "label": "Sale Of Fitzgerald Industries [Member]", "terseLabel": "Sale of Fitzgerald Industries [Member]" } } }, "auth_ref": [] }, "trib_SatisfiedByAbstract": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "SatisfiedByAbstract", "presentation": [ "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSDetails" ], "lang": { "en-us": { "role": { "label": "Satisfied By [Abstract]", "terseLabel": "Satisfied by:" } } }, "auth_ref": [] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "ScenarioForecastMember", "presentation": [ "http://trinitybiotech.com/role/BASISOFPREPARATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]" } } }, "auth_ref": [] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://trinitybiotech.com/role/BASISOFPREPARATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "auth_ref": [] }, "trib_ScheduleOfAdditionalInformationOnRightOfUseAssets": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ScheduleOfAdditionalInformationOnRightOfUseAssets", "presentation": [ "http://trinitybiotech.com/role/PropertyPlantAndEquipmentTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of additional information on the right-of-use assets.", "label": "Schedule Of Additional Information On Right Of Use Assets" } } }, "auth_ref": [] }, "trib_ScheduleOfIncomeFromSubLettingRightOfUseBuildings": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ScheduleOfIncomeFromSubLettingRightOfUseBuildings", "presentation": [ "http://trinitybiotech.com/role/PropertyPlantAndEquipmentTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of income from sub-letting right-of-use buildings.", "label": "Schedule Of Income From Sub Letting Right Of Use Buildings", "terseLabel": "Schedule of Income From Sub-Letting Right-of-Use Buildings" } } }, "auth_ref": [] }, "trib_ScheduleOfMovementInTermLoanExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ScheduleOfMovementInTermLoanExplanatoryTableTextBlock", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about movement in the term loan.", "label": "Schedule Of Movement In Term Loan Explanatory [Table Text Block]", "terseLabel": "Schedule Of Movement In Term Loan" } } }, "auth_ref": [] }, "trib_ScheduleOfReconciliationOfChangesInProvisionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ScheduleOfReconciliationOfChangesInProvisionsTableTextBlock", "presentation": [ "http://trinitybiotech.com/role/ProvisionsTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of reconciliation of changes in provisions.", "terseLabel": "Schedule of reconciliation of changes in provisions", "label": "Schedule Of Reconciliation of Changes in Provisions [Table Text Block]" } } }, "auth_ref": [] }, "trib_ScheduleOfShareBasedPaymentExpenseByGeographicalArea": { "xbrltype": "textBlockItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ScheduleOfShareBasedPaymentExpenseByGeographicalArea", "presentation": [ "http://trinitybiotech.com/role/SegmentInformationTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about share based payment expenses by geographical area.", "label": "Schedule Of Share Based Payment Expense By Geographical Area", "terseLabel": "Schedule Of Share Based Payment Expense By Geographical Area" } } }, "auth_ref": [] }, "ifrs-full_SecuredBankLoansReceived": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SecuredBankLoansReceived", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfInterestRateProfileOfFinancialAssetsliabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Secured bank loans received", "negatedLabel": "Variable rate financial liabilities (senior secured term loan)" } }, "en": { "role": { "documentation": "The amount of loans received from banks that have been secured by collateral. [Refer: Loans received]" } } }, "auth_ref": [ "r612" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "Security12bTitle", "presentation": [ "http://trinitybiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r540" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SecurityExchangeName", "presentation": [ "http://trinitybiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r542" ] }, "trib_SegmentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "SegmentAssets", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/SegmentInformationScheduleOfSegmentAssetsAndSegmentLiabilitiesByGeographicalAreaDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of segment assets.", "label": "Segment assets" } } }, "auth_ref": [] }, "trib_SegmentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "SegmentLiabilities", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/SegmentInformationScheduleOfSegmentAssetsAndSegmentLiabilitiesByGeographicalAreaDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of segment liabilities.", "label": "Segment liabilities" } } }, "auth_ref": [] }, "trib_SellingGeneralAdministrationExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "SellingGeneralAdministrationExpensesAbstract", "presentation": [ "http://trinitybiotech.com/role/IMPAIRMENTTRANSFORMATIONANDONCEOFFCOSTSScheduleofStatementofOperationDetails" ], "lang": { "en-us": { "role": { "label": "Selling General Administration Expenses Abstract", "terseLabel": "Selling, general & administration expenses" } } }, "auth_ref": [] }, "ifrs-full_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfOperations": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Selling, general and administrative expenses", "label": "Selling, general and administrative expense" } } }, "auth_ref": [ "r619" ] }, "trib_SellingGeneralAndAdministrativeExpensesClosureCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "SellingGeneralAndAdministrativeExpensesClosureCosts", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfOperations": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://trinitybiotech.com/role/LossBeforeTaxNarrativeDetails", "http://trinitybiotech.com/role/LossBeforeTaxScheduleOfAmountChargedToStatementOfOperationDetails" ], "lang": { "en-us": { "role": { "documentation": "Selling, general and administrative expenses - closure costs.", "negatedLabel": "Selling, general and administrative expenses - closure costs", "negatedTerseLabel": "Amount of charge for closing facility", "label": "Selling General And Administrative Expenses Closure Costs", "terseLabel": "Selling, General and Administrative Expenses \u2013 Closure Costs" } } }, "auth_ref": [] }, "trib_SellingGeneralAndAdministrativeExpensesTransformationCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "SellingGeneralAndAdministrativeExpensesTransformationCosts", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfOperations": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfOperations", "http://trinitybiotech.com/role/IMPAIRMENTTRANSFORMATIONANDONCEOFFCOSTSNarrativeDetails", "http://trinitybiotech.com/role/IMPAIRMENTTRANSFORMATIONANDONCEOFFCOSTSScheduleoftransformationcostsincurredduringtheyearDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfSegmentResultsByGeographicalAreaDetails" ], "lang": { "en-us": { "role": { "label": "Selling General And Administrative Expenses Transformation Costs", "terseLabel": "Selling, general and administrative expenses \u2013 Transformation costs", "documentation": "It Represents the selling, general and administrative expenses - transformation costs.", "verboseLabel": "Total Transformation costs", "negatedLabel": "Selling, general and administrative expenses \u2013 Transformation costs", "negatedTerseLabel": "Selling, general and administrative expenses \u2013 Transformation costs" } } }, "auth_ref": [] }, "trib_SeniorSecuredTermLoanAnnualRate": { "xbrltype": "percentItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "SeniorSecuredTermLoanAnnualRate", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents about senior secured term loan annual rate.", "label": "Senior Secured Term Loan Annual Rate", "terseLabel": "Senior secured term loan annual rate" } } }, "auth_ref": [] }, "trib_SeniorSecuredTermLoanCreditFacilityOneMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "SeniorSecuredTermLoanCreditFacilityOneMember", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "senior secured term loan credit facility one [Member]", "label": "Senior Secured Term Loan Credit Facility One [Member]", "terseLabel": "Amended and restated senior secured term loan credit facility [Member]" } } }, "auth_ref": [] }, "trib_SeniorSecuredTermLoanFixedRate": { "xbrltype": "percentItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "SeniorSecuredTermLoanFixedRate", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents about senior secured term loan fixed rate.", "label": "Senior Secured Term Loan Fixed Rate", "terseLabel": "Senior secured term loan fixed rate" } } }, "auth_ref": [] }, "trib_SeniorSecuredTermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "SeniorSecuredTermLoanMember", "presentation": [ "http://trinitybiotech.com/role/BASISOFPREPARATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfInterestRateRiskEffectiveAndRepricingAnalysisDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails", "http://trinitybiotech.com/role/PostBalanceSheetEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represent information about the senior secured term loan member.", "label": "Senior Secured Term Loan [Member]", "terseLabel": "Senior secured term loan [Member]" } } }, "auth_ref": [] }, "ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SensitivityAnalysisForEachTypeOfMarketRisk", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Sensitivity Analysis" } }, "en": { "role": { "documentation": "The disclosure of the sensitivity analysis for types of market risk to which the entity is exposed, showing how profit or loss and equity would have been affected by changes in the relevant risk variable that were reasonably possible at that date. [Refer: Market risk [member]]" } } }, "auth_ref": [ "r230" ] }, "ifrs-full_ServicesExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ServicesExpense", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Services Expense", "terseLabel": "Payments for CEO Services" } } }, "auth_ref": [ "r619" ] }, "trib_SevenYearConvertibleNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "SevenYearConvertibleNoteMember", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails2", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represent information about the 7-year convertible note member.", "label": "Seven Year Convertible Note [Member]", "terseLabel": "7-year Convertible Note [Member]" } } }, "auth_ref": [] }, "trib_ShareBasedPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ShareBasedPayments", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/LossBeforeTaxScheduleOfAmountChargedToStatementOfOperationDetails" ], "lang": { "en-us": { "role": { "documentation": "Share based payments.", "label": "Share based payments" } } }, "auth_ref": [] }, "trib_ShareBasedPaymentsCapitalisedIntangibleDevelopmentProjectAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ShareBasedPaymentsCapitalisedIntangibleDevelopmentProjectAssets", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/ShareOptionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents share based payments capitalised in intangible development project assets.", "label": "Share Based Payments Capitalised Intangible Development Project Assets", "verboseLabel": "Share based payments capitalised in intangible development project assets" } } }, "auth_ref": [] }, "trib_ShareBasedPaymentsContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ShareBasedPaymentsContinuingOperations", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/ShareOptionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Share based payments continuing operations.", "netLabel": "Share based payments continuing operations", "label": "Share Based Payments Continuing Operations", "totalLabel": "Total - continuing operations", "verboseLabel": "Continuing operations" } } }, "auth_ref": [] }, "trib_ShareIssueCostForExchangeableNotesPurchase": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ShareIssueCostForExchangeableNotesPurchase", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/CapitalAndReservesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Share issue cost for Exchangeable Notes purchase.", "label": "Share Issue Cost For Exchangeable Notes Purchase" } } }, "auth_ref": [] }, "ifrs-full_ShareIssueRelatedCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ShareIssueRelatedCost", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/CapitalAndReservesNarrativeDetails", "http://trinitybiotech.com/role/ConsolidatedStatementOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Share issue related cost", "negatedLabel": "Share issue expenses" } } }, "auth_ref": [ "r610" ] }, "trib_ShareOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ShareOptionMember", "presentation": [ "http://trinitybiotech.com/role/RelatedPartyTransactionsScheduleOfCompanysSharesAndShareOptionPlanDetails" ], "lang": { "en-us": { "role": { "documentation": "Share Option [Member]", "label": "Share Option [Member]" } } }, "auth_ref": [] }, "ifrs-full_SharePremium": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SharePremium", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Share premium" } }, "en": { "role": { "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value." } } }, "auth_ref": [ "r529", "r537" ] }, "ifrs-full_SharePremiumMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SharePremiumMember", "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Share premium [Member]" } }, "en": { "role": { "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value." } } }, "auth_ref": [ "r416" ] }, "trib_ShareRepurchasedUnderBuybackProgram": { "xbrltype": "sharesItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ShareRepurchasedUnderBuybackProgram", "presentation": [ "http://trinitybiotech.com/role/CapitalAndReservesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Share repurchased under buyback program.", "label": "Share repurchased under buyback program" } } }, "auth_ref": [] }, "trib_SharebasedPaymentExpenseCapitalisedInIntangibleDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "SharebasedPaymentExpenseCapitalisedInIntangibleDevelopment", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/ShareOptionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Share-based payment Expense Capitalised in Intangible Development", "terseLabel": "Share-based payment expense capitalised", "documentation": "Amount of share-based payment expense capitalised in intangible development." } } }, "auth_ref": [] }, "trib_SharesConsideration": { "xbrltype": "sharesItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "SharesConsideration", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of shares consideration.", "label": "Shares Consideration", "terseLabel": "Shares consideration" } } }, "auth_ref": [] }, "trib_SharesIssuableOnConversionOfExchangeableNotes": { "xbrltype": "sharesItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "SharesIssuableOnConversionOfExchangeableNotes", "presentation": [ "http://trinitybiotech.com/role/LossPerShareScheduleOfDilutedEarningsPerAdsShareCalculationDetails", "http://trinitybiotech.com/role/LossPerShareScheduleOfDilutedEarningsPerOrdinaryShareDetails" ], "lang": { "en-us": { "role": { "documentation": "Shares issuable on conversion of exchangeable notes .", "label": "Shares Issuable On Conversion Of Exchangeable Notes", "terseLabel": "Issuable on conversion of Exchangeable notes" } } }, "auth_ref": [] }, "trib_SharesIssuedAsConsiderationForExchangeableNotesPurchase": { "xbrltype": "sharesItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "SharesIssuedAsConsiderationForExchangeableNotesPurchase", "presentation": [ "http://trinitybiotech.com/role/CapitalAndReservesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Shares issued as consideration for Exchangeable Notes purchase.", "label": "Shares Issued As Consideration For Exchangeable Notes Purchase", "terseLabel": "Issued as consideration for Exchangeable Notes purchase", "verboseLabel": "Shares issued as consideration for Exchangeable Notes purchase" } } }, "auth_ref": [] }, "trib_SharesIssuedAsConsiderationForExchangeableNotesPurchaseValue": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "SharesIssuedAsConsiderationForExchangeableNotesPurchaseValue", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/CapitalAndReservesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Value of shares issued as consideration for Exchangeable Notes purchase.", "label": "Shares Issued As Consideration For Exchangeable Notes Purchase Value", "terseLabel": "Shares issued as consideration for Exchangeable Notes purchase, value" } } }, "auth_ref": [] }, "trib_SharesIssuedAsConsiderationForPurchaseOfExchangeableNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "SharesIssuedAsConsiderationForPurchaseOfExchangeableNotes", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/ReconciliationOfLiabilitiesArisingFromFinancingActivitiesScheduleOfLiabilitiesArisingFromFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "Shares issued as consideration for purchase of Exchangeable Notes.", "negatedLabel": "Shares issued as consideration for purchase of Exchangeable Notes", "label": "Shares Issued As Consideration For Purchase Of Exchangeable Notes" } } }, "auth_ref": [] }, "trib_SharesIssuedToNoteHoldersAsConsiderationBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "SharesIssuedToNoteHoldersAsConsiderationBorrowings", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSDetails1" ], "lang": { "en-us": { "role": { "documentation": "The amount of shares issued to note holders as consideration, borrowings.", "label": "Shares Issued To Note Holders As Consideration, Borrowings", "terseLabel": "Shares issued to Note holders as consideration" } } }, "auth_ref": [] }, "trib_SharesPurchasedDuringYear": { "xbrltype": "sharesItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "SharesPurchasedDuringYear", "presentation": [ "http://trinitybiotech.com/role/RelatedPartyTransactionsScheduleOfCompanysSharesAndShareOptionPlanDetails" ], "lang": { "en-us": { "role": { "documentation": "Shares purchased during the year.", "label": "Shares Purchased During Year" } } }, "auth_ref": [] }, "trib_SharesRepresentationRateComparedToADS": { "xbrltype": "perShareItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "SharesRepresentationRateComparedToADS", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the representation rate of shares compared to companies ADS.", "label": "Shares Representation Rate Compared To A D S", "terseLabel": "Shares amount representing companies ADS" } } }, "auth_ref": [] }, "trib_SharesSoldDuringYear": { "xbrltype": "sharesItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "SharesSoldDuringYear", "presentation": [ "http://trinitybiotech.com/role/RelatedPartyTransactionsScheduleOfCompanysSharesAndShareOptionPlanDetails" ], "lang": { "en-us": { "role": { "documentation": "Shares sold during the year.", "label": "Shares sold during the year" } } }, "auth_ref": [] }, "trib_SharesToBeIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "SharesToBeIssued", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfChangesInEquity" ], "lang": { "en-us": { "role": { "documentation": "The amount represents shares to be issued.", "label": "Shares To Be Issued", "terseLabel": "Shares to be issued" } } }, "auth_ref": [] }, "trib_SharesToBeIssuedForHedgingReservesValue": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "SharesToBeIssuedForHedgingReservesValue", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/CapitalAndReservesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Value of shares to be issued for hedging reserves.", "label": "Shares To Be Issued For Hedging Reserves Value", "terseLabel": "Value of shares to be issued for hedging reserves" } } }, "auth_ref": [] }, "trib_ShortTermDepositsAndShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "ShortTermDepositsAndShortTermInvestments", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfInterestRateProfileOfFinancialAssetsliabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of short term deposits and investment.", "label": "Short Term Deposits And Short Term Investments", "verboseLabel": "Financial assets (short-term deposits and short-term investments)" } } }, "auth_ref": [] }, "ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ShorttermDepositsClassifiedAsCashEquivalents", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONDetail5": { "parentTag": "ifrs-full_CashAndCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfInterestRateProfileOfFinancialAssetsliabilitiesDetails", "http://trinitybiotech.com/role/CashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "label": "Short-term deposits, classified as cash equivalents", "terseLabel": "Short-term deposits", "verboseLabel": "Financial assets (short-term deposits and short-term investments)" } }, "en": { "role": { "documentation": "A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]" } } }, "auth_ref": [ "r605" ] }, "ifrs-full_ShorttermEmployeeBenefitsExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ShorttermEmployeeBenefitsExpense", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/EmploymentNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Total personnel expenses, inclusive of amounts capitalised for wages and salaries, social welfare costs and pension costs" } } }, "auth_ref": [ "r612" ] }, "ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ShorttermInvestmentsClassifiedAsCashEquivalents", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfFairValuesOfFinancialAssetsliabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Short term investments", "terseLabel": "Short term investments (Note 20)", "verboseLabel": "Investments (deposits)" } }, "en": { "role": { "documentation": "A classification of cash equivalents representing short-term investments. [Refer: Cash equivalents]" } } }, "auth_ref": [ "r605" ] }, "ifrs-full_SignificantInvestmentsInSubsidiariesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SignificantInvestmentsInSubsidiariesAxis", "presentation": [ "http://trinitybiotech.com/role/CapitalAndReservesNarrativeDetails", "http://trinitybiotech.com/role/GROUPUNDERTAKINGSDetails", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Subsidiaries [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r48", "r51", "r134", "r390" ] }, "ifrs-full_SignificantInvestmentsInSubsidiariesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SignificantInvestmentsInSubsidiariesDomain", "presentation": [ "http://trinitybiotech.com/role/CapitalAndReservesNarrativeDetails", "http://trinitybiotech.com/role/GROUPUNDERTAKINGSDetails", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Subsidiaries [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Subsidiaries' axis if no other member is used." } } }, "auth_ref": [ "r48", "r51", "r134", "r390" ] }, "trib_SiteTransferCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "SiteTransferCostsMember", "presentation": [ "http://trinitybiotech.com/role/IMPAIRMENTTRANSFORMATIONANDONCEOFFCOSTSScheduleoftransformationcostsincurredduringtheyearDetails" ], "lang": { "en-us": { "role": { "documentation": "Site Transfer Costs [Member]", "label": "Site Transfer Costs [Member]", "terseLabel": "Site transfer costs [Member]" } } }, "auth_ref": [] }, "trib_SiteTransferCostsRelatedToTheImpairmentOfPlantEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "SiteTransferCostsRelatedToTheImpairmentOfPlantEquipmentMember", "presentation": [ "http://trinitybiotech.com/role/IMPAIRMENTTRANSFORMATIONANDONCEOFFCOSTSNarrativeDetails", "http://trinitybiotech.com/role/ProvisionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Site Transfer Costs Related To The Impairment Of Plant & Equipment [Member]" } } }, "auth_ref": [] }, "trib_SixMonthOrLessMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "SixMonthOrLessMember", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfInterestRateRiskEffectiveAndRepricingAnalysisDetails", "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfLiquidityRiskEstimatedInterestPaymentsOfMaturitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "6 mths or less [Member]", "label": "Six Month Or Less Member", "terseLabel": "6 mths or less [Member]" } } }, "auth_ref": [] }, "trib_SixMonthToTwelveMonthMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "SixMonthToTwelveMonthMember", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfInterestRateRiskEffectiveAndRepricingAnalysisDetails", "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfLiquidityRiskEstimatedInterestPaymentsOfMaturitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "6 mths - 12 mths [Member]", "label": "Six Month To Twelve Month Member", "terseLabel": "6 mths - 12 mths [Member]" } } }, "auth_ref": [] }, "trib_SjogrensTestsMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "SjogrensTestsMember", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfPrincipalDevelopmentProjectsDetails" ], "lang": { "en-us": { "role": { "documentation": "Sjogrens tests [Member]", "label": "Sjogrens Tests [Member]" } } }, "auth_ref": [] }, "ifrs-full_SocialSecurityContributions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SocialSecurityContributions", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/EmploymentScheduleOfEmploymentCostsDetails": { "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://trinitybiotech.com/role/EmploymentScheduleOfEmploymentCostsDetails" ], "lang": { "en-us": { "role": { "label": "Social welfare costs" } } }, "auth_ref": [ "r584" ] }, "ifrs-full_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of cash flows [abstract]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfChangesInEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of changes in equity [abstract]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfChangesInEquityLineItems", "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Statement of changes in equity [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfChangesInEquityTable", "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Statement of changes in equity [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to changes in equity." } } }, "auth_ref": [ "r416" ] }, "ifrs-full_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of financial position [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "StatementScenarioAxis", "presentation": [ "http://trinitybiotech.com/role/BASISOFPREPARATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "auth_ref": [] }, "trib_StrandedCostMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "StrandedCostMember", "presentation": [ "http://trinitybiotech.com/role/IMPAIRMENTTRANSFORMATIONANDONCEOFFCOSTSScheduleoftransformationcostsincurredduringtheyearDetails" ], "lang": { "en-us": { "role": { "label": "Stranded Cost [Member]", "terseLabel": "Stranded costs [Member]", "documentation": "This member stands for information pertaining to \"Stranded cost\"." } } }, "auth_ref": [] }, "trib_StrategicPartnershipWithImawareIncMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "StrategicPartnershipWithImawareIncMember", "presentation": [ "http://trinitybiotech.com/role/FINANCIALASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "strategic partnership with imaware, Inc.", "label": "Strategic Partnership With Imaware Inc [Member]", "terseLabel": "Strategic partnership with imaware, Inc. [Member]" } } }, "auth_ref": [] }, "trib_SyphilisPointOfCareMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "SyphilisPointOfCareMember", "presentation": [ "http://trinitybiotech.com/role/GOODWILLANDINTANGIBLEASSETSDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Syphilis Point-of-Care.", "label": "Syphilis Point Of Care [Member]", "verboseLabel": "Syphilis Point-of-Care [Member]" } } }, "auth_ref": [] }, "trib_SyphilisPointOfCareTestMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "SyphilisPointOfCareTestMember", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfPrincipalDevelopmentProjectsDetails" ], "lang": { "en-us": { "role": { "documentation": "Syphilis point-of-care test [Member]", "label": "Syphilis Point-of-Care Test [Member]" } } }, "auth_ref": [] }, "trib_T10HplcAnalyzerMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "T10HplcAnalyzerMember", "presentation": [ "http://trinitybiotech.com/role/GOODWILLANDINTANGIBLEASSETSDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for T10 HPLC Analyzer.", "label": "T10 Hplc Analyzer [Member]", "verboseLabel": "T10 HPLC Analyzer [Member]" } } }, "auth_ref": [] }, "trib_TRIBBiosensorsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "TRIBBiosensorsIncMember", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "TRIB Biosensors Inc [Member]", "terseLabel": "TRIB Biosensors Inc. (\u201cTRIB B\u201d) [Member]", "documentation": "This member stands for information pertaining to \"TRIB Biosensors Inc.\"" } } }, "auth_ref": [] }, "ifrs-full_TaxExpenseRelatingToGainLossOnDiscontinuance": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TaxExpenseRelatingToGainLossOnDiscontinuance", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfChargeForTaxDetails" ], "lang": { "en-us": { "role": { "label": "Tax charge on discontinued operations (see Note 10)", "terseLabel": "Tax charge on discontinued operations (see Note 8)", "verboseLabel": "Tax credit recovered" } } }, "auth_ref": [ "r7", "r210" ] }, "ifrs-full_TaxExpenseRelatingToProfitLossFromOrdinaryActivitiesOfDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TaxExpenseRelatingToProfitLossFromOrdinaryActivitiesOfDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Total income tax credit", "negatedNetLabel": "Tax expense", "negatedTerseLabel": "Tax income (expense)", "label": "Tax expense (income) relating to profit (loss) from ordinary activities of discontinued operations", "totalLabel": "Total tax expense (income)", "verboseLabel": "Tax (expense)/credit" } } }, "auth_ref": [ "r8", "r208" ] }, "trib_TaxFees": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "TaxFees", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/LossBeforeTaxScheduleOfAmountChargedToStatementOfOperationDetails" ], "lang": { "en-us": { "role": { "documentation": "Tax fees.", "label": "Tax fees" } } }, "auth_ref": [] }, "ifrs-full_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods", "calculation": { "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfStatutoryTaxRateDetails": { "parentTag": "ifrs-full_AverageEffectiveTaxRate", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfStatutoryTaxRateDetails" ], "lang": { "en-us": { "role": { "label": "Adjustments in respect of prior years" } } }, "auth_ref": [ "r575" ] }, "trib_TaxRateEffectOfCurrentTaxOfPriorPeriods": { "xbrltype": "percentItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "TaxRateEffectOfCurrentTaxOfPriorPeriods", "presentation": [ "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfOverseasTaxJurisdictionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Current tax.", "label": "Tax Rate Effect Of Current Tax Of Prior Periods", "terseLabel": "Current tax %" } } }, "auth_ref": [] }, "ifrs-full_TaxRateEffectOfForeignTaxRates": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TaxRateEffectOfForeignTaxRates", "calculation": { "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfStatutoryTaxRateDetails": { "parentTag": "ifrs-full_AverageEffectiveTaxRate", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfStatutoryTaxRateDetails" ], "lang": { "en-us": { "role": { "label": "Effect of tax rates on overseas earnings" } }, "en": { "role": { "documentation": "The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from the application of foreign tax rates. [Refer: Average effective tax rate; Applicable tax rate]" } } }, "auth_ref": [ "r3", "r309" ] }, "ifrs-full_TaxRateEffectOfImpairmentOfGoodwill": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TaxRateEffectOfImpairmentOfGoodwill", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsNarrativeDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfSignificantGoodwillAndIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Discount rate applied (real pre-tax)" } }, "en": { "role": { "documentation": "Tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from the impairment of goodwill. [Refer: Average effective tax rate; Applicable tax rate; Goodwill]" } } }, "auth_ref": [ "r575" ] }, "trib_TaxRateEffectOfResearchAndDevelopmentTaxOfPriorPeriods": { "xbrltype": "percentItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "TaxRateEffectOfResearchAndDevelopmentTaxOfPriorPeriods", "calculation": { "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfStatutoryTaxRateDetails": { "parentTag": "ifrs-full_AverageEffectiveTaxRate", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfStatutoryTaxRateDetails" ], "lang": { "en-us": { "role": { "documentation": "R and D tax credits.", "label": "Tax Rate Effect Of Research And Development Tax Of Prior Periods", "verboseLabel": "R&D tax credits" } } }, "auth_ref": [] }, "ifrs-full_TaxRateEffectOfTaxLosses": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TaxRateEffectOfTaxLosses", "calculation": { "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfStatutoryTaxRateDetails": { "parentTag": "ifrs-full_AverageEffectiveTaxRate", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfStatutoryTaxRateDetails" ], "lang": { "en-us": { "role": { "label": "Effect of current year net operating losses and temporary differences for which no deferred tax asset was recognised" } }, "en": { "role": { "documentation": "The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from tax losses. [Refer: Average effective tax rate; Applicable tax rate]" } } }, "auth_ref": [ "r3", "r309" ] }, "trib_TaxValueOfLossCarryForwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "TaxValueOfLossCarryForwardsMember", "presentation": [ "http://trinitybiotech.com/role/DeferredTaxAssetsAndLiabilitiesScheduleOfRecognisedDeferredTaxAssetsAndLiabilitiesDetails", "http://trinitybiotech.com/role/DeferredTaxAssetsAndLiabilitiesScheduleOfUnrecognisedDeferredTaxLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Tax value of loss carry-forwards [Member]", "label": "Tax value of loss carry-forwards [Member]" } } }, "auth_ref": [] }, "ifrs-full_TechnologybasedIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TechnologybasedIntangibleAssetsMember", "presentation": [ "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsNarrativeDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfGoodwillAndIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Technology-based intangible assets [member]", "verboseLabel": "Technology based intangibles [Member]" } }, "en": { "role": { "documentation": "This member stands for a class of intangible assets representing assets based on technology. Such assets may include patented and unpatented technology, databases as well as trade secrets. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r596" ] }, "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis", "presentation": [ "http://trinitybiotech.com/role/DeferredTaxAssetsAndLiabilitiesScheduleOfRecognisedDeferredTaxAssetsAndLiabilitiesDetails", "http://trinitybiotech.com/role/DeferredTaxAssetsAndLiabilitiesScheduleOfUnrecognisedDeferredTaxLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Temporary difference, unused tax losses and unused tax credits [Axis]", "verboseLabel": "Temporary difference, unused tax losses and unused tax credits [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r6", "r312" ] }, "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain", "presentation": [ "http://trinitybiotech.com/role/DeferredTaxAssetsAndLiabilitiesScheduleOfRecognisedDeferredTaxAssetsAndLiabilitiesDetails", "http://trinitybiotech.com/role/DeferredTaxAssetsAndLiabilitiesScheduleOfUnrecognisedDeferredTaxLiabilitiesDetails" ], "lang": { "en": { "role": { "documentation": "This member stands for temporary differences, unused tax losses and unused tax credits. It also represents the standard value for the 'Temporary difference, unused tax losses and unused tax credits' axis if no other member is used. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]" } } }, "auth_ref": [ "r6", "r312" ] }, "trib_TenPercentStrengtheningUSDollarMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "TenPercentStrengtheningUSDollarMember", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "documentation": "10% Strengthening US Dollar [Member]", "label": "Ten Percent Strengthening U S Dollar Member", "terseLabel": "10% strengthening US Dollar [Member]" } } }, "auth_ref": [] }, "trib_TenPercentWeakeningUSDollarMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "TenPercentWeakeningUSDollarMember", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "documentation": "10% Weakening US Dollar [Member]", "label": "Ten Percent Weakening U S Dollar Member", "terseLabel": "10% Weakening US Dollar [Member]" } } }, "auth_ref": [] }, "trib_TermLoanAgreementDescription": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "TermLoanAgreementDescription", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents about term loan agreement description.", "label": "Term Loan Agreement Description", "terseLabel": "Term loan agreement description" } } }, "auth_ref": [] }, "trib_TermLoanFacility": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "TermLoanFacility", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Term loan facility", "terseLabel": "Term loan facility", "documentation": "The amount of term loan facility obtained by the reporting entity." } } }, "auth_ref": [] }, "trib_TermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "TermLoanMember", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSScheduleOfMovementInTermLoan" ], "lang": { "en-us": { "role": { "documentation": "Term Loan [Member]", "label": "Term Loan [Member]" } } }, "auth_ref": [] }, "trib_TermOfExchangeableSeniorNotes": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "TermOfExchangeableSeniorNotes", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Term of exchangeable senior notes.", "label": "Term of exchangeable senior notes" } } }, "auth_ref": [] }, "trib_TermOfLease": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "TermOfLease", "presentation": [ "http://trinitybiotech.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Term of lease.", "label": "Term of lease" } } }, "auth_ref": [] }, "ifrs-full_TopOfRangeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TopOfRangeMember", "presentation": [ "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesScheduleOfAmortisationDetails", "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesScheduleOfOwnedAssetsDetails", "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfInterestRateRiskEffectiveAndRepricingAnalysisDetails", "http://trinitybiotech.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsNarrativeDetails", "http://trinitybiotech.com/role/LossPerShareNarrativeDetails", "http://trinitybiotech.com/role/PostBalanceSheetEventsDetails", "http://trinitybiotech.com/role/PropertyPlantAndEquipmentScheduleOfIncomeFromSub-lettingRight-of-useBuildingsDetails", "http://trinitybiotech.com/role/ShareOptionsNarrativeDetails", "http://trinitybiotech.com/role/ShareOptionsScheduleOfAssumptionDeterminingFairValueOfShareOptionsDetails", "http://trinitybiotech.com/role/ShareOptionsScheduleOfGrantsOfShareOptionsAndWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Top of range [Member]", "terseLabel": "Maximum [Member]", "verboseLabel": "Top of range [Member]" } }, "en": { "role": { "documentation": "This member stands for top of a range." } } }, "auth_ref": [ "r101", "r140", "r164", "r181", "r296", "r490", "r491", "r607" ] }, "trib_TotalExchangeableNotesPercentage": { "xbrltype": "percentItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "TotalExchangeableNotesPercentage", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represented total exchangeable notes percentage.", "label": "Total Exchangeable Notes Percentage", "terseLabel": "Total exchangeable notes percentage" } } }, "auth_ref": [] }, "trib_TotalExposureFinancialInstruments": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "TotalExposureFinancialInstruments", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfForeignCurrencyRiskShortTermFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "The total credit exposure associated with derivative financial assets and liabilities.", "label": "Total Exposure Financial Instruments", "terseLabel": "Total exposure" } } }, "auth_ref": [] }, "trib_TotalShareOptionsGrantedAdsEquivalent": { "xbrltype": "sharesItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "TotalShareOptionsGrantedAdsEquivalent", "presentation": [ "http://trinitybiotech.com/role/ShareOptionsScheduleOfAssumptionDeterminingFairValueOfShareOptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Total number of shares granted.", "negatedLabel": "Total 'A' share options granted / (ADS's equivalent)", "label": "Total Share Options Granted Ads Equivalent", "terseLabel": "Total 'A' share options granted / (ADS's equivalent)" } } }, "auth_ref": [] }, "trib_TotalTransformationCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "TotalTransformationCostsMember", "presentation": [ "http://trinitybiotech.com/role/IMPAIRMENTTRANSFORMATIONANDONCEOFFCOSTSScheduleoftransformationcostsincurredduringtheyearDetails" ], "lang": { "en-us": { "role": { "label": "Total Restructuring Costs [Member]", "terseLabel": "Total transformation costs [Member]", "documentation": "This member stands for information pertaining to \"Total restructuring costs\"" } } }, "auth_ref": [] }, "ifrs-full_TradeAndOtherCurrentPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherCurrentPayables", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONDetail5": { "parentTag": "ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONDetail5", "http://trinitybiotech.com/role/TradeAndOtherPayablesScheduleOfTradeAndOtherPayablesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Trade and other payables", "label": "Trade and other current payables", "verboseLabel": "Trade payables" } }, "en": { "role": { "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]" } } }, "auth_ref": [ "r426" ] }, "ifrs-full_TradeAndOtherCurrentPayablesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherCurrentPayablesAbstract", "lang": { "en-us": { "role": { "label": "Trade and other current payables [Abstract]", "verboseLabel": "Trade and other current payables [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition", "http://trinitybiotech.com/role/TradeAndOtherPayablesScheduleOfTradeAndOtherPayablesDetails" ], "lang": { "en-us": { "role": { "label": "Trade and other payables", "terseLabel": "Total trade and other payables", "totalLabel": "Total trade and other payables" } }, "en": { "role": { "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]" } } }, "auth_ref": [ "r534", "r618" ] }, "ifrs-full_TradeAndOtherCurrentReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherCurrentReceivables", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 1.0 }, "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONDetail5": { "parentTag": "ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners", "weight": 1.0, "order": 4.0 }, "http://trinitybiotech.com/role/TradeAndOtherReceivablesScheduleOfTradeAndOtherReceivablesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition", "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONDetail5", "http://trinitybiotech.com/role/TradeAndOtherReceivablesScheduleOfTradeAndOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Trade and other current receivables", "terseLabel": "Trade and other receivables", "totalLabel": "Total and other receivables", "verboseLabel": "Trade and other receivables" } }, "en": { "role": { "documentation": "The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]" } } }, "auth_ref": [ "r404", "r423", "r438" ] }, "ifrs-full_TradeAndOtherCurrentReceivablesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherCurrentReceivablesAbstract", "lang": { "en-us": { "role": { "label": "Trade and other current receivables [Abstract]", "verboseLabel": "Trade and other current receivables [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_TradeAndOtherPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherPayables", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfFairValuesOfFinancialAssetsliabilitiesDetails", "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfForeignCurrencyRiskShortTermFinancialAssetsAndLiabilitiesDetails", "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfLiquidityRiskEstimatedInterestPaymentsOfMaturitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Trade and other payables (excluding deferred income)", "negatedTerseLabel": "Trade and other payables", "label": "Trade & other payables", "verboseLabel": "Trade and other payables (excluding deferred income)" } }, "en": { "role": { "documentation": "The amount of trade payables and other payables. [Refer: Trade payables; Other payables]" } } }, "auth_ref": [ "r426" ] }, "ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherPayablesRecognisedAsOfAcquisitionDate", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSDetails": { "parentTag": "ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSDetails" ], "lang": { "en-us": { "role": { "label": "Trade and other payables recognised as of acquisition date", "negatedTerseLabel": "Trade and other payables", "terseLabel": "Trade and other payables" } }, "en": { "role": { "documentation": "The amount recognised as of the acquisition date for trade and other payables assumed in a business combination. [Refer: Trade and other payables; Total for all business combinations [member]]" } } }, "auth_ref": [ "r606" ] }, "ifrs-full_TradeAndOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherReceivables", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfForeignCurrencyRiskShortTermFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Trade and other receivable" } }, "en": { "role": { "documentation": "The amount of trade receivables and other receivables. [Refer: Trade receivables; Other receivables]" } } }, "auth_ref": [ "r404", "r423", "r438" ] }, "ifrs-full_TradeAndOtherReceivablesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherReceivablesAbstract", "lang": { "en-us": { "role": { "label": "Trade and other receivables [abstract]" } } }, "auth_ref": [] }, "trib_TradeAndOtherReceivablesRecognisedAsOfAcquisitionDate": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "TradeAndOtherReceivablesRecognisedAsOfAcquisitionDate", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSDetails": { "parentTag": "ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount recognised as of the acquisition date for trade and other receivables assumed in a business combination.", "negatedLabel": "Trade and other receivables", "label": "Trade And Other Receivables Recognised As Of Acquisition Date", "terseLabel": "Trade and other receivables" } } }, "auth_ref": [] }, "ifrs-full_TradeReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeReceivables", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfAgeingOfTradeReceivablesDetails", "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfFairValuesOfFinancialAssetsliabilitiesDetails", "http://trinitybiotech.com/role/TradeAndOtherReceivablesNarrativeDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Balance at December 31", "periodStartLabel": "Balance at January 1", "label": "Trade receivables, net impairment losses provision", "verboseLabel": "Trade receivables" } }, "en": { "role": { "documentation": "The amount due from customers for goods and services sold." } } }, "auth_ref": [ "r527", "r535" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "TradingSymbol", "presentation": [ "http://trinitybiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ifrs-full_TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis", "presentation": [ "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Transactions recognised separately from acquisition of assets and assumption of liabilities in business combination [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r193" ] }, "ifrs-full_TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationDomain", "presentation": [ "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Transactions recognised separately from acquisition of assets and assumption of liabilities in business combination [domain]" } }, "en": { "role": { "documentation": "This member stands for transactions that are recognised separately from the acquisition of assets and assumption of liabilities in business combinations. It also represents the standard value for the 'Transactions recognised separately from acquisition of assets and assumption of liabilities in business combination' axis if no other member is used. [Refer: Total for all business combinations [member]]" } } }, "auth_ref": [ "r193" ] }, "trib_TransformationProvision": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "TransformationProvision", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/ProvisionsScheduleOfProvisionsDetails": { "parentTag": "ifrs-full_Provisions", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://trinitybiotech.com/role/ProvisionsScheduleOfProvisionsDetails" ], "lang": { "en-us": { "role": { "label": "Transformation Provision", "terseLabel": "Transformation provision", "documentation": "The amount of provision for transformation." } } }, "auth_ref": [] }, "trib_TransitionImpactOnRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "TransitionImpactOnRevenue", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/PostBalanceSheetEventsDetails" ], "lang": { "en-us": { "role": { "label": "Transition Impact on Revenue", "terseLabel": "Transition impact on revenue", "documentation": "Amount of transition impact on revenue." } } }, "auth_ref": [] }, "ifrs-full_TreasuryShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TreasuryShares", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://trinitybiotech.com/role/CapitalAndReservesScheduleOfShareCapitalDetails", "http://trinitybiotech.com/role/ConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "negatedLabel": "Treasury shares", "periodEndLabel": "At period end", "periodStartLabel": "Balance at January 1", "label": "Treasury shares" } }, "en": { "role": { "documentation": "An entity\u2019s own equity instruments, held by the entity or other members of the consolidated group." } } }, "auth_ref": [ "r52", "r529", "r537" ] }, "ifrs-full_TreasurySharesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TreasurySharesMember", "presentation": [ "http://trinitybiotech.com/role/ConsolidatedStatementOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Treasury Shares [Member]" } }, "en": { "role": { "documentation": "This member stands for the entity\u2019s own equity instruments, held by the entity or other members of the consolidated group." } } }, "auth_ref": [ "r416" ] }, "trib_TriStatPointOfCareInstrumentMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "TriStatPointOfCareInstrumentMember", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfPrincipalDevelopmentProjectsDetails" ], "lang": { "en-us": { "role": { "documentation": "Tristat Point-of-Care Instrument [Member]", "label": "Tri Stat Point Of Care Instrument [Member]", "terseLabel": "Tri-stat point-of-care instrument [Member]" } } }, "auth_ref": [] }, "trib_TribBiosensorsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "TribBiosensorsIncMember", "presentation": [ "http://trinitybiotech.com/role/GROUPUNDERTAKINGSDetails" ], "lang": { "en-us": { "role": { "documentation": "Represent the Trib Biosensors Inc member", "label": "Trib Biosensors Inc [Member]" } } }, "auth_ref": [] }, "trib_TrinityBiotechDoBrasilMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "TrinityBiotechDoBrasilMember", "presentation": [ "http://trinitybiotech.com/role/GROUPUNDERTAKINGSDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfImpairmentLossDetails" ], "lang": { "en-us": { "role": { "documentation": "Trinity Biotech Do Brasil [Member]", "label": "Trinity Biotech Do Brasil [Member]" } } }, "auth_ref": [] }, "trib_TrinityBiotechIncMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "TrinityBiotechIncMember", "presentation": [ "http://trinitybiotech.com/role/GROUPUNDERTAKINGSDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Trinity Biotech Inc.", "label": "Trinity Biotech Inc [Member]" } } }, "auth_ref": [] }, "trib_TrinityBiotechInvestmentLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "TrinityBiotechInvestmentLtdMember", "presentation": [ "http://trinitybiotech.com/role/GROUPUNDERTAKINGSDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Trinity Biotech Investment Ltd.", "label": "Trinity Biotech Investment Ltd [Member]" } } }, "auth_ref": [] }, "trib_TrinityBiotechJointVentureLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "TrinityBiotechJointVentureLimitedMember", "presentation": [ "http://trinitybiotech.com/role/GROUPUNDERTAKINGSDetails" ], "lang": { "en-us": { "role": { "documentation": "Represent member of Trinity Biotech Joint Venture Limited", "label": "Trinity Biotech Joint Venture Limited [Member]" } } }, "auth_ref": [] }, "trib_TrinityBiotechLuxembourgSarlMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "TrinityBiotechLuxembourgSarlMember", "presentation": [ "http://trinitybiotech.com/role/GROUPUNDERTAKINGSDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Trinity Biotech Luxembourg Sarl.", "label": "Trinity Biotech Luxembourg Sarl [Member]" } } }, "auth_ref": [] }, "trib_TrinityBiotechManufacturingLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "TrinityBiotechManufacturingLimitedMember", "presentation": [ "http://trinitybiotech.com/role/GROUPUNDERTAKINGSDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfImpairmentLossDetails" ], "lang": { "en-us": { "role": { "documentation": "Trinity Biotech Manufacturing Limited [Member]", "label": "Trinity Biotech Manufacturing Limited [Member]" } } }, "auth_ref": [] }, "trib_TrinityBiotechManufacturingServicesLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "TrinityBiotechManufacturingServicesLimitedMember", "presentation": [ "http://trinitybiotech.com/role/GROUPUNDERTAKINGSDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Trinity Biotech Manufacturing Services Limited.", "label": "Trinity Biotech Manufacturing Services Limited [Member]" } } }, "auth_ref": [] }, "trib_TrinityBiotechUkLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "TrinityBiotechUkLtdMember", "presentation": [ "http://trinitybiotech.com/role/GROUPUNDERTAKINGSDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Trinity Biotech (UK) Ltd.", "label": "Trinity Biotech (Uk) Ltd [Member]" } } }, "auth_ref": [] }, "trib_TrinityResearchLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "TrinityResearchLimitedMember", "presentation": [ "http://trinitybiotech.com/role/GROUPUNDERTAKINGSDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Trinity Research Limited.", "label": "Trinity Research Limited [Member]" } } }, "auth_ref": [] }, "trib_TrinscreenPlantAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "TrinscreenPlantAndEquipmentMember", "presentation": [ "http://trinitybiotech.com/role/GOODWILLANDINTANGIBLEASSETSDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Trinscreen plant & equipment.", "label": "Trinscreen Plant And Equipment [Member]", "verboseLabel": "Trinscreen plant & equipment [Member]" } } }, "auth_ref": [] }, "trib_TwoPercentageOfGrossInventoryMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "TwoPercentageOfGrossInventoryMember", "presentation": [ "http://trinitybiotech.com/role/AccountingEstimatesAndJudgementsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "2% of gross inventory [Member]", "label": "Two Percentage Of Gross Inventory Member", "terseLabel": "2% of gross inventory [Member]" } } }, "auth_ref": [] }, "trib_TwoYearToFiveYearsMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "TwoYearToFiveYearsMember", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfInterestRateRiskEffectiveAndRepricingAnalysisDetails", "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfLiquidityRiskEstimatedInterestPaymentsOfMaturitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "2-5 years [Member]", "label": "Two Year To Five Years Member", "terseLabel": "2-5 years [Member]" } } }, "auth_ref": [] }, "ifrs-full_TypesOfCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfCustomersAxis", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfExposureOfTradeReceivablesByCustomerDetails" ], "lang": { "en-us": { "role": { "label": "Types of customers [Axis]", "verboseLabel": "Types of customers [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r494", "r518" ] }, "ifrs-full_TypesOfCustomersDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfCustomersDomain", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfExposureOfTradeReceivablesByCustomerDetails" ], "lang": { "en-us": { "role": { "label": "Types of customers [domain]" } }, "en": { "role": { "documentation": "This member stands for all types of customers. It also represents the standard value for the 'Types of customers' axis if no other member is used." } } }, "auth_ref": [ "r494", "r518" ] }, "ifrs-full_TypesOfRisksAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfRisksAxis", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfLiquidityRiskEstimatedInterestPaymentsOfMaturitiesDetails", "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "label": "Types of risks [Axis]", "verboseLabel": "Types of risks [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r33", "r165", "r166", "r167", "r168", "r217", "r222", "r223", "r326" ] }, "ifrs-full_TypesOfRisksDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfRisksDomain", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfLiquidityRiskEstimatedInterestPaymentsOfMaturitiesDetails", "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "label": "Types of risks [domain]" } }, "en": { "role": { "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used." } } }, "auth_ref": [ "r33", "r165", "r166", "r167", "r168", "r217", "r222", "r223", "r326" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2025", "localname": "US", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfExposureOfTradeReceivablesByGeographicLocationDetails", "http://trinitybiotech.com/role/IncomeTaxCreditNarrativeDetails", "http://trinitybiotech.com/role/SegmentInformationScheduleOfRevenueByGeographicalAreaBasedOnLocationOfAssetsDetails" ], "lang": { "en-us": { "role": { "label": "USA [Member]", "terseLabel": "United States [Member]", "verboseLabel": "Americas [Member]" } } }, "auth_ref": [] }, "trib_US1Member": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "US1Member", "presentation": [ "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfUnrecognisedDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "USA Tax Credits [Member]", "label": "U S 1 Member", "terseLabel": "USA Tax Credits [Member]", "verboseLabel": "Americas \u2013 unused tax credits [Member]" } } }, "auth_ref": [] }, "trib_UltraGenesysMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "UltraGenesysMember", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfPrincipalDevelopmentProjectsDetails" ], "lang": { "en-us": { "role": { "documentation": "Ultra Genesys [Member]", "label": "Ultra Genesys [Member]" } } }, "auth_ref": [] }, "trib_UnallocatedAssetsBySegmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "UnallocatedAssetsBySegmentAbstract", "presentation": [ "http://trinitybiotech.com/role/SegmentInformationScheduleOfSegmentAssetsAndSegmentLiabilitiesByGeographicalAreaDetails" ], "lang": { "en-us": { "role": { "label": "Unallocated Assets By Segment Abstract", "terseLabel": "Unallocated assets:" } } }, "auth_ref": [] }, "trib_UnallocatedExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "UnallocatedExpenses", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/SegmentInformationScheduleOfSegmentResultsByGeographicalAreaDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of unallocated expenses.", "label": "Unallocated expenses" } } }, "auth_ref": [] }, "trib_UnallocatedLiabilitiesBySegmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "UnallocatedLiabilitiesBySegmentAbstract", "presentation": [ "http://trinitybiotech.com/role/SegmentInformationScheduleOfSegmentAssetsAndSegmentLiabilitiesByGeographicalAreaDetails" ], "lang": { "en-us": { "role": { "label": "Unallocated Liabilities By Segment Abstract", "terseLabel": "Unallocated liabilities:" } } }, "auth_ref": [] }, "ifrs-full_UnconsolidatedStructuredEntitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "UnconsolidatedStructuredEntitiesAxis", "presentation": [ "http://trinitybiotech.com/role/BASISOFPREPARATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfFairValuesOfFinancialAssetsliabilitiesDetails", "http://trinitybiotech.com/role/CapitalAndReservesNarrativeDetails", "http://trinitybiotech.com/role/FINANCIALASSETSNarrativeDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails", "http://trinitybiotech.com/role/PostBalanceSheetEventsDetails" ], "lang": { "en-us": { "role": { "label": "Unconsolidated structured entities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r135", "r391" ] }, "ifrs-full_UnconsolidatedStructuredEntitiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "UnconsolidatedStructuredEntitiesDomain", "presentation": [ "http://trinitybiotech.com/role/BASISOFPREPARATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfFairValuesOfFinancialAssetsliabilitiesDetails", "http://trinitybiotech.com/role/CapitalAndReservesNarrativeDetails", "http://trinitybiotech.com/role/FINANCIALASSETSNarrativeDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails", "http://trinitybiotech.com/role/PostBalanceSheetEventsDetails" ], "lang": { "en-us": { "role": { "label": "Unconsolidated structured entities [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Unconsolidated structured entities' axis if no other member is used." } } }, "auth_ref": [ "r135", "r391" ] }, "ifrs-full_UnderlyingEquityInstrumentAndDepositaryReceiptsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "UnderlyingEquityInstrumentAndDepositaryReceiptsAxis", "presentation": [ "http://trinitybiotech.com/role/IMPAIRMENTTRANSFORMATIONANDONCEOFFCOSTSNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Underlying equity instrument and depositary receipts [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r612" ] }, "ifrs-full_UnderlyingEquityInstrumentAndDepositaryReceiptsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "UnderlyingEquityInstrumentAndDepositaryReceiptsDomain", "presentation": [ "http://trinitybiotech.com/role/IMPAIRMENTTRANSFORMATIONANDONCEOFFCOSTSNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Underlying equity instrument and depositary receipts [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the \u2018Underlying equity instrument and depositary receipts\u2019 axis if no other member is used." } } }, "auth_ref": [ "r612" ] }, "ifrs-full_UndiscountedOperatingLeasePaymentsToBeReceived": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "UndiscountedOperatingLeasePaymentsToBeReceived", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/TradeAndOtherReceivablesScheduleOfFutureMinimumRentalsReceivableUnderNon-cancellableOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Future minimum rentals receivable under non-cancellable operating leases" } }, "en": { "role": { "documentation": "The amount of undiscounted operating lease payments to be received. Operating lease is a lease that does not transfer substantially all the risks and rewards incidental to ownership of an underlying asset." } } }, "auth_ref": [ "r158", "r278" ] }, "trib_UnearnedFinanceIncomeOnFinanceLease": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "UnearnedFinanceIncomeOnFinanceLease", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/TradeAndOtherReceivablesScheduleOfFutureMinimumFinanceLeaseReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Unearned income.", "label": "Unearned Finance Income On Finance Lease", "terseLabel": "Unearned income" } } }, "auth_ref": [] }, "trib_UnforgivenLoansAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "UnforgivenLoansAmount", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Unforgiven loans amount", "label": "Unforgiven loans amount", "verboseLabel": "Unforgiven Loans amount" } } }, "auth_ref": [] }, "trib_UniGoldAntigenImprovementMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "UniGoldAntigenImprovementMember", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfPrincipalDevelopmentProjectsDetails" ], "lang": { "en-us": { "role": { "documentation": "Uni-Gold Antigen Improvement [Member]", "label": "Uni-Gold Antigen Improvement [Member]" } } }, "auth_ref": [] }, "trib_UniGoldHIVMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "UniGoldHIVMember", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "UniGold HIV [Member]", "terseLabel": "UniGold HIV [Member]", "documentation": "This member stands for information pertaining to \"UniGold HIV\"" } } }, "auth_ref": [] }, "trib_UniGoldRawMaterialStabilisationMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "UniGoldRawMaterialStabilisationMember", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfPrincipalDevelopmentProjectsDetails" ], "lang": { "en-us": { "role": { "documentation": "Uni-gold raw material stabilisation.", "label": "Uni Gold Raw Material Stabilisation [Member]", "terseLabel": "Uni-Gold Raw Material Stabilisation [Member]" } } }, "auth_ref": [] }, "trib_UniGoldTestMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "UniGoldTestMember", "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfPrincipalDevelopmentProjectsDetails" ], "lang": { "en-us": { "role": { "documentation": "Uni-Gold Test [Member]", "label": "Uni-Gold Test [Member]" } } }, "auth_ref": [] }, "trib_UnrecognizedDeferredTaxAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "UnrecognizedDeferredTaxAsset", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/DeferredTaxAssetsAndLiabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Unrecognized deferred tax asset.", "label": "Unrecognized deferred tax asset" } } }, "auth_ref": [] }, "trib_UnutilisedNetOperatingLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "UnutilisedNetOperatingLosses", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/IncomeTaxCreditScheduleOfNetOperatingLossesDetails" ], "lang": { "en-us": { "role": { "documentation": "Unutilised net operating losses.", "label": "Unutilised net operating losses" } } }, "auth_ref": [] }, "trib_UnwindingOfDiscountOnDeferredContingentConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "UnwindingOfDiscountOnDeferredContingentConsideration", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/FinancialIncomeAndExpensesScheduleOfFinancialIncomeExpensesNetDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of unwinding of discount on deferred contingent consideration.", "label": "Unwinding Of Discount On Deferred Contingent Consideration", "negatedLabel": "Unwinding of discount on deferred contingent consideration" } } }, "auth_ref": [] }, "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill": { "xbrltype": "durationItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill", "presentation": [ "http://trinitybiotech.com/role/BASISOFPREPARATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesScheduleOfAmortisationDetails" ], "lang": { "en-us": { "role": { "label": "Useful life measured as period of time, intangible assets other than goodwill", "terseLabel": "Estimated useful lives of intangible assets (In years)" } }, "en": { "role": { "documentation": "The useful life, measured as period of time, used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r74", "r343" ] }, "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment": { "xbrltype": "durationItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment", "presentation": [ "http://trinitybiotech.com/role/BasisOfPreparationAndSignificantAccountingPoliciesScheduleOfOwnedAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Useful life measured as period of time, property, plant and equipment", "terseLabel": "Estimated useful lives of property, plant and equipment (In years)" } }, "en": { "role": { "documentation": "The useful life, measured as period of time, used for property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r10", "r313" ] }, "trib_VariableRateInstruments": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "VariableRateInstruments", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfInterestRateProfileOfFinancialAssetsliabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of variable rate instruments.", "label": "Variable Rate Instruments", "totalLabel": "Variable rate instruments" } } }, "auth_ref": [] }, "trib_VariableRateInstrumentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "VariableRateInstrumentsAbstract", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfInterestRateProfileOfFinancialAssetsliabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Variable Rate Instruments [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_VehiclesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "VehiclesMember", "presentation": [ "http://trinitybiotech.com/role/PropertyPlantAndEquipmentScheduleOfIncomeFromSub-lettingRight-of-useBuildingsDetails" ], "lang": { "en-us": { "role": { "label": "Vehicles [Member]" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing vehicles used in the entity's operations, specifically to include aircraft, motor vehicles and ships. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r578" ] }, "ifrs-full_WagesAndSalaries": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WagesAndSalaries", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/EmploymentScheduleOfEmploymentCostsDetails": { "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://trinitybiotech.com/role/EmploymentScheduleOfEmploymentCostsDetails" ], "lang": { "en-us": { "role": { "label": "Wages and salaries" } } }, "auth_ref": [ "r584" ] }, "trib_WagesAndSalariesNetOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "WagesAndSalariesNetOfCredit", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/EmploymentNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Wages and salaries net of credit.", "label": "Wages and salaries net of credit" } } }, "auth_ref": [] }, "trib_WagesSubsidiesReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "WagesSubsidiesReceived", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/EmploymentNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of wage subsidies received.", "label": "Wages Subsidies Received", "terseLabel": "Wage subsidies received" } } }, "auth_ref": [] }, "ifrs-full_WarrantReserveMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WarrantReserveMember", "presentation": [ "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Warrant reserve [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity resulting from issuing share purchase warrants, other than those resulting from share-based payment arrangements. [Refer: Reserve of share-based payments [member]]" } } }, "auth_ref": [ "r611" ] }, "ifrs-full_WarrantyProvision": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WarrantyProvision", "crdr": "credit", "calculation": { "http://trinitybiotech.com/role/ProvisionsScheduleOfProvisionsDetails": { "parentTag": "ifrs-full_Provisions", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://trinitybiotech.com/role/ProvisionsScheduleOfProvisionsDetails" ], "lang": { "en-us": { "role": { "label": "Product warranty provision" } }, "en": { "role": { "documentation": "The amount of provision for estimated costs of making good under warranties for products sold. [Refer: Provisions]" } } }, "auth_ref": [ "r469", "r470" ] }, "trib_WaveformTechnologiesIncMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "WaveformTechnologiesIncMember", "presentation": [ "http://trinitybiotech.com/role/CapitalAndReservesNarrativeDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsNarrativeDetails", "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsScheduleOfSignificantGoodwillAndIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member is stand for Waveform Technologies Inc.", "label": "Waveform Technologies Inc [Member]", "verboseLabel": "Waveform Technologies Inc [Member]" } } }, "auth_ref": [] }, "trib_WaveformTechnologiesIncorporationMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "WaveformTechnologiesIncorporationMember", "presentation": [ "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSDetails", "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://trinitybiotech.com/role/BUSINESSCOMBINATIONSTables", "http://trinitybiotech.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://trinitybiotech.com/role/GROUPUNDERTAKINGSDetails", "http://trinitybiotech.com/role/INTERESTBEARINGLOANSANDBORROWINGSNarrativeDetails", "http://trinitybiotech.com/role/TRADEANDOTHERPAYABLESNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Waveform Technologies Incorporation [Member]", "label": "Waveform Technologies Incorporation [Member]", "terseLabel": "Waveform Technologies Inc. [Member]" } } }, "auth_ref": [] }, "trib_WeightedAverageExercisePriceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "WeightedAverageExercisePriceAbstract", "presentation": [ "http://trinitybiotech.com/role/ShareOptionsScheduleOfGrantsOfShareOptionsAndWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price Abstract", "terseLabel": "Weighted Average exercise price" } } }, "auth_ref": [] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019", "presentation": [ "http://trinitybiotech.com/role/ShareOptionsScheduleOfGrantsOfShareOptionsAndWarrantsDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Exercisable at end of year", "label": "Weighted average exercise price of share options exercisable in share-based payment arrangement" } }, "en": { "role": { "documentation": "The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r178", "r369" ] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019", "presentation": [ "http://trinitybiotech.com/role/ShareOptionsScheduleOfGrantsOfShareOptionsAndWarrantsDetails", "http://trinitybiotech.com/role/ShareOptionsSummaryOfRangeOfPricesOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price of share options exercised in share-based payment arrangement", "terseLabel": "Exercised", "verboseLabel": "Weighted average exercise price" } }, "en": { "role": { "documentation": "The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r175", "r366" ] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019", "presentation": [ "http://trinitybiotech.com/role/ShareOptionsScheduleOfGrantsOfShareOptionsAndWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Expired/ Forfeited" } }, "en": { "role": { "documentation": "The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r174", "r365" ] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019", "presentation": [ "http://trinitybiotech.com/role/ShareOptionsScheduleOfGrantsOfShareOptionsAndWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price of share options granted in share-based payment arrangement", "verboseLabel": "Granted" } }, "en": { "role": { "documentation": "The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r173", "r364" ] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019", "presentation": [ "http://trinitybiotech.com/role/ShareOptionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average share price date of exercise for options exercised" } }, "en": { "role": { "documentation": "The weighted average share price at the date of exercise for share options that are exercised in a share-based payment arrangement. [Refer: Types of share-based payment arrangements [domain]; Weighted average [member]]" } } }, "auth_ref": [ "r180" ] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019", "presentation": [ "http://trinitybiotech.com/role/ShareOptionsScheduleOfGrantsOfShareOptionsAndWarrantsDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Outstanding at end of year", "periodStartLabel": "Outstanding Beginning Balance", "label": "Weighted average exercise price of share options outstanding in share-based payment arrangement" } }, "en": { "role": { "documentation": "The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r172", "r177", "r363", "r368" ] }, "trib_WeightedAverageExercisePriceOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "WeightedAverageExercisePriceOutstanding", "crdr": "debit", "presentation": [ "http://trinitybiotech.com/role/ShareOptionsSummaryOfRangeOfPricesOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price outstanding.", "label": "Weighted Average Exercise Price Outstanding", "terseLabel": "Weighted average exercise price" } } }, "auth_ref": [] }, "ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageFairValueAtMeasurementDateShareOptionsGranted", "crdr": "credit", "presentation": [ "http://trinitybiotech.com/role/ShareOptionsScheduleOfAssumptionDeterminingFairValueOfShareOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average fair value at measurement date per 'A' share / (per ADS)" } }, "en": { "role": { "documentation": "The weighted average fair value of share options granted during the period at the measurement date. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r184" ] }, "trib_WeightedAverageNumberOfSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "WeightedAverageNumberOfSharesIssued", "presentation": [ "http://trinitybiotech.com/role/LossPerShareScheduleOfBasicEarningsPerOrdinaryShareDetails", "http://trinitybiotech.com/role/LossPerShareScheduleOfEarningsPerAdsDetails" ], "lang": { "en-us": { "role": { "documentation": "Weighted average number of shares issued.", "label": "Weighted Average Number Of Shares Issued", "terseLabel": "Weighted average number of shares issued during the year", "verboseLabel": "Weighted average number of \u2018A\u2019 ordinary shares issued during the year" } } }, "auth_ref": [] }, "trib_WeightedAverageNumberOfTreasuryShares": { "xbrltype": "sharesItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "WeightedAverageNumberOfTreasuryShares", "presentation": [ "http://trinitybiotech.com/role/LossPerShareScheduleOfBasicEarningsPerOrdinaryShareDetails", "http://trinitybiotech.com/role/LossPerShareScheduleOfEarningsPerAdsDetails" ], "lang": { "en-us": { "role": { "documentation": "Weighted average number of treasury shares.", "label": "Weighted average number of treasury shares" } } }, "auth_ref": [] }, "trib_WeightedAverageRemainingContractualLifeOfExercisableShareOptions2019": { "xbrltype": "durationItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "WeightedAverageRemainingContractualLifeOfExercisableShareOptions2019", "presentation": [ "http://trinitybiotech.com/role/ShareOptionsSummaryOfRangeOfPricesOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "The weighted average remaining contractual life of exercisable share options.", "label": "Weighted Average Remaining Contractual Life Of Exercisable Share Options 2019", "terseLabel": "Weighted average contractual life remaining (years)" } } }, "auth_ref": [] }, "ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019": { "xbrltype": "durationItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019", "presentation": [ "http://trinitybiotech.com/role/ShareOptionsNarrativeDetails", "http://trinitybiotech.com/role/ShareOptionsSummaryOfRangeOfPricesOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted-average remaining contractual life of options outstanding", "verboseLabel": "Weighted average contractual life remaining (years)" } }, "en": { "role": { "documentation": "The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r181" ] }, "ifrs-full_WeightedAverageSharePrice2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageSharePrice2019", "presentation": [ "http://trinitybiotech.com/role/ShareOptionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Average share price" } }, "en": { "role": { "documentation": "The weighted average share price. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r180" ] }, "ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageSharePriceShareOptionsGranted2019", "presentation": [ "http://trinitybiotech.com/role/ShareOptionsScheduleOfAssumptionDeterminingFairValueOfShareOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average share price per 'A' share / (per ADS)" } }, "en": { "role": { "documentation": "The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]" } } }, "auth_ref": [ "r183" ] }, "ifrs-full_WeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageShares", "presentation": [ "http://trinitybiotech.com/role/LossPerShareNarrativeDetails", "http://trinitybiotech.com/role/LossPerShareScheduleOfBasicEarningsPerOrdinaryShareDetails", "http://trinitybiotech.com/role/LossPerShareScheduleOfEarningsPerAdsDetails" ], "lang": { "en-us": { "role": { "label": "Basic (loss)/earnings per ADS denominator", "terseLabel": "Weighted average number of shares", "verboseLabel": "Basic (loss)/earnings per share denominator" } }, "en": { "role": { "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor." } } }, "auth_ref": [ "r57" ] }, "trib_WeightedAverageSharesDiscontinuedOperations": { "xbrltype": "sharesItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "WeightedAverageSharesDiscontinuedOperations", "presentation": [ "http://trinitybiotech.com/role/PROFITFORTHEYEARONDISCONTINUEDOPERATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Weighted average shares discontinued operations.", "label": "Weighted Average Shares Discontinued Operations", "terseLabel": "Weighted average number of shares", "verboseLabel": "Basic earnings per ordinary share - discontinued operations" } } }, "auth_ref": [] }, "trib_WithinOneYearMember": { "xbrltype": "domainItemType", "nsuri": "http://trinitybiotech.com/20251231", "localname": "WithinOneYearMember", "presentation": [ "http://trinitybiotech.com/role/ProvisionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Within One Year [Member]", "label": "Within One Year [Member]" } } }, "auth_ref": [] }, "ifrs-full_WorkInProgress": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WorkInProgress", "crdr": "debit", "calculation": { "http://trinitybiotech.com/role/InventoriesScheduleOfInventoriesDetails": { "parentTag": "ifrs-full_Inventories", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://trinitybiotech.com/role/InventoriesScheduleOfInventoriesDetails" ], "lang": { "en-us": { "role": { "label": "Work-in-progress" } }, "en": { "role": { "documentation": "A classification of current inventory representing the amount of assets currently in production, which require further processes to be converted into finished goods or services. [Refer: Current finished goods; Inventories]" } } }, "auth_ref": [ "r528", "r536", "r586" ] }, "ifrs-full_WritedownsReversalsOfPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WritedownsReversalsOfPropertyPlantAndEquipment", "calculation": { "http://trinitybiotech.com/role/IMPAIRMENTTRANSFORMATIONANDONCEOFFCOSTSScheduleofStatementofOperationDetails": { "parentTag": "ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://trinitybiotech.com/role/GoodwillAndIntangibleAssetsNarrativeDetails", "http://trinitybiotech.com/role/IMPAIRMENTTRANSFORMATIONANDONCEOFFCOSTSScheduleofStatementofOperationDetails", "http://trinitybiotech.com/role/PropertyPlantAndEquipmentNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Capitalised development cost write off", "terseLabel": "Impairment losses (Reversals impairment loss)", "verboseLabel": "Impairment of PP&E (Note 11)" } } }, "auth_ref": [ "r455" ] }, "currency_XXX": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2025", "localname": "XXX", "presentation": [ "http://trinitybiotech.com/role/CapitalAndFinancialRiskManagementScheduleOfForeignCurrencyRiskShortTermFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Other [Member]" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "10", "IssueDate": "2025-01-01", "Paragraph": "21", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2025-en-r&anchor=para_21&doctype=Standard", "URIDate": "2025-03-27" }, "r1": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_79&doctype=Standard", "URIDate": "2025-03-27" }, "r2": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "c", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_c_i&doctype=Standard", "URIDate": "2025-03-27" }, "r3": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "c", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_c_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r4": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "g", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_g_i&doctype=Standard", "URIDate": "2025-03-27" }, "r5": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "g", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_g_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r6": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_g&doctype=Standard", "URIDate": "2025-03-27" }, "r7": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "h", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_h_i&doctype=Standard", "URIDate": "2025-03-27" }, "r8": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "h", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_h_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r9": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI", "URIDate": "2025-03-27" }, "r10": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_c&doctype=Standard", "URIDate": "2025-03-27" }, "r11": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2025-03-27" }, "r12": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e_i&doctype=Standard", "URIDate": "2025-03-27" }, "r13": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "e", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r14": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "e", "Clause": "ix", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e_ix&doctype=Standard", "URIDate": "2025-03-27" }, "r15": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "e", "Clause": "v", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e_v&doctype=Standard", "URIDate": "2025-03-27" }, "r16": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "e", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e_viii&doctype=Standard", "URIDate": "2025-03-27" }, "r17": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2025-03-27" }, "r18": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73&doctype=Standard", "URIDate": "2025-03-27" }, "r19": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "74", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_74_b&doctype=Standard", "URIDate": "2025-03-27" }, "r20": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "75", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_75_b&doctype=Standard", "URIDate": "2025-03-27" }, "r21": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS16_g73-79_TI", "URIDate": "2025-03-27" }, "r22": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "137", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_137&doctype=Standard", "URIDate": "2025-03-27" }, "r23": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "138", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_138&doctype=Standard", "URIDate": "2025-03-27" }, "r24": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "142", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_142&doctype=Standard", "URIDate": "2025-03-27" }, "r25": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "53", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_53&doctype=Standard", "URIDate": "2025-03-27" }, "r26": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "36", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2025-en-r&anchor=para_36_a&doctype=Standard", "URIDate": "2025-03-27" }, "r27": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "36", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2025-en-r&anchor=para_36_b&doctype=Standard", "URIDate": "2025-03-27" }, "r28": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "36", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2025-en-r&anchor=para_36_d&doctype=Standard", "URIDate": "2025-03-27" }, "r29": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "2", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS02_g36-39_TI", "URIDate": "2025-03-27" }, "r30": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "20", "IssueDate": "2025-01-01", "Paragraph": "39", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=20&code=ifrs-tx-2025-en-r&anchor=para_39_a&doctype=Standard", "URIDate": "2025-03-27" }, "r31": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2025-01-01", "Paragraph": "52", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2025-en-r&anchor=para_52_b&doctype=Standard", "URIDate": "2025-03-27" }, "r32": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2025-01-01", "Paragraph": "A19", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2025-en-r&anchor=para_A19_c&doctype=Standard", "URIDate": "2025-03-27" }, "r33": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2025-01-01", "Paragraph": "A19", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2025-en-r&anchor=para_A19_f&doctype=Standard", "URIDate": "2025-03-27" }, "r34": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "23", "IssueDate": "2025-01-01", "Paragraph": "26", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=23&code=ifrs-tx-2025-en-r&anchor=para_26_a&doctype=Standard", "URIDate": "2025-03-27" }, "r35": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2025-03-27" }, "r36": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17_b&doctype=Standard", "URIDate": "2025-03-27" }, "r37": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17_d&doctype=Standard", "URIDate": "2025-03-27" }, "r38": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2025-03-27" }, "r39": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17&doctype=Standard", "URIDate": "2025-03-27" }, "r40": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "19", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_19_f&doctype=Standard", "URIDate": "2025-03-27" }, "r41": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "19", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_19&doctype=Standard", "URIDate": "2025-03-27" }, "r42": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Section": "Disclosures", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI", "URIDate": "2025-03-27" }, "r43": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "26", "IssueDate": "2025-01-01", "Paragraph": "35", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2025-en-r&anchor=para_35_b_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r44": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "26", "IssueDate": "2025-01-01", "Paragraph": "35", "Subparagraph": "b", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2025-en-r&anchor=para_35_b_vi&doctype=Standard", "URIDate": "2025-03-27" }, "r45": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "26", "IssueDate": "2025-01-01", "Paragraph": "35", "Subparagraph": "b", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2025-en-r&anchor=para_35_b_viii&doctype=Standard", "URIDate": "2025-03-27" }, "r46": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2025-01-01", "Paragraph": "16", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_16_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r47": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2025-01-01", "Paragraph": "16", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_16_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r48": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2025-01-01", "Paragraph": "16", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_16_b&doctype=Standard", "URIDate": "2025-03-27" }, "r49": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_17_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r50": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_17_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r51": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_17_b&doctype=Standard", "URIDate": "2025-03-27" }, "r52": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "32", "IssueDate": "2025-01-01", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2025-en-r&anchor=para_34&doctype=Standard", "URIDate": "2025-03-27" }, "r53": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r54": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "67", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_67&doctype=Standard", "URIDate": "2025-03-27" }, "r55": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "68", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_68&doctype=Standard", "URIDate": "2025-03-27" }, "r56": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "70", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_a&doctype=Standard", "URIDate": "2025-03-27" }, "r57": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "70", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_b&doctype=Standard", "URIDate": "2025-03-27" }, "r58": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI", "URIDate": "2025-03-27" }, "r59": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_126&doctype=Standard", "URIDate": "2025-03-27" }, "r60": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "130", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_130_b&doctype=Standard", "URIDate": "2025-03-27" }, "r61": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "130", "Subparagraph": "d", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_130_d_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r62": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "130", "Subparagraph": "f", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_130_f_i&doctype=Standard", "URIDate": "2025-03-27" }, "r63": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "130", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_130&doctype=Standard", "URIDate": "2025-03-27" }, "r64": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "134", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_134_b&doctype=Standard", "URIDate": "2025-03-27" }, "r65": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "134", "Subparagraph": "d", "Clause": "v", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_134_d_v&doctype=Standard", "URIDate": "2025-03-27" }, "r66": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "134", "Subparagraph": "e", "Clause": "iiA", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_134_e_iiA&doctype=Standard", "URIDate": "2025-03-27" }, "r67": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "134", "Subparagraph": "e", "Clause": "v", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_134_e_v&doctype=Standard", "URIDate": "2025-03-27" }, "r68": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "135", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_135_b&doctype=Standard", "URIDate": "2025-03-27" }, "r69": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS36_g126-137_TI", "URIDate": "2025-03-27" }, "r70": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2025-01-01", "Paragraph": "84", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&anchor=para_84_a&doctype=Standard", "URIDate": "2025-03-27" }, "r71": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2025-01-01", "Paragraph": "84", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&anchor=para_84_b&doctype=Standard", "URIDate": "2025-03-27" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2025-01-01", "Paragraph": "84", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&anchor=para_84_c&doctype=Standard", "URIDate": "2025-03-27" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2025-01-01", "Paragraph": "84", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&anchor=para_84&doctype=Standard", "URIDate": "2025-03-27" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_a&doctype=Standard", "URIDate": "2025-03-27" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2025-03-27" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e_i&doctype=Standard", "URIDate": "2025-03-27" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2025-03-27" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118&doctype=Standard", "URIDate": "2025-03-27" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "122", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_122_a&doctype=Standard", "URIDate": "2025-03-27" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "122", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_122_b&doctype=Standard", "URIDate": "2025-03-27" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "124", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_124_b&doctype=Standard", "URIDate": "2025-03-27" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_126&doctype=Standard", "URIDate": "2025-03-27" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2025-01-01", "Paragraph": "76", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_76_g&doctype=Standard", "URIDate": "2025-03-27" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2025-01-01", "Paragraph": "76", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_76&doctype=Standard", "URIDate": "2025-03-27" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2025-03-27" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "d", "Clause": "v", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_79_d_v&doctype=Standard", "URIDate": "2025-03-27" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_79_d&doctype=Standard", "URIDate": "2025-03-27" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "41", "IssueDate": "2025-01-01", "Paragraph": "50", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2025-en-r&anchor=para_50&doctype=Standard", "URIDate": "2025-03-27" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "41", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2025-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2025-03-27" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_10&doctype=Standard", "URIDate": "2025-03-27" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20&doctype=Standard", "URIDate": "2025-03-27" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_25&doctype=Standard", "URIDate": "2025-03-27" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_28&doctype=Standard", "URIDate": "2025-03-27" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_31&doctype=Standard", "URIDate": "2025-03-27" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35&doctype=Standard", "URIDate": "2025-03-27" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "40", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_40_a&doctype=Standard", "URIDate": "2025-03-27" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "44B", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44B_c&doctype=Standard", "URIDate": "2025-03-27" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "44B", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44B_d&doctype=Standard", "URIDate": "2025-03-27" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "44B", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44B_e&doctype=Standard", "URIDate": "2025-03-27" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "44H", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44H_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "46", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_46&doctype=Standard", "URIDate": "2025-03-27" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "50", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_50_d&doctype=Standard", "URIDate": "2025-03-27" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Section": "Presentation of a statement of cash flows", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS07_g10-17_TI", "URIDate": "2025-03-27" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "f", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_f_i&doctype=Standard", "URIDate": "2025-03-27" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "29", "Subparagraph": "c", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2025-en-r&anchor=para_29_c_i&doctype=Standard", "URIDate": "2025-03-27" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "30", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2025-en-r&anchor=para_30_b&doctype=Standard", "URIDate": "2025-03-27" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "39", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2025-en-r&anchor=para_39&doctype=Standard", "URIDate": "2025-03-27" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "49", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2025-en-r&anchor=para_49_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "49", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2025-en-r&anchor=para_49_c&doctype=Standard", "URIDate": "2025-03-27" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2025-03-27" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2025-03-27" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_32_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_32_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "10", "IssueDate": "2025-01-01", "Paragraph": "22", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=10&code=ifrs-tx-2025-en-r&anchor=para_22&doctype=Standard", "URIDate": "2025-03-27" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "12", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_12_a&doctype=Standard", "URIDate": "2025-03-27" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "12", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_12_f&doctype=Standard", "URIDate": "2025-03-27" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "19B", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_19B_a&doctype=Standard", "URIDate": "2025-03-27" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "19B", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_19B_c&doctype=Standard", "URIDate": "2025-03-27" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "21", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_21_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "v", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "vii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_vii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B13", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B13", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_d&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B13", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_f&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B13", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B16", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B16&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B4", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B4", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B4_e&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_a&doctype=Standard", "URIDate": "2025-03-27" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_b&doctype=Standard", "URIDate": "2025-03-27" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_e&doctype=Standard", "URIDate": "2025-03-27" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93&doctype=Standard", "URIDate": "2025-03-27" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "14", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2025-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2025-03-27" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "105", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_105&doctype=Standard", "URIDate": "2025-03-27" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "113", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_113_a&doctype=Standard", "URIDate": "2025-03-27" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "114", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_114&doctype=Standard", "URIDate": "2025-03-27" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "116", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_116_a&doctype=Standard", "URIDate": "2025-03-27" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "120", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_120_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_47_a&doctype=Standard", "URIDate": "2025-03-27" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2025-03-27" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "53", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53_a&doctype=Standard", "URIDate": "2025-03-27" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "53", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53_b&doctype=Standard", "URIDate": "2025-03-27" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "53", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53_c&doctype=Standard", "URIDate": "2025-03-27" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "53", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53_f&doctype=Standard", "URIDate": "2025-03-27" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "53", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53_h&doctype=Standard", "URIDate": "2025-03-27" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "53", "Subparagraph": "j", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53_j&doctype=Standard", "URIDate": "2025-03-27" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "53", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53&doctype=Standard", "URIDate": "2025-03-27" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "90", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_90_b&doctype=Standard", "URIDate": "2025-03-27" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "94", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_94&doctype=Standard", "URIDate": "2025-03-27" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "95", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_95&doctype=Standard", "URIDate": "2025-03-27" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "97", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_97&doctype=Standard", "URIDate": "2025-03-27" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS16_g51-60_TI", "URIDate": "2025-03-27" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Section": "Presentation", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS16_g47-50_TI", "URIDate": "2025-03-27" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "109", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_109&doctype=Standard", "URIDate": "2025-03-27" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "109A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_109A&doctype=Standard", "URIDate": "2025-03-27" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "113", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2025-03-27" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "120", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_120&doctype=Standard", "URIDate": "2025-03-27" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "124", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_124&doctype=Standard", "URIDate": "2025-03-27" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "125", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_125&doctype=Standard", "URIDate": "2025-03-27" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "127", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_127&doctype=Standard", "URIDate": "2025-03-27" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "128", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_128_a&doctype=Standard", "URIDate": "2025-03-27" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "132", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_132_b&doctype=Standard", "URIDate": "2025-03-27" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "C32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_C32&doctype=Appendix&subtype=C", "URIDate": "2025-03-27" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_a&doctype=Standard", "URIDate": "2025-03-27" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "v", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_v&doctype=Standard", "URIDate": "2025-03-27" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_vi&doctype=Standard", "URIDate": "2025-03-27" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "vii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_vii&doctype=Standard", "URIDate": "2025-03-27" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b&doctype=Standard", "URIDate": "2025-03-27" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_c&doctype=Standard", "URIDate": "2025-03-27" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_d&doctype=Standard", "URIDate": "2025-03-27" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_47_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_47_a&doctype=Standard", "URIDate": "2025-03-27" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2025-03-27" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2025-01-01", "Paragraph": "B64", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B64_c&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2025-01-01", "Paragraph": "B64", "Subparagraph": "f", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B64_f_i&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2025-01-01", "Paragraph": "B64", "Subparagraph": "f", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B64_f_iv&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2025-01-01", "Paragraph": "B64", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B64_f&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2025-01-01", "Paragraph": "B64", "Subparagraph": "g", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B64_g_i&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2025-01-01", "Paragraph": "B64", "Subparagraph": "g", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B64_g_ii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2025-01-01", "Paragraph": "B64", "Subparagraph": "j", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B64_j&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2025-01-01", "Paragraph": "B64", "Subparagraph": "l", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B64_l&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2025-01-01", "Paragraph": "B64", "Subparagraph": "m", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B64_m&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2025-01-01", "Paragraph": "B64", "Subparagraph": "q", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B64_q_i&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2025-01-01", "Paragraph": "B64", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B64&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2025-01-01", "Paragraph": "B67", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B67_a_iii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2025-01-01", "Paragraph": "B67", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B67_b_i&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2025-01-01", "Paragraph": "B67", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B67_c&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2025-01-01", "Paragraph": "B67", "Subparagraph": "d", "Clause": "v", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B67_d_v&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2025-01-01", "Paragraph": "B67", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2025-01-01", "Paragraph": "B67", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B67_e&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2025-01-01", "Paragraph": "B67", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B67&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2025-01-01", "Section": "Disclosures", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS03_g59-63_TI", "URIDate": "2025-03-27" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2025-01-01", "Section": "Disclosures application of paragraphs 59 and 61", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&doctype=Appendix&subtype=B&dita_xref=IFRS03_gB64-B67_TI", "URIDate": "2025-03-27" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "5", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2025-en-r&anchor=para_33_a&doctype=Standard", "URIDate": "2025-03-27" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "5", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2025-en-r&anchor=para_33_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "5", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2025-en-r&anchor=para_33_b_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "5", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2025-en-r&anchor=para_33_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "5", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2025-en-r&anchor=para_33_b_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "5", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2025-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2025-03-27" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "5", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2025-en-r&anchor=para_33_c&doctype=Standard", "URIDate": "2025-03-27" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "5", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2025-en-r&anchor=para_33_d&doctype=Standard", "URIDate": "2025-03-27" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "5", "IssueDate": "2025-01-01", "Paragraph": "38", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2025-en-r&anchor=para_38&doctype=Standard", "URIDate": "2025-03-27" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "5", "IssueDate": "2025-01-01", "Section": "Presentation and disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS05_g30-42_TI", "URIDate": "2025-03-27" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "18", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_18_b&doctype=Standard", "URIDate": "2025-03-27" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "21C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_21C&doctype=Standard", "URIDate": "2025-03-27" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "23B", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_23B_a&doctype=Standard", "URIDate": "2025-03-27" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "24C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_24C&doctype=Standard", "URIDate": "2025-03-27" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_25&doctype=Standard", "URIDate": "2025-03-27" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_31&doctype=Standard", "URIDate": "2025-03-27" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_33&doctype=Standard", "URIDate": "2025-03-27" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_34&doctype=Standard", "URIDate": "2025-03-27" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35H", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35H&doctype=Standard", "URIDate": "2025-03-27" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35I", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35I&doctype=Standard", "URIDate": "2025-03-27" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35K", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35K_a&doctype=Standard", "URIDate": "2025-03-27" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35K", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35K&doctype=Standard", "URIDate": "2025-03-27" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35M", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35M&doctype=Standard", "URIDate": "2025-03-27" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "36", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_36&doctype=Standard", "URIDate": "2025-03-27" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "40", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_40_a&doctype=Standard", "URIDate": "2025-03-27" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "40", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_40_b&doctype=Standard", "URIDate": "2025-03-27" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "42E", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_42E_d&doctype=Standard", "URIDate": "2025-03-27" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "42E", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_42E_e&doctype=Standard", "URIDate": "2025-03-27" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "42I", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_42I&doctype=Standard", "URIDate": "2025-03-27" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_6&doctype=Standard", "URIDate": "2025-03-27" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_7&doctype=Standard", "URIDate": "2025-03-27" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "8", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_8_g&doctype=Standard", "URIDate": "2025-03-27" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "9", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_9_a&doctype=Standard", "URIDate": "2025-03-27" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B52", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B52&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Section": "Credit risk", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS07_g35A-38_TI", "URIDate": "2025-03-27" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Section": "Scope", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A_TI", "URIDate": "2025-03-27" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_a&doctype=Standard", "URIDate": "2025-03-27" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_d&doctype=Standard", "URIDate": "2025-03-27" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_e&doctype=Standard", "URIDate": "2025-03-27" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_h&doctype=Standard", "URIDate": "2025-03-27" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23&doctype=Standard", "URIDate": "2025-03-27" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2025-03-27" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_a&doctype=Standard", "URIDate": "2025-03-27" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2025-03-27" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_c&doctype=Standard", "URIDate": "2025-03-27" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_d&doctype=Standard", "URIDate": "2025-03-27" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_e&doctype=Standard", "URIDate": "2025-03-27" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_32&doctype=Standard", "URIDate": "2025-03-27" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_33_a&doctype=Standard", "URIDate": "2025-03-27" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_33&doctype=Standard", "URIDate": "2025-03-27" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_34&doctype=Standard", "URIDate": "2025-03-27" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS08_g20-24_TI", "URIDate": "2025-03-27" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "9", "IssueDate": "2025-01-01", "Paragraph": "6.5.11", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2025-en-r&anchor=para_6.5.11&doctype=Standard", "URIDate": "2025-03-27" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "9", "IssueDate": "2025-01-01", "Paragraph": "7.2.34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2025-en-r&anchor=para_7.2.34&doctype=Standard", "URIDate": "2025-03-27" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "9", "IssueDate": "2025-01-01", "Paragraph": "7.2.42", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2025-en-r&anchor=para_7.2.42&doctype=Standard", "URIDate": "2025-03-27" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2026-01-01", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "30A", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_30A_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103&doctype=Standard", "URIDate": "2025-03-27" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "105", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_105_a&doctype=Standard", "URIDate": "2025-03-27" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "108", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_108_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "115", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115_a&doctype=Standard", "URIDate": "2025-03-27" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "115", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115_b&doctype=Standard", "URIDate": "2025-03-27" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "115", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115_c&doctype=Standard", "URIDate": "2025-03-27" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "115", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115_g&doctype=Standard", "URIDate": "2025-03-27" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "115", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115_i&doctype=Standard", "URIDate": "2025-03-27" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "115", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115&doctype=Standard", "URIDate": "2025-03-27" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "122", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_122_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "122", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_122_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "122", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_122_a_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "122", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_122_a&doctype=Standard", "URIDate": "2025-03-27" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "124", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_124_a&doctype=Standard", "URIDate": "2025-03-27" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "124", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_124_b&doctype=Standard", "URIDate": "2025-03-27" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "124", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_124_c&doctype=Standard", "URIDate": "2025-03-27" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "124", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_124&doctype=Standard", "URIDate": "2025-03-27" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "125", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_125&doctype=Standard", "URIDate": "2025-03-27" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "133", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_133_a_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "133", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_133_a_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "141", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_141_a&doctype=Standard", "URIDate": "2025-03-27" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a&doctype=Standard", "URIDate": "2025-03-27" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_b&doctype=Standard", "URIDate": "2025-03-27" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160&doctype=Standard", "URIDate": "2025-03-27" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "164", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_164_a&doctype=Standard", "URIDate": "2025-03-27" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "164", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_164_b&doctype=Standard", "URIDate": "2025-03-27" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "164", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_164_c&doctype=Standard", "URIDate": "2025-03-27" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "166", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_166_c&doctype=Standard", "URIDate": "2025-03-27" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "166", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_166_d&doctype=Standard", "URIDate": "2025-03-27" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "166", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_166_e&doctype=Standard", "URIDate": "2025-03-27" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "166", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_166&doctype=Standard", "URIDate": "2025-03-27" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "168", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_168_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "169", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_169&doctype=Standard", "URIDate": "2025-03-27" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "170", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_170&doctype=Standard", "URIDate": "2025-03-27" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "178", "Subparagraph": "f", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_178_f_i&doctype=Standard", "URIDate": "2025-03-27" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "179", "Subparagraph": "c", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_179_c_i&doctype=Standard", "URIDate": "2025-03-27" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "180", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_180_b&doctype=Standard", "URIDate": "2025-03-27" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "182", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_182&doctype=Standard", "URIDate": "2025-03-27" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "184", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_184&doctype=Standard", "URIDate": "2025-03-27" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "186", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_186_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "186", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_186_c&doctype=Standard", "URIDate": "2025-03-27" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "190", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_190&doctype=Standard", "URIDate": "2025-03-27" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "192", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_192&doctype=Standard", "URIDate": "2025-03-27" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "c", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_c_i&doctype=Standard", "URIDate": "2025-03-27" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "c", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_c_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "f", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_f_i&doctype=Standard", "URIDate": "2025-03-27" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "f", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_f_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_f&doctype=Standard", "URIDate": "2025-03-27" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_c&doctype=Standard", "URIDate": "2025-03-27" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_d&doctype=Standard", "URIDate": "2025-03-27" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_e_i&doctype=Standard", "URIDate": "2025-03-27" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "Subparagraph": "e", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_e_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "Subparagraph": "e", "Clause": "v", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_e_v&doctype=Standard", "URIDate": "2025-03-27" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "Subparagraph": "e", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_e_viii&doctype=Standard", "URIDate": "2025-03-27" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_e&doctype=Standard", "URIDate": "2025-03-27" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200&doctype=Standard", "URIDate": "2025-03-27" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "203", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_203&doctype=Standard", "URIDate": "2025-03-27" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "204", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_204&doctype=Standard", "URIDate": "2025-03-27" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "216", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_216_a&doctype=Standard", "URIDate": "2025-03-27" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "218", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_218_b&doctype=Standard", "URIDate": "2025-03-27" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "223", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_223_c&doctype=Standard", "URIDate": "2025-03-27" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "223", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_223_f&doctype=Standard", "URIDate": "2025-03-27" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "225", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_225_a&doctype=Standard", "URIDate": "2025-03-27" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "227", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_227&doctype=Standard", "URIDate": "2025-03-27" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "231", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_231_f&doctype=Standard", "URIDate": "2025-03-27" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "231", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_231&doctype=Standard", "URIDate": "2025-03-27" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2025-03-27" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2025-03-27" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "250", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_250&doctype=Standard", "URIDate": "2025-03-27" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "254", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_254_b&doctype=Standard", "URIDate": "2025-03-27" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "254", "Subparagraph": "d", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_254_d_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "254", "Subparagraph": "e", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_254_e_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "254", "Subparagraph": "f", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_254_f_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "255", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_255_b&doctype=Standard", "URIDate": "2025-03-27" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "257", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_257_a&doctype=Standard", "URIDate": "2025-03-27" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "257", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_257_b&doctype=Standard", "URIDate": "2025-03-27" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "257", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_257_c&doctype=Standard", "URIDate": "2025-03-27" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "257", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_257&doctype=Standard", "URIDate": "2025-03-27" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_a&doctype=Standard", "URIDate": "2025-03-27" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_c&doctype=Standard", "URIDate": "2025-03-27" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e_i&doctype=Standard", "URIDate": "2025-03-27" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "e", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e&doctype=Standard", "URIDate": "2025-03-27" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263&doctype=Standard", "URIDate": "2025-03-27" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "264", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_264_a&doctype=Standard", "URIDate": "2025-03-27" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "264", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_264_b&doctype=Standard", "URIDate": "2025-03-27" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "265", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_265_b&doctype=Standard", "URIDate": "2025-03-27" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "266", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_266&doctype=Standard", "URIDate": "2025-03-27" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "269", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_269_f&doctype=Standard", "URIDate": "2025-03-27" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "269", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_269&doctype=Standard", "URIDate": "2025-03-27" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "271", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_271_c&doctype=Standard", "URIDate": "2025-03-27" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "271", "Subparagraph": "d", "Clause": "v", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_271_d_v&doctype=Standard", "URIDate": "2025-03-27" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "271", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_271_d&doctype=Standard", "URIDate": "2025-03-27" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "273", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_273&doctype=Standard", "URIDate": "2025-03-27" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "274", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_274_e&doctype=Standard", "URIDate": "2025-03-27" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_28_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_28_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_a&doctype=Standard", "URIDate": "2025-03-27" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "v", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_v&doctype=Standard", "URIDate": "2025-03-27" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_vi&doctype=Standard", "URIDate": "2025-03-27" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "vii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_vii&doctype=Standard", "URIDate": "2025-03-27" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b&doctype=Standard", "URIDate": "2025-03-27" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31&doctype=Standard", "URIDate": "2025-03-27" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "35", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_35_c&doctype=Standard", "URIDate": "2025-03-27" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "35", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_35_e_i&doctype=Standard", "URIDate": "2025-03-27" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "35", "Subparagraph": "e", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_35_e_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "35", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_35_e&doctype=Standard", "URIDate": "2025-03-27" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "35", "Subparagraph": "f", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_35_f_i&doctype=Standard", "URIDate": "2025-03-27" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "35", "Subparagraph": "f", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_35_f_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_35&doctype=Standard", "URIDate": "2025-03-27" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "36", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_36_a&doctype=Standard", "URIDate": "2025-03-27" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "37", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_37_c&doctype=Standard", "URIDate": "2025-03-27" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "37", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_37&doctype=Standard", "URIDate": "2025-03-27" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "43", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_43&doctype=Standard", "URIDate": "2025-03-27" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "44", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_44_d&doctype=Standard", "URIDate": "2025-03-27" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_54_b&doctype=Standard", "URIDate": "2025-03-27" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "62", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_62&doctype=Standard", "URIDate": "2025-03-27" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "64A", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_64A_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "70", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_70&doctype=Standard", "URIDate": "2025-03-27" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "71", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_71&doctype=Standard", "URIDate": "2025-03-27" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "75", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_75_a&doctype=Standard", "URIDate": "2025-03-27" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "75", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_75_d&doctype=Standard", "URIDate": "2025-03-27" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "88", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_88_a&doctype=Standard", "URIDate": "2025-03-27" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "89", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_89&doctype=Standard", "URIDate": "2025-03-27" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "95", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95_a&doctype=Standard", "URIDate": "2025-03-27" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "95", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95_b&doctype=Standard", "URIDate": "2025-03-27" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "95", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95&doctype=Standard", "URIDate": "2025-03-27" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_i&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_iii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_iv&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B15", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B15&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B18", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B18_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_e&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_f&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2026-01-01", "Name": "IFRS", "Number": "9", "IssueDate": "2025-01-01", "Paragraph": "7.2.49", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2025-en-r&anchor=para_7.2.49&doctype=Standard", "URIDate": "2025-03-27" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_103&doctype=Standard", "URIDate": "2025-03-27" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "104", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_104&doctype=Standard", "URIDate": "2025-03-27" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_a&doctype=Standard", "URIDate": "2025-03-27" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_b&doctype=Standard", "URIDate": "2025-03-27" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_i&doctype=Standard", "URIDate": "2025-03-27" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d&doctype=Standard", "URIDate": "2025-03-27" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106&doctype=Standard", "URIDate": "2025-03-27" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "125", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_125&doctype=Standard", "URIDate": "2025-03-27" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "138", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_138_a&doctype=Standard", "URIDate": "2025-03-27" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_a&doctype=Standard", "URIDate": "2025-03-27" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_d&doctype=Standard", "URIDate": "2025-03-27" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_e&doctype=Standard", "URIDate": "2025-03-27" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_g&doctype=Standard", "URIDate": "2025-03-27" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_h&doctype=Standard", "URIDate": "2025-03-27" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_i&doctype=Standard", "URIDate": "2025-03-27" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "j", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_j&doctype=Standard", "URIDate": "2025-03-27" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "k", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_k&doctype=Standard", "URIDate": "2025-03-27" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "l", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_l&doctype=Standard", "URIDate": "2025-03-27" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "n", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_n&doctype=Standard", "URIDate": "2025-03-27" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "o", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_o&doctype=Standard", "URIDate": "2025-03-27" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "q", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_q&doctype=Standard", "URIDate": "2025-03-27" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_55&doctype=Standard", "URIDate": "2025-03-27" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "56", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_56&doctype=Standard", "URIDate": "2025-03-27" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "61", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_61_a&doctype=Standard", "URIDate": "2025-03-27" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "61", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_61&doctype=Standard", "URIDate": "2025-03-27" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "69", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_69&doctype=Standard", "URIDate": "2025-03-27" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_7&doctype=Standard", "URIDate": "2025-03-27" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_b&doctype=Standard", "URIDate": "2025-03-27" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_d&doctype=Standard", "URIDate": "2025-03-27" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard", "URIDate": "2025-03-27" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a&doctype=Standard", "URIDate": "2025-03-27" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79&doctype=Standard", "URIDate": "2025-03-27" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81A", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_a&doctype=Standard", "URIDate": "2025-03-27" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81A", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_b&doctype=Standard", "URIDate": "2025-03-27" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81B", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81B_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81B", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81B_b_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "82", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_a&doctype=Standard", "URIDate": "2025-03-27" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "82", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_b&doctype=Standard", "URIDate": "2025-03-27" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "82", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_d&doctype=Standard", "URIDate": "2025-03-27" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "82", "Subparagraph": "ea", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_ea&doctype=Standard", "URIDate": "2025-03-27" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "91", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_91_a&doctype=Standard", "URIDate": "2025-03-27" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "98", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_98_a&doctype=Standard", "URIDate": "2025-03-27" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "98", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_98_c&doctype=Standard", "URIDate": "2025-03-27" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "98", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_98_e&doctype=Standard", "URIDate": "2025-03-27" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "99", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_99&doctype=Standard", "URIDate": "2025-03-27" }, "r459": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "80", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_80_a&doctype=Standard", "URIDate": "2025-03-27" }, "r460": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "80", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_80_b&doctype=Standard", "URIDate": "2025-03-27" }, "r461": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "80", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_80_c&doctype=Standard", "URIDate": "2025-03-27" }, "r462": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "37", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_37_b&doctype=Standard", "URIDate": "2025-03-27" }, "r463": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "37", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_37_h&doctype=Standard", "URIDate": "2025-03-27" }, "r464": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "138", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_138_a&doctype=Standard", "URIDate": "2025-03-27" }, "r465": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "147", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_147_c&doctype=Standard", "URIDate": "2025-03-27" }, "r466": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "32", "IssueDate": "2025-01-01", "Paragraph": "IE33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2025-en-r&anchor=para_IE33&doctype=Illustrative%20Examples", "URIDate": "2025-03-27" }, "r467": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "127", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_127&doctype=Standard", "URIDate": "2025-03-27" }, "r468": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "37", "IssueDate": "2025-01-01", "Paragraph": "70", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&anchor=para_70&doctype=Standard", "URIDate": "2025-03-27" }, "r469": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "37", "IssueDate": "2025-01-01", "Paragraph": "87", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&anchor=para_87&doctype=Standard", "URIDate": "2025-03-27" }, "r470": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "37", "IssueDate": "2025-01-01", "Section": "Example 1 Warranties", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&doctype=Illustrative%20Examples&dita_xref=IAS37_IE_C_ex1_TI", "URIDate": "2025-03-27" }, "r471": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "37", "IssueDate": "2025-01-01", "Section": "Example 10 A court case", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&doctype=Illustrative%20Examples&dita_xref=IAS37_IE_C_ex10_TI", "URIDate": "2025-03-27" }, "r472": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "119", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_119_a&doctype=Standard", "URIDate": "2025-03-27" }, "r473": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "119", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_119_e&doctype=Standard", "URIDate": "2025-03-27" }, "r474": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "119", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_119_g&doctype=Standard", "URIDate": "2025-03-27" }, "r475": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "14", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_14_f&doctype=Standard", "URIDate": "2025-03-27" }, "r476": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "16", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_16_a&doctype=Standard", "URIDate": "2025-03-27" }, "r477": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2025-03-27" }, "r478": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_c&doctype=Standard", "URIDate": "2025-03-27" }, "r479": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_d&doctype=Standard", "URIDate": "2025-03-27" }, "r480": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2025-03-27" }, "r481": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20&doctype=Standard", "URIDate": "2025-03-27" }, "r482": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "44", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44_c&doctype=Standard", "URIDate": "2025-03-27" }, "r483": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "44C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44C&doctype=Standard", "URIDate": "2025-03-27" }, "r484": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "44D", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44D&doctype=Standard", "URIDate": "2025-03-27" }, "r485": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "50", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_50_c&doctype=Standard", "URIDate": "2025-03-27" }, "r486": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "50", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_50&doctype=Standard", "URIDate": "2025-03-27" }, "r487": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Section": "A Statement of cash flows for an entity other than a financial institution", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A_TI", "URIDate": "2025-03-27" }, "r488": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Section": "C Reconciliation of liabilities arising from financing activities", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_C_TI", "URIDate": "2025-03-27" }, "r489": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r490": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "B6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_B6&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r491": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "IE63", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_IE63&doctype=Illustrative%20Examples", "URIDate": "2025-03-27" }, "r492": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "B89", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_B89_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r493": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "B89", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r494": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "B89", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_B89_c&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r495": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "113", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2025-03-27" }, "r496": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "96", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_96_b&doctype=Standard", "URIDate": "2025-03-27" }, "r497": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "3", "IssueDate": "2025-01-01", "Paragraph": "B64", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B64_i&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r498": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "3", "IssueDate": "2025-01-01", "Paragraph": "B64", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B64&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r499": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "3", "IssueDate": "2025-01-01", "Paragraph": "IE72", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_IE72&doctype=Illustrative%20Examples", "URIDate": "2025-03-27" }, "r500": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_32&doctype=Standard", "URIDate": "2025-03-27" }, "r501": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35H", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35H&doctype=Standard", "URIDate": "2025-03-27" }, "r502": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35I", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35I_c&doctype=Standard", "URIDate": "2025-03-27" }, "r503": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35N", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35N&doctype=Standard", "URIDate": "2025-03-27" }, "r504": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B11", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B11_d&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r505": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B11", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B11&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r506": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B11D", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B11D_e&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r507": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B35", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B35_g&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r508": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B35&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r509": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "IG20B", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_IG20B&doctype=Implementation%20Guidance", "URIDate": "2025-03-27" }, "r510": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "IG20D", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_IG20D&doctype=Implementation%20Guidance", "URIDate": "2025-03-27" }, "r511": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "IG31A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance", "URIDate": "2025-03-27" }, "r512": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23&doctype=Standard", "URIDate": "2025-03-27" }, "r513": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2025-03-27" }, "r514": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28&doctype=Standard", "URIDate": "2025-03-27" }, "r515": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "IG4", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_IG4&doctype=Implementation%20Guidance", "URIDate": "2025-03-27" }, "r516": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "103", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103_a&doctype=Standard", "URIDate": "2025-03-27" }, "r517": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "103", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103_b&doctype=Standard", "URIDate": "2025-03-27" }, "r518": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "103", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103_c&doctype=Standard", "URIDate": "2025-03-27" }, "r519": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "193", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_193_a&doctype=Standard", "URIDate": "2025-03-27" }, "r520": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "193", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_193_b&doctype=Standard", "URIDate": "2025-03-27" }, "r521": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "193", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_193_c&doctype=Standard", "URIDate": "2025-03-27" }, "r522": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "251", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_251&doctype=Standard", "URIDate": "2025-03-27" }, "r523": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "35", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_35_g&doctype=Standard", "URIDate": "2025-03-27" }, "r524": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_35&doctype=Standard", "URIDate": "2025-03-27" }, "r525": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r526": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "70", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_70_c&doctype=Standard", "URIDate": "2025-03-27" }, "r527": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r528": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_c&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r529": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_f&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r530": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "102", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_102&doctype=Standard", "URIDate": "2025-03-27" }, "r531": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_103&doctype=Standard", "URIDate": "2025-03-27" }, "r532": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_108&doctype=Standard", "URIDate": "2025-03-27" }, "r533": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "68", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_68&doctype=Standard", "URIDate": "2025-03-27" }, "r534": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "70", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_70&doctype=Standard", "URIDate": "2025-03-27" }, "r535": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_b&doctype=Standard", "URIDate": "2025-03-27" }, "r536": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_c&doctype=Standard", "URIDate": "2025-03-27" }, "r537": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard", "URIDate": "2025-03-27" }, "r538": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "IG6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_IG6&doctype=Implementation%20Guidance", "URIDate": "2025-03-27" }, "r539": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r540": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r541": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r542": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r544": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r545": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r546": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K" }, "r547": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1" }, "r548": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r549": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r550": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "iii" }, "r551": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "2" }, "r552": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "1" }, "r553": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2" }, "r554": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r555": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "ii" }, "r556": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "iii" }, "r557": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r558": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r560": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r561": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106" }, "r562": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1" }, "r563": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r564": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r565": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "iii" }, "r566": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "2" }, "r567": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "1" }, "r568": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2" }, "r569": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r570": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "ii" }, "r571": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "iii" }, "r572": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r573": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r574": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "80", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_80&doctype=Standard", "URIDate": "2025-03-27" }, "r575": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "c", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_c_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r576": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "g", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_g_i&doctype=Standard", "URIDate": "2025-03-27" }, "r577": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81&doctype=Standard", "URIDate": "2025-03-27" }, "r578": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "37", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_37&doctype=Standard", "URIDate": "2025-03-27" }, "r579": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2025-03-27" }, "r580": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2025-03-27" }, "r581": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "135", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_135_b&doctype=Standard", "URIDate": "2025-03-27" }, "r582": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "144", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_144&doctype=Standard", "URIDate": "2025-03-27" }, "r583": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "5", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_5&doctype=Standard", "URIDate": "2025-03-27" }, "r584": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "9", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_9&doctype=Standard", "URIDate": "2025-03-27" }, "r585": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "36", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2025-en-r&anchor=para_36&doctype=Standard", "URIDate": "2025-03-27" }, "r586": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "37", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2025-en-r&anchor=para_37&doctype=Standard", "URIDate": "2025-03-27" }, "r587": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "20", "IssueDate": "2025-01-01", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=20&code=ifrs-tx-2025-en-r&anchor=para_28&doctype=Standard", "URIDate": "2025-03-27" }, "r588": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "20", "IssueDate": "2025-01-01", "Paragraph": "39", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=20&code=ifrs-tx-2025-en-r&anchor=para_39_b&doctype=Standard", "URIDate": "2025-03-27" }, "r589": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "70", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_c&doctype=Standard", "URIDate": "2025-03-27" }, "r590": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "37", "IssueDate": "2025-01-01", "Paragraph": "84", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&anchor=para_84_b&doctype=Standard", "URIDate": "2025-03-27" }, "r591": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "37", "IssueDate": "2025-01-01", "Paragraph": "84", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&anchor=para_84&doctype=Standard", "URIDate": "2025-03-27" }, "r592": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2025-03-27" }, "r593": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r594": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "vii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e_vii&doctype=Standard", "URIDate": "2025-03-27" }, "r595": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118&doctype=Standard", "URIDate": "2025-03-27" }, "r596": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "119", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_119&doctype=Standard", "URIDate": "2025-03-27" }, "r597": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "40", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2025-03-27" }, "r598": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "41", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2025-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2025-03-27" }, "r599": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "16", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_16&doctype=Standard", "URIDate": "2025-03-27" }, "r600": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17&doctype=Standard", "URIDate": "2025-03-27" }, "r601": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20_a&doctype=Standard", "URIDate": "2025-03-27" }, "r602": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20_b&doctype=Standard", "URIDate": "2025-03-27" }, "r603": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20_c&doctype=Standard", "URIDate": "2025-03-27" }, "r604": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20&doctype=Standard", "URIDate": "2025-03-27" }, "r605": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r606": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "3", "IssueDate": "2025-01-01", "Paragraph": "B64", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B64_i&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r607": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_7&doctype=Standard", "URIDate": "2025-03-27" }, "r608": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "10", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_10_e&doctype=Standard", "URIDate": "2025-03-27" }, "r609": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "104", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_104&doctype=Standard", "URIDate": "2025-03-27" }, "r610": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d&doctype=Standard", "URIDate": "2025-03-27" }, "r611": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_108&doctype=Standard", "URIDate": "2025-03-27" }, "r612": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "112", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_112_c&doctype=Standard", "URIDate": "2025-03-27" }, "r613": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "117", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_117&doctype=Standard", "URIDate": "2025-03-27" }, "r614": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "20", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_20_d&doctype=Standard", "URIDate": "2025-03-27" }, "r615": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_55&doctype=Standard", "URIDate": "2025-03-27" }, "r616": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_b&doctype=Standard", "URIDate": "2025-03-27" }, "r617": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard", "URIDate": "2025-03-27" }, "r618": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78&doctype=Standard", "URIDate": "2025-03-27" }, "r619": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "85", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_85&doctype=Standard", "URIDate": "2025-03-27" } } }